1 DESCRIPTION TITLE OF INVENTION: OXIME-SUBSTITUTED AMIDE COMPOUND AND PEST CONTROL AGENT 5 TECHNICAL FIELD The present invention relates to a novel oxime-substituted amide compound or its salt, and a pesticidal composition containing the compound as an active ingredient. BACKGROUND ART 10 Heretofore, with respect to oxime-substituted amide compounds, N-[2- (methoxyimino)-2-phenylethyl]-4-(trifluoromethyl)nicotinamide and 3-iodo-N2-[2- (methoxyimino)-2-phenylethyl]-N1-[2-methyl-4-[1,2,2,2-tetrafluoro-1- (trifluoromethyl)ethyl]phenyl]phthalic acid diamide are known to have insecticidal activity (for example, Patent Documents 1 and 2). 15 Further, 2-chloro-N-[2-(4-chlorophenyl)-2-(methoxyimino)ethyl]benzamide, N-[2- (4-chlorophenyl)-2-(methoxyimino)ethyl]-2,4-dichlorobenzamide and the like are known to alter the lifespan of eukaryotic organisms (Patent Document 3). Further, certain pyrazole-4-carboxamide derivatives are known to have fungicidal activity (for example, Patent Documents 4 to 7). 20 However, the oxime-substituted amide compound of the present invention is not disclosed at all, and its usefulness as a pesticide has not been known. PRIOR ART DOCUMENTS PATENT DOCUMENTS 25 Patent Document 1: JP-A-2004-035439 Patent Document 2: WO2001/021576 Patent Document 3: U.S. Patent Application Publication No. 2009/0163545 Patent Document 4: WO2001 -055136 Patent Document 5: WO2009-127722 30 Patent Document 6: WO2011 -151369 Patent Document 7: WO2011 -151370 DISCLOSURE OF INVENTION TECHNICAL PROBLEM 35 Infection or parasitism of pests such as pathogens and parasites causes, in a case where the hosts are plants such as grain, fruits, vegetables or ornamental plants, a decrease in the quality of agricultural crops and a remarkable decrease in the yield, and in some cases, serious damages such as death of the plants, and inflicts heavy economic losses not only on the producers but also on the consumers. Thus, to 40 effectively control such pests is a very important object to achieve efficient and stable production of agricultural crops. Further, in a case where the hosts are animals such as companion creatures/pets or livestock/poultry, to effectively control such pests is an important object also for the purpose of maintaining health of the target animals and further, in a case where the target animals are livestock or poultry, for the purpose of 45 stably producing safe food or high quality general merchandise such as wool, feathers or leathers. From such a viewpoint, heretofore, development of pesticides targeted at pathogens or parasites has advanced, and various effective pesticides have been put into practical use. 2 However, recently, control of pests with conventional pesticides has become difficult in more and more cases, as pathogens or parasites acquire resistance to them over many years of their use. Problems of the high toxicity of some conventional pesticides and of the disturbance of the ecosystem by some conventional pesticides 5 which remain in the environment for a long period are becoming apparent. Under these circumstances, development of novel pesticides not only having excellent pesticidal activity on pathogens and parasites but also having high pesticidal properties such as low toxicity and low persistence and of an effective controlling method is always expected. 10 SOLUTION TO PROBLEM The present inventors have conducted extensive studies to achieve the above object and as a result, found that a novel oxime-substituted amide compound represented by the following formula (I) is a very useful compound which is excellent in 15 pesticidal activities, especially in antifungal and nematicidal activities, and has little harmful effect on non-target organisms such as plants, mammals, fishes, useful insects and natural enemies, and accomplished the present invention. That is, the present invention relates to an oxime-substituted amide compound represented by the formula (I), or its N-oxide or salt: W R2R3 / -X V_y R4 N^ 9 R1 20 wherein G1 is a structure represented by any one of G1-1 to G1-51: G2 is a structure represented by any one of G2-1 to G2-19: W is an oxygen atom or a sulfur atom, X1 is a halogen atom, cyano, nitro, -SFs, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R6, C3-C8 cycloalkyi, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-Ce alkynyl, C2-C6 haloalkynyl, -OR7, -S(0)rR7, -N(R9)R8, -C(0)NH2, - C(S)NH2, tri(Ci-Ce alkyl)silyl, phenyl, phenyl substituted with (Z)m or D-3, each of X2, X3, X4 and X5 is independently a hydrogen atom, a halogen atom, cyano, nitro, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R6, C3-C8 cycloalkyi, C3- C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, - OH, -OR7, -SH, -S(0)rR7, -N(R9)R8, Ci-Ce alkylcarbonyl, Ci-Ce alkoxycarbonyl, - C(0)NH2, -C(S)NH2, phenyl, phenyl substituted with (Z)m, D-2 or D-32, provided that when G1 is a structure represented by G1-27 and X1 is dihalomethyl, X2 is a hydrogen atom, each of Y1 and Y3 is independently a hydrogen atom, a halogen atom, cyano, nitro, -SCN, -SF5, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R6, C3-C10 cycloalkyi, (C3-Cio)cycloalkyl optionally substituted with R6, E-1 to E-22, C2-C6 alkenyl, (C2-C6)alkenyl optionally substituted with R6, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C6 alkynyl, (C2-C6)alkynyl optionally substituted with R6, -OH, -OR7, -OS(0)2R7, -SH, -S(0)rR7, -N(R9)R8, -N=C(R9a)R8a, -C(0)R10, -C(R10)=NOH, - 6 C(R10)=NOR11, M-3, M-13, M-30, -C(0)OH, -C(0)OR11, -C(0)SR11, -C(0)N(R13)R12, M- 7, M-17, M-23, M-26, -C(S)OR11, -C(S)SR11, -C(S)N(R13)R12, M-9, M-19, M-23, M-24, M-28, M-25, M-29, -S(0)2OR11, -S(0)2N(R13)R12, -Si(R14a)(R14b)R14, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, 5 each of Y2, Y4 and Y5 is independently a hydrogen atom, a halogen atom, cyano, nitro, -SCN, -SF5, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R6, Ca-Cs cycloalkyl, Ca-Cs halocycloalkyl, -OH, -OR7, -SH, -S(0)rR7, -NH2) Ci-Ce alkylamino, di(Ci-Ce alkyl)amino, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, Ci-Ce alkoxycarbonyl, -C(0)NH2 or -C(S)NH2, 10 or, Y1, Y2, Y3 and Y4 represent that Y1 or Y3 and Y2, or Y3 and Y4, together form - CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2O-, -CH2CH2CH2CH2-, -CH2CH2S-, - CH2SCH2-, -SCH2S-, -CH2CH2N(R5)-, -CH2N(R5)CH2-, -CH2CH2CH2CH2-, - CH2CH2CH2O-, -CH2CH2OCH2-, -CH2OCH2O-, -OCH2CH2O-, -OCH2CH2S-, - SCH2CH2S-, -CH2CH=CH-, -N(R5)N=CH-, -OCH2CH=CH-, -CH=CHCH=CH-, - 15 CH=CHCH=N-, -CH=CHN=CH-, -CH=NCH=N- or -N=CHCH=N- to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y1, Y2, Y3 and Y4, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom, cyano, nitro, C1-C4 alkyl or C1-C4 haloalkyl, 20 and further, when G1 is a structure represented by G1-1, G1-9, G1-10, G1-12, G1- 13, G1-16 to G1-20, G1-22 to G1-24, G1-26, G1-27, G1-30, G1-32, G1-35, G1-38, G1-40 or G1-42 to G1-50, Y1 and Y2, Y2 and Y3, or Y3 and Y4, together may form -OCH=CH-, - SCH=CH-, -N(R5)CH=CH-, -OCH=N-, -SCH=N- or -N(R5)CH=N- to form a 5-membered ring together with the carbon atoms attached to Y1, Y2, Y3 and Y4, wherein hydrogen 25 atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom, cyano, nitro, C1-C4 alkyl or C1-C4 haloalkyl, D-1 to D-38 are aromatic heterocyclic rings represented by the following structural formulae, respectively: E-1 to E-22 are saturated heterocyclic rings represented by the following structural formulae, respectively: Z is a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy(Ci- C4)alkyl, C1-C4 haloalkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 haloalkylthio(Ci-C4)alkyl, C1-C4 alkylsulfinyl(Ci-C4)alkyl, C1-C4 haloalkylsulfinyl(Ci- C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, C1-C4 haloalkylsulfonyl(Ci-C4)alkyl, Ca-Ce 5 cycloalkyl, C3-C6 halocycloalkyl, -OH, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylsulfonyloxy, C1-C4 haloalkylsulfonyloxy, C1-C4 alkylthio, C1-C4 haloalkylthio, C1-C4 alkylsulfinyl, C1-C4 haloalkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, -NH2, C1-C4 alkylamino, di(Ci-C4 alkyl)amino, C1-C4 alkoxycarbonyl, C1-C4 haloalkoxycarbonyl, -C(0)NH2, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkyl)aminocarbonyl, 10 -C(S)NH2, -S(0)2NH2 or phenyl, when m or n is an integer of at least 2, the respective Z's may be identical with or 10 different from one another, and when there are two neighboring Z's, the two neighboring Z's may form -CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2O-, -CH2CH2S-, - CH2SCH2-, -CH2CH2CH2CH2-, -CH2CH2CH2O-, -CH2CH2OCH2-, -CH2OCH2O-, - OCH2CH2O-, -CH2CH2CH2S-, -OCH2CH2S- or -CH=CH-CH=CH- to form a 5-membered 5 ring or a 6-membered ring together with the carbon atoms attached to the two Z's, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom, a cyano group, a nitro group, a methyl group, a trifluoromethyl group, a methoxy group or a methylthio group, Ft1 is Ci-Ce alkyl, (Ci-C8)alkyl optionally substituted with Ft18, C3-C10 cycloalkyi, C3- 10 C10 halocycloalkyi, E-2 to E-8, E-14 to E-18, E-21, Cs-Ce alkenyl, Cs-Ce haloalkenyl, C5- C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, phenyl(C3- C6)alkynyl, phenyl or phenyl substituted with (Z)m, R2 is a hydrogen atom, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C4 alkoxy(Ci- C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfinyl(Ci-C4)alkyl, C1-C4 15 alkylsulfonyl(Ci-C4)alkyl, C3-C6 cycloalkyi or phenyl, or may form the after-mentioned ring together with R3, provided that when G1 is a structure represented by G1-1, X1 is a chlorine atom, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom or a chlorine atom, G2 is a structure represented by G2-1, Y3 is a chlorine atom, and Y1, Y2, Y4 and Y5 are hydrogen 20 atoms, R2 is cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfinyl(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, C3- C6 cycloalkyi or phenyl, R3 is a hydrogen atom or C1-C6 alkyl, or R3 may form, together with R2, a C2-C5 alkylene chain to form a 3- to 6- 25 membered ring together with the carbon atom attached to R2 and R3, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a C1-C4 alkyl group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a C1-C4 alkylaminocarbonyl group, a C1-C4 haloalkylaminocarbonyl group, a di(Ci-C4 alkyl)aminocarbonyl group or a phenyl group, 30 R4 is a hydrogen atom, cyano, nitro, C1-C6 alkyl, (Ci-C6)alkyl optionally substituted with R19, C3-C8 cycloalkyi, C3-C6 alkenyl, C3-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, Cs-Ce haloalkynyl, -C(0)R20, -C(0)OR21, -C(0)SR21, - C(0)N(R23)R22, -C(0)C(0)OR21, -C(S)OR21, -C(S)SR21, -C(S)N(R23)R22, -OH, -OR21, - SR21, -N(R25)R24, -N=C(R25a)R24a, -S(0)2R21, -S(0)2N(R23)R22 or-SN(R27)R26, 35 R5 is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, C3-C6 cycloalkyi, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl or C2-C6 haloalkynyl, R6 is a halogen atom, cyano, nitro, C3-C8 cycloalkyi, C3-C8 halocycloalkyi, hydroxy(C3-C8)cycloalkyl, C1-C6 alkoxy(C3-C8)cycloalkyl, C3-C6 alkenyl, C3-C8 cycloalkenyl, E-1 to E-22, -OH, -OR7, -SH, -S(0)rR7, -N(R9)R8, -C(R10)=NOH, - 40 C(R10)=NOR11, -C(0)OR11, -C(0)N(R13)R12, -Si(R14a)(R14b)R14, phenyl, phenyl substituted with (Z)m or D-1 to D-38, R7 is Ci-Ce alkyl, (Ci-Ce) alkyl optionally substituted with R28, C3-C8 cycloalkyi, (C3-Ca)cycloalkyl optionally substituted with R28, E-2 to E-8, E-14 to E-18, E-21, C2-C6 alkenyl, (C2-C6)alkenyl optionally substituted with R28, C5-C10 cycloalkenyl, C5-C10 45 halocycloalkenyl, C3-C6 alkynyl, (C3-C6)alkynyl optionally substituted with R28, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D-6, D-8 to D-10, D-12 to D-19, D-21, D-23, D-25, D-27 or D-30 to D-38, R8 is a hydrogen atom, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3- 11 Cs cycloalkyi, C3-C8 halocycloalkyi, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3- Ce haloalkynyl, -C(0)R10, -C(0)C(0)R11, -C(0)OR11, -C(0)C(0)OR11, -C(0)SR11, - C(0)N(R13)R12, -C(S)OR11, -C(S)SR11, -C(S)N(R13)R12, -OH, -S(0)2R11 or- S(0)2N(R13)R12, or may form the after-mentioned ring together with R9, 5 R9 is a hydrogen atom, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3- Cs cycloalkyi, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, -CHO, C1-C6 alkylcarbonyl, C1-C6 haloalkylcarbonyl or C1-C6 alkoxycarbonyl, or R9 may form, together with R8, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R8 and R9, wherein the 10 alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, an oxo group or a thioxo group, R8a is Ci-Ce alkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 alkenyloxy, phenoxy or phenoxy substituted with (Z)m, or may form the after-mentioned ring together with R9a, 15 R9a is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 alkenyl, phenyl or phenyl substituted with (Z)m, or R9a may form, together with R8a, a C4-C6 alkylene chain to form a 5- to 7- membered ring together with the carbon atom attached to R8a and R9a, wherein the alkylene chain may contain an oxygen atom or sulfur atom, 20 R10 is a hydrogen atom, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3-C8 cycloalkyi, C3-C8 halocycloalkyi, C2-C6 alkenyl, C2-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R11 is Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3-C8 cycloalkyi, C3- 25 Ce halocycloalkyi, C3-C6 alkenyl, C3-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D-6, D-8 to D-10, D-12 to D-19, D-21, D-23, D-25, D-27 or D-30 to D- 38, R12 is a hydrogen atom, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, 30 C3-C8 cycloalkyi, C3-C8 halocycloalkyi, C2-C6 alkenyl, C2-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, Ci-Ce alkylcarbonyl, Ci-Ce haloalkylcarbonyl, phenylcarbonyl, Ci-Ce alkoxycarbonyl, phenyl, phenyl substituted with (Z)m, D-1 to D-25 or D-27 to D-38, or may form the after-mentioned ring together with R13, R13 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, 35 C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, cyano(Ci-C4)alkyl, C3-C6 alkenyl or C3-C6 alkynyl, or R13 may form, together with R12, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R12 and R13, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may 40 optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group or a C1-C4 alkoxycarbonyl group, R14 is Ci-Ce alkyl, C1-C6 haloalkyl, Ci-Ce alkoxy, phenyl or phenyl substituted with (Z)m, each of R14a and R14b is independently Ci-Ce alkyl, Ci-Ce haloalkyl or Ci-Ce 45 alkoxy, R15 is a hydrogen atom, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci- C4)alkyl, hydroxy(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 haloalkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 haloalkylthio(Ci-C4)alkyl, C1-C4 alkylamino(Ci12 C4)alkyl, di(Ci-C4 alkyl)amino(Ci-C4)alkyl, cyano(Ci-C4)alkyl, C1-C4 alkoxycarbonyl(Ci- C4)alkyl, C1-C4 haloalkoxycarbonyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl substituted with (Z)m, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 alkylcarbonyl, phenylcarbonyl, phenylcarbonyl substituted with 5 (Z)m, C1-C6 alkoxycarbonyl, C1-C6 haloalkoxycarbonyl, di(Ci-C6 alkyl)aminocarbonyl, Ci- Ce alkylsulfonyl, phenylsulfonyl, phenylsulfonyl substituted with (Z)m, di(Ci-Ce alkyl)aminosulfonyl, phenyl, phenyl substituted with (Z)m, or C1-C6 alkoxy, and further, when R15 and Z are neighboring, the neighboring R15 and Z may form -CH2CH2CH2CH2-, -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH- 10 N=CH- or -CH=CH-CH=N- to form a 6-membered ring together with the atoms respectively attached to R15 and Z, wherein hydrogen atoms on the respective ringconstituting carbon atoms may optionally be substituted with a halogen atom, a methyl group or a trifluoromethyl group, R16 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl, C3-C6 15 halocycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, - C(0)R10, -C(0)C(0)R11, -C(0)OR11, -C(0)C(0)OR11, -C(0)SR11, -C(0)N(R13)R12, - C(S)OR11, -C(S)SR11, -C(S)N(R13)R12, -S(0)2R11, -S(0)2N(R13)R12, phenyl, phenyl substituted with (Z)m or D-3, R16a is a hydrogen atom, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 20 alkylcarbonyl, C1-C6 haloalkylcarbonyl, C1-C6 alkoxycarbonyl, C1-C6 haloalkoxycarbonyl, C1-C6 alkylsulfonyl or C1-C6 haloalkylsulfonyl, R17 is a halogen atom, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, hydroxy(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4) alkyl, C1-C4 alkoxycarbonyl(Ci-C4)alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, di(Ci-C6 alkyl)amino, C1-C6 alkoxycarbonyl, phenyl or 25 phenyl substituted with (Z)m, when p is an integer of at least 2, the respective R17's may be identical with or different from one another, and further, when two R17's are on the same carbon atom, the two R17's together may form C1-C4 alkylidene, oxo, thioxo, imino, C1-C4 alkylimino or C1-C4 alkoxyimino, 30 R18 is a halogen atom, cyano, nitro, C3-C10 cycloalkyl, C3-C10 halocycloalkyl, E-1 to E-22, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, -OR29, -N(R30)R29, -SH, -S(0)rR31, - S(0)t(R31)=NR16a, -C(0)R32, -C(R32)=NOH, -C(R32)=NOR33, -C(0)OH, -C(0)OR33, - C(0)SR33, -C^NCR^R3 4 , -C(0)C(0)OR33, -C(S)OR33, -C(S)SR33, -C(S)N(R35)R34, - S(0)2OH, -S(0)2OR33, -S(0)2N(R35)R34, -Si(R14a)(R14b)R14, M-1 to M-30, phenyl, phenyl 35 substituted with (Z)m or D-1 to D-38, M-1 to M-30 are partial saturated heterocyclic rings represented by the following structural formulae, respectively: R19 is a halogen atom, cyano, nitro, C3-C8 cycloalkyi, E-5, E-6, E-14, E-15, C5-C10 cycloalkenyl, -OR36, -S(0)rR37, -C(R32)=NOH, -C(R32)=NOR33, M-3, -C(0)OR33, - C(0)SR33, -C(0)NH2, M-7, M-17, -C(0)C(0)OR33, -C(S)OR33, -C(S)SR33, -C(S)NH2, M14 9, M-19, -S(0)2N(R35)R34 or-Si(R14a)(R14b)R14, R20 is a hydrogen atom, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C6 alkynyl or C2-C6 haloalkynyl, 5 R21 is Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, Cs-Cs cycloalkyl, C3- Cs halocycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl or C3-C6 haloalkynyl, R22 is a hydrogen atom, C1-C6 alkyl, (Ci-C6)alkyl optionally substituted with R28, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C3-C6 alkynyl, 10 C3-C6 haloalkynyl, C1-C6 alkylcarbonyl, C1-C6 haloalkylcarbonyl, phenylcarbonyl, C1-C6 alkoxycarbonyl, phenyl, phenyl substituted with (Z)m, D-1 to D-25 or D-27 to D-38, or may form the after-mentioned ring together with R23, R23 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, 15 cyano(Ci-C4)alkyl, C3-C6 alkenyl or C3-C6 alkynyl, or R23 may form, together with R22, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R22 and R23, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy 20 group, a -CHO group, a C1-C4 alkylcarbonyl group or a C1-C4 alkoxycarbonyl group, R24 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C8 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, - S(0)2R33 or -S(0)2N(R35)R34, or may form the after-mentioned ring together with R25, R25 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 alkenyl, C3-C6 25 haloalkenyl, C3-C6 alkynyl or C3-C6 haloalkynyl, or R25 may form, together with R24, a C4-C5 alkylene chain to form a 5- to 6- membered ring together with the nitrogen atom attached to R24 and R25, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl 30 group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, an oxo group or a thioxo group, R24a is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, phenyl or phenyl substituted with (Z)m, or may form the after-mentioned ring together with R25a, R25a is a hydrogen atom, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio or di(Ci-C6 35 alkyl)amino, or R25a may form, together with R24a, a C3-C5 alkylene chain to form a 4- to 6- membered ring together with the carbon atom attached to R24a and R25a, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl 40 group, a -CHO group, a C1-C4 alkylcarbonyl group or a C1-C4 alkoxycarbonyl group, R26 is C1-C12 alkyl, C1-C12 haloalkyl, C1-C12 alkoxy(Ci-Ci2)alkyl, cyano(Ci- Ci2)alkyl, C1-C12 alkoxycarbonyl(Ci-Ci2)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl substituted with (Z)m, C3-C12 alkenyl, C3-C12 haloalkenyl, C3-C12 alkynyl, C3-C12 haloalkynyl, C1-C12 alkylcarbonyl, C1-C12 alkoxycarbonyl, -C(0)ON=C(CH3)SCH3, - 45 C(0)ON=C(SCH3)C(0)N(CH3)2, phenyl or phenyl substituted with (Z)m, or may form the after-mentioned ring together with R27, R27 is C1-C12 alkyl, C1-C12 haloalkyl, C1-C12 alkoxy(Ci-Ci2 alkyl), cyano(Ci-Ci2) alkyl, C1-C12 alkoxycarbonyl(Ci-Ci2)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl 15 substituted with (Z)m, C3-C12 alkenyl, C3-C12 haloalkenyl, C3-C12 alkynyl, C3-C12 haloalkynyl, phenyl or phenyl substituted with (Z)m, or R27 may form, together with R26, a C4-C7 alkylene chain to form a 5- to 8- membered ring together with the nitrogen atom attached to R26 and R27, wherein the 5 alkylene chain may contain an oxygen atom or sulfur atom, and may optionally be substituted with a C1-C4 alkyl group or a C1-C4 alkoxy group, R28 is a halogen atom, cyano, nitro, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C1-C6 alkoxy, Ci-Ce haloalkoxy, Ci-Ce alkylthio, Ci-Ce haloalkylthio, Ci-Ce alkylsulfinyl, Ci-Ce haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, di(Ci-C6 10 alkyl)amino, C1-C6 alkoxycarbonyl, C1-C6 haloalkoxycarbonyl, -C(0)NH2, C1-C6 alkylaminocarbonyl, di(Ci-C6 alkyl)aminocarbonyl, -C(S)NH2, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R29 is a hydrogen atom, C-i-Cs alkyl, (Ci-Cs)alkyl optionally substituted with R38, C3-C8 cycloalkyl, (Cs-Csjcycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 15 to E-21, C3-C8 alkenyl, (C3-Cs)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3- Cs)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR4°, - C(0)C(0)OR4°, -C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR4°, - C(S)N(R42)R41, -S(0)2R4°, -S(0)2N(R42)R41, -Si(R14a)(R14b)R14, -P(0)(OR43)2, - P(S)(OR43)2, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D-6, D-8 to D-10, D- 20 12 to D-19, D-21, D-23, D-25, D-27 or D-30 to D-38, or may form the after-mentioned ring together with R30, R30 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C4 cycloalkyl(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, cyano(Ci-C4)alkyl, Cs-Ce cycloalkyl, C3-C6 alkenyl, C3-C6 alkynyl, Ci-Ce haloalkylcarbonyl, Ci-Ce alkoxycarbonyl, 25 C1-C6 alkoxy, C1-C6 alkylsulfonyl, phenyl or phenyl substituted with (Z)m, or R30 may form, together with R29, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R29 and R30, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl 30 group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a phenyl group, a phenyl group substituted with (Z)m, an oxo group or a thioxo group, R31 is Ci-Ce alkyl, (Ci-Cs)alkyl optionally substituted with R38, Cs-Cs cycloalkyl, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C3-C8 35 alkenyl, (C3-Cs)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-Cs)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR4°, -C(0)C(0)OR4°, - C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR40, -C(S)N(R42)R41, -SH, Ci-Ce alkylthio, Ci-Ce haloalkylthio, phenylthio, phenylthio substituted with (Z)m, -P(0)(OR43)2, -P(S)(OR43)2, phenyl, phenyl substituted with (Z)m, D-9, D-10, D-12, D-14 to D-17, D-30 40 or D-32 to D-35, R32 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, Ci-Ce alkoxy(Ci-C4)alkyl, Ci-Ce haloalkoxy(Ci-C4)alkyl, Ci-Ce alkylthio(Ci-C4)alkyl, Ci- Ce haloalkylthio(Ci-C4)alkyl, Ci-Ce alkylsulfonyl(Ci-C4)alkyl, Ci-Ce haloalkylsulfonyl(Ci- C4)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl substituted with (Z)m, C3-C6 cycloalkyl, 45 phenyl or phenyl substituted with (Z)m, R33 is Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R38, Cs-Cs cycloalkyl, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C2-C6 alkenyl, (C2-Ce)alkenyl optionally substituted with R38, C3-C6 alkynyl, (C3-Ce)alkynyl 16 optionally substituted with R38, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D- 6, D-8toD-10, D-12toD-19, D-21, D-23, D-25, D-27 or D-30 to D-38, R34 is a hydrogen atom, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R38, Cs-Cs cycloalkyi, (Cs-Csjcycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 5 to E-21, C2-C6 alkenyl, (C2-Ce)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3- C6)alkynyl optionally substituted with R38, phenyl, phenyl substituted with (Z)m, D-1 to D25 or D-27 to D-38, or may form the after-mentioned ring together with R35, R35 is a hydrogen atom, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R38, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, phenyl or phenyl 10 substituted with (Z)m, or R35 may form, together with R34, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the nitrogen atom attached to R34 and R35, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy 15 group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a phenyl group, a phenyl group substituted with (Z)m or an oxo group, R36 is a hydrogen atom, Ci-Cs alkyl, (Ci-Cs)alkyl optionally substituted with R38, Cs-Cs cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C3-C8 alkenyl, (C3-Cs)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3- 20 Cs)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR40, - C(0)C(0)OR4°, -C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR4°, - C(S)N(R42)R41, -S(0)2R4°, -S(0)2N(R42)R41, -Si(R14a)(R14b)R14, -P(0)(OR43)2 or- P(S)(OR43)2, R37 is Ci-Cs alkyl, (Ci-Cs)alkyl optionally substituted with R38, Cs-Cs cycloalkyi, 25 (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, Cs-Cs alkenyl, (C3-Cs)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-Cs)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR40, -C(0)C(0)OR40, - C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR40, -C(S)N(R42)R41, -SH, Ci-Ce alkylthio, Ci-Ce haloalkylthio, phenylthio, phenylthio substituted with (Z)m, -P(0)(OR43)2 30 or -P(S)(OR43)2, R38 is a halogen atom, cyano, nitro, C3-C8 cycloalkyi, C3-C8 halocycloalkyl, E-5, E- 6, E-9, E-10, E-12, E-14, E-15, E-18, E-19, E-21, -OH, -OR40, -OC(0)R39, -OC(0)OR40, -OC(0)N(R42)R41, -OC(S)N(R42)R41, -SH, -S(0)rR4°, -SC(0)R39, -SC(0)OR40, - SC(0)N(R42)R41, -SC(S)N(R42)R41, -N(R42)R41, -N(R42)C(0)R39, -N(R42)C(0)OR40, - 35 N(R42)C(0)SR40, -N(R42)C(0)N(R42)R41, -N(R42)C(S)N(R42)R41, -N(R42)S(0)2R4°, - C(0)R39, -C(0)OH, -C(0)OR40, -C(0)SR40, -C(0)N(R42)R41, -C(0)C(0)OR40, -C(S)SR40, -C(S)N(R42)R41, -Si(R14a)(R14b)R14, -P(0)(OR43)2, -P(S)(OR43)2, -P(phenyl)2, - P(0)(phenyl)2, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R39 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, (Ci-C4)alkyl optionally 40 substituted with R44, C3-C6 cycloalkyi, C3-C6 halocycloalkyl, E-5, E-6, E-14, E-15, C2-C8 alkenyl, C2-C8 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R40 is Ci-Ce alkyl, Ci-Ce haloalkyl, (Ci-C4)alkyl optionally substituted with R44, C3- Ce cycloalkyi, E-5, E-6, C2-C8 alkenyl, C2-C8 haloalkenyl, C3-C8 alkynyl or phenyl, 45 R41 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, (Ci-C4)alkyl optionally substituted with R44, C3-C6 cycloalkyi, E-5, E-6, E-14, C2-C8 alkenyl, C2-C8 haloalkenyl, C3-C8 alkynyl, phenyl, phenyl substituted with (Z)m, D-1 to D-25 or D-27 to D-38, or may form the after-mentioned ring together with R42, 17 R42 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C8 cycloalkyl, C3-C6 alkenyl or C3-C6 alkynyl, or R42 may form, together with R41, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the nitrogen atom attached to R41 and R42, wherein the 5 alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a phenyl group or a phenyl group substituted with (Z)m, R43 is Ci-Ce alkyl or Ci-Ce haloalkyl, 10 R44 is cyano, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, E-5, E-6, E-14, E-15, C1-C4 alkoxy, C1-C4 haloalkoxy, phenoxy, phenoxy substituted with (Z)m, C1-C4 alkylthio, C1-C4 haloalkylthio, phenylthio, phenylthio substituted with (Z)m, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, phenylsulfonyl, phenylsulfonyl substituted with (Z)m, -N(R46)R45, C1-C4 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkoxycarbonyl, C1-C4 alkylaminocarbonyl, 15 di(Ci-C4 alkyl)aminocarbonyl, tri(Ci-C4 alkyl)silyl, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R45 is a hydrogen atom, C1-C4 alkyl, C1-C4 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkoxycarbonyl, phenylcarbonyl or phenylcarbonyl substituted with (Z)m, R46 is a hydrogen atom or C1-C4 alkyl, 20 m is an integer of 1, 2, 3, 4 or 5, n is an integer of 0, 1, 2, 3 or 4, p is an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, r is an integer of 0, 1 or 2, and t is an integer of 0 or 1. 25 Further, the present invention relates to all stereoisomers thereof, its intermediate, and a pesticide containing it as an active ingredient. ADVANTAGEOUS EFFECTS OF INVENTION The compound of the present invention represented by the formula (I) and the 30 pesticide containing the compound as an active ingredient have excellent controlling effect on pests, especially fungi and nematodes in agricultural fields or zootechnical/hygienic fields, and have sufficient controlling effect on pests which have acquired resistance to conventional pesticides. Further, they have little harmful effect on non-target organisms such as plants, mammals, fishes, useful insects and natural 35 enemies, show low persistence and are environmentally friendly. Thus, the present invention can provide useful novel pesticides. DESCRIPTION OF EMBODIMENT(S) The oxime-substituted amide compounds of the present invention represented by 40 the formula (I) can have geometrical isomers such as E-isomers and Z-isomers, and the present invention covers both E-isomers and Z-isomers and mixtures containing them in any ratios. The compounds of the present invention can have optically active isomers due to the presence of one or more asymmetric carbon atoms depending on the types of substituents in them, and the present invention covers any optically active isomers 45 and any racemates. As a halogen atom herein, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom may be mentioned. Herein, the expression "halo" also means such a halogen atom. 18 In the specific description of the substituents herein, the expression "n-" denotes "normal", V "iso", "s-" "secondary", "tert-" "tertiary", and "Ph" "phenyl". The expression "Ca-Cb alkyl" herein means a linear or branched hydrocarbon group containing from a to b carbon atoms such as a methyl group, an ethyl group, a n- 5 propyl group, an i-propyl group, a n-butyl group, an i-butyl group, a s-butyl group, a tertbutyl group, a pentyl group, a 1 -ethylpropyl group, a 2,2-dimethylpropyl group or a hexyl group, and those within the designated carbon number range are selected. The expression "Ca-Cb haloalkyl" herein means a linear or branched hydrocarbon group containing from a to b carbon atoms in which hydrogen atom(s) on carbon 10 atom(s) are optionally substituted with halogen atom(s) which may be identical with or different from one another if two or more halogen atoms are present, such as a fluoromethyl group, a chloromethyl group, a bromomethyl group, an iodomethyl group, a difluoromethyl group, a dichloromethyl group, a trifluoromethyl group, a chlorodifluoromethyl group, a trichloromethyl group, a bromodifluoromethyl group, a 1- 15 fluoroethyl group, a 2-fluoroethyl group, a 2-chloroethyl group, a 2-bromoethyl group, a 2,2-difluoroethyl group, a 2,2,2-trifluoroethyl group, a 2-chloro-2,2-difluoroethyl group, a 2,2,2-trichloroethyl group, a 2-bromo-2,2-difluoroethyl group, a 1,1,2,2-tetrafluoroethyl group, a 2-chloro-1,1,2-trifluoroethyl group, a pentafluoroethyl group, a 2,2- difluoropropyl group, a 3,3,3-trifluoropropyl group, a 3-bromo-3,3-difluoropropyl group, a 20 2,2,3,3-tetrafluoropropyl group, a 2,2,3,3,3-pentafluoropropyl group, a 1,1,2,3,3,3- hexafluoropropyl group, a heptafluoropropyl group, a 2,2,2-trifluoro-1-(methyl)ethyl group, a2,2,2-trifluoro-1-(trifluoromethyl)ethyl group, a 1,2,2,2-tetrafluoro-1- (trifluoromethyl)ethyl group, a 2,2,3,4,4,4-hexafluorobutyl group, a 2,2,3,3,4,4,4- heptafluorobutyl group or a nonafluorobutyl group, and those within the designated 25 carbon number range are selected. The expression "Ca-Cb cycloalkyl" herein means a cyclic hydrocarbon group containing from a to b carbon atoms in the form of a 3- to 10-membered monocyclic or polycyclic ring which may optionally be substituted with an alkyl group as long as the number of carbon atoms does not exceed the designated carbon number range, such 30 as a cyclopropyl group, a 1 -methylcyclopropyl group, a 2-methylcyclopropyl group, a 2,2-dimethylcyclopropyl group, a cyclobutyl group, a cyclopentyl group or a cyclohexyl group, and those within the designated carbon number range are selected. The expression "Ca-Cb halocycloalkyl" herein means a cyclic hydrocarbon group containing from a to b carbon atoms in the form of a 3- to 10-membered monocyclic or 35 polycyclic ring which may optionally be substituted with an alkyl group as long as the number of carbon atoms does not exceed the designated carbon number range, in which hydrogen atom(s) on carbon atom(s) in a ring moiety and/or in a side chain are optionally substituted with halogen atom(s) which may be identical with or different from one another if two or more halogen atoms are present, such as a 2,2-difluorocyclopropyl 40 group, a 2,2-dichlorocyclopropyl group, a 2,2-dibromocyclopropyl group, a 2,2-difluoro- 1-methylcyclopropyl group, a 2,2-dichloro-1-methylcyclopropyl group, a 2,2-dibromo-1- methylcyclopropyl group or a 2,2,3,3-tetrafluorocyclobutyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkenyl" herein means a linear or branched unsaturated 45 hydrocarbon group containing from a to b carbon atoms and having one or more double bonds in the molecule such as a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-methylethenyl group, a 1-butenyl group, a 2-butenyl group, a 1-methyl-1-propenyl group, a 2-methyl-1-propenyl group, a 2-methyl-2-propenyl group or a 3-methyl-2- 19 butenyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb haloalkenyl" herein means a linear or branched unsaturated hydrocarbon group containing from a to b carbon atoms and having one or more double bonds in the molecule, in which hydrogen atom(s) on carbon atom(s) are 5 optionally substituted with halogen atom(s) which may be identical with or different from one another if two or more halogen atoms are present, such as a 2-fluorovinyl group, a 2-chlorovinyl group, a 1,2-dichlorovinyl group, a 2,2-dichlorovinyl group, a 2-fluoro-2- propenyl group, a 2-chloro-2-propenyl group, a 3-chloro-2-propenyl group, a 3,3- difluoro-2-propenyl group, a 2,3-dichloro-2-propenyl group, a 3,3-dichloro-2-propenyl 10 group, a 2,3,3-trifluoro-2-propenyl group, a 2,3,3-trichloro-2-propenyl group, a 1- (trifluoromethyl)ethenyl group, a 4,4-difluoro-3-butenyl group, a 3,4,4-trifluoro-3-butenyl group, a 2,4,4,4-tetrafluoro-2-butenyl group or a 3-chloro-4,4,4-trifluoro-2-butenyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb cycloalkenyl" herein means a cyclic unsaturated 15 hydrocarbon group containing from a to b carbon atoms and containing one or more endo- or exo-double bonds in the form of a 3- to 10-membered monocyclic or polycyclic ring which may optionally be substituted with an alkyl group as long as the number of carbon atoms does not exceed the designated carbon number range, such as a 1- cyclopentenyl group, a 2-cyclopentenyl group, a 1-cyclohexenyl group, a 2-cyclohexenyl 20 group or a bicyclo[2.2.1 ]-5-hepten-2-yl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb halocycloalkenyl" herein means a cyclic unsaturated hydrocarbon group containing from a to b carbon atoms and containing one or more endo- or exo-double bonds in the form of a 3- to 10-membered monocyclic or polycyclic 25 ring which may optionally be substituted with an alkyl group as long as the number of carbon atoms does not exceed the designated carbon number range, in which hydrogen atom(s) on carbon atom(s) in the ring moiety and/or in the side chain are optionally substituted with halogen atom(s) which may be identical with or different from one another if two or more halogen atoms are present, such as a 2-fluoro-1-cyclopentenyl 30 group, a 2-chloro-1-cyclopentenyl group, a 3-chloro-2-cyclopentenyl group or a 2-fluoro- 1-cyclohexenyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkylidene" herein means a linear or branched hydrocarbon group containing from a to b carbon atoms which attaches by a double bond, such as a methylidene group, an ethylidene group, a propylidene group or a 1-methylethylidene 35 group, and those within the designated carbon number range are selected. The expression "Ca-Cb alkynyl" herein means a linear or branched unsaturated hydrocarbon group containing from a to b carbon atoms and having one or more triple bonds in the molecule such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a 1-methyl-2-propynyl group, a 40 2-pentynyl group or a 3-hexynyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb haloalkynyl" herein means a linear or branched unsaturated hydrocarbon group containing from a to b carbon atoms and having one or more triple bonds in the molecule, in which hydrogen atom(s) on carbon atom(s) are 45 optionally substituted with halogen atom(s) which may be identical with or different from one another if two or more halogen atoms are present, such as a 2-chloroethynyl group, a 2-bromoethynyl group, a 2-iodoethynyl group, a 3-chloro-2-propynyl group or a 3- bromo-2-propynyl group or a 3-iodo-2-propynyl group, and those within the designated 20 carbon number range are selected. The expression "Ca-Cb alkoxy" herein means an alkyl-O- group in which the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as a methoxy group, an ethoxy group, a n-propyloxy group, an i-propyloxy group, a n- 5 butyloxy group, an i-butyloxy group, a s-butyloxy group, a tert-butyloxy group, a pentyloxy group or a hexyloxy group, and those within the designated carbon atom range are selected. The expression "Ca-Cb haloalkoxy" herein means a haloalkyl-O- group in which the haloalkyl is a previously mentioned haloalkyl group containing from a to b carbon atoms, 10 such as a difluoromethoxy group, a trifluoromethoxy group, a chlorodifluoromethoxy group, a bromodifluoromethoxy group, a 2-fluoroethoxy group, a 2-chloroethoxy group, a 2,2,2-trifluoroethoxy group, a 1,1,2,2,-tetrafluoroethoxy group, a 2-chloro-1,1,2- trifluoroethoxy group or a 1,1,2,3,3,3-hexafluoropropyloxy group, and those within the designated carbon atom range are selected. 15 The expression "Ca-Cb alkenyloxy" herein means an alkenyl-O- group in which the alkenyl is a previously mentioned alkenyl group containing from a to b carbon atoms, such as a 2-propenyloxy group, a 2-butenyloxy group, a 2-methyl-2-propenyloxy group or a 3-methyl-2-butenyloxy group, and those within the designated carbon atom range are selected. 20 The expression "Ca-Cb alkylthio" herein means an alkyl-S- group in which the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as a methylthio group, an ethylthio group, a n-propylthio group, an i-propylthio group, a nbutylthio group, an i-butylthio group, a s-butylthio group or a tert-butylthio group, and those within the designated carbon atom range are selected. 25 The expression "Ca-Cb haloalkylthio" herein means a haloalkyl-S- group in which the haloalkyl is a previously mentioned haloalkyl group containing from a to b carbon atoms, such as a difluoromethylthio group, a trifluoromethylthio group, a chlorodifluoromethylthio group, a bromodifluoromethylthio group, a 2,2,2- trifluoroethylthio group, a 1,1,2,2-tetrafluoroethylthio group, a 2-chloro-1,1,2- 30 trifluoroethylthio group, a pentafluoroethylthio group, a 1,1,2,3,3,3-hexafluoropropylthio group, a heptafluoropropylthio group, a 1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethylthio group or a nonafluorobutylthio group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkylsulfinyl" herein means an alkyl-S(O)- group in which 35 the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as a methylsulfinyl group, an ethylsulfinyl group, a n-propylsulfinyl group, an ipropylsulfinyl group, a n-butylsulfinyl group, an i-butylsulfinyl group, a s-butylsulfinyl group or a tert-butylsulfinyl group, and those within the designated carbon atom range are selected. 40 The expression "Ca-Cb haloalkylsulfinyl" herein means a haloalkyl-S(O)- group in which the haloalkyl is a previously mentioned haloalkyl group containing from a to b carbon atoms, such as a difluoromethylsulfinyl group, a trifluoromethylsulfinyl group, a chlorodifluoromethylsulfinyl group, a bromodifluoromethylsulfinyl group, a 2,2,2- trifluoroethylsulfinyl group or a nonafluorobutylsulfinyl group, and those within the 45 designated carbon atom range are selected. The expression "Ca-Cb alkylsulfonyl" herein means an alkyl-S(0)2- group in which the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as a methylsulfonyl group, an ethylsulfonyl group, a n-propylsulfonyl group, an i21 propylsulfonyl group, a n-butylsulfonyl group, an i-butylsulfonyl group, a s-butylsulfonyl group or a tert-butylsulfonyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb haloalkylsulfonyl" herein means a haloalkyl-S(0)2- group in 5 which the haloalkyl is a previously mentioned haloalkyl group containing from a to b carbon atoms, such as a difluoromethylsulfonyl group, a trifluoromethylsulfonyl group, a chlorodifluoromethylsulfonyl group, a bromodifluoromethylsulfonyl group, a 2,2,2- trifluoroethylsulfonyl group, a 1,1,2,2-tetrafluoroethylsulfonyl group or a 2-chloro-1,1,2- trifluoroethylsulfonyl group, and those within the designated carbon atom range are 10 selected. The expression "Ca-Cb alkylamino" herein means an amino group in which either hydrogen atom is replaced by a previously mentioned alkyl group containing from a to b carbon atoms, such as a methylamino group, an ethylamino group, a n-propylamino group, an i-propylamino group, a n-butylamino group, an i-butylamino group or a tert- 15 butylamino group, and those within the designated carbon atom range are selected. The expression "di(Ca-Cb alkyl)amino" herein means an amino group in which both hydrogen atoms are replaced by previously mentioned alkyl groups containing from a to b carbon atoms which may be identical with or different from each other, such as a dimethylamino group, an ethyl(methyl)amino group, a diethylamino group, a di(n- 20 propyl)amino group or a di(n-butyl)amino group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkylimino" herein means an alkyl-N= group in which the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as a methylimino group, an ethylimino group, a n-propylimino group, an i-propylimino group, 25 a n-butylimino group, an i-butylimino group or a s-butylimino group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkoxyimino" herein means an alkoxy-N= group in which the alkoxy is a previously mentioned alkoxy group containing from a to b carbon atoms, such as a methoxyimino group, an ethoxyimino group, a n-propyloxyimino group, an i- 30 propyloxyimino group or a n-butyloxyimino group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkylcarbonyl" herein means an alkyl-C(O)- group in which the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a 35 valeryl group, an isovaleryl group, a 2-methylbutanoyl group or a pivaloyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb haloalkylcarbonyl" herein means a haloalkyl-C(O)- group in which the haloalkyl is a previously mentioned haloalkyl group containing from a to b carbon atoms, such as a fluoroacetyl group, a chloroacetyl group, a difluoroacetyl group, 40 a dichloroacetyl group, a trifluoroacetyl group, a chlorodifluoroacetyl group, a bromodifluoroacetyl group, a trichloroacetyl group, a pentafluoropropionyl group, a heptafluorobutanoyl group or a 3-chloro-2,2-dimethylpropanoyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb cycloalkylcarbonyl" herein means a cycloalkyl-C(O)- group 45 in which the cycloalkyi is a previously mentioned cycloalkyi group containing from a to b carbon atoms, such as a cyclopropylcarbonyl group, a cyclobutylcarbonyl group, a cyclopentylcarbonyl group, a 2,2-dimethylcyclopropylcarbonyl group or a cyclohexylcarbonyl group, and those within the designated carbon atom range are 22 selected. The expression "Ca-Cb alkoxycarbonyl" herein means an alkyl-O-C(O)- group in which the alkyl is a previously mentioned alkyl group containing from a to b carbon atoms, such as a methoxycarbonyl group, an ethoxycarbonyl group, a n- 5 propyloxycarbonyl group, an i-propyloxycarbonyl group, a n-butoxycarbonyl group, an ibutoxycarbonyl group or a tert-butoxycarbonyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb haloalkoxycarbonyl" herein means a haloalkyl-O-C(O)- group in which the haloalkyl is a previously mentioned haloalkyl group containing from a 10 to b carbon atoms, such as a chloromethoxycarbonyl group, a 2-chloroethoxycarbonyl group, a 2,2-difluoroethoxycarbonyl group, a 2,2,2-trifluoroethoxycarbonyl group or a 2,2,2-trichloroethoxycarbonyl group, and those within the designated carbon atom range are selected. The expression "Ca-Cb alkylaminocarbonyl" herein means a carbamoyl group in 15 which either hydrogen atom is replaced by a previously mentioned alkyl group containing from a to b carbon atoms, such as a methylcarbamoyl group, an ethylcarbamoyl group, a n-propylcarbamoyl group, an i-propylcarbamoyl group, a nbutylcarbamoyl group, an i-butylcarbamoyl group, a s-butylcarbamoyl group or a tertbutylcarbamoyl group, and those within the designated carbon atom range are selected. 20 The expression "Ca-Cb haloalkylaminocarbonyl" herein means a carbamoyl group in which either hydrogen atom is replaced by a previously mentioned haloalkyl group containing from a to b carbon atoms, such as a 2-fluoroethylcarbamoyl group, a 2- chloroethylcarbamoyl group, a 2,2-difluoroethylcarbamoyl group or a 2,2,2- trifluoroethylcarbamoyl group, and those within the designated carbon atom range are 25 selected. The expression "di(Ca-Cb alkyl)aminocarbonyl" herein means a carbamoyl group in which both hydrogen atoms are replaced by previously mentioned alkyl groups containing from a to b carbon atoms which may be identical with or different from each other, such as an N,N-dimethylcarbamoyl group, an N-ethyl-N-methylcarbamoyl group, 30 an N,N-diethylcarbamoyl group, an N,N-di(n-propyl)carbamoyl group or an N,N-di(nbutyl) carbamoyl group, and those within the designated carbon atom range are selected. The expression "di(Ca-Cb alkyl)aminosulfonyl" herein means a sulfamoyl group in which both hydrogen atoms are replaced by previously mentioned alkyl groups containing from a to b carbon atoms which may be identical with or different from each 35 other, such as an N,N-dimethylsulfamoyl group, an N-ethyl-N-methylsulfamoyl group, an N,N-diethylsulfamoyl group, an N,N-di(n-propyl)sulfamoyl group or an N,N-di(nbutyl) sulfamoyl group, and those within the designated carbon atom range are selected. The expression "tri(Ca-Cb alkyl)silyl" herein means a silyl group replaced by previously mentioned alkyl groups containing from a to b carbon atoms which may be 40 identical with or different from one another, such as a trimethylsilyl group, a triethylsilyl group, a tri(n-propyl)silyl group, an ethyldimethylsilyl group, a n-propyldimethylsilyl group, a n-butyldimethylsilyl group, an i-butyldimethylsilyl group or a tertbutyldimethylsilyl group, and those within the designated carbon atom range are selected. 45 The expression "Ca-Cb alkylsulfonyloxy" herein means an alkylsulfonyl-O- group in which the alkylsulfonyl is a previously mentioned alkylsulfonyl group containing from a to b carbon atoms, such as a methylsulfonyloxy group, an ethylsulfonyloxy group, a npropylsulfonyloxy group or an i-propylsulfonyloxy group, and those within the 23 designated carbon atom range are selected. The expression "Ca-Cb haloalkylsulfonyloxy" herein means a haloalkylsulfonyl-Ogroup in which the haloalkylsulfonyl is a previously mentioned haloalkylsulfonyl group containing from a to b carbon atoms, such as a difluoromethylsulfonyloxy group, a 5 trifluoromethylsulfonyloxy group, a chlorodifluoromethylsulfonyloxy group or a bromodifluoromethylsulfonyloxy group, and those within the designated carbon atom range are selected. The expression such as "Ca-Cb cycloalkyl(Cd-Ce)alkyl", "hydroxy(Cd-Ce)alkyl", "Ca- Cb alkoxy(Cd-Ce)alkyl", "Ca-Cb haloalkoxy(Cd-Ce)alkyl", "Ca-Cb alkylthio(Cd-Ce)alkyl", "Ca- 1 o Cb haloalkylthio(Cd-Ce)alkyl", "Ca-Cb alkylsulfinyl(Cd-Ce)alkyl", "Ca-Cb haloalkylsulfinyl(Cd-Ce)alkyl", "Ca-Cb alkylsulfonyl(Cd-Ce)alkyl", "Ca-Cb haloalkylsulfonyl(Cd-Ce)alkyl", "Ca-Cb alkylamino(Cd-Ce)alkyl", "di(Ca-Cb alkyl)amino(Cd- Ce)alkyl", "cyano(Cd-Ce)alkyl", "Ca-Cb alkoxycarbonyl(Cd-Ce)alkyl", "Ca-Cb haloalkoxycarbonyl(Cd-Ce)alkyl", "phenyl(Cd-Ce)alkyl" or "phenyl(Cd-Ce)alkyl substituted 15 with (Z)m" herein means a previously mentioned alkyl group containing from d to e carbon atoms in which hydrogen atom(s) on carbon atom(s) are optionally substituted with previously mentioned optional Ca-Cb cycloalkyl group, Ca-Cb alkoxy group, Ca-Cb haloalkoxy group, Ca-Cb alkylthio group, Ca-Cb haloalkylthio group, Ca-Cb alkylsulfinyl group, Ca-Cb haloalkylsulfinyl group, Ca-Cb alkylsulfonyl group, Ca-Cb haloalkylsulfonyl 20 group, Ca-Cb alkylamino group, di(Ca-Cb alkyl)amino group, Ca-Cb alkoxycarbonyl group, Ca-Cb haloalkoxycarbonyl group, hydroxy group, cyano group, phenyl group or phenyl group substituted with (Z)m, and those within the designated carbon atom range are selected. The expression such as "hydroxy(Cd-Ce)cycloalkyl" or "Ca-Cb alkoxy(Cd- 25 Ce)cycloalkyl" herein means a previously mentioned cycloalkyl group containing from d to e carbon atoms in which hydrogen atom(s) on carbon atom(s) are optionally substituted with previously mentioned optional Ca-Cb alkoxy group(s) or hydroxy group(s), and those within the designated carbon atom range are selected. The expression "phenyl(Ca-Cb)alkynyl" herein means a previously mentioned 30 alkynyl group containing from a to b carbon atoms in which hydrogen atom(s) on carbon atom(s) are optionally substituted with phenyl group(s), and those within the designated carbon atom range are selected. The expression such as "(Ca-Cb) alkyl optionally substituted with R6", "(Ca-Cb) alkyl optionally substituted with R18", "(Ca-Cb) alkyl optionally substituted with R19", "(Ca-Cb) 35 alkyl optionally substituted with R28", "(Ca-Cb) alkyl optionally substituted with R38" or "(Ca-Cb) alkyl optionally substituted with R44" herein means a previously mentioned alkyl group containing from a to b carbon atoms in which hydrogen atom(s) on carbon atom(s) are optionally substituted with optional R6, R18, R19, R28, R38 or R44, and those within the designated carbon atom range are selected. When there are two or more 40 R6's, R18's, R19's, R28's, R38's or R^'s on a (Ca-Cb) alkyl group, each R6, R18, R19, R28, R38 or R44 may be identical with or different from one another. The expression such as "(Ca-Cb) cycloalkyl optionally substituted with R6", "(Ca-Cb) cycloalkyl optionally substituted with R28" or "(Ca-Cb) cycloalkyl optionally substituted with R38" herein means a previously mentioned cycloalkyl group containing from a to b 45 carbon atoms in which hydrogen atom(s) on carbon atom(s) in the ring moiety and/or in the side chain are optionally substituted with optional R6, R28 or R38, and those within the designated carbon atom range are selected. When there are two or more R6's, R28's or R38's on a (Ca-Cb) cycloalkyl group, each R6, R28 or R38 may be identical with or 24 different from one another. The expression such as "(Ca-Cb) alkenyl optionally substituted with R6", "(Ca-Cb) alkenyl optionally substituted with R28" or "(Ca-Cb) alkenyl optionally substituted with R38" herein means a previously mentioned alkenyl group containing from a to b carbon 5 atoms in which hydrogen atom(s) on carbon atom(s) are optionally substituted with optional R6, R28 or R38, and those within the designated carbon atom range are selected. When there are two or more R6's, R28's or R38's on a (Ca-Cb) alkenyl group, each R6, R28 or R38 may be identical with or different from one another. The expression such as "(Ca-Cb) alkynyl optionally substituted with R6", "(Ca-Cb) 10 alkynyl optionally substituted with R28" or "(Ca-Cb) alkynyl optionally substituted with R38" herein means a previously mentioned alkynyl group containing from a to b carbon atoms in which hydrogen atom(s) on carbon atom(s) are optionally substituted with optional R6, R28 or R38, and those within the designated carbon atom range are selected. When there are two or more R6's, R28's or R38's on a (Ca-Cb) alkynyl group, each R6, R28 15 or R38 may be identical with or different from one another. The expression "R3 may form, together with R2, a C2-C5 alkylene chain to form a 3- to 6-membered ring together with the carbon atom attached to R2 and R3, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom" is specifically exemplified by a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, 20 a tetrahydrofuran ring, a tetrahydrothiophene ring, a pyrrolidine ring, a cyclohexane ring, a tetrahydropyran ring, a tetrahydrothiopyran ring, a piperidine ring, a cycloheptane ring, an oxepane ring, a thiepane ring, an azepane ring or the like, and those within the designated carbon atom range are selected. The expression such as "R9 may form, together with R8, a C2-C6 alkylene chain to 25 form a 3- to 7-membered ring together with the nitrogen atom attached to R8 and R9, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with an oxo group or a thioxo group", "R25 and R24 together may form a C4-C5 alkylene chain to form a 5- to 6-membered ring together with the nitrogen atom attached to R24 and R25, wherein the alkylene chain may contain an 30 oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with an oxo group or a thioxo group", "R30 may form, together with R29, a C2-C6 alkylene chain to form a 3- to 7-membered ring together with the nitrogen atom attached to R29 and R30, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with an oxo group or a thioxo group" or "R35 may form, 35 together with R34, a C2-C5 alkylene chain to form a 3- to 6-membered ring together with the nitrogen atom attached to R34 and R35, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with an oxo group" is specifically exemplified by aziridine, azetidine, azetidin-2-one, pyrrolidine, pyrrolidin-2-one, oxazolidine, oxazolidin-2-one, oxazolidine-2-thione, thiazolidine, 40 thiazolidin-2-one, thiazolidine-2-thione, imidazolidine, imidazolidin-2-one, imidazolidine- 2-thione, piperidine, piperidin-2-one, piperidine-2-thione, 2H-3,4,5,6-tetrahydro-1,3- oxazin-2-one, 2H-3,4,5,6-tetrahydro-1,3-oxazine-2-thione, morpholine, 2H-3,4,5,6- tetrahydro-1,3-thiazin-2-one, 2H-3,4,5,6-tetrahydro-1,3-thiazine-2-thione, thiomorpholine, thiomorpholine-1 -oxide, thiomorpholine-1,1-dioxide, perhydropyrimidin-2-one, 45 piperazine, homopiperidine, homopiperidin-2-one, heptamethyleneimine or the like, and those within the designated carbon atom range are selected. The expression such as "R13 may form, together with R12, a C2-C6 alkylene chain to form a 3- to 7-membered ring together with the nitrogen atom attached to R12 and R13, 25 wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom", "R23 may form, together with R22, a C2-C6 alkylene chain to form a 3- to 7-membered ring together with the nitrogen atom attached to R22 and R23, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom", "R27 may form, together 5 with R26, a C4-C7 alkylene chain to form a 5- to 8-membered ring together with the nitrogen atom attached to R26 and R27, wherein the alkylene chain may contain an oxygen atom or sulfur atom" or "R42 may form, together with R41, a C2-C5 alkylene chain to form a 3- to 6-membered ring together with the nitrogen atom attached to R41 and R42, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom" 10 is specifically exemplified by aziridine, azetidine, pyrrolidine, oxazolidine, thiazolidine, imidazolidine, piperidine, morpholine, thiomorpholine, thiomorpholine-1 -oxide, thiomorpholine-1,1 -dioxide, piperazine, homopiperidine, heptamethyleneimine or the like, and those within the designated carbon atom range are selected. The expression such as "R9a may form, together with R8a, a C4-C6 alkylene chain 15 to form a 5- to 7-membered ring together with the carbon atom attached to R8a and R9a, wherein the alkylene chain may contain an oxygen atom or sulfur atom" or "R25a may form, together with R24a, a C3-C5 alkylene chain to form a 4- to 6-membered ring together with the carbon atom attached to R24a and R25a, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom" is specifically exemplified by 20 cyclopentylidene, tetrahydrofuran-3-ylidene, tetrahydrothiophen-3-ylidene, cyclohexylidene, tetrahydropyran-3-ylidene, tetrahydropyran-4-ylidene, tetrahydrothiopyran-3-ylidene, tetrahydrothiopyran-4-ylidene or the like, and those within the designated carbon atom range are selected. As the preferred range of the substituent represented by G1 in the compounds 25 which fall within the present invention, the following sets may, for example, be mentioned. G1-l: G1-1 [wherein X1 is a bromine atom, an iodine atom, methyl, difluoromethyl or trifluoromethyl, and X2, X3, X4 and X5 are hydrogen atoms]. G1-ll: G1-1 [wherein X1 is a chlorine atom, and X2, X3, X4 and X5 are hydrogen 30 atoms]. G1-lll: G1-2 [wherein X1 is a halogen atom, methyl or trifluoromethyl, and X3, X4 and X5 are hydrogen atoms]. G1-IV: G1-3 [wherein X1 is a halogen atom or trifluoromethyl, and X2, X3 and X4 are hydrogen atoms]. 35 G1-V: G1-7 [wherein X1 is trifluoromethyl, and X3 and X4 are hydrogen atoms]. G1-VI: G1-11 [wherein X1 is a halogen atom, methyl or trifluoromethyl, and X3 and X4 are hydrogen atoms]. G1-VII: G1-12 [wherein X1 is a halogen atom or trifluoromethyl, and X2 and X3 are hydrogen atoms]. 40 G1-VIII: G1-16 [wherein X1 is trifluoromethyl, X2 and X4 are hydrogen atoms, and R5 is methyl]. G1-IX: G1-27 [wherein X1 is difluoromethyl or trifluoromethyl, X2 is a hydrogen atom, and R5 is methyl]. G1-X: G1-33 [wherein X1 is difluoromethyl or trifluoromethyl, and X3 is methyl], 45 G1-XI: G1-1 [wherein X1 is nitro, and X2, X3, X4 and X5 are hydrogen atoms]. G1-XII: G1-1 [wherein X1 is trifluoromethyl, X2 and X3 are hydrogen atoms, X4 is a halogen atom, and X5 is a hydrogen atom]. G1-XIII: G1-9 [wherein X1 is methyl or trifluoromethyl, X2 is a hydrogen atom, and 26 X3 is methyl]. G1-XIV: G1-27 [wherein X1 is a halogen atom or trifluoromethyl, X2 is a halogen atom, and R5 is methyl]. G1-XV: G1-32 [wherein X1 and X3 are methyl]. 5 G1-XVI: G1-50 [wherein X1 is trifluoromethyl, and r is 0]. G1-XVII: G1-1 [wherein X1 is a fluorine atom, cyano, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio or phenyl, and X2, X3, X4 and X5 are hydrogen atoms]. G1-XVIII: G1-1 [wherein X1 is a halogen atom, methyl or trifluoromethyl, X2 is a hydrogen atom or a halogen atom, X3 and X4 are hydrogen atoms, and X5 is a hydrogen 10 atom or a halogen atom]. G1-XIX: G1-2 [wherein X1 is a halogen atom, X3 is a hydrogen atom, X4 is trifluoromethyl, and X5 is a hydrogen atom]. G1-XX: G1-4 [wherein X1 is trifluoromethyl, and X2, X3 and X5 are hydrogen atoms]. 15 G1-XXI: G1-8 [wherein X1 is a halogen atom or methyl, and X3 and X4 are hydrogen atoms]. G1-XXII: G1-9 [wherein X1 is trifluoromethyl, X2 is a hydrogen atom, and X3 is phenyl]. G1-XXIII: G1-13 [wherein X1 is a halogen atom, and X2 and X4 are hydrogen 20 atoms]. G1-XXIV: G1-20 [wherein X1 is trifluoromethyl, and X2 is a hydrogen atom]. G1-XXV: G1-30 [wherein X1 is trifluoromethyl, and X3 is methyl]. G1-XXVI: G1-33 [wherein X1 and X3 are trifluoromethyl]. G1-XXVII: G1-44 [wherein X1 is trifluoromethyl, and R5 is C1-C4 alkyl]. 25 G1-XXVIII: G1-1 [wherein X1 is C1-C4 alkyl, C1-C4 haloalkyl, Ca-Ce cycloalkyl, C1- C4 haloalkylthio, -NH2 or D-3, X2, X3, X4 and X5 are hydrogen atoms, and n is 0]. G1-XXIX: G1-2 [wherein X1 is difluoromethyl, and X3, X4 and X5 are hydrogen atoms]. G1-XXX: G1-3 [wherein X1 is methyl, and X2, X3 and X4 are hydrogen atoms]. 30 G1-XXXI: G1-5 [wherein X1 is trifluoromethyl, and X4 and X5 are hydrogen atoms]. G1-XXXII: G1-7 [wherein X1 is a halogen atom or methyl, and X3 and X4 are hydrogen atoms]. G1-XXXIII: G1-8 [wherein X1 is trifluoromethyl, and X3 and X4 are hydrogen 35 atoms]. G1-XXXIV: G1-9 and G1-12 [wherein X1 is difluoromethyl, and X2 and X3 are hydrogen atoms]. G1-XXXV: G1-10 and G1-13 [wherein X1 is difluoromethyl or trifluoromethyl, and X2 and X4 are hydrogen atoms]. 40 G1-XXXVI: G1-11 [wherein X1 is difluoromethyl, and X3 and X4 are hydrogen atoms]. G1-XXXVII: G1-16 [wherein X1 is difluoromethyl or trifluoromethyl, X2 and X4 are hydrogen atoms, and R5 is C1-C4 alkyl]. G1-XXXVIII: G1-19 and G1-23 [wherein X1 is difluoromethyl or trifluoromethyl, 45 and X2 is a hydrogen atom]. G1-XXXIX: G1-27 [wherein X1 is a halogen atom, C1-C4 alkyl, C2-C4 haloalkyl or C1-C4 alkoxy, X2 is a hydrogen atom, a fluorine atom or a chlorine atom, and R5 is C1-C4 alkyl]. 27 G1-XL: G1-27 [wherein X1 is C1-C4 alkyl or C1-C4 haloalkyi, X2 is a hydrogen atom, and R5 is C1-C4 alkyl, C1-C4 haloalkyi or C3-C6 cycloalkyl]. G1-XLI: G1-31 [wherein X1 is trifluoromethyl, and X3 is a halogen atom or methyl]. G1-XLII: G1-32 [wherein X1 is a halogen atom, difluoromethyl or trifluoromethyl, 5 and X3 is a hydrogen atom or methyl]. G1-XLIII: G1-33 [wherein X1 is a halogen atom, methyl, difluoromethyl or trifluoromethyl, and X3 is a hydrogen atom, a halogen atom, C1-C4 alkyl, C1-C4 haloalkyi, C3-C6 cycloalkyl, C1-C4 alkoxy or -NH2]. G1-XLIV: G1-41 and G1-43 [wherein X1 is trifluoromethyl]. 10 G1-XLV: G1-45, G1-46, G1-49 and G1-51 [wherein X1 is methyl or trifluoromethyl]. G1-XLVI: G1-50 [wherein X1 is methyl or trifluoromethyl, and r is an integer of from 0 to 2]. Among them, as the scope of the substituent represented by G\ more preferred are G1-l to G1-XVI, G1-XXIX, G1-XXX, G1-XXXII to G1-XXXVII and G1-XLII, particularly 15 preferred are G1-l to G1-X. As the preferred range of the substituent represented by G2 in the compounds which fall within the present invention, the following sets may, for example, be mentioned. G2-l: G2-1 [wherein Y1 is a halogen atom, Y2 is a hydrogen atom, Y3 is a halogen 20 atom or methyl, and Y4 and Y5 are hydrogen atoms]. G2-ll: G2-2 [wherein Y1 is a halogen atom, Y2 is a hydrogen atom or a halogen atom, Y3 is a halogen atom, cyano, trifluoromethyl, C1-C4 haloalkoxy, -C(R10)=NOR11, C2-C6 alkynyl, cyclopropylethynyl, trimethylsilylethynyl or phenylethynyl, Y4 is a hydrogen atom or a halogen atom, R10 is methyl, and R11 is methyl or ethyl]. 25 G2-lll: G2-1 [wherein Y1 and Y2 are hydrogen atoms, Y3 is a halogen atom or methyl, and Y4 and Y5 are hydrogen atoms]. G2-IV: G2-1 [wherein Y1 is a hydrogen atom, Y2 and Y3 together may form -CH=CHCH=CH- to form a 6-membered ring together with the carbon atoms attached to Y2 and Y3, and Y4 and Y5 are hydrogen atoms]. 30 G2-V: G2-1 [wherein Y1 is a halogen atom, methyl, trifluoromethyl or methoxy, Y2 is a hydrogen atom or a halogen atom, Y3 is a hydrogen atom, a halogen atom, methyl, trifluoromethyl, C1-C4 alkoxy, -C(R10)=NOR11, C2-C4 alkenyl, phenyl or D-7, Y4 is a hydrogen atom or a halogen atom, Y5 is a hydrogen atom or a halogen atom, Z is trifluoromethyl, R10 is methyl, R11 is methyl or ethyl, and n is 1]. 35 G2-VI: G2-2 [wherein Y1 is a halogen atom, Y2 is a hydrogen atom, Y3 is methyl, C1-C4 alkoxy, C2-C4 alkenyl, (C2-Ce)alkynyl substituted with R6, D-3 or D-7, Y4 is a hydrogen atom, R6 is a halogen atom, C3-C6 cycloalkyl, -OH, trimethylsilyl or phenyl, and n is 0]. G2-VII: G2-2 [wherein Y1 is a halogen atom, Y2 is cyano, Y3 is a halogen atom, 40 and Y4 is a hydrogen atom]. G2-VIII: G2-6 [wherein Y1 and Y3 are halogen atoms, and Y4 is a hydrogen atom]. G2-IX: G2-9 [wherein Y1 is a halogen atom, Y2 is a hydrogen atom or a halogen atom, and Y3 is a halogen atom]. G2-X: G2-10 [wherein Y1 is a halogen atom, Y3 is a hydrogen atom or a halogen 45 atom, and Y4 is a hydrogen atom]. G2-XI: G2-1 [wherein Y1 and Y2 are hydrogen atoms, Y3 is C2-C4 alkyl, C1-C4 haloalkyi, C1-C4 haloalkoxy, phenoxy or phenyl, and Y4 and Y5 are hydrogen atoms]. G2-XII: G2-1 [wherein Y1 is a hydrogen atom, Y2 is a halogen atom or C1-C4 28 alkoxy, Y3 is a hydrogen atom or a halogen atom, Y4 is a hydrogen atom, a halogen atom or trifluoromethyl, and Y5 is a hydrogen atom]. G2-XIII: G2-1 [wherein Y1 is a halogen atom, E-9 or -C(R10)=NOR11, Y2 is a hydrogen atom, or Y2 may form, together with Y1, -CH=CHCH=CH- to form a 6- 5 membered ring together with the carbon atoms attached to Y1 and Y2, Y3 is a hydrogen atom, a halogen atom, cyano, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, - C(0)R10, M-7, phenyl substituted with (Z)m, D-3 or D-7, Y4 is a hydrogen atom or trifluoromethyl, Y5 is a hydrogen atom, Z is trifluoromethoxy, R10 is a hydrogen atom or C1-C4 alkyl, R11 is C1-C4 alkyl, R17 is methyl, m is 1, n is 0, and p is an integer of from 0 10 to 2. G2-XIV: G2-2 [wherein Y1 is a hydrogen atom, a halogen atom, trifluoromethyl or methoxy, Y2 is a hydrogen atom, Y3 is a halogen atom, C1-C4 haloalkyl, C1-C4 alkoxymethyl, -OR7 or D-22, Y4 is a hydrogen atom or methoxy, R7 is phenyl or phenyl substituted with (Z)m, Z is a halogen atom, m is 1, and n is 0]. 15 G2-XV: G2-3 [wherein Y1 is a halogen atom, each of Y3 and Y4 is independently a hydrogen atom or a halogen atom, and Y5 is a hydrogen atom]. G2-XVI: G2-11 [wherein Y1 is a halogen atom, Y2 is C1-C4 alkoxy, and R5 is methyl]. G2-XVII: G2-12 [wherein Y1 is trifluoromethyl, Y4 is a hydrogen atom, and R5 is 20 methyl]. G2-XVIII: G2-17 [wherein Y1 and Y3 are halogen atoms]. G2-XIX: G2-1 [wherein Y1 is a hydrogen atom, Y2 is a hydrogen atom, a halogen atom, methyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy or phenoxy, Y3 is a hydrogen atom, a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 25 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy or C1-C4 haloalkylthio, or Y3 may form, together with Y2, -OCH2O-, -OCH2CH2O- or -CH=CHCH=CH- to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y2 and Y3, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom or methyl, Y4 is a hydrogen atom, a 30 halogen atom, methyl or trifluoromethyl, and Y5 is a hydrogen atom]. G2-XX: G2-1 [wherein Y1 is a halogen atom, methyl or trifluoromethyl, Y2 is a hydrogen atom, Y3 is cyano, nitro, -OR7, -S(0)rR7, -C(R10)=NOR11, -C(0)NH2, - C(S)NH2, C2-C6 alkynyl or (C2-Ce)alkynyl substituted with R6, Y4 and Y5 are hydrogen atoms, R6 is a halogen atom, C3-C6 cycloalkyl, -OH, C1-C3 alkoxy, C1-C3 alkylthio, C1-C3 35 alkylsulfinyl, C1-C3 alkylsulfonyl or -Si(R14a)(R14b)R14, R7 is C1-C4 haloalkyl, C2-C4 haloalkenyl, C3-C4 haloalkynyl, phenyl or phenyl substituted with (Z)m, R10 is a hydrogen atom or C1-C4 alkyl, R11 is C1-C4 alkyl, R14 is C1-C4 alkyl or phenyl, each of R14a and R14b is independently C1-C4 alkyl, Z is a halogen atom, m is 1, and r is an integer of from 0 to 2]. 40 G2-XXI: G2-1 [wherein Y1 is a halogen atom, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxymethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, phenoxy or C1-C4 alkylthio, Y2 is a hydrogen atom, methyl or methoxy, or Y2 may form, together with Y1, -OCH2O- or -OCH2CH2O-, to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y1 and Y2, wherein hydrogen atoms on the respective ring- 45 constituting carbon atoms may optionally be substituted with a halogen atom or methyl, Y3 is a hydrogen atom, a halogen atom, cyano, nitro, methyl or trifluoromethyl, or Y3 may form, together with Y2, -OCH2O- or -OCH2CH2O- to form a 5-membered ring or a 6- membered ring together with the carbon atoms attached to Y2 and Y3, wherein 29 hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom or methyl, and Y4 and Y5 are hydrogen atoms]. G2-XXII: G2-1 [wherein Y1 is a halogen atom, methyl or methoxy, Y2 is a hydrogen atom, Y3 is a hydrogen atom, a halogen atom, methyl or trifluoromethyl, Y4 is 5 a halogen atom, methyl or methoxy, or Y4 may form, together with Y3, -OCH2O- or - OCH2CH2O-, to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y3 and Y4, wherein hydrogen atoms on the respective ringconstituting carbon atoms may optionally be substituted with a halogen atom or methyl, and Y5 is a hydrogen atom]. 10 G2-XXIII: G2-1 [wherein Y1 is a halogen atom, methyl or trifluoromethyl, Y2 is a hydrogen atom or a halogen atom, Y3 is a hydrogen atom, a halogen atom, C1-C4 alkyl, trifluoromethyl or methoxy, Y4 is a hydrogen atom, and Y5 is a halogen atom or methyl]. G2-XXIV: G2-2 [wherein Y1 is cyano, nitro, difluoromethoxy, trifluoromethoxy or methylthio, Y2 is a hydrogen atom, Y3 is a halogen atom, C1-C4 alkyl or trifluoromethyl, 15 and Y4 is a hydrogen atom]. G2-XXV: G2-2 [wherein Y1 is a halogen atom, methyl or trifluoromethyl, Y2 is cyano, methyl, C1-C4 alkoxy, C1-C4 haloalkoxy or C1-C4 alkylthio, Y3 is a halogen atom, methyl or trifluoromethyl, and Y4 is a hydrogen atom]. G2-XXVI: G2-2 [wherein Y1 is a halogen atom, methyl or trifluoromethyl, Y2 is a 20 hydrogen atom, Y3 is a halogen atom, cyano, nitro, methyl, difluoromethyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, -N(R9)R8, -C(R10)=NOR11, M-3, -C(0)NH2, -C(S)NH2, -S02N(CH3)2, C2-C6 alkynyl, (C2-C6)alkynyl substituted with R6, D-11, D-28 or D-29, Y4 is a hydrogen atom, R6 is a halogen atom, C3-C6 cycloalkyl, hydroxy(C3-C6)cycloalkyl, C3-C4 alkenyl, C5-C6 cycloalkenyl, -OH, C1- 25 C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, - Si(R14a)(R14b)R14, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4, D-12 or D-32, R8 and R9 together may form a C4-C5 alkylene chain to form a 5- to 6-membered ring together with the nitrogen atom attached to R8 and R9, wherein the alkylene chain may contain an oxygen atom or sulfur atom, R10 is a hydrogen atom or C1-C4 alkyl, R11 is C1- 30 C4 alkyl, R14 is C1-C4 alkyl or phenyl, each of R14a and R14b is independently a C1-C4 alkyl, R17 is C1-C4 alkyl, Z is a halogen atom or C1-C4 alkyl, m is an integer of 1 or 2, n is 0, and p is an integer of from 0 to 2]. G2-XXVII: G2-3 [wherein Y1 is a halogen atom or methyl, Y3 is a halogen atom, methyl, trifluoromethyl or methoxy, Y4 is a halogen atom or cyano, and Y5 is a hydrogen 35 atom]. G2-XXVIII: G2-4 [wherein Y1 is a halogen atom or methyl, Y2 is a hydrogen atom, Y3 is a halogen atom or methoxy, and Y5 is a hydrogen atom]. G2-XXIX: G2-5 [wherein Y1 is a halogen atom, methyl, difluoromethyl or trifluoromethyl, Y2 is a hydrogen atom, and Y3 is a halogen atom, methyl, trifluoromethyl 40 or methoxy]. G2-XXX: G2-6 [wherein each of Y1 and Y3 is independently a halogen atom or methyl, and Y4 is a hydrogen atom or methyl]. G2-XXXI: G2-7 [wherein Y1, Y2 and Y3 are halogen atoms]. G2-XXXII: G2-9 [wherein Y1 is a halogen atom or methyl, Y2 is a hydrogen atom, 45 a halogen atom or methyl, Y3 is a halogen atom, or Y3 may form, together with Y2, -CH=CHCH=CH- to form a 6-membered ring together with the carbon atoms attached to Y2 and Y3, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom]. 30 G2-XXXI11: G2-10 [wherein Y1 is methyl, Y3 is a hydrogen atom, a halogen atom or methyl, and Y4 is a hydrogen atom]. G2-XXXIV: G2-10 [wherein Y1 is a hydrogen atom or a halogen atom, Y3 is a halogen atom, Y4 is a halogen atom, or Y4 may form, together with Y3, 5 -CH2CH2CH2CH2- or -CH=CHCH=CH- to form a 6-membered ring together with the carbon atoms attached to Y3 and Y4, wherein hydrogen atoms on the respective ringconstituting carbon atoms may optionally be substituted with a halogen atom]. G2-XXXV: G2-14 [wherein Y1 is methyl, and Y3 is trifluoromethyl]. G2-XXXVI: G2-16 and G2-17 [wherein Y1 is methyl, and Y3 is a halogen atom or 10 trifluoromethyl]. Among them, as the scope of the substituent represented by G2, more preferred are G2-l to G2-X, G2-XX, G2-XXVIII, G2-XXIX and G2-XXX, particularly preferred are G2-l and G2-ll. In the compounds which fall within the present invention, the substituent 15 represented by W may be an oxygen atom or a sulfur atom, and W is preferably an oxygen atom. As the preferred range of the substituent represented by R1 in the compounds which fall within the present invention, the following sets may, for example, be mentioned. 20 R1-l: Ci-Ce alkyl, (Ci-C4)alkyl substituted with R18 [wherein R18 is Cs-Ce cycloalkyl or trimethylsilyl], C3-C6 cycloalkyl, C3-C6 alkenyl and C3-C6 alkynyl. R1-ll: C1-C4 haloalkyl, (Ci-C4)alkyl substituted with R18 [wherein R18 is phenyl, phenyl substituted with (Z)m or D-32, Z is a halogen atom, cyano, nitro, methyl, trifluoromethyl or trifluoromethoxy, when m is an integer of at least 2, the respective Z's 25 may be identical with or different from one another, m is an integer of from 1 to 3, and n is 1], and C3-C4 haloalkenyl. R1-lll: (Ci-C4)alkyl substituted with R18 [wherein R18 is cyano, E-5, C1-C4 alkoxy, C1-C4 alkylthio, -C(R32)=NOR33, D-5 or D-10, R32 is methyl, R33 is methyl or ethyl, Z is a halogen atom or methyl, n is an integer of 0 or 1, and p is 0], and phenyl. 30 R1-IV: (Ci-C4)alkyl substituted with R18 [wherein R18 is phenyl substituted with (Z)m or D-32, Z is a halogen atom, C1-C4 alkyl, methoxy, trifluoromethylthio or phenyl, when m and n are 2, the two Z's may be identical with or different from each other, and when there are two neighboring Z's, the two neighboring Z's may form -CH=CHCH= CH- to form a 6-membered ring together with the carbon atoms attached to the Z's, 35 m is an integer of 1 or 2, and n is an integer of from 0 to 2]. R1-V: (Ci-C4)alkyl substituted with R18 [wherein R18 is E-9, -C(R32)=NOR33, M-4, C1-C4 alkoxycarbonyl, C1-C4 haloalkylaminocarbonyl or D-1, R32 is a hydrogen atom or C1-C4 alkyl, R33 is C1-C4 alkyl, Z is methyl or trifluoromethyl, n is 1, and p is 0], E-2 [wherein p is 0] and E-14 [wherein p is 0]. 40 R1-VI: C3-C6 halocycloalkyl and C3-C4 haloalkynyl. R1-VII: E-3 [wherein p is 0, and r is an integer of from 0 to 2], E-4 [wherein R16 is -C(0)R10 or -C(0)OR11, R10 is a hydrogen atom, C1-C4 alkyl or cyclopropyl, R11 is C1-C4 alkyl or C1-C4 haloalkyl, and p is 0], E-5 [wherein p is 0], E-6 [wherein p is 0, and r is an integer of from 0 to 2], E-8 [wherein R16 is -C(0)R10 or -C(0)OR11, R10 is a hydrogen 45 atom, C1-C4 alkyl or cyclopropyl, R11 is C1-C4 alkyl or C1-C4 haloalkyl, and p is 0], E-15 [wherein p is 0, and r is an integer of from 0 to 2], and E-17 [wherein R16 is -C(0)R10 or - C(0)OR11, R10 is a hydrogen atom, C1-C4 alkyl or cyclopropyl, R11 is C1-C4 alkyl or C1- C4 haloalkyl, and p is 0]. 31 R1-VIII: (Ci-C4)alkyl optionally substituted with R18 [wherein R18 is a halogen atom, C3-C6 halocycloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy or C1-C4 alkylthio]. R1-IX: (Ci-C4)alkyl optionally substituted with R18 [wherein R18 is a halogen atom, E-2 to E-4, E-6, E-8, M-3, -C(R32)=NOR33, -C(0)NH2 or -C(S)NH2, R16 is -C(0)R10 5 or -C(0)OR11, R10 is a hydrogen atom, C1-C4 alkyl or cyclopropyl, R11 is C1-C4 alkyl or C1-C4 haloalkyl, R17 is C1-C4 alkyl, R32 is a hydrogen atom or methyl, R33 is C1-C4 alkyl or C1-C4 haloalkyl, p is an integer of from 0 to 2, and r is an integer of from 0 to 2]. R1-X: (Ci-C4)alkyl optionally substituted with R18 [wherein R18 is a halogen atom, phenyl substituted with (Z)m, D-2, D-4, D-6, D-8, D-9, D-12, D-14, D-15 or D-17, R15 is 10 methyl, Z is a halogen atom, methyl, ethyl, trifluoromethyl, difluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, trifluoromethylsulfinyl or trifluoromethylsulfony, when m and n are 2, the respective Z's may be identical with or different from each other, m is an integer of 1 or 2, and n is an integer of from 0 to 2]. Among them, as the scope of the substituent represented by R1, more preferred 15 are R1-l to R1-IV, particularly preferred are R1-l and R1-ll. As the preferred range of the substituent represented by R2 in the compounds which fall within the present invention, the following sets may, for example, be mentioned. R2-l: A hydrogen atom. 20 R2-ll: Methyl R2-lll Ethyl. R2-IV: C3-C4 alkyl and phenyl. R2-V: Fluoromethyl and trifluoromethyl. R2-VI: Methoxymethyl, methylthiomethyl, methylsulfinylmethyl and 25 methylsulfonylmethyl. R2-VII: Cyclopropyl and cyclobutyl. Among them, as the scope of the substituted represented by R2, more preferred are R2-l to R2-lll and R2-V, particularly preferred are R2-l and R2-ll. As the scope of the substituent represented by R3 in the compounds which fall 30 within the present invention, the following sets may, for example, be mentioned. R3-1: A hydrogen atom. R3-ll: Methyl. R3-III: R3 forms a cyclopropyl ring together with R2. R3-IV: R3 forms, together with R2, a C3-C5 alkylene chain to form a 4- to 6- 35 membered ring together with the carbon atom attached to R2 and R3. R3-V: C2-C4 alkyl. R3-VI: R3 form, together with R2, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the carbon atom attached to R2 and R3, wherein the alkylene chain contains an oxygen atom or sulfur atom. 40 Among them, as the scope of the substituent represented by R3, more preferred are R3-l to R3-III, and particularly preferred is R3-l. As the scope of the substituent represented by R4 in the compounds which fall within the present invention, the following sets may, for example, be mentioned. R4-l: A hydrogen atom. 45 R4-ll: C1-C4 alkylcarbonyl. R4-lll: C1-C4 alkoxycarbonyl. R4-IV: C1-C4 haloalkylthio. R4-V: C1-C4 alkyl, (Ci-C2)alkyl substituted with R19 [wherein R19 is cyano or C1- 32 C4 alkoxy], cyclopropyl, allyl and propargyl. R4-VI: Ca-Ce cycloalkyl, C2-C4 alkenyl and C2-C4 alkynyl. R4-VII: (Ci-C2)alkyl substituted with R19 [wherein R19 is -OR36, -C(0)NH2 or -C(S)NH2, R36 is C2-C4 haloalkyi, C1-C4 alkylcarbonyl, Ca-Ce cycloalkylcarbonyl or C1-C4 5 alkoxycarbonyl]. R4-VIII: -C(0)R20 [wherein R20 is C1-C4 alkoxymethyl, C1-C4 alkylthiomethyl, C1- C4 alkylsulfonylmethyl, C3-C4 cycloalkyl or C2-C4 alkenyl]. R4-IX: -C(0)OR21 [wherein R21 is C1-C4 haloalkyi, C1-C4 alkoxy(Ci-C2)alkyl, allyl or propargyl]. 10 R4-X: C1-C4 alkoxy. Among them, as the scope of the substituent represented by R4, more preferred are R4-l to R4-IV, particularly preferred is R4-l. The sets indicating the preferred range of each substituent in the compounds which fall within the present invention may be combined arbitrarily to indicate the 15 preferred range of the compounds of the present invention. The preferred range of G\ G2, R1 and R2 of the compound represented by the formula (I) may be combined, for example, as shown in Table 1. The combinations shown in Table 1 merely exemplify the present invention, and the compound of the present invention represented by the formula (I) is by no means restricted thereto. Some of the compounds of the present invention represented by the formula (I) 5 can be converted, by ordinary methods, to acid addition salts with hydrogen halides such as hydrofluoric acid, hydrochloric acid, hydrobromic acid and hydroiodic acid, with inorganic acids such as nitric acid, sulfuric acid, phosphoric acid, chloric acid and perchloric acid, with sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid, with 10 carboxylic acids such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, fumaric acid, tartaric acid, oxalic acid, maleic acid, malic acid, succinic acid, benzoic acid, mandelic acid, ascorbic acid, lactic acid, gluconic acid and citric acid, with amino acids such as glutamic acid and aspartic acid. Some of the compounds of the present invention represented by the formula (I) 15 can be converted, by ordinary methods, to metal salts with alkali metals such as lithium, sodium and potassium, with alkaline earth metals such as calcium, barium and magnesium, with metals such as aluminum. The pesticides herein mean fungicides and parasiticides for controlling harmful pathogens and parasites which infect/parasitize plants or animals. 20 Plants herein mean grain, fruits and vegetables, cultivated as food for human, feed crop for livestock and poultry, ornamental plants of which appearances are enjoyed, or Tracheophyta such as planting of parks, streets and the like, and specifically, the following plants may, for example, be mentioned, but the present invention is not restricted thereto. 25 Plants of the order Pinales belonging to the family Pinaceae such as Japanese Red Pine (Pinus densiflora), Scots Pine (Pinus sylvestris), Japanese Black Pine (Pinus thunberqii), etc. Plants of the group Magnoliids belonging to the family Piperaceae such as pepper (Piper nigrum), etc., the family Lauraceae such as Avocado (Persea americana), etc. 30 Plants of the group monocots belonging to the family Araceae such as Konjac (Amorphophallus konjac), Eddoe (Colocasia esculenta), etc., the family Dioscoreaceae such as Chinese yam (Dioscorea batatas), Japanese yam (Dioscorea iaponica), etc., 37 the family Alliaceae such as Leek (Allium ampeloprasum var. porrum), Onion (Allium cega), Rakkyo (Allium chinense), Welsh onion (Allium fistulosum), Garlic (Allium sativum), Chives (Allium schoenoprasum). Chive (Allium schoenoprasum var. foliosum), Oriental garlic (Allium tuberosum), Scallion (Allium x wakegi), etc., the family 5 Asparagaceae such as Asparagus (Asparagus officinalis), etc., the family Arecaceae subfamily Arecoideae such as Coconut palm (Cocos nucifera), Oil palm (Elaeis quineensis), etc., the family Arecaceae the subfamily Coryphoideae such as Date palm (Phoenix dactyl if era), etc., the family Bromeliaceae such as Pineapple (Ananas comosus), etc., the family Poaceae subfamily Ehrhartoideae such as Rice (Oryza 10 sativa), etc., the family Poaceae subfamily Pooideae such as Bent grass (Aqrostis spp.), Blue grass (Poa spp.), Barley (Hordeum vulqare), Wheat (Triticum aestivum, T. durum), Rye (Secale cereale), etc., the family Poaceae subfamily Chloridoideae such as Bermuda grass (Cvnodon dactvlon), Grass (Zovsia spp.), etc., the family Poaceae subfamily Panicoideae such as Sugarcane (Saccharum officinarum), Sorgum (Sorghum 15 bicolor), Corn (Zea mays), etc., the family Musaceae such as Banana (Musa spp.), etc., the family Zingiberaceae such as Myoga (Zingiber mioqa), Ginger (Zingiber officinale), etc. Plants of the group eudicots belonging to the family Nelumbonaceae such as Lotus root (Nelumbo nucifera), etc., the family Fabaceae such as Peanut (Arachis 20 hypogaea). Chickpea (Cicer arietinum). Lentil (Lens culinaris). Pea (Pisum sativum), Broad bean (Vicia faba). Soybean (Glycine max). Common bean (Phaseolus vulgaris), Adzuki bean (Vigna angularis), Cowpea (Vigna unguiculata), etc., the family Cannabaceae such as Hop (Humulus lupulus), etc., the family Moraceae such as Fig Tree (Ficus carica), Mulberry (Moms spp.), etc., the family Rhamnaceae such as 25 Common jujube (Ziziphus jujuba), etc., the family Rosaceae subfamily Rosoideae such as Strawberry (Fragaria), Rose (Rosa spp.), etc.,the family Rosaceae subfamily Maloideae such as Japanese loquat (Eriobotrya iaponica), Apple (Malus pumila), European Pear (Pyrus communis), Nashi Pear (Pyrus pvrifolia var. culta), etc., the family Rosaceae subfamily Prunoideae such as Peach (Amygdalus persica), Apricot 30 (Prunus armeniaca), Cherry (Prunus avium), Prune (Prunus domestica), Almond (Prunus dulcis), Japanese Apricot (Prunus mume), Japanese Plum (Prunus salicina), Cerasus speciosa, Cerasus x yedoensis 'Somei-yoshino', etc., the family Cucurbitaceae such as Winter melon (Benincasa hispida), Watermelon (Citrullus lanatus). Bottle gourd (Lagenaria siceraria var. hispida), Luffa (Luffa cvlindrica), Pumpkin (Cucurbita spp.), 35 Zucchini (Cucurbita pepo), Bitter melon (Momordica charantia var. pavel), Muskmelon (Cucumis melo), Oriental pickling melon (Cucumis melo var. conomon), Oriental melon (Cucumis melo var. makuwa), Cucumber (Cucumis sativus), etc., the family Fagaceae such as Japanese Chestnut (Castanea crenata), etc., the family Juglandaceae such as Walnut (Juglans spp.), etc., the family Anacardiaceae such as Cashew (Anacardium 40 occidentale). Mango (Mangifera indica), Pistachio (Pistacia vera), etc., the family Rutaceae subfamily Rutoideae such as Japanese pepper (Zanthoxvlum piperitum), etc., the family Rutaceae subfamily Aurantioideae such as Bitter orange (Citrus aurantium), Lime (Citrus aurantifolia), Hassaku orange (Citrus hassaku), Yuzu (Citrus junos), Lemon (Citrus limon), Natsumikan (Citrus natsudaidai). Grapefruit (Citrus x paradisi). Orange 45 (Citrus sinensis), Kabosu (Citrus sphaerocarpa), Sudachi (Citrus sudachi), Mandarin Orange (Citrus tangerina), Satsuma (Citrus unshiu), Kumquat (Fortunella spp.), etc., the family Brassicaceae such as Horseradish (Armoracia rusticana), Mustard (Brassica juncea), Takana (Brassica juncea var. integrifolia), Rapeseed (Brassica 38 napus), Cauliflower (Brassica oleracea var. botrvtis), Cabbage (Brassica oleracea var. capjtata), Brussels sprout (Brassica oleracea var. gemmifera), Broccoli (Brassica oleracea var. italica), Green pak choi (Brassica rapa var. chinensis), Nozawana (Brassica rapa var. hakabura), Napa cabbage (Brassica rapa var. nippo-oleifera), 5 Potherb Mustard (Brassica rapa var. nipposinica), Napa cabbage (Brassica rapa var. pekinensis), Turnip leaf (Brassica rapa var. perviridis), Turnip (Brassica rapa var. rapa), Garden rocket (Eruca vesicaria), Daikon (Raphanus sativus var. lonqipinnatus), Wasabi (Wasabia japonica), etc., the family Caricaceae such as Papaya (Carica papaya), etc., the family Malvaceae such as Okra (Abelmoschus esculentus), Cotton plant 10 (Gossvpium spp.), Cacao (Theobroma cacao), etc., the family Vitaceae such as Grape (Vitis spp.), etc., the family Amaranthaceae such as Sugar beet (Beta vulgaris ssp. vulgaris var. altissima). Table beet (Beta vulgaris ssp. vulgaris var. vulgaris), Spinach (Spinacia oleracea), etc., the family Polygonaceae such as Buckwheat (Fagopyrum esculentum), etc., the family Ebenaceae such as Kaki Persimmon (Diospyros kaki), etc., 15 the family Theaceae scuh as Tea plant (Camellia sinensis), etc., the family Actinidiaceae such as Kiwifruit (Actinidia deliciosa, A. chinensis), etc., the family Ericaceae such as Blueberry (Vaccinium spp.), Cranberry (Vaccinium spp.), etc., the family Rubiaceae such as Coffee plants (Coffea spp.), etc., the family Lamiaceae such as Lemon balm (Melissa officinalis). Mint (Mentha spp.), Basil (Qcimum basilicum), Shiso (Perilla 20 frutescens var. crispa), Perilla frutescens var. frutescens, Common Sage (Salvia officinalis). Thyme (Thymus spp.), etc., the family Pedaliaceae such as Sesame (Sesamum indicum), etc., the family Oleaceae such as Olive (Qlea europaea), etc. the family Convolvulaceae such as Sweet potato (Ipomoea batatas), etc., the family Solanaceae such as Tomato (Solanum Ivcopersicum), Eggplant (Solanum 25 melongena). Potato (Solanum tuberosum), Chili pepper (Capsicum annuum), Bell pepper (Capsicum annuum var. 'grossum'). Tobacco (Nicotiana tabacum), etc., the family Apiaceae such as Celery (Apium graveolens var. dulce), Coriander (Coriandrum sativum), Japanese honeywort (Crvptotaenia Canadensis subsp. japonica), Carrot (Daucus carota subsp. sativus), Parsley (Petroselium crispum), Italian parsley 30 (Petroselinum neapolitanum), etc., the family Araliaceae such as Udo (Aralia cordata), Aralia elata, etc., the family Asteraceae subfamily Carduoideae such as Artichoke (Cvnara scolvmus), etc., the family Asteraceae subfamily Asteraceae such as Chicory (Cichorium intvbus). Lettuce (Lactuca sativa), etc., the family Asteraceae subfamily Asteraceae such as Florists' daisy (Dendranthema grandiflorum), Crown daisy 35 . (Glebionis coronaria), Sunflower (Helianthus annuus), Fuki (Petasites iaponicus), Burdock (Arctium lappa), etc. Animals herein mean human, companion creatures/pets, livestock/poultry, and vertebrate such as research/laboratory animals, and specifically, the following animals may, for example, be mentioned, but the present invention is not restricted thereto. 40 Animals of the class Mammalia belonging to the family Cebidae such as Tufted capuchin (Cebus apella), etc., the family Cercopithecidae such as Crab-eating macaque (Macaca fascicularis). Rhesus macaque (Macaca mulatta), etc., the family Hominidae such as Chimpanzee (Pan troglodytes). Human (Homo sapiens), etc., the family Leporidae such as European rabbit (Qrvctolagus cuniculus), etc., the family 45 Chinchillidae such as Long-tailed chinchilla (Chinchilla lanigera), etc., the family Caviidae such as Guinea pig (Cavia porcellus), etc., the family Cricetidae such as Golden hamster (Mesocricetus auratus), Djungarian hamster (Phodopus sungorus), Chinese hamster (Cricetulus griseus), etc., the family Muridae such as Mongolian gerbil 39 (Meriones unguiculatus), House mouse (Mus musculus), Black rat (Rattus rattus), etc., the family Sciuridae such as Chipmunk (Tamias sibiricus), etc., the family Camelidae such as Dromedary (Camelus dromedarius), Bactrian camel (Camelus bactrianus), Alpaca (Vicugna pacos), Llama (Lama glama), etc., the family Suidae such as Pig (Sus 5 scrofa domesticus), etc., the family Cervidae such as Reindeer (Rangifer tarandus), Red deer (Cervus elaphus), etc., the family Bovidae such as Yak (Bos grunniens), Cattle (Bos taurus), Water buffalo (Bubalus arnee), Goat (Capra hi reus), Sheep (Ovis arjes), etc., the family Felidae such as Cat (Felis silvestris catus), etc., the family Canidae such as Dog (Canis lupus familiaris), Red fox (Vulpes vulpes), etc., the family 10 Mustelidae such as European mink (Mustela lutreola), American mink (Mustela yison), Ferret (Mustela putorius furo). etc., the family Equidae such as Donkey (Eguus asinus), Horse (Eguus caballus), etc., the family Macropodidae such as Red kangaroo (Macropus rufus), etc. Animals of the class Aves belonging to the 15 family Struthionidae such as Ostrich (Struthio camelus), etc., the family Rheidae such as American rhea (Rhea americana), etc., the family Dromaiidae such as Emu (Dromaius novaehollandiae), etc., the family Phasianidae such as Ptarmigan (Lagopus muta), Wild turkey (Meleagris gallopavo), Japanese quail (Cotumix japonica), Chicken (Gallus gallus domesticus), Common pheasant (Phasianus colchicus), Golden pheasant 20 (Chrvsolophus pictus), Indian peafowl (Pavo cristatus), etc., the family Numididae such as Helmeted guineafowl (Numida meleagris), etc., the family Anatidae such as Mallard (Anas platyrhynchos), Domesticated duck (Anas platyrhynchos var.domesticus), Spotbilled duck (Anas poecilorhyncha), Greylag goose (Anser anser), Swan goose (Anser cygnoides), Whooper swan (Cygnus cygnus). Mute swan (Cygnus olor), etc., the family 25 Columbidae such as Rock dove (Columba livia), Oriental turtle dove (Streptopelia orientalis), European turtle dove (Streptopelia turtur), etc., the family Cacatuidae such as Sulphur-crested cockatoo (Cacatua galerita), Galah (Eolophus roseicapilla), Cockatiel (Nymphicus hollandicus), etc., the family Psittacidae such as Rosy-faced lovebird (Agapornis roseicollis), Blue-and-yellow macaw (Ara ararauna), Scarlet Macaw 30 (Ara macao), Budgerigar (Melopsittacus undulatus), African grey parrot (Psittacus erithacus), etc., the family Stumidae such as Common hill myna (Gracula religiosa), etc., the family Estrildidae such as Red avadavat (Amandava amandava), Zebra finch (Taeniopygia guttata), Bengalese finch (Lonchura striata var. domestica), Java sparrow (Padda oryzivora), etc., the family Fringillidae such as Domestic canary (Serinus 35 canaria domestica), European goldfinch (Carduelis carduelis), etc. Animals of the class Reptilia belonging to the family Chamaeleonidae such as Veiled chameleon (Chamaeleo calyptratus), etc., the family Iguanidae such as Green iguana (Iguana iguana), Carolina anole (Anolis carolinensis), etc., the family Varanidae such as Nile monitor (Varanus niloticus), Water monitor (Varanus salvator), etc., the 40 family Scincidae such as Solomon islands skink (Corucia zebrata), etc., the family Colubridae such as Beauty rat snake (Elaphetaeniura), etc., the family Boidae such as Boa constrictor (Boa constrictor), etc., the family Pythonidae such as Indian python (Python molurus). Reticulated python (Python reticulatus), etc., the family Chelydridae such as Common snapping turtle (Chelvdra serpentina), etc., the family Emydidae such 45 as Diamondback terrapin (Malaclemys terrapin), Pond slider (Trachemys scripta), etc., the family Geoemydidae such as Japanese pond turtle (Mauremys japonica), etc., the family Testudinidae such as Central Asian tortoise (Agrionemys horsfieldii), etc., the family Trionychidae such as Soft-shelled turtle (Pelodiscus sinensis), etc., the family 40 Alligatoridae such as American alligator (Alligator mississippiensis), Black caiman (Melanosuchus niger), etc., the family Crocodylidae such as Siamese crocodile (Crocodylus siamensis), etc. Animals of the class Actinopterygii belonging to the family Cyprinidae such as 5 Carp (Cyprinus carpjo), Goldfish (Carassius auratus auratus), Zebrafish (Danio re ho), etc., the family Cobitidae such as Kuhli loach (Panqio kuhjii), etc., the family Characidae such as Red piranha (Pygocentrus nattereri), Neon tetra (Paracheirodon innesi), etc., the family Salmonidae such as Maraena whitefish (Coregonus lavaretus maraena), Coho salmon (Oncorhynchus kisutsh), Rainbow trout (Oncorhynchus mykiss), Chinook 10 salmon (Oncorhynchus tshawvtscha), Atlantic salmon (Salmo salar), Brown trout (Salmo trutta), etc., the family Percichthyidae such as Spotted sea bass (Lateolabrax maculatus), etc., the family Serranidae such as Sea goldie (Pseudanthias squamipinnis), Longtooth grouper (Epinephelus bruneus), Convict grouper (Epinephelus septemfasciatus), etc., the family Centrarchidae such as Bluegill (Lepomis macrochirus), 15 etc., the family Carangidae such as White trevally (Pseudocaranx dentex), Greater amberjack (Seriola dumerili), Japanese amberjack (Seriola quinqueradiata), etc., the family Sparidae such as Red sea bream (Pagrus major), etc., the family Cichlidae such as Nile tilapia (Oreochromis niloticus), Angelfish (Pterophvllum scalare), etc., the family Scombridae such as Pacific bluefin tuna (Thunnus orientalis), etc., the family 20 Tetraodontidae such as Japanese pufferfish (Takifugu rubripes), etc. Pathogens herein mean microorganisms which cause plant diseases and animal infections, and specifically, the following microorganisms may, for example, be mentioned, but the present invention is not restricted thereto. Fungi of the phylum Ascomycota, such as Taphrina spp. (e.g. Taphrina deformans. 25 T. pruni, etc.), Pneumocystis spp., Geotrichum spp., Candida spp.(e.g. Candida albicans, C. sorbosa, etc.), Pichia spp.(e.g. Pichia kluyveri, etc.), Geotrichum spp., Capnodium spp., Fumago spp., Hypocapnodium spp., Cercospora spp.(e.g. Cercospora apii. C. asparaoi. C. beticola. C. capsici. C. carotae, C. kaki, C. kikuchii, C. zonata. etc.), Cercosporidium spp., Cladosporium spp.(e.g. Cladosporium colocasiae, C. 30 cucumerinum. C. variabile, etc.), Davidiella spp., Didymosporium spp., Heterosporium spp.(e.g. Heterosporium allii, etc.), Mvcosphaerella spp.(e.g. Mycosphaerella arachidis, M. berkeleyi. M. cerasella, M. fijiensis, M. fraqariae, M. qraminicola, M. nawae, M. pinodes, M. pomi. M. zinqiberis. etc.), Mvcovellosiella spp.(e.g. Mvcovellosiella fulva, M. nattrassii, etc.), Paracercospora spp.(e.g. Paracercospora eqenula, etc.), 35 Phaeoisariopsis spp., Phaeoramularia spp., Pseudocercospora spp.(e.g. Pseudocercospora abelmoschi. P. fuliqena, £. vitis, etc.), Pseudocercosporella spp.(e.g. Pseudocercosporella capsellae, etc.), Ramichloridium spp., Ramularia spp., Septoqloeum spp., Septoria spp.(e.g. Septoria albopunctata, S. apiicola, S. chrysanthemella. S. helianthi, S. obesa, etc.), Sphaerulina spp., Aureobasidium spp., 40 Kabatiella spp., Plowrightia spp., Stigmina spp., Elsinoe spp.(e.g. Elsinoe ampelina. E. araliae, E. fawcettii. etc.), Sphaceloma spp.(e.g. Sphaceloma caricae, etc.), Ascochyta spp.(e.g. Ascochyta pisi, etc.), Corvnespora spp.(e.g. Corvnespora cassiicola, etc.), Leptosphaeria spp.(e.g. Leptosphaeria coniothvrium, L maculans, etc.), Saccharicola spp., Phaeosphaeria spp., Qphiosphaerella spp., Setophoma spp., Helminthosporium 45 spp., Altemaria spp.(e.g. Altemaria altemata. A. brassicae, A. brassicicola. A. citri. A. dauci, A. helianthi. A. iaponica. A. kikuchiana. A. mali. A. panax, A. porri. A. radicina. A. solani, etc.), Bipolaris spp.(e.g. Bipolaris sorghicola, etc.), Cochliobolus spp.(e.g. Cochliobolus heterostrophus. C. lunatus, C. miyabeanus, etc.), Curvularia spp.(e.g. 41 Curvularia geniculata, C. verruculosa, etc.), Drechslera spp., Pleospora spp.(e.g. Pleospora herbarum. etc.), Pyrenophora spp. (e.g. Pyrenophora graminea, P. teres, etc.), Setosphaeria spp. (e.g. Setosphaeria turcica, etc.), Stemphvlium spp.(e.g. Stemphylium botrvosum, S. lycopersici, S. solani, S. vesicarium, etc.), Fusicladium spp., 5 Venturia spp.(e.g. Venturia carpophila, V. Inaegualis, V. nashicola, V. pirina, etc.), Didymella spp.(e.g. Didymella bryoniae, D. fabae, etc.), Hendersonia spp., Phoma spp.(e.g. Phoma erratica var. mikan, P. exigua var. exigua, P. wasabiae, etc.), Pyrenochaeta spp.(e.g. Pyrenochaeta lycopersici. etc.), Stagonospora spp.(e.g. Stagonospora sacchari, etc.), Botryosphaeria spp.(e.g. Botrvosphaeria berengeriana f. 10 sp. piricola, B. dothidea, etc.), Dothiorella spp., Fusicoccum spp., Guignardia spp., Lasiodiplodia spp.(e.g. Lasiodiplodia theobromae. etc.), Macrophoma spp., Macrophomina spp., Neofusicoccum spp., Phyllosticta spp. (e.g. Phyllosticta zingiberis, etc.), Schizothvrium spp.(e.g. Schizothvrium pomi, etc.), Acrospermum spp., Leptosphaerulina spp., Aspergillus spp., Penicillium spp.(e.g. 15 Penicillium digitatum, P. italicum, P. sclerotigenum, etc.), Microsporum spp., Trichophyton spp.(e.g. Trichophyton mentagrophvtes, T. rubrum, etc.), Histoplasma spp., Blumeria spp.(e.g. Blumeria graminis f. sp. hordei, B. g. f. sp. tritici, etc.), Erysiphe spp.(e.g. Erysiphe betae, E. cichoracearum, E. c. var. cichoracearum, E. heraclei, E. pisi, etc.), Golovinomvces spp.(e.g. Golovinomvces cichoracearum var. latisporus, etc.), 20 Leveillula spp.(e.g. Leveillula taurica, etc.), Microsphaera spp., Oidium spp.(e.g. Oidium neolvcopersici, etc.), Phyllactinia spp.(e.g. Phvllactinia kakicola, P. mali, P. moricola, etc.), Podosphaera spp.(e.g. Podosphaera fusca, P. leucotricha, P. pannosa, P. tridactyla var. tridactyla, P. xanthii, etc.), Sphaerotheca spp.(e.g. Sphaerotheca aphanis var. aphanis, S. fuliginea, etc.), Uncinula spp.(e.g. Uncinula necator, LJ. n. var. necator, 25 etc.), Uncinuliella spp.(e.g. Uncinuliella simulans var. simulans, U. s. var. tandae, etc.), Blumeriella spp.(e.g. Blumeriella jaapii, etc.), Cvlindrosporium spp., Diplocarpon spp.(e.g. Diplocarpon mali, D. mespili, D. rosae, etc.), Gloeosporium spp.(e.g. Gloeosporium minus, etc.), Marssonina spp., Tapesia spp.(e.g. Tapesia acuformis, T. yallundae, etc.), Lachnum spp., Scleromitrula spp., Botryotinia spp.(e.g. Botrvotinia 30 fuckeliana, etc.), Botrvtis spp.(e.g. Botrvtis allii, B. bvssoidea, B. cinerea, B. elliptica, B. fabae, B. sguamosa, etc.), Ciborinia spp., Grovesinia spp., Monilia mumecola, Monilinia spp.(e.g. Monilinia fructicola, M- fructigena, M. laxa, M. mali, M. vaccinii-corvmbosi, etc.), Sclerotinia spp.(e.g. Sclerotinia borealis, S. homoeocarpa, S. minor, S. sclerotiorum, etc.), Valdensia spp.(e.g. Valdensia heterodoxa, etc.), 35 Claviceps spp.(e.g. Claviceps sorghi, C. sorghicola, etc.), Epichloe spp., Ephelis iaponica. Villosiclava virens, Hypomyces spp.(e.g. Hypomyces solani f. sp. rnori, H. s. f. sp. pisi. etc.), Trichoderma spp.(e.g. Trichoderma viride, etc.), Calonectria spp.(e.g. Calonectria ilicicola, etc.), Candelospora spp., Cylindrocarpon spp., Cvlindrocladium spp., Fusarium spp.(e.g. Fusarium arthrosporioides, F. crookwellense, F. culmorum, F. 40 cuneirostrum, F. oxysporum, F. o. f. sp. adzukicola, F. o. f. sp. allii. F. o. f. sp. asparagi, F. o. f. sp. batatas, F. o. f. sp. cepae, F. o. f. sp. colocasiae, F. o. f. sp. conglutinans, F. o. f. sp. cubense, F. o. f. sp. cucumerinum, F. o. f. sp. fabae, F. o. f. sp. fragariae, F. o. f. sp. lactucae, F. o. f. sp. lagenariae, F. o. f. sp. lycopersici, F. o. f. sp. melongenae, F. o. f. sp. melonis, F. o. f. sp. nelumbinicola, F. o. f. sp. niveum, F. o. f. sp. radicis-lvcopersici, 45 F. o. f. sp. raphani, F. o. f. sp. spinaciae, F. sporotrichioides, F. solani, F. s. f. sp. cucurbitae, F. s. f. sp. eumartii, F. s. f. sp. pisi, F. s. f. sp. radicicola, etc.), Gibberella spp.(e.g. Gibberella avenacea, G. baccata, G. fuiikuroi, G. zeae, etc.), Haematonectria spp., Nectria spp., Ophionectria spp., Caldariomvces spp., Myrothecium spp., 42 Trichothecium spp., Verticillium spp.(e.g. Verticillium albo-atrum, V. dahliae, V. longisporum, etc.), Ceratocystis spp.(e.g. Ceratocystis ficicola, C. fimbriata, etc.), Thielaviopsis spp.(e.g. Thielaviopsis basicola. etc.), Adisciso spp., Monochaetia spp., Pestalotia spp.(e.g. Pestalotia eriobotrifolia, etc.), Pestalotiopsis spp.(e.g. Pestalotiopsis 5 funerea. P. lonqiseta. P. neqlecta. P. theae, etc.), Phvsalospora spp., Nemania spp., Nodulisporium spp., Rosellinia spp.(e.g. Rosellinia necatrix, etc.), Monographella spp.(e.g. Monographella nivalis, etc.), Ophiostoma spp., Cryphonectria spp.(e.g. Cryphonectria parasitica, etc.), Diaporthe spp.(e.g. Diaporthe citri, D. kvushuensis, D. nomurai, D. tanakae, etc.), Diaporthopsis spp., Phomopsis spp.(e.g. Phomopsis 10 asparagi, P. fukushii, P. obscurans, P. vexans, etc.), Cryptosporella spp., Discula spp.(e.g. Discula theae-sinensis, etc.), Gnomonia spp., Coniella spp., Coryneum spp., Greeneria spp., Melanconis spp., Cvtospora spp., Leucostoma spp., Valsa spp.(e.g. Valsa ceratosperma, etc.), Tubakia spp., Monosporascus spp., Clasterosporium spp., Gaeumannomyces spp.(e.g. 15 Gaeumannomyces graminis, etc.). Magnaporthe spp.fe.g. Magnaporthe grisea, etc.), Pyricularia spp.(e.g. Pyricularia zingiberis, etc.), Monilochaetes infuscans, Colletotrichum spp.(e.g. Colletotrichum acutatum, C. capsici, C. cereale, C. destructivum, C. fragariae, C. lindemuthianum, C. nigrum, C. orbiculare, C. spinaciae, etc.), Glomerella spp.(e.g. Glomerella cingulata, etc.), Khuskia oryzae, Phvllachora 20 spp.(e.g. Phvllachora pomigena. etc.), Ellisembia spp., Briosia spp., Cephalosporium spp.(e.g. Cephalosporium gramineum. etc.), Epicoccum spp., Gloeocercospora sorghi, Mycocentrospora spp., Peltaster spp.(e.g. Peltaster fructicola, etc.), Phaeocvtostroma spp., Phialophora spp.(e.g. Phialophora gregata, etc.), Pseudophloeosporella dioscoreae, Pseudoseptoria spp., Rhvnchosporium spp.(e.g. Rhvnchosporium secalis, 25 etc.), Sarocladium spp., Coleophoma spp., Helicoceras oryzae, etc. Fungi of the phylum Basidiomycota, such as Septobasidium spp.(e.g. Septobasidium bogoriense, S. tanakae, etc.), Helicobasidium spp.(e.g. Helicobasidium longisporum, etc.), Coleosporium spp.(e.g. Coleosporium plectranthi. etc.), Cronartium spp., Phakopsora spp.(e.g. Phakopsora artemisiae, P. nishidana, P. pachyrhizi, etc.), 30 Physopella spp.(e.g. Physopella ampelopsidis, etc.), Kuehneola spp.(e.g. Kuehneola iaponica, etc.), Phragmidium spp.(e.g. Phragmidium fusiforme, P. mucronatum, P. rosae-multiflorae, etc.), Gymnosporangium spp.(e.g. Gvmnosporangium asiaticum, G. vamadae, etc.), Puccinia spp.(e.g. Puccinia allii, P. brachypodii var. poae-nemoralis, P. coronata, P. c. var. coronata, P. cvnodontis. P. graminis. P. g. subsp. graminicola, P. 35 hordei. P. horiana. P. kuehnii. P. melanocephala. P. recondita, P. striiformis var. striiformis, P. tanaceti var. tanaceti, P. tokyensis, P. zoysiae, etc.), Uromyces spp.(e.g. Uromvces phaseoli var. azukicola. U. p_. var. phaseoli, Uromyces viciae-fabae var. viciae-fabae, etc.), Naohidemyces vaccinii, Nvssopsora spp., Leucotelium spp., Tranzschelia spp.(e.g. Tranzschelia discolor, etc.), Aecidium spp., Blastospora spp.(e.g. 40 Blastospora smilacis, etc.), Uredo spp., Sphacelotheca spp., Urocvstis spp., Sporisorium spp.(e.g. Sporisorium scitamineum, etc.), Ustilago spp.(e.g. Ustilago mavdis, LJ. nuda. etc.), Entyloma spp., Exobasidium spp.(e.g. Exobasidium reticulatum, E. vexans, etc.), Microstroma spp., Tilletia spp.(e.g. Tilletia caries, T. controversa, T. laevis, etc.), Itersonilia spp.(e.g. Itersonilia perplexans, etc.), Crvptococcus spp., Bovista 45 spp.(e.g. Bovista dermoxantha, etc.), Lycoperdon spp.(e.g. Lycoperdon curtisii, L perlatum, etc.), Conocvbe spp.(e.g. Conocvbe apala. etc.), Marasmius spp.(e.g. Marasmius oreades, etc.), Armillaria spp., Helotium spp., Lepista spp.(e.g. Lepista subnuda, etc.), Sclerotium spp.(e.g. Sclerotium cepivorum, etc.), Typhula spp.(e.g. 43 Typhula incarnata. T. ishikariensis var. ishikariensis, etc.), Athelia spp.(e.g. Athelia rolfsii, etc.), Ceratobasidium spp.(e.g. Ceratobasidium corniqerum, etc.), Ceratorhiza spp., Rhizoctonia spp.(e.g. Rhizoctonia solani, etc.), Thanatephorus spp.(e.g. Thanatephorus cucumeris. etc.), Laetisaria spp., Waitea spp., Fomitiporia spp., Ganoderma spp., 5 Chondrostereum purpureum. Phanerochaete spp., etc. Fungi of the phylum Chitridiomycota such as Olpidium spp., etc. Fungi of the phylum Blastocladiomycota such as Physoderma spp., etc. Fungi of the phylum Mucoromycotina such as Choanephora spp., Choanephoroidea cucurbitae, Mucor spp. (e.g. Mucor fragilis, etc.), Rhizopus spp. (e.g. 10 Rhizopus arrhizus. R. chinensis, R. oryzae. R. stolonifer var. stolonifer, etc.), etc. Protists of the phylum Cercozoa such as Plasmodiophora spp. (e.g. Plasmodiophora brassicae, etc.), Sponqospora subterranea f. sp. subterranea, etc. Microorganisms of the phylum Heterokontophyta class Oomycetes such as Aphanomvces spp. (e.g. Aphanomvces cochlioides, A. raphani, etc.), Albugo spp. (e.g. 15 Albugo macrospora, A. wasabiae, etc.), Bremia spp. (e.g. Bremia lactucae, etc.), Hvaloperonospora spp., Peronosclerospora spp., Peronospora spp. (e.g. Peronospora alliariae-wasabi. P. chrvsanthemi-coronarii, P. destructor, P. farinosa f. sp. spinaciae, P. manshurica, P. parasitica, P. sparsa, etc.), Plasmopara spp. (e.g. Plasmopara halstedii, P. nivea, P. viticola, etc.), Pseudoperonospora spp. (e.g. Pseudoperonospora cubensis. 20 etc.), Sclerophthora spp., Phvtophthora spp. (e.g. Phvtophthora cactorum, P. capsici, P. citricola, P. citrophthora, P. cryptogea, P. fragariae, P. infestans, P. melonis, P. nicotianae, P. palmivora, P. porri, P. spjae, P. svrinqae, P. vignae f. sp. adzukicola, etc.), Pythium spp. (e.g. Pvthium afertile, P. aphanidermatum, P. apleroticum, P. aristosporum, P. arrhenomanes, P. buismaniae, P. debarvanum, P. qraminicola, P. 25 horinouchiense, P. irregulare, P. iwavamai, P. myriotylum, P. okanoganense, P. paddicum, P. paroecandrum, P. periplocum, P. spinosum, P. sulcatum, P. svlvaticum, P. ultimum var. ultimum, P. vanterpoolii, P. vexans, P. volutum, etc.), etc. Gram-positive bacteria of the phylum Actinobacteria such as Clavibacter spp. (e.g. Clavibacter michiganensis subsp. michiganensis, etc.), Curtobacterium spp., Leifsonia 30 spp. (e.g. Leifsonia xvli subsp. xyj], etc.), Streptomyces spp. (e.g. Streptomyces ipomoeae, etc.), etc. Gram-positive bacteria of the phylum Firmicutes such as Clostridium sp., etc. Gram-positive bacteria of the phylum Tenericutes such as Phvtoplasma, etc. Gram-negative bacteria of the phylum Proteobacteria such as Rhizobium spp.(e.g. 35 Rhizobium radiobacter, etc.), Acetobacterspp., Burkholderia spp. (e.g. Burkholderia andropogonis, B. cepacia, B. gladioli, B. glumae, B. plantarii, etc.), Acidovorax spp. (e.g. Acidovorax avenae subsp. avenae, A. a. subsp. citrulli, A. konjaci, etc.), Herbaspirillum spp., Ralstonia spp. (e.g. Ralstonia solanacearum, etc.), Xanthomonas spp. (e.g. Xanthomonas albilineans, X. arboricola p_y. pruni, X. axonopodis p_y. vitians, X. 40 campestris p_y. campestris, X. c. JDV. cucurbitae, X. c. p_y. glycines, X. c. p_y. mangiferaeindicae, X. c. p_y. nigromaculans, X. c. p_y. vesicatoria, X. citri subsp. cjtri, X. oryzae p_y. oryzae, etc.), Pseudomonas spp. (e.g. Pseudomonas cichorii, P. fluorescens, P. marginalis, P. m. gy. marginalis, P. savastanoi gy. glvcinea, P. svringae, P. s. gy. actinidiae, P. s. p_y. eriobotrvae, P. s. p_y. helianthi, P. s. p_y. lachrymans, P. s. p_y. 45 maculicola, P. s. JDV. mori, P. s. p_y. morsprunorum, P. s. p_y. spinaciae, P. s. QV. svringae, P. s. py. theae, P. viridiflava, etc.), Rhizobacter spp., Brenneria spp. (e.g. Brenneria nigrifluens, etc.), Dickeva spp.(e.g. Dickeva dianthicola, D. zeae, etc.), Erwinia spp. (e.g. Erwinia amylovora, E. rhapontici, etc.), Pantoea spp., Pectobacterium spp. (e.g. 44 Pectobacterium atrosepticum. P. carotovorum. P. wasabiae. etc.), etc. As specific examples the plant diseases and animal infections caused by infection/proliferation of such pathogens, the following plant diseases and animal infections may, for example, be mentioned, but the present invention is not restricted 5 thereto. Plant diseases: Leaf curl (Taphrina deformans). Plum pockets (Taphrina pruni). Leaf spot (Cercospora asparaqi). Cercospora leaf spot (Cercospora beticola). Frogeye leaf spot (Cercospora capsici). Angular leaf spot (Cercospora kaki), Purple stain (Cercospora 10 kikuchii). Brown Leaf spot (Mvcosphaerella arachidis). Cylindrosporium leaf spot (Mvcosphaerella cerasella. Blumeriella iaapii). Speckled leaf blotch (Mvcosphaerella graminicola). Circular leaf spot (Mvcosphaerella nawae), Mycosphaerella blight (Mvcosphaerella pinodes), Leaf spot (Mvcosphaerella zinpjberis), Leaf mold (Mvcovellosiella fulva). Leaf mold (Mvcovellosiella nattrassii), Cercospora leaf mold 15 (Pseudocercospora fuliqena). Isariopsis leaf spot (Pseudocercospora vitis), Leaf spot (Pseudocercosporella capsellae). Leaf spot (Septoria chrvsanthemella). Leaf blight (Septoria obesa). Anthracnose (Elsinoe ampelina), Spot anthracnose (Elsinoe araliae). Scab (Elsinoe fawcettii). Leaf spot (Ascochvta pisi). Corynespora leaf spot (Corynespora cassiicola). Stem canker (Leptosphaeria coniothvrium), Leaf spot 20 (Alternaria alternata). Leaf blight (Alternaria dauci). Black spot (Alternaria kikuchiana). Alternaria blotch (Alternaria mali). Alternaria leaf spot (Alternaria porri). Target spot (Bipolaris sorqhicola). Southern leaf blight (Cochliobolus heterostrophus). Brown spot (Cochliobolus mivabeanus). Tip blight (Pleospora herbarum). Stripe (Pvrenophora qraminea). Net blotch (Pvrenophora teres). Leaf blight (Setosphaeria 25 turcica). Northern leaf blight (Setosphaeria turcica). Leaf spot (Stemphvlium botrvosum). Scab (Venturia carpophila). Scab (Venturia Inaequalis). Scab (Venturia nashicola). Gummy stem blight (Didymella brvoniae). Leaf spot (Phoma exiqua var. exiqua). Streak (Phoma wasabiae), Ring rot (Botrvosphaeria berenqeriana f. sp. piricola). Soft rot (Botrvosphaeria dothidea. Lasiodiplodia theobromae. Diaporthe sp.), Common green 30 mold (Penicillium diqitatum). Blue mold (Penicillium italicum). Powdery mildew (Blumeria qraminis f. sp. hordei). Powdery mildew (Blumeria qraminis f. sp. tritici), Powdery mildew (Ervsiphe betae, Leveillula taurica. Oidium sp., Podosohaera xanthii). Powdery mildew (Ervsiphe cichoracearum. Leveillula taurica. Sphaerotheca fuliqinea). Powdery mildew (Ervsiphe heraclei), Powdery mildew (Ervsiphe pisi). Powdery mildew 35 (Leveillula taurica. Oidium neolvcopersici. Oidium sp.), Powdery mildew (Leveillula taurica). Powdery mildew (Oidium sp., Podosohaera xanthii). Powdery mildew (Oidium sp.), Powdery mildew (Phvllactinia kakicola). Powdery mildew (Podosohaera fusca). Powdery mildew (Podosohaera leucotricha). Powdery mildew (Podosohaera pannosa. Uncinuliella simulans var. simulans. U. s. var. tandae), Powdery mildew (Podosohaera 40 xanthii). Powdery mildew (Sphaerotheca aphanis var. aphanis). Powdery mildew (Sphaerotheca fuliqinea). Powdery mildew (Uncinula necator. U. n. var. necator), Blotch (Diplocarpon mali). Black spot (Diplocarpon rosae). Gray mold neck rot (Botrvtis allii). Gray mold, Botrytis blight (Botrvtis cinerea). Leaf blight (Botrvtis cinerea. B. bvssoidea. B. squamosa), Chocolate spot (Botrvtis cinerea. B. elliptica. B. fabae), 45 Brown rot (Monilinia fructicola. M. fructigena. M. laxa). Blossom blight (Monilinia mali). Dollar spot (Sclerotinia homoeocarpa). Cottony rot, Sclerotinia rot, Stem rot (Sclerotinia sclerotiorum). False smut (Villosiclava virens). Root necrosis (Calonectria ilicicola). Fusarium blight (Fusarium crookwellense. F. culmorum, Gibberella avenacea. G. zeae. 45 Monoqraphella nivalis), Fusarium blight (Fusarium culmorum, Gibberella avenacea, G. zeae), Dry rot (Fusarium oxysporum, F. solani f. sp. radicicola), Brown rot (Fusarium oxysporum, F. solani f. sp. pisi, F. s. f. sp. radicicola), Fusarium wilt (Fusarium oxysporum f. sp. adzukicola), Fusarium basal rot (Fusarium oxysporum f. sp. allii. F. 5 solani f. sp. radicicola), Stem rot (Fusarium oxysporum f. sp. batatas, F. solani), Dry rot (Fusarium oxysporum f. sp. colocasiae), Yellows (Fusarium oxysporum f. sp. conqlutinans), Panama disease (Fusarium oxysporum f. sp. cubense), Fusarium wilt (Fusarium oxysporum f. sp. fraqariae), Root rot (Fusarium oxysporum f. sp. lactucae), Fusarium wilt (Fusarium oxysporum f. sp. laqenariae, F. o. f. sp. niveum), Fusarium wilt 10 (Fusarium oxysporum f. sp. lycopersici), Fusarium wilt (Fusarium oxysporum f. sp. melonis), Yellows (Fusarium oxysporum f. sp. raphani), Fusarium wilt (Fusarium oxysporum f. sp. spinaciae), "Bakanae" disease (Gibberella fuiikuroi). Verticillium black spot (Verticillium albo-atrum, V. dahliae), Verticillium wilt (Verticillium dahliae), Ceratocystis canker (Ceratocvstis 15 ficicola), Black rot (Ceratocvstis fimbriata), Gray blight (Pestalotiopsis lonqiseta, P. theae), Endothia canker (Cryphonectria parasitica), Melanose (Diaporthe citri), Stem blight (Phomopsis asparaqi), Phomopsis canker (Phomopsis fukushii), Brown spot (Phomopsis vexans), Anthracnose (Discula theae-sinensis), Valsa canker (Valsa ceratosperma). Blast (Maqnaporthe qrisea), Crown rot (Colletotrichum acutatum, C. 20 fraqariae, Glomerella cinqulata), Bitter rot (Colletotrichum acutatum, Glomerella cinqulata), Anthracnose (Colletotrichum acutatum, Glomerella cinqulata), Anthracnose (Colletotrichum acutatum), Ripe rot (Colletotrichum acutatum, Glomerella cinqulata), Anthracnose (Colletotrichum acutatum), Anthracnose (Colletotrichum lindemuthianum), Anthracnose (Colletotrichum orbiculare), Anthracnose (Glomerella cinqulata), 25 Anthracnose (Glomerella cinqulata), Anthracnose (Glomerella cinqulata), Brown stem rot (Phialophora qreqata), Leaf spot (Pseudophloeosporella dioscoreae), Scald (Rhynchosporium secalis), Rust (Phakopsora nishidana), Rust (Phakopsora pachyrhizi). Rust (Kuehneola iaponica, Phraqmidium fusiforme, P. mucronatum, P. rosae-multiflorae), Rust (Gymnosporangium 30 asiaticum). Rust (Gymnosporangium vamadae), Rust (Puccinia allii), Rust (Puccinia horiana), Brown rust (Puccinia recondita), Rust (Puccinia tanaceti var. tanaceti), Rust (Uromvces viciae-fabae var. viciae-fabae), Smut (Sporisorium scitamineum), Smut (Ustilago maydis), Loose smut (Ustilago nuda), Net blister blight (Exobasidium reticulatum), Blister blight (Exobasidium vexans), Stem rot, Southern blight (Athelia 35 rolfsii), Root and stem rot (Ceratobasidium comiqerum, Rhizoctonia solani), (Rhizoctonia solani), Damping-off (Rhizoctonia solani), Damping-off (Rhizoctonia solani), Bottom rot (Rhizoctonia solani), Brown patch, Large patch (Rhizoctonia solani), Sheath blight (Thanatephorus cucumeris). Root rot/Leaf blight (Thanatephorus cucumeris), Rhizopus rot (Rhizopus stolonifer var. stolonifer), Clubroot (Plasmodiophora brassicae), 40 Aphanomyces root rot (Aphanomyces cochlioides), White rust (Albugo macrospora), Downy mildew (Bremia lactucae), Downy mildew (Peronospora chrvsanthemi-coronarii). Downy mildew (Peronospora destructor), Downy mildew (Peronospora farinosa f. sp. spinaciae). Downy mildew (Peronospora manshurica), Downy mildew (Peronospora parasitica), Downy mildew (Peronospora sparsa), Downy mildew (Plasmopara halstedii), 45 Downy mildew (Plasmopara nivea), Downy mildew (Plasmopara viticola), Downy mildew (Pseudoperonospora cubensis), Phytophthora root rot (Phvtophthora cactorum), Brown rot (Phvtophthora capsici), Phytophthora rot (Phvtophthora capsici), Phytophthora blight (Phvtophthora capsici), Phytophthora rot (Phvtophthora cryptoqea). 46 Late blight (Phvtophthora infestans), White powdery rot (Phvtophthora palmivora), Leaf blight (Phvtophthora porri), Phytophthora root and stem rot (Phvtophthora soiae), Phytophthora stem rot (Phvtophthora viqnae f. sp. adzukicola), Damping-off (Pvthium aphanidermatum, P. myriotvlum, P. paroecandrum, P. ultimum var. ultimum), Root rot 5 (Pvthium aristosporum), Browning root rot (Pvthium arrhenomanes, P. qraminicola), Damping-off (Pvthium buismaniae, P. myriotvlum), Root rot (Pvthium myriotvlum), Root rot (Pvthium myriotvlum, P. ultimum var. ultimum), Brown blotted root rot (Pvthium sulcatum), Bacterial canker (Clavibacter michiqanensis subsp. michiqanensis), Scab (Streptomvces spp.), 10 Crown gall (Rhizobium radiobacter), Bacterial stripe (Burkholderia andropogonis), Soft rot (Burkholderia cepacia, Pseudomonas marqinalis p_v. marqinalis, Erwinia rhapontici). Bacterial grain rot (Burkholderia gladioli, B. qlumae). Bacterial fruit blotch (Acidovorax avenae subsp. citrulli). Bacterial leaf blight (Acidovorax koniaci), Bacterial wilt (Ralstonia solanacearum). Bacterial shot hole (Xanthomonas arboricola pv. pruni, Pseudomonas 15 syrinqae p_v. syrinqae, Brenneria niqrifluens), Bacterial leaf spot (Xanthomonas arboricola pv. pruni), Bacterial spot (Xanthomonas axonopodis pv. vitians), Black rot (Xanthomonas campestris p_v. campestris), Bacterial pustule (Xanthomonas campestris p_v. glycines), Bacterial spot (Xanthomonas campestris pv. niqromaculans), Bacterial spot (Xanthomonas campestris p_v. vesicatoria). Citrus canker (Xanthomonas citri subsp. 20 citri), (Pseudomonas cichorii, P. marqinalis p_y_. marqinalis, Erwinia sp.), Bacterial rot (Pseudomonas cichorii, P. marqinalis p_y_. marqinalis, P. viridiflava), Bacterial blossom blight (Pseudomonas marqinalis p_v. marqinalis, P. syrinqae p_y_. syrinqae, P. viridiflava), Bacterial canker (Pseudomonas syrinqae p_y_. actinidiae), Canker (Pseudomonas syrinqae p_v. eriobotryae), Bacterial spot (Pseudomonas syrinqae p_v. lachrvmans), 25 Bacterial black spot (Pseudomonas syrinqae p_y_. maculicola). Bacterial canker (Pseudomonas syrinqae p_v. morsprunorum, Erwinia sp.), Bacterial shoot blight (Pseudomonas syrinqae p_v. theae). Bacterial soft rot (Dickeva sp., Pectobacterium carotovorum), Fire blight (Erwinia amylovora), Soft rot (Pectobacterium carotovorum), Bacterial soft rot (Pectobacterium carotovorum). 30 Animal diseases: Pneumocystis pneumonia (Pneumocystis iirovecii). Candidiasis (Candida albicans), Aspergillosis (Aspergillus fumigatus), Trichophytosis (Microsporum canis, M. gypseum, Trichophyton mentagrophytes, T. rubrum, T. tonsurans, T. verrucosum), Histoplasmosis (Histoplasma capsulatum). Cryptococcosis (Cryptococcus neoformans). 35 Parasites herein mean plant-parasitic nematodes parasitizing plants, animalparasitic nematodes parasitizing animals, Acanthocephala, Platyhelminthes, Protozoa and the like, and specifically, the following parasites may, for example, be mentioned, but the present invention is not restricted thereto. Nematodes of the order Enoplida such as Giant kidney worm (Dioctophvma 40 renale), Thread worms (Capillaria annulata), Cropworm (Capillaria contorta), Capillary liver worm (Capillaria hepatica), Capillaria perforans, Capillaria philippinensis, Capillaria suis, Whipworm (Trichuris discolor). Whipworm (Trichuris ovis), Pig whipworm (Trichuris suis), Human whipworm (Trichuris trichiura), Dog whipworm (Trichuris vulpis), Pork worm (Trichinella spiralis), etc. 45 Nematodes of the order Rhabditida such as Intestinal threadworm (Strongyloides papillosus), Strongyloides planiceps, Pig threadworm (Strongyloides ransomi), Threadworm (Strongyloides stercoralis), Micronema spp., etc. Nematodes of the order Strongylida such as Hookworm (Ancvlostoma braziliense), 47 Dog hookworm (Ancvlostoma caninum), Old World hookworm (Ancylostoma duodenale), Cat hookworm (Ancvlostoma tubaeforme), The Northern hookworm of dogs (Uncinaria stenocephala), Cattle hookworm (Bunostomum phlebotomum), Small ruminant hookworm (Bunostomum triqonocephalum), New World hookworm (Necator 5 americanus), Cvathostomum spp., Cvlicocyclus spp.. Cvlicodontophorus spp., Cylicostephanus spp., Stronqylus asini, Stronqylus edentatus, Blood worm (Stronqylus eguinus), Blood worm (Stronqylus vulgaris), Large-mouthed bowel worm (Chabertia ovina), Nodular worm (Oesophaqostomum brevicaudatum), Nodule worm (Oesophaqostomum columbianum), Nodule worm (Oesophaqostomum dentatum), 10 Nodular worm (Oesophaqostomum qeorqianum), Nodular worm (Oesophaqostomum mapjestonei), Nodular worm (Oesophaqostomum quadrispinulatum), Nodular worm (Oesophaqostomum radiatum), Nodular worm (Oesophaqostomum venulosum), Svnqamus skriabinomorpha, Gapeworm (Synqamus trachea), Swine kidney worm (Stephanurus dentatus). Cattle bankrupt worm (Cooperia oncophora), Red stomach 15 worm (Hvostrongylus rubidus), Stomach hair worm (Trichostronqylus axei), Trichostrongylus colubriformis, Oriental trichostrongylus (Trichostronqylus orientalis), Red stomach worm (Haemonchus contortus). Cattle stomach worm (Mecistocirrus digjtatus), Brown stomach worm (Ostertaqia ostertagi), Common lungworm (Dictvocaulus filaria). Bovine lungworm (Dictvocaulus viviparus), Thin-necked intestinal 20 worm (Nematodirus filicollis), Swine lungworm (Metastronqylus elonqatus), Lungworm (Filaroides hirthi), Lungworm (Crenosoma aerophila), Fox lungworm (Crenosoma vulpis), Rat lung worm (Anqiostronqylus cantonensis), French heartworm (Anqiostronqylus vasorum), Protostronqylus spp., etc. Nematodes of the order Aphelenchida such as Rice white tip nematode 25 (Aphelenchoides besseyi), Strawberry foliar nematode (Aphelenchoides fraqariae), Chrysanthemum foliar nematode (Aphelenchoides ritzemabosi), Pine wood nematode (Bursaphelenchus xylophilus), etc. Nematodes of the order Tylenchida such as White potato cyst nematode (Globodera pallida). Potato cyst nematode (Globodera rostochiensis). Cereal cyst 30 nematode (Heterodera avenae). Soybean cyst nematode (Heterodera glycines), Sugarbeet cyst nematode (Heterodera schachtii). Clover cyst nematode (Heterodera trifolii). Peanut root-knot nematode (Meloidogyne arenaria). Northern root-knot nematode (Meloidogyne hapla). Southern root-knot nematode (Meloidogyne incognita), Javanese root-knot nematode (Meloidogyne iavanica), Apple root-knot nematode 35 (Meloidogyne mali). Coffee root-lesion nematode (Pratvlenchus coffeae), (Pratvlenchus drenatus), Tea root-lesion nematode (Pratvlenchus loosi), California root-lesion nematode (Pratvlenchus neqlectus), Cobb's root-lesion nematode (Pratvlenchus penetrans), Walnut root-lesion nematode (Pratvlenchus vulnus), Citrus burrowing nematode (Radopholus citrophilus), Banana burrowing nematode (Radopholus similis), 40 etc. Nematodes of the order Oxyurida such as Pinworm (Enterobius vermicularis), Equine pinworm (Oxyuris equi). Rabbit pinworm (Passalurus ambiquus), etc. Nematodes of the order Ascaridida such as Pig roundworm (Ascaris suum), Horse roundworm (Parascaris equorum), Dog roundworm (Toxascaris leonina), Dog intestinal 45 roundworm (Toxocara canis), Feline roundworm (Toxocara cati), Large cattle roundworm (Toxocara vitulorum), Anisakis spp., Pseudoterranova spp., Caecal worm (Heterakis gallinarum), Chicken roundworm (Ascaridia galli), etc. Nematodes of the order Spirurida such as Guinea worm (Dracunculus 48 medinensis), Gnathostoma doloresi, Gnathostoma hispidum, Gnathostoma nipponicum, Reddish-coloured worm (Gnathostoma spinigerum), Dog stomach worm (Physaloptera canis), Cat stomach worm (Physaloptera felidis, P. praeputialis), Feline/canine stomach worm (Physaloptera rara), Eye worm (Thelazia callipaeda), Bovine eyeworm (Thelazia 5 rhodesi), Large mouth stomach worm (Draschia megastoma), Equine stomach worm (Habronema microstoma), Stomach worm (Habronema muscae), Gullet worm (Gongylonema pulchrum). Thick stomach worm (Ascarops strongylina), Parafilaria (Parafilaria boyicola), Parafilaria multipapillosa, Stephanofilaria okinawaensis, Bancroft filarial (Wuchereria bancrofti), Bruqia malayi, Neck threadworm (Onchocerca cervicalis), 1 o Onchocerca qibsoni, Cattle filarial worm (Onchocerca gutturosa). Onchocerca volvulus, Bovine filarial worm (Setaria diqitata), Peritoneal worm (Setaria equina), Setaria labiatopapillosa. Setaria marshalli, Dog heartworm (Dirofilaria immitis), African eye worm (Loajoa), etc. Microorganisms of the phylum Acanthocephala such as Moniliformis moniliformis, 15 Giant thorny-headed worm (Macracanthorhynchus hirudinaceus), etc. Cestodes of the order Pseudophyllidea such as Fish tapeworm (Diphvllobothrium latum), Diphvllobothrium nihonkaiense, Manson tapeworm (Spirometra erinaceieuropaei), Diploqonoporus qrandis, etc. Cestodes of the order Cyclophyllidea such as (Mesocestoides lineatus), Chicken 20 tapeworm (Raillietina cesticillus), Fowl tapeworm (Raillietina echinobothrida), Chicken tapeworm (Raillietina tetraqona), Canine tapeworm (Taenia hydatiqena), Canine tapeworm (Taenia multiceps). Sheep measles (Taenia ovis), Dog tapeworm (Taenia pisiformis), Beef tapeworm (Taenia saqinata), Tapeworm (Taenia serialis). Pork tapeworm (Taenia solium), Feline tapeworm (Taenia taeniaeformis), Hydatid tapeworm 25 (Echinococcus granulosus). Small fox tapeworm (Echinococcus multilocularis), Echinococcus oligarthrus, Echinococcus vogeli, Rat tapeworm (Hymenolepis diminuta), Dwarf tapeworm (Hymenolepis nana). Double-pored dog tapeworm (Dipylidium caninum), Amoebotaenia sphenoides, Choanotaenia infundibulum, Metroliasthes coturnix, Equine tapeworm (Anoplocephala magna), Cecal tapeworm (Anoplocephala 30 perfoliata), Dwarf equine tapeworm (Paranoplocephala mamillana), Common tapeworm (Moniezia benedeni). Sheep tapeworm (Moniezia expansa), Stilesia spp., etc. Trematodes of the order Strigeidida such as Pharvngostomum cordatum, Blood fluke (Schistosoma haematobium), Blood fluke (Schistosoma iaponicum), Blood fluke (Schistosoma mansoni), etc. 35 Trematodes of the order Echinostomida such as Echinostoma cinetorchis, Echinostoma hortense. Giant liver fluke (Fasciola gigantica), Common liver fluke (Fasciola hepatica), Fasciolopsis buski, Homalogaster paloniae, etc. Trematodes of the order Plagiorchiida such as Dicrocoelium chinensis, Lancet liver fluke (Dicrocoelium dendriticum), African lancet fluke (Dicrocoelium hospes), 40 Eurytrema coelomaticum, Pancreatic fluke (Eurvtrema pancreaticum), Paragonimus miyazakii, Paragonimus ohirai, Lung fluke (Paragonimus westermani), etc. Trematodes of the order Opisthorchiida such as Amphimerus spp., Chinese liver fluke (Clonorchis sinensis), Cat liver fluke (Opisthorchis felineus). Southeast Aasian liver fluke (Opisthorchis viverrini), Pseudamphistomum spp., Metorchis spp., Parametorchis 45 spp., Intestinal fluke (Heterophves heterophves), Metagonimus yokokawai, Pygidiopsis summa, etc. Amebas such as Entamoeba histolytica, E. invadens, etc. Piroplasmida sporozoa such as Babesia bigemina, Babesia bovis, Babesia caballi, 49 Babesia can is, Babesia felis, Babesia qibsoni, Babesia ovate, Cvtauxzoon felis, Theileria annulata. Theileria mutans, Theileria orientalis, Theileria parva, etc. Haemosporida sporozoa such as Haemoproteus mansoni, Leucocytozoon caulleryi, Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, 5 Plasmodium vivax, etc. Eucoccidiorida sporozoa such as Carvospora spp., Eimeria acervulina, Eimeria bo vis, Eimeria brunetti, Eimeria maxima, Eimeria necatrix, Eimeria ovinoidalis, Eimeria stiedae, Eimeria tenella, Isospora canis, Isospora felis, Isospora suis, Tvzzeria alleni, Tyzzeria anseris, Tvzzeria perniciosa, Wenyonella anatis, Wenvonella qaqari, 10 Cryptosporidium canis, Cryptosporidium felis, Cryptosporidium hominis, Cryptosporidium meleaqridis, Cryptosporidium muris, Cryptosporidium parvum, Sarcocystis canis, Sarcocystis cruzi, Sarcocystis felis, Sarcocystis hominis, Sarcocystis miescheriana, Sarcocystis neurona, Sarcocystis tenella, Sarcocystis oyalis, Toxoplasma gondii, Hepatozoon canis, Hepatozoon felis, etc. 15 Vestibuliferida ciliata such as Balantidium coli, etc. Trichomonadida flagellata such as Histomanas meleaqridis, Pentatrichomonas hominis, Trichomonas tenax, etc. Diplomonadida flagellata such as Giardia intestinalis, Giardia muris, Hexamita meleaqridis, Hexamita parva, etc. 20 Kinetoplastida flagellata such as Leishmania donovani, Leishmania infantum, Leishmania major, Leishmania tropica, Trypanosoma brucei qambiense, Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Trypanosoma equiperdum, Trypanosoma evansi, etc. Useful insects herein mean insects useful for human life by utilizing their products, 25 or useful to make agricultural work efficient e.g. by using them for pollination of orchard trees/vegetables, and specifically, Japanese honeybee (Apis cerana iaponica), Western honey bee (Apis mellifera), Bumblebee (Bombus consobrinus wittenburqi, B. diversus diversus, B. hypocrita hypocrita, B. iqnitus, B. terrestris), Hornfaced bee (Osmia cornifrons), Silkworm (Bombvx mori) may, for example, be mentioned, but the present 30 invention is not restricted thereto. Natural enemies herein mean organisms which kill specific organisms particularly specific organisms damaging agricultural crops by predation or parasitism or which inhibit propagation of such organisms, and specifically, the following organisms may, for example, be mentioned, but the present invention is not restricted thereto. 35 Parasitic wasps belonging to the family Braconidae such as Dacnusa sasakawai, Dacnusa sibirica, Aphidius colemani, Apanteles qlomeratus, etc., the family Aphelinidae such as Aphelinus albipodus, Aphelinus asvchis, Aphelinus qossypii, Aphelinus maculatus, Aphelinus varipes, Encarsia formosa, Eretmocerus eremicus, Eretmocerus mundus, etc., and the family Eulophidae such as Chrysocharis pentheus, 40 Neochrvsocharis formosa, Diqlyphus isaea, Hemiptarsenus varicornis, etc.; Aphidophagous gall midge (Aphidoletes aphidimyza); Seven-spot ladybird (Coccinella septempunctata); Asian lady beetle (Harmonia axyrjdjs); Predatory beetle (Propylea iaponica); Anthocorid predatory bugs belonging to the family Anthocoridae such as Orius minutus, Orius naqaii, Orius sauteri. Minute pirate bug (Orius strigicollis), etc.; 45 Predatory mirids belonging to the family Miridae such as Pilophorus typicus, Nesidiocoris tenuis, etc.; Predatory thrips belonging to the family Aeolothripidae such as Franklinothrips vespiformis, etc.; Green lacewing belonging to the family Chrysopidae such as Dichochrvsa formosanus, Chrysoperla nipponensis, etc.; Predatory mites 50 belonging to the family Phytoseiidae such as Neoseiulus californicus, Amblvseius cucumeris, Amblvseius degenerans, Amblvseius swirskii, Phvtoseiulus persimilis, etc.; Wolf spider (Pardosa pseudoannulata); Crab spider (Misumenops tricuspidatus). The compounds of the present invention represented by the formula (I) can be 5 produced, for example, by the following processes. Process A R2 R3 S~\ ° R2 R3 /^i(&J N^Q base W N^ R1 R1 (HI) (II) (la) A compound represented by the formula (II) [wherein G2, R1, R2 and R3 are the same as defined above] or its salt (such as a hydrochloride or a hydrobromide) is 10 reacted with a compound represented by the formula (III) [wherein G1 is the same as defined above, and J1 is a chlorine atom, a bromine atom, a C1-C4 alkylcarbonyloxy group (such as a pivaloyloxy group), a C1-C4 alkoxycarbonyloxy group (such as an isobutyloxycarbonyloxy group), an azolyl group (such as an imidazol-1-yl group) or the like], if necessary in a solvent such as benzene, toluene, dichloromethane, chloroform, 15 1,2-dichloroethane, diethyl ether, tert-butyl methyl ether, tetrahydrofuran, 1,4-dioxane, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, water or a mixture of two or more of them in an any ratio, if necessary in the presence of a base such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium acetate, triethylamine, ethyl diisopropylamine, N-methylmorpholine, pyridine or 4- 20 (dimethylamino)pyridine in an amount of from 1 to 3 equivalents per 1 equivalent of the compound represented by the formula (II), within a temperature range of from 0°C to the refluxing temperature of the reaction mixture for from 30 minutes to 24 hours, to obtain a compound of the present invention represented by the formula (la) [wherein G1, R1, R2 and R3 are the same as defined above] which is a compound of the formula (I) wherein 25 W is an oxygen atom, and R4 is a hydrogen atom. Some of the compounds represented by the formula (III) used in this process are known compounds, and some of them are commercially available. The rest of them can be synthesized in accordance with known methods disclosed in the literature, for example, by a method in accordance with the method disclosed in J. Med. Chem., 30 1991, vol.34, p.1630, etc., in which a corresponding known carboxylic acid is reacted with a halogenating agent such as thionyl chloride, phosphorus pentachloride or oxalyl chloride, a method in accordance with the method disclosed in Tetrahedron Letters, 2003, vol.44, p.4819, J. Med. Chem., 1991, vol.34, p.222, etc., in which a corresponding known carboxylic acid is reacted with an organic acid halide such as pivaloyl chloride or 35 isobutyl chloroformate in the presence of a base if necessary, or a method disclosed in J. Org. Chem., 1989, vol.54, p.5620, etc., in which a corresponding known carboxylic acid is reacted with carbonyl diimidazole, sulfonyl diimidazole or the like. Process B 51 W R2R3 HjNO-R1 (V) ®"i R4 O (IV) (I) 1 Equivalent of a compound represented by the formula (IV) [wherein G\ G2, W, R2, R3 and R4 are the same as defined above] is reacted with from 1 to 3 equivalents of a compound represented by the formula (V) [wherein R1 is the same as defined above] or its salt (such as a hydrochloride or a hydrobromide), if necessary in a solvent such as benzene, toluene, methanol, ethanol, tetrahydrofuran, acetic acid, pyridine, water or a mixture of two or more of them in any ratio, if necessary in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium acetate, triethylamine or pyridine in an amount of from 1 to 4 equivalents per 1 equivalent of the compound represented by the formula (IV), or with hydrochloric acid, sulfuric acid or the like as a catalyst in an amount of from 0.1 to 1 equivalent per 1 equivalent of the compound represented by the formula (IV), within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 1 to 48 hours to obtain a compound of the present invention represented by the formula (I) [wherein G\ G2, W, R1, R2, R3 and R4 are the same as defined above]. Process C & W II c, i . II H2NOH R" (IV) O OH (VI) J2-R' (VII) base (I) 1 Equivalent of a compound represented by the formula (IV) [wherein G1, G2, W, R2, R3 and R4 are the same as defined above] and from 1 to 3 equivalents of hydroxylamine or its salt (such as a hydrochloride or a sulfate) are reacted, if necessary in a solvent such as methanol, ethanol, 1,4-dioxane, acetonitrile, pyridine, water or a mixture of two or more of them in any ratio, if necessary in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium acetate, ethyldiisopropylamine or pyridine in an amount of from 1 to 4 equivalents per 1 equivalent of the compound represented by the 52 formula (IV), within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 1 to 24 hours to obtain a compound represented by the formula (VI) [wherein G\ G2, W, R2, R3 and R4 are the same as defined above]. 1 Equivalent of the obtained compound represented by the formula 5 (VI) and from 1 to 10 equivalents of a compound represented by the formula (VII) [wherein R1 is the same as defined above, J2 is a chlorine atom, a bromine atom, an iodine atom, a C1-C4 alkylsulfonate group (such as a methanesulfonyloxy group), a C1- C4 haloalkylsulfoante group (such as a trifluoromethanesulfonyloxy group) or the like] are reacted, if necessary in an atmosphere of an inert gas such as nitrogen or argon, if 10 necessary in a solvent such as benzene, toluene, dichloromethane, chloroform, tetrahydrofuran, acetone, acetonitrile, N,N-dimethylformamide, dimethylsulfoxide, water or a mixture of two or more of them in any ratio, if necessary in the presence of a base such as sodium hydride, sodium methoxide, sodium ethoxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate or 15 triethylamine in an amount of from 1 to 3 equivalents per 1 equivalent of the compound represented by the formula (VI), if necessary with tetrabutylammonium bromide, potassium iodide or the like as a catalyst in an amount of from 0.01 to 1 equivalent per 1 equivalent of the compound represented by the formula (VI), within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 1 20 to 24 hours to obtain a compound of the present invention represented by the formula (I) [wherein G1, G2, W, R\ R2, R3 and R4 are the same as defined above]. The compounds represented by the formula (VII) used in this process are known compounds, and some of them are commercially available. The rest of them can be synthesized in accordance with known methods disclosed in the literature regarding 25 known compounds. Process D (VIII) OH (VI) J2-R] (VII) base (I) 30 A compound represented by the formula (VIII) [wherein G\ G2, W, R2, R3 and R4 are the same as defined above] is reacted, for example, with sodium nitrite by a method in accordance with J. Org. Chem., 2004, vol. 69, p. 8997, etc., with tin(ll) chloridephenylmercaptan by a method in accordance with Tetrahedron, 1990, vol. 46, p. 587, etc., or with carbon disulfide by a method in accordance with J. Org. Chem., 1983, vol. 48, p. 2766, etc., to obtain a compound represented by the formula (VI) [wherein G1, G2, 53 W, R2, R3 and R4 are the same as defined above]. The compound represented by formula (VI) thus obtained may be reacted with a compound represented by the formula (VII) [wherein R1 and J2 are the same as defined above] in the same manner as in process C to obtain a compound of the present invention represented by the formula (I) [wherein G1, G2, W, R1, R2, R3 and R4 are the same as defined above]. Process E ^~>* ® O II R2 H R3 if C&I R1 J3-R4 (IX) (la) 1 Equivalent of a compound of the present invention represented by the formula (la) [wherein G\ G2, R1, R2 and R3 are the same as defined above] which is a 10 compound of the formula (I) wherein W is an oxygen atom and R4 is a hydrogen atom, is reacted with from 1 to 10 equivalents of a compound represented by the formula (IX) [wherein R4 is the same as defined above except for a hydrogen atom, and J3 is a favorable leaving group such as a chlorine atom, a bromine atom, an iodine atom, a Ci- C4 alkylcarbonyloxy group (such as a pivaloyloxy group), a C1-C4 alkylsulfonate (such 15 as a methanesulfonyloxy group), a C1-C4 haloalkylsulfonate group (such as a trifluoromethanesulfonyloxy group), an arylsulfonate group (such as a benzenesulfonyloxy group or a p-toluenesulfonyloxy group), an azolyl group (such as an imidazol-1-yl group) or the like], if necessary in a polar solvent such as tert-butyl methyl ether, tetrahydrofuran, 1,4-dioxane, acetonitrile or N,N-dimethylformamide, if necessary 20 in the presence of a base such as sodium hydride, potassium tert-butoxide, potassium hydroxide, potassium carbonate, triethylamine or pyridine in an amount of from 1 to 3 equivalents per 1 equivalent of the compound represented by the formula (la), within a temperature range of from 0 to 90°C for from 10 minutes to 24 hours to obtain a compound of the present invention represented by the formula (lb) [wherein G1, G2, R1, 25 R2 and R3 are the same as defined above, and R4 is the same as defined above except for a hydrogen atom] which is a compound of the formula (I) wherein W is an oxygen atom. Some of the compounds represented by the formula (IX) used in this process are known compounds, and some of them are commercially available. The rest of them 30 can be synthesized in accordance with known methods disclosed in the literature regarding known compounds, for example, the method disclosed in Chem. Pharm. Bull., 1986, vol. 34, p. 540 and 2001, vol. 49, p. 1102, J.Am. Chem. Soc, 1964, vol. 86, p. 4383, J. Org. Chem., 1983, vol. 48, p. 5280, Org. Synth., 1988, collective vol. 6, p. 101, Synlett, 2005, p. 2847, Synthesis, 1990, p. 1159, JP05/125017, EP0,051,273, 35 GB2,161,802 or the like. Process F 54 P2,Sa5 1 Equivalent of a compound of the present invention represented by the formula (lb) [wherein G1, G2, R1, R2, R3 and R4 are the same as defined above] which is a compound of the formula (I) wherein W is an oxygen atom, and from 1 to 10 equivalents of a sulfidizing agent such as phosphorus pentasulfide, phosphorus pentasulfide-HMDO 5 (hexamethyldisiloxane) or Lawesson's Reagent (2,4-bis(4-methoxyphenyl)-1,3,2,4- dithiadiphosphetane=2,4-disulfide) are reacted, if necessary in a solvent such as benzene, toluene, chlorobenzene, dichloromethane, chloroform, 1,2-dimethoxyethane, tetrahydrofuran, 1,4-dioxane or HMPA, if necessary in the presence of a base such as sodium hydrogen carbonate, triethylamine or pyridine in an amount of from 1 to 4 10 equivalents per 1 equivalent of the compound represented by the formula (lb), within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 10 minutes to 50 hours, or in pyridine as a base in an amount sufficient as a solvent within a temperature range of from 80°C to the refluxing temperature of the reaction mixture for from 1 to 3 hours, to obtain a compound of the present invention 15 represented by the formula (Ic) [wherein G1, G2, R\ R2, R3 and R4 are the same as defined above] which is a compound of the formula (I) wherein W is a sulfur atom. In processes A to F, the reaction mixture after a reaction can be worked up by an ordinary procedure such as direct concentration, a procedure such that the reaction mixture is dissolved in an organic solvent, washed with water and concentrated, or a 20 procedure such that the reaction mixture is poured into ince water, extracted with an organic solvent and concentrated, to obtain the desired oxime-substituted amide compound. If purification is needed, the desired oxime-substituted amide compound may be isolated or purified by an optional purification method such as recrystallization or fractionation by column chromatography, thin layer chromatography or liquid 25 chromatography. The compound represented by the formula (II) used in process A may be synthesized, for example, by reaction schemes 1 to 3. Reaction Scheme 1 55 C II o R2R3 / "N (X) o w o HjNO-R1 (V) R2 R3 H2»NH2 R2N (XII) 1 Equivalent of a compound represented by the formula (X) [wherein G2, R2 and R3 are the same as defined above, and J4 is a chlorine atom, bromine atom, an iodine atom or the like] and from 1 to 1.5 equivalents of potassium phthalimide are reacted, in a solvent such as toluene, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetone, N,N-dimethylformamide, N,N-dimethylacetamide or dimethylsulfoxide, if necessary in the presence of from 0.1 to 2 equivalents of a base such as sodium carbonate, potassium carbonate or sodium hydrogen carbonate, if necessary with from 0.1 to 1 equivalent of tetrabutylammonium iodide, tributylhexadecylphosphonium bromide, crown ether (18-Crown-6) or the like as a catalyst, within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 0.5 to 24 hours to obtain a compound represented by the formula (XI) [wherein G2, R2 and R3 are the same as defined above]. The obtained compound represented by the formula (XI) is reacted with a compound represented by the formula (V) [wherein R1 is the same as defined above] under the same conditions as in process B to obtain a compound represented by the formula (XII) [wherein G2, R1, R2 and R3 are the same as defined above]. Then, the compound represented by the formula (XII) is reacted with hydrazine monohydrate or aqueous hydrazine in an amount of from 1 to 4 equivalents per 1 equivalent of the compound represented by the formula (XII), if necessary in a solvent such as toluene, dichloromethane, chloroform, methanol, ethanol, tetrahydrofuran, 1,4- dioxane, water or a mixture of two or more of them in any ratio, if necessary in an atmosphere of an inert gas such as nitrogen or argon, within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 1 to 24 hours to obtain a compound represented by the formula (II) [wherein G2, R1, R2 and R3 are the same as defined above]. Some of the compounds represented by the formula (X) used in this process are known compounds, and some of them are commercially available. The rest of them can be synthesized in accordance with known methods disclosed in the literature regarding known compounds. Reaction Scheme 2 56 XB C II o (X) R2 R3 H2NNH2 HN 10 15 A compound represented by the formula (X) [wherein G2, R2, R3 and J4 are the same as defined above] and the compound represented by the formula (V) [wherein R1 is the same as defined above] are reacted under the same conditions as in process B to obtain a compound represented by the formula (XIII) [wherein G2, R1, R2, R3 and J4 are the same as defined above], and the obtained compound represented by the formula (XIII) is reacted with potassium phthalimide in the same manner as in reaction scheme 1 to obtain a compound represented by the formula (XII) [wherein G2, R1, R2 and R3 are the same as defined above]. Then, the compound represented by the formula (XII) is reacted with hydrazine monohydrate or aqueous hydrazine in the same manner as in reaction scheme 1 to obtain a compound represented by the formula (II) [wherein G2, R1, R2, and R3are the same as defined above]. Reaction Scheme 3 M (XIV) (XV) 57 O R2R3 O N X H (XVI) II o R o' O R2R3 C N ^ C H M O (XVII) Gz HjNO-R1 (V) R2 R H2N (XVIII) A known compound represented by the formula (XIV) [wherein G2 is the same as defined above, and J4 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom or the like] is reacted with an alkyllithium, a Grignard reagent or the like in accordance with a method disclosed in Tetrahedron Lett., 2002, vol. 43, p. 8223 and 5 2005, vol. 46, p. 8587, J. Org. Chem., 2006, vol. 71, p. 9861, etc., to prepare a compound represented by the formula (XV) [wherein G2 is the same as defined above, and M is Li, MgCI, MgBr, Mgl or the like], and the prepared compound represented by the formula (XV) and a compound represented by the formula (XVI) [wherein R2 and R3 are the same as defined above, R is a tert-butyl group, a benzyl group or the like, and J5 10 is a dimethylamino group, a N-methylmethoxyamino group, a piperidin-1-yl group, a benzotriazol-1-yl group or the like] are reacted to obtain a compound represented by the formula (XVII) [wherein G2, R2, R3 and R are the same as defined above]. Some of the compounds represented by the formula (XVI) are known compounds, and some of them are commercially available. The rest of them can be synthesized in 15 accordance with known methods disclosed in the literature regarding known compounds. Then, the compound represented by the formula (XVII) and a compound represented by the formula (V) [wherein R1 is the same as defined above] are reacted under the same conditions as in process B to obtain a compound represented by the 20 formula (XVIII) [wherein G2, R\ R2, R3 and R are the same as defined above]. The obtained compound represented by the formula (XVIII) is deprotected under known reaction conditions with respect to the substituent R to obtain a compound represented by the formula (II) [wherein G2, R1 R2, and R3 are the same as defined above] or its salt (such as a hydrochloride, a hydrobromide, a trifluoroacetate or a p-toluenesulfonate). 25 The compound represented by the formula (IV) used in processes B and C may be synthesized, for example, by reaction scheme 4 or 5. Reaction Scheme 4 58 v_y R4 o v_y R4 o (III) (XIX) (IVb) A compound represented by the formula (III) [wherein G1 and J1 are the same as defined above] and a compound represented by the formula (XIX) [wherein G2, R2 and R3 are the same as defined above, and R4 is a hydrogen atom, a C1-C6 alkyl group or the like] or its salt (such as a hydrochloride, a hydrobromide, a trifluoroacetate or a ptoluenesulfonate) are reacted under the same conditions as in process A to obtain a compound represented by the formula (IVb) [wherein G\ G2, R2 and R3 are the same as defined above, and R4 is a hydrogen atom, a C1-C6 alkyl group or the like] which is a compound of the formula (IV) wherein W is an oxygen atom. Reaction Scheme 5 O R2R3 O R2 R3 ^ C . X OH _ / ^ X ^ v_y R4 o v_y R4 o (XX) (XXI) (XV) V RyRJ f G2) O R2 R3 / ^N *N C v_y R4 O (IVb) 10 A compound represented by the formula (XX) [wherein G\ R2, R3 and R4 are the same as defined above] is reacted for example by a method disclosed in J. Med. Chem., 2004, vol. 47, p. 6884, Bioorganic & Med. Chem. Lett., 2012, vol. 22, p. 5485, etc. to prepare a compound represented by the formula (XXI) [wherein G1, R2, R3, R4 and J5 are the same as defined above], and the obtained compound represented by the 15 formula (XXI) is reacted with a compound represented by the formula (XV) [wherein G2 and M are the same as defined above] in the same manner as in reaction scheme 3 to obtain a compound represented by the formula (IVb) [wherein G\ G2, R2 and R3 are the same as defined above, and R4 is a hydrogen atom, a C1-C6 alkyl group or the like] which is a compound of the formula (IV) wherein W is an oxygen atom. 20 Some of the compounds represented by the formula (XX) used in this process are known compounds, and some of them are commercially available. The rest of them can be synthesized in accordance with known methods disclosed in the literature regarding known compounds. Some of the compounds represented by the formula (V) used in process B are 25 known compounds, and some of them are commercially available. The rest of them can be synthesized, for example, as follows. Reaction Scheme 6 59 if^rx P J6-Ri W (XXII) f ^ ^ A /R H2^H2 [-OH *~ I N-O *• HjNO-R1 ^ W (V) o o (XXIII) That is, N-hydroxyphthalimide and a compound represented by the formula (XXII) [wherein R1 is the same as defined above, and J6 is a chlorine atom, a bromine atom, an iodine atom or hydroxy group] are reacted, for example, in accordance with a method disclosed in J. Med. Chem., 2008, vol. 51, p. 4601, WO2008/055013, etc. to 5 obtain a compound represented by the formula (XXIII) [wherein R1 is the same as defined above], and the obtained compound represented by the formula (XXIII) is reacted with hydrazine monohydrate or aqueous hydrazine under the same conditions as in reaction scheme 1 to obtain a compound represented by the formula (V) [wherein R1 is the same as defined above]. 10 Some of the compounds represented by the formula (XXII) used in this process are known compounds, and some of them are commercially available. The rest of them can be synthesized in accordance with known methods disclosed in the literature regarding known compounds. The compound represented by the formula (VIII) used in process D may be 15 synthesized, for example, as follows. Reaction Scheme 7 O 2 O O N (XXIV) M n &**—~&^~&Tf (HI) (XXV) (XXVI) r 02N (XXVII) That is, a compound represented by the formula (III) [wherein G1 and J1 are the same as defined above] and a compound represented by the formula (XXIV) [wherein R4 is a hydrogen atom, a C1-C6 alkyl group or the like] or its salt (such as a 20 hydrochloride) are reacted under the same conditions as in process A to obtain a compound represented by the formula (XXV) [wherein G1 is the same as defined above, and R4 is a hydrogen atom, a C1-C6 alkyl group or the like]. The primary amines represented by the formula (XXIV) used in this process are known compounds, and some of them are commercially available. The rest of them 25 can be synthesized in accordance with known methods disclosed in the literature regarding known primary amines. 60 Then, the obtained compound represented by the formula (XXV) is reacted, for example, in accordance with a method disclosed in WO2007/026965, Tetrahedron Lett., 1994, vol. 35, p. 7107, WO2006/067103, J. Org. Chem., 1987, vol. 52, p. 5475, etc. to obtain a compound represented by the formula (XXVI) [wherein G1 is the same as 5 defined above, R4 is a hydrogen atom, a C1-C6 alkyl group or the like, and J7 is a chlorine atom, a C1-C4 alkylcarbonyloxy group (such as an acetoxy group), a C1-C4 alkylsulfonate group (such as a methanesulfonyloxy group) or an arylsulfonate group (such as a benzenesulfonyloxy group)]. The obtained compound represented by the formula (XXVI) and a compound 10 represented by the formula (XXVII) [wherein G2 is the same as defined above] are reacted, for example, in accordance with a method disclosed in Bull. Chem. Soc. Jpn., 2004, vol. 77, p. 2219, Tetrahedron Lett., 2006, vol. 47, p. 3501, J. Org. Chem., 2004, vol. 69, p. 8997, etc. to obtain a compound represented by the formula (Vlllb) [wherein G1 and G2 are the same as defined above, and R4 is a hydrogen atom, a C1-C6 alkyl 15 group or the like] which is the compound of the formula (VIII) wherein W is an oxygen atom, and R2 and R3 are hydrogen atoms. The compound represented by the formula (XIX) may be produced by deprotecting a compound represented by the formula (XVII) obtainable by reaction scheme 3 by a known method or may be synthesized, for example, by any of reaction 20 schemes 8 to 11. Reaction Scheme 8 r• pN R2R3 / O i N-L-N -J4-R'R3 zO\ ^ R2R3 / Ot Lij o J4 x r "—' ** 71 ^> v —*~ H2N' ^c II L\ J n " (X) (XXVIII) (XlXa) A compound represented by the formula (X) [wherein G2, R2, R3 and J4 are the same as defined above] and hexamethylenetetramine are reacted, for example, in accordance with a method disclosed in J. Heterocyclic Chem., 1987, vol. 24, p. 297 etc., 25 if necessary in a solvent such as toluene, dichloromethane, chloroform, ethanol, diethyl ether, tetrahydrofuran, acetone, ethyl acetate, acetonitrile, water or a mixture of two or more of them in any ratio, if necessary with sodium iodide or the like, within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 1 to 24 hours to obtain a quaternary ammonium salt represented by the 30 formula (XXVIII) [wherein G2, R2, R3 and J4 are the same as defined above]. The obtained quaternary ammonium salt represented by the formula (XXVIII) is hydrolyzed in a solvent such as methanol, ethanol, acetonitrile, water or a mixture of two or more of them in any ratio, in the presence of an acid catalyst such as hydrochloric acid or hydrobromic acid within a temperature range of from room temperature to the refluxing 35 temperature of the reaction mixture for from 0.5 to 48 hours to obtain a hydrochloride or hydrobromide of a compound represented by the formula (XlXa) [wherein G2, R2 and R3 are the same as defined above] which is a compound of the formula (XIX) wherein R4 is a hydrogen atom. Further, after completion of the reaction, by neutralization with a base such as sodium hydroxide or potassium hydroxide, a free amine may be isolated. 40 Reaction Scheme 9 61 ii II n o o o (X) (XXIX) (XlXa) A compound represented by the formula (X) [wherein G2, R2, R3 and J4 are the same as defined above] and sodium azide or lithium azide are reacted, for example, in accordance with a method disclosed in J. Org. Chem., 1986, vol. 51, p. 3374, etc., if necessary in a solvent such as toluene, methanol, tetrahydrofuran, acetone, N,N- 5 dimethylformamide, acetonitrile, dimethylsulfoxide, water or a mixture of two or more of them in any ratio, if necessary with methyl trioctylammonium chloride, potassium iodide or the like as a catalyst, within a temperature range of from 0 to 50°C for from 0.5 to 18 hours to obtain a compound represented by the formula (XXIX) [wherein G2, R2 and R3 are the same as defined above]. The obtained compound represented by formula 10 (XXIX) is hydrogenated in a solvent such as methanol, ethanol, diethyl ether, water or a mixture of two or more of them in any ratio in the presence of palladium or a platinum catalyst, if necessary with hydrochloric acid or the like, in an atmosphere of hydrogen under 1 to 10 atm at room temperature for from 0.5 to 24 hours; is reacted with a reducing agent such as tin(ll) chloride in a solvent such as dichloromethane, methanol, 15 ethanol or ethyl acetate within a temperature range of from room temperature to 60°C for from 3 to 18 hours; or is reacted with triphenylphosphine and water in a solvent such as tetrahydrofuran, water or a mixture of the two in any ratio within a temperature range of from 0°C to room temperature for from 0.5 to 24 hours, to obtain a compound (XlXa) [wherein G2, R2 and R3 are the same as defined above] which is a compound of the 20 formula (XIX) wherein R4 is a hydrogen atom. Further, after completion of the reaction if necessary, the compound of the formula (XlXa) may be treated with hydrochloric acid, hydrobromic acid, trifluoroacetic acid, p-toluenesulfonic acid or the like to obtain a salt thereof. Reaction Scheme 10 CHO R 2 R 3 /7J\ Na NN ?\ Rv,R U«\ + R2R3 y (G2 ) NCHO C X X J H V II I II L II (X) (XXX) (XlXa) 25 A compound represented by the formula (X) [wherein G2, R2, R3 and J4 are the same as defined above] and diformylimide sodium salt are reacted, for example, in accordance with a method disclosed in Tetrahedron Lett., 1989, vol. 30, p. 5285 etc., in a solvent such as N,N-dimethylformamide or acetonitrile within a temperature range of from room temperature to the refluxing temperature of the reaction mixture for from 2 to 30 24 hours to obtain a compound represented by the formula (XXX) [wherein G2, R2 and R3 are the same as defined above]. The obtained compound represented by the formula (XXX) is hydrolyzed in a solvent such as methanol, ethanol, 1,4-dioxane, water or a mixture of two or more of them in any ratio with an acid such as hydrochloric acid within a temperature range of from room temperature to the refluxing temperature of the 35 reaction mixture for from 1 to 24 hours to obtain a hydrochloride or the like of a 62 compound represented by the formula (XlXa) [wherein G2, R2 and R3 are the same as defined above] which is a compound of the formula (XIX) wherein R4 is a hydrogen atom. Further, after completion of the reaction, by neutralization with a base such as sodium hydroxide or potassium hydroxide, a free amine may be isolated. Reaction Scheme 11 H2IN-R4 RyR3 f & ) RyR3 ( & ) n i. n O R4 O (X) (XIX) A compound represented by the formula (X) [wherein G2, R2, R3 and J4 are the same as defined above] and an amine represented by the formula (XXIV) [wherein R4 is a hydrogen atom, a Ci-Ce alkyl group or the like] or its salt are reacted, if necessary in a solvent such as toluene, dichloromethane, methanol, ethanol, diethyl ether, tetrahydrofuran, 4-methyl-2-pentanone, ethyl acetate, N,N-dimethylformamide, acetonitrile, water or a mixture of two or more of them in any ratio, in an excessive amount of the compound represented by the formula (XXIV) or in the presence of a base such as sodium hydroxide, potassium carbonate, sodium carbonate, sodium hydrogen carbonate, triethylamine or ethyldiisopropylamine, within a temperature range of from 0°C to the refluxing temperature of the reaction mixture for from 1 to 24 hours to obtain a compound represented by the formula (XIX) [wherein G2, R2 and R3 are the same as defined above, and R4 is a hydrogen atom, a C1-C6 alkyl group or the like]. Some of the compounds represented by the formula (XXVII) are known compounds, and some of them are commercially available. The rest of them may be synthesized, for example, by reaction scheme 12 or 13. Reaction Scheme 12 AgN02 o r r ^ r ^ Y4 J4 Y5 2 N02 Y (XXXI) (XXVIIa) A compound represented by the formula (XXXI) [wherein Y1, Y2, Y3, Y4, Y5 and J4 are the same as defined above] is reacted with silver nitrite in accordance with a known method disclosed in the literature, for example, a method disclosed in J. Org. Chem., 2004, vol. 69, p. 6907, etc., if necessary in a solvent such as benzene, diethyl ether, tert-butyl methyl ether, acetonitrile, water or a mixture of two or more of them in any ratio, within a temperature range of from 0°C to room temperature for from 30 minutes to 24 hours, or reacted with sodium nitrite-urea, for example, in accordance with a method disclosed in Tetrahedron, 2009, vol. 65, p. 1660, etc., if necessary in a solvent such as N,N-dimethylformamide within a temperature range of from -78°C to room temperature for from 1 to 6 hours, to obtain a compound represented by the formula (XXVIIa) [wherein Y1, Y2, Y3, Y4 and Y5 are the same as defined above] which is a compound of the formula (XXVII) wherein G2 is G2-1. 63 The compounds represented by the formula (XXXI) used are known compounds, and some of them are commercially available. The rest of them can be synthesized from known compounds in accordance with known methods disclosed in the literature. Reaction Scheme 13 CH3NO2 base NO, (XXXII) (XXVIIb) 5 A compound represented by the formula (XXXII) [wherein Y1, Y2, Y3, Y4 and J4 are the same as defined above] and nitromethane are reacted in accordance with a known method disclosed in the literature, for example, a method disclosed in Heterocycles, 1987, vol. 26, p. 3259, WO2004/096772, etc., if necessary in a solvent such as tetrahydrofuran or dimethylsulfoxide, if necessary in the presence of a base such as 10 sodium hydride or potassium tert-butoxide within a temperature range of from 0 to 80°C for from 1 to 24 hours to obtain a compound of the formula (XXVIIb) [wherein Y1, Y2, Y3 and Y4 are the same as defined above] which is a compound of the formula (XXVII) wherein G2 is G2-2. The compounds represented by the formula (XXXII) used in this process are 15 known compounds, and some of them are commercially available. The rest of them can be synthesized in accordance with known methods disclosed in the literature regarding known compounds. In the respective reaction schemes, the compounds after a reaction can be worked up by an ordinary procedure to obtain intermediates to be material compounds 20 in processes A to D. Further, the respective intermediates produced in such procedure may be used in the next step reaction without isolation nor purification. As the oxime-substituted amide compounds of the present invention represented by the formula (I) which can be produced by such processes, specifically, the following 25 compounds of a first group and compounds of a second group may, for example, be mentioned. However, the following compounds of a first group and compounds of a second group merely exemplify the present invention, and the oxime-substituted amide compounds of the present invention are by no means restricted thereto. Further, combinations of substituents in the compounds of the above respective 30 groups are shown in Tables 2 and 3. In the Tables, Et denotes ethyl group, n-Pr and Pr-n denote normal propyl group, i-Pr and Pr-i denote isopropyl group, c-Pr and Pr-c denote cyclopropyl group, n-Bu and Bu-n denote normal butyl group, i-Bu and Bu-i denote isobutyl group, s-Bu and Bu-s denote secondary butyl group, c-Bu and Bu-c denote cyclobutyl group, t-Bu and Bu-t denote tertiary butyl group, Pen denotes pentyl 35 group, c-Pen and Pen-c denote cyclopentyl group, Hex denotes hexyl group, c-Hex and Hex-c denote cyclohexyl group, Ph denotes phenyl group, 1-Naph denotes 1-naphthyl group, and 2-Naph denotes 2-naphthyl group. Further, in Tables 2 and 3, aromatic heterocyclic rings represented by D-1-1a to D- 35-b have the following structures, respectively. For example, the expression "CH2(D-5-3b)-3-G" means a 3-chloroisoxazol-5- ylmethyl group. In the Tables, aliphatic heterocyclic rings represented by E-2-1a to E-17-3a have the following structures, respectively. For example, the expression "CH2(E-4-1a)CHO" means a 1-formylazetidin-2- ylmethyl group. In the Tables, partial saturated heterocyclic rings represented by M-3-b to M-19-a have the following structures, respectively. For example, the expression "CH2(M-4-2a)CH3" means a 3-methyl-4,5- dihydroisoxazol-5-ylmethyl group. Further, in the Tables, T-1 to T-9 have the following structures, respectively. Compounds of First Group ([l]-1 to [l]-68) Combinations of substituents in the compounds of the above first group are shown in Table 2. In Table 2, the expression (R) or (S) in the column substituent R2 means 5 that the proportion of the R isomer or the S isomer is at least 90% in a mixture ratio of optical isomers due to the carbon atom attached to R2. The expressions G2-1 to G2-10 in the column substituent G2 mean the following specific structures, respectively. The expression "-" in the columns substituents Y2, Y4 and Y5 means that there is no corresponding substituent present. The expression (E) or (Z) in the column substituent R1 means that the proportion 5 of the E-isomer or the Z-isomer is at least 90% in a mixture ratio of oxime geometrical isomers attached to the substituent R1. Compounds of Second Group ([l]-69 to [l]-92) Combinations of substituents in the compounds of a second group are shown in Table 3. 159 The compounds of the present invention are capable of controlling pathogens causing plant diseases in Tracheophyta such as plants of the order Pinales, the group magnoliids, the group monocots and the group eudicots, and pathogens causing infections of Vertebrata such as animals of the class Mammalia, the class Aves, the 5 class Reptilia and the class Actinopterygii, and pests such as plant-parasitic or animalparasitic nematodes, Acanthocephala, Platyhelminthes and Protozoa. Pests against plants may, for example, be fungi of the phylum Ascomycota, fungi of the phylum Basidiomycota, fungi of the phylum Chitridiomycota, fungi of the phylum Blastocladiomycota, fungi of the phylum Mucoromycotina, protists of the phylum 10 Cercozoa, microorganisms of the phylum Heterokontophyta class Oomycetes, grampositive bacteria of the phylum Actinobacteria, gram-positive bacteria of the phylum Tenericutes, gram-negative bacteria of the phylum Proteobacteria, nematodes of the order Aphelenchida and nematodes of the order Tylenchida. The compounds of the present invention have excellent controlling effect particularly on plant pathogenic fungi 15 belonging to the phylum Ascomycota and the phylum Basidiomycota, and plant-parasitic nematodes belonging to the order Aphelenchida and the order Tylenchida at low doses. Pests against animals may, for example, be fungi of the phylum Ascomycota, fungi of the phylum Basidiomycota, gram-positive bacteria of the phylum Actinobacteria, gram-positive bacteria of the phylum Firmicutes, gram-positive bacteria of the phylum 20 Tenericutes, gram-negative bacteria of the phylum Proteobacteria, nematodes of the order Enoplida, nematodes of the order Rhabditida, nematodes of the order Strongylida, nematodes of the order Ascaridida, nematodes of the order Spirurida, microorganisms of the phylum Acanthocephala, cestodes of the order Pseudophyllidea, cestodes of the order Cyclophyllidea, trematodes of the order Strigeidida, trematodes of 25 the order Echinostomida, trematodes of the order Plagiorchiida, trematodes of the order Opisthorchiida, amebas, Piroplasmida sporozoa, Haemosporida sporozoa, Eucoccidiorida sporozoa, Vestibuliferida ciliata, Trichomonadida flagellata, Diplomonadida flagellata and Kinetoplastida flagellata. Particularly, the compounds of the present invention have excellent effect to control internal parasites parasitizing 30 animals of the class Mammalia belonging to the family Cebidae, the family Cercopithecidae, the family Hominidae, the family Leporidae, the family Chinchillidae, the family Caviidae, the family Cricetidae, the family Muridae, the family Sciuridae, the family Camelidae, the family Suidae, the family Cervidae, the family Bovidae, the family Felidae, the family Canidae, the family Mustelidae, the family Equidae, the family 35 Macropodidae and the like, especially animal-parasitic nematodes belonging to the order Enoplida, the order Rhabditida, the order Strongylida, the order Aphelenchida, the order Tylenchida, the order Ascaridida and the order Spirurida, parasitizing mammals of the family Suidae, the family Bovidae, the family Felidae, the family Canidae and the family Equidae. 40 The compounds of the present invention are also effective on pests which have acquired resistance to conventional fungicides or nematicides, and the compounds of the present invention have very useful characteristics such that they have little harmful effect on non-target animals such as mammals, fishes, crustaceans, natural enemies and useful insects. 45 The compounds of the present invention may be used in any dosage form such as a soluble concentrate, an emulsifiable concentrate, a wettable powder, a water soluble powder, a water dispersible granule, a water soluble granule, a suspension concentrate, a concentrated emulsion, a suspoemulsion, a microemulsion, a dustable powder, a 160 granule, a tablet or an emulsifiable gel usually after mixed with an appropriate solid carrier or a liquid carrier, and if necessary, with a surfactant, a penetrant, a spreader, a thickener, an anti-freezing agent, a binder, an anti-caking agent, a disintegrant, an antifoaming agent, a preservative, a stabilizer or the like. A formulation in an arbitrary 5 dosage form may be sealed in water-soluble packaging such as a water-soluble capsule or a water-soluble film, for labor saving or improved safety. As solid carriers, natural minerals such as quartz, calcite, meerschaum, dolomite, chalk, kaolinite, pyrophyllite, sericite, halloysite, methahalloysite, kibushi clay, gairome clay, pottery stone, zeeklite, allophone, Shirasu, mica, talc, bentonite, activated clay, 10 acid clay, pumice, attapulgite, zeolite and diatomaceous earth, calcined natural minerals such as calcined clay, pearlite, Shirasu-balloons, vermiculite, attapulgus clay and calcined diatomaceous earth, inorganic salts such as magnesium carbonate, calcium carbonate, sodium carbonate, sodium hydrogen carbonate, ammonium sulfate, sodium sulfate, magnesium sulfate, diammonium hydrogen phosphate, ammonium dihydrogen 15 phosphate and potassium chloride, saccharides such as glucose, fructose, sucrose and lactose, polysaccharides such as starch, cellulose powder and dextrin, organic substances such as urea, urea derivatives, benzoic acid and benzoic acid salts, plants such as wood flour, powdered cork, corncob, walnut shell and tobacco stems, fly ash, white carbon (such as hydrated synthetic silica, anhydrous synthetic silica and hydrous 20 synthetic silicate), fertilizers and the like may be mentioned. As liquid carriers, aromatic hydrocarbons such as xylene, alkyl (C9 or C10 etc.) benzene, phenylxylylethane and alkyl (C1 or C3 etc.)naphthalene, aliphatic hydrocarbons such as machine oil, normal paraffin, isoparaffin and naphthene, mixtures of aromatic hydrocarbons and aliphatic hydrocarbons such as kerosene, alcohols such 25 as ethanol, isopropanol, cyclohexanol, phenoxyethanol and benzyl alcohol, polyhydric alcohols such as ethylene glycol, propylene glycol, diethylene glycol, hexylene glycol, polyethylene glycol and polypropylene glycol, ethers such as propyl cellosolve, butyl cellosolve, phenyl cellosolve, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether 30 and propylene glycol monophenyl ether, ketones such as acetophenone, cyclohexanone and y-butyrolactone, esters such as fatty acid methyl esters, dialkyl succinates, dialkyl glutamate, dialkyl adipates and dialkyl phthalates, acid amides such as N- alkyl (C1, Cs or C12 etc.)pyrrolidone, fats and oils such as soybean oil, linseed oil, rapeseed oil, coconut oil, cottonseed oil and castor oil, dimethyl sulfoxide, water and the 35 like may be mentioned. These solid and liquid carriers may be used alone or in combinations of two or more. As surfactants, nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene alkyl(mono or di)phenyl ether, polyoxyethylene(mono, di or 40 tri)styrylphenyl ether, polyoxyethylenepolyoxypropylene block copolymers, polyoxyethylene fatty acid (mono or di)ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, ethylene oxide adducts of castor oil, acetylene glycol, acetylene alcohol, ethylene oxide adducts of acetylene glycol, ethylene oxide adducts of acetylene alcohol and alkyl glycosides, anionic surfactants such as alkyl sulfate salts, 45 alkylbenzenesulfonic acid salts, lignin sulfonate, alkylsulfosuccinic acid salts, naphthalenesulfonic acid salts, alkylnaphthalenesulfonic acid salts, salts of naphthalenesulfonic acid-formalin condensates, salts of alkylnaphthalenesulfonic acidformalin condensates, polyoxyethylene alkyl ether sulfate or phosphate salts, 161 polyoxyethylene(mono or di) alkylphenyl ether sulfate or phosphate salts, polyoxyethylene(mono, di or tri)styrylphenyl ether sulfate or phosphate salts, polycarboxylic acid salts (such as polyacrylates, polymaleates and copolymers of maleic acid and an olefin) and polystyrenesulfonic acid salts, cationic surfactants such as 5 alkylamine salts and alkyl quaternary ammonium salts, amphoteric surfactants such as amino acid types and betaine types, silicone surfactants and fluorine surfactants may be mentioned. The amount of these surfactants is usually preferred to be from 0.05 to 20 parts by weight per 100 parts by weight of the agent of the present invention, though there is no 10 particular restrictions. These surfactants may be used alone or in combination of two or more. The suitable application dose of the compounds of the present invention is generally about from 0.005 to 50 kg per hectare (ha) in terms of the active ingredient, though it varies depending on the application situation, the application season, the 15 application method and the cultivated crop. When the compounds of the present invention are used to control internal parasites in mammals and birds as farm animals/poultry and pet animals, the compounds of the present invention may be administered in an effective amount together with pharmaceutical^ acceptable additives orally, parenterally by injection 20 (intramuscular, subcutaneously, intravenously or intraperitoneally); percutaneously by dipping, spraying, bathing, washing, pouring-on and spotting-on and dusting, or intranasally. The compounds of the present invention may be administered through molded articles such as chips, plates, bands, collars, ear marks, limb bands and ID tags. The compounds of the present invention are administered in an arbitrary dosage form 25 suitable for the administration route. The dosage form may be a solid preparation such as a dust, a granule, a wettable powder, a pellet, a tablet, a ball, a capsule and an molded article containing an active ingredient, a liquid preparation such as an injection fluid, an oral liquid, a liquid preparation applied to the skin or coelom, a pour-on preparation, a spot-on preparation, 30 a flowable, an emulsion, and a semisolid preparation such as an ointment and a gel. A solid preparation may generally be used by oral administration or by percutaneous or by environmental application after dilution with water or the like. A solid preparation can be prepared by mixing an active ingredient with an appropriate vehicle, and with an adjuvant if necessary, and formulating the mixture into a desired 35 dosage form. As the vehicle, an inorganic vehicle such as a carbonate, a hydrogen carbonate, a phosphate, aluminum oxide, silica or clay or an organic vehicle such as a saccharide, cellulose, cereal flour or starch may, for example, be mentioned. An injection fluid may be administered intravenously, intramuscularly or subcutaneously. An injection fluid can be prepared by dissolving an active ingredient in 40 an appropriate solvent and, if necessary, adding additives such as a solubilizer, an acid, a base, a buffering salt, an antioxidant and a protectant. As appropriate solvents, water, ethanol, butanol, benzyl alcohol, glycerin, propylene glycol, polyethylene glycol, N-methylpyrrolidone and mixtures thereof, physiologically acceptable vegetable oils and synthetic oils suitable for injection may be mentioned. As solubilizers, 45 polyvinylpyrrolidone, polyoxyethylated castor oil, polyoxyethylated sorbitan ester and the like may be mentioned. As protectants, benzyl alcohol, trichlorobutanol, phydroxybenzoic acid esters, n-butanol and the like may be mentioned. An oral liquid may be administered directly or after dilution and can be prepared in 162 the same manner as an injection fluid. A flowable, an emulsion or the like may be administered directly or after dilution percutaneously or by environmental application. A liquid preparation applied to the skin is administered by dripping, spreading, 5 rubbing, spraying, sprinkling or dipping (soaking, bathing or washing) and can be prepared in the same manner as an injection fluid. A pour-on preparation and a spot-on preparation are dripped or sprayed to a limited area of the skin so that they permeate through the skin and act systemically. A pour-on preparation and a spot-on preparation can be prepared by dissolving, 10 suspending or emulsifying an active ingredient in an appropriate skin-friendly solvent or solvent mixture. If necessary, additives such as a surfactant, a colorant, an absorbefacient, an antioxidant, a light stabilizer and an adhesive may be added. As appropriate solvents, water, alkanol, glycol, polyethylene glycol, polypropylene glycol, glycerin, benzyl alcohol, phenylethanol, phenoxyethanol, ethyl acetate, butyl 15 acetate, benzyl benzoate, dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, acetone, methyl ethyl ketone, aromatic and/or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, liquid paraffin, light liquid paraffin, silicone, dimethylacetamide, N-methylpyrrolidone or 2,2-dimethyl-4-oxy-methylene-1,3-dioxolane may be mentioned. As absorbefacients, DMSO, isopropyl myristate, pelargonic acid 20 dipropylene glycol, silicone oil, fatty acid esters, triglycerides and aliphatic alcohols may be mentioned. As antioxidants, sulfites, metabisulfites, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole and tocopherol may be mentioned. An emulsion may be administered orally, percutaneously or by injection. An emulsion can be prepared by dissolving an active ingredient in a hydrophobic phase or 25 a hydrophilic phase and homogenizing the resulting solution with another liquid phase together with an appropriate emulsifier, and further if necessary with additives such as a colorant, an absorbefacient, a protectant, an antioxidant, a light screen and a thickner. As hydrophobic phases (oils), paraffin oil, silicone oil, sesame oil, almond oil, castor oil, synthetic triglycerides, ethyl stearate, di-n-butyryl adipate, hexyl laurate, 30 pelargonic acid dipropylene glycol, esters of branched short-chain fatty acids with Ci6- Ci8 saturated fatty acids, isopropyl myristate, isopropyl palmitate, esters of C12-C18 saturated alcohols with caprylic/capric acid, isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, ethyl lactate, fatty acid ester waxes, dibutyl phthalate, diisopropyl adipate, isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol and oleyl alcohol may be 35 mentioned. As hydrophilic phases, water, propylene glycol, glycerin and sorbitol may be mentioned. As emulsifiers, nonionic surfactants such as polyoxyethylated castor oil, polyoxyethylated sorbitan monoolefinic acid, sorbitan monostearate, glycerin 40 monostearate, polyoxyethyl stearate and alkyl phenol polyglycol ether; amphoteric surfactants such as disodium N-lauryl-(3-iminodipropionate and lecithin; anionic surfactants such as sodium lauryl sulfate, aliphatic alcohol sulfate ether, mono/dialkylpolyglycol orthophosphate monoethanolamine salt; and cationic surfactants such as cetyltrimethylammonium chloride may, for example, be mentioned. 45 As other additives, carboxymethylcellulose, methylcellulose, polyacrylate, alginate, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, methyl vinyl ether, maleic anhydride copolymers, polyethylene glycol, waxes and colloidal silica may be mentioned. 163 A semisolid preparation is administered by applying or spreading onto the skin or introducing into the coelom. A gel can be prepared by adding a thickener to a solution prepared in the same manner as an injection fluid sufficiently to give a transparent viscous substance like an ointment. 5 Formulation examples of preparations using the compounds of the present invention are given below. However, formulations of the present invention are by no means restricted thereto. In the following formulation examples, "parts" means parts by weight. [Wettable powder] 10 Compound of the present invention 0.1 to 80 parts Solid carrier 5 to 98.9 parts Surfactant 1 to 10 parts Others 0 to 5 parts As the others, an anti-caking agent, a stabilizer and the like may be mentioned. 15 [Emulsifiable concentrate] Compound of the present invention 0.1 to 30 parts Organic solvent 45 to 95 parts Surfactant 4.9 to 30 parts Water 0 to 50 parts 20 Others 0 to 10 parts As the others, a spreader, a stabilizer and the like may be mentioned. [Suspension concentrate] Compound of the present invention 0.1 to 70 parts Liquid carrier 15 to 98.89 parts 25 Surfactant 1 to 12 parts Others 0.01 to 30 parts As the others, an anti-freezing agent, a thickener and the like may be mentioned. [Water dispersible granule] Compound of the present invention 0.1 to 90 parts 30 Solid carrier 0 to 98.9 parts Surfactant 1 to 20 parts Others 0 to 10 parts As the others, a binder, a stabilizer and the like may be mentioned. [Soluble concentrate] 35 Compound of the present invention 0.01 to 70 parts Liquid carrier 20 to 99.99 parts Others 0 to 10 parts As the others, an anti-freezing agent, a spreader and the like may be mentioned. [Granule] 40 Compound of the present invention 0.01 to 80 parts Solid carrier 10 to 99.99 parts Others 0 to 10 parts As the others, a binder, a stabilizer and the like may be mentioned. [Dustable powder] 45 Compound of the present invention 0.01 to 30 parts Solid carrier 65 to 99.99 parts Others 0 to 5 parts As the others, an anti-drift agent, a stabilizer and the like may be mentioned. 164 Next, more specific examples of preparations containing compounds of the present invention as an active ingredient are given below. However, the present invention is by no means restricted thereto. In the following Formulation Examples, "parts" means parts by weight. 5 [Formulation Example 1] Wettable powder Compound No.2-132 of the present invention 20 parts Pyrophyllite 74 parts Sorpol 5039 4 parts (tradename for a mixture of a nonionic surfactant and an anionic surfactant: 10 manufactured by TOHO Chemical Industry Col., Ltd.) CARPLEX #80D 2 parts (hydrous synthetic silicic acid: tradename manufactured by Shionogi & Co., Ltd.) The above ingredients are mixed and pulverized homogenously to obtain a wettable powder. 15 [Formulation Example 2] Emulsifiable concentrate Compound No.2-124 of the present invention 5 parts Xylene 75 parts N-methylpyrrolidone 15 parts Sorpol 2680 5 parts 20 (tradename for a mixture of a nonionic surfactant and an anionic surfactant: manufactured by TOHO Chemical Industry Co., Ltd.) The above ingredients are mixed homogenously to obtain an emulsifiable concentrate. [Formulation Example 3] Emulsifiable concentrate 25 Compound No.2-117 of the present invention 4 parts DBE 36 parts (tradename for a mixture of dimethyl adipate, dimethyl glutarate and dimethyl succinate: manufactured by INVISTA) Diisobutyl adipate 30 parts 30 N-methylpyrrolidone 10 parts SoprofolBSU 14 parts (tradename for a nonionic surfactant: manufactured by Rhodia Nicca. Ltd.) Rhodacal 70BC 6 parts (tradename for an anionic surfactant: manufactured by Rhodia Nicca. Ltd.) 35 The above ingredients are mixed homogenously to obtain an emulsifiable concentrate. [Formulation Example 4] Emulsifiable concentrate Compound No.2-020 of the present invention 4 parts DBE 11 parts 40 (tradename for a mixture of dimethyl adipate, dimethyl glutarate and dimethyl succinate: manufactured by INVISTA) Diisobutyl adipate 30 parts N-methylpyrrolidone 5 parts SoprofolBSU 14 parts 45 (tradename for a nonionic surfactant: manufactured by Rhodia Nicca. Ltd.) Rhodacal 70BC 6 parts (tradename for an anionic surfactant: manufactured by Rhodia Nicca. Ltd.) Propylene glycol 10 parts 165 Water 20 parts The above ingredients are mixed homogenously to obtain an emulsifiable concentrate. [Formulation Example 5] Suspension concentrate 5 Compound No.2-136 of the present invention 25 parts AGRISOLS-710 10 parts (tradename for a nonionic surfactant: manufactured by Kao Corporation) LunoxlOOOC 0.5 part (tradename for an anionic surfactant: manufactured by TOHO Chemical Industry Co., 10 Ltd.) Xanthan gum 0.2 part Water 64.3 parts The above ingredients are mixed homogenously and wet-pulverized to obtain a suspension concentration. 15 [Formulation Example 6] Water soluble granule Compound No.2-128 of the present invention 75 parts HITENOLNE-15 5 parts (tradename for an anionic surfactant: manufactured by Dai-ichi Kogyo Seiyaku Co., Ltd.) 20 VANILLEXN 10 parts (tradename for an anionic surfactant: manufactured by Nippon Paper Industries Co., LTD.) CARPLEX#80D 10 parts (tradename for hydrous synthetic silicic acid: manufactured by Shionogi & Co., Ltd.) 25 The above ingredients are mixed and pulverized homogenously, then kneaded with a small amount of water, granulated through an extrusion granulator and dried to obtain a water soluble granule. [Formulation Example 7] Granule Compound No.2-120 of the present invention 5 parts 30 Benton ite 50 parts Talc 45 parts The above ingredients are mixed and pulverized homogenously, then kneaded with a small amount of water, granulated through an extrusion granulator and dried to obtain a granule. 35 [Formulation Example 8] Dustable powder Compound No.2-140 of the present invention 3 parts CARPLEX #80D 0.5 part (tradename for a hydrous synthetic silicic acid: manufactured by Shionogi & Co., Ltd.) Kaolinite 95 parts 40 Diisopropyl phosphate 1.5 parts The above ingredients are mixed and pulverized homogeneously to obtain a dustable powder. It is applied after diluted with water by a factor of from 1 to 20000 so as to achieve an active ingredient concentration of from 0.005 to 50 kg/ha. 45 [Formulation Example 9] Wettable powder preparation Compound No.2-126 of the present invention 25 parts Sodium diisobutylnaphthalenesulfonate 1 part Calcium n-dodecylbenzenesulfonate 10 parts 166 Alkyl aryl polyglycol ether 12 parts Naphthalenesulfonic acid-formalin condensate sodium salt 3 parts Silicone emulsion 1 part Silicon dioxide 3 parts 5 Kaolin 45 parts [Formulation Example 10] Water-soluble concentrate preparation Compound No.2-212 of the present invention 20 parts Polyoxyethylenelauryl ether 3 parts Sodium dioctylsulfosuccinate 3.5 parts 10 Dimethyl sulfoxide 37 parts 2-Propanol 36.5 parts [Formulation Example 11] Liquid preparation for spraying Compound No.2-185 of the present invention 2 parts Dimethyl sulfoxide 10 parts 15 2-Propanol 35 parts Acetone 53 parts [Formulation Example 12] Liquid preparation for percutaneous administration Compound No.2-151 of the present invention 5 parts Hexylene glycol 50 parts 20 Isopropanol 45 parts [Formulation Example 13] Liquid preparation for percutaneous administration Compound No.2-114 of the present invention 5 parts Propylene glycol monomethyl ether 50 parts Dipropylene glycol 45 parts 25 [Formulation Example 14] Liquid preparation for percutaneous administration (by dripping) Compound No.2-174 of the present invention 2 parts Light liquid paraffin 98 parts [Formulation Example 15] Liquid preparation for percutaneous administration (by 30 dripping) Compound No.2-240 of the present invention 2 parts Light liquid paraffin 58 parts Olive oil 30 parts ODO-H 9 parts 35 Shin-etsu silicone 1 part For use as agricultural fungicides or nematocides, if necessary, the compounds of the present invention may be mixed with other fungicides, other nematocides, insecticides, miticides, plant growth regulators, herbicides, synergists, fertilizers, soil conditioners and the like at the time of formulation or application. 40 Further, for use as internal parasiticides, the compounds of the present invention in effective amounts may be applied alone as active ingredients, or if necessary, they may be mixed with other antibiotics, other vermicides and the like at the time of formulation or application. Particularly, the combined use with other fungicides, other nematocides, other 45 antibiotics, other vermicides or the like is expected to broaden the pesticidal spectrum by the additive or synergistic effect of the other agrochemicals, to improve the pesticidal effect, to reduce the application cost by enabling control at lower doses, and further, to prolong the pesticidal effect for a long period of time. Particularly, the combined use 167 with other fungicides, nematocides, antibiotics or vermicides differing in the mechanism of action is a very useful controlling method with a view to preventing the pests from acquiring resistance to pesticides. In such cases, they may be combined with a plurality of known fungicides, known nematocides, known insecticides, known miticides, 5 known antibiotics or known vermicides simultaneously. The fungicides, nematocides, insecticides, miticides, vermicides and antibiotics to be used in combination with the compounds of the present invention include, for example, the compounds disclosed in e.g. The Pesticidal Manual, 15th edition, 2009, having the generic names listed below, but are not necessarily restricted thereto. 10 Fungicides: such as acibenzolar-S-methyl, acypetacs, aldimorph, ametoctradin, amisulbrom, amobam, ampropylfos, anilazine, azaconazole, azoxystrobin, benalaxyl, benalaxyl-M, benodanil, benomyl, benthiavalicarb-isopropyl, benthiazole, benzovindiflupyr, biphenyl, bitertanol, bixafen, bordeaux mixture, boscalid, bromuconazole, bupirimate, calcium polysulfide, captan, carbendazim, carboxin, 15 carpropamid, carvone, cheshunt mixture, chinomethionat, chloroneb, chloropicrin, chlorothalonil, chlozolinate, climbazole, copper carbonate, basic, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper sulfate, copper sulfate, basic, coumoxystrobin, cresol, cufraneb, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dazomet, dichlofluanid, dichlorophen, diclobutrazol, 20 diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethomorph, dimoxystrobin, diniconazole, diniconazole-M, dinobuton, dinocap, dinocap-4, dinocap-6, diphenylamine, dithianon, DNOC, dodemorph-acetate, dodine, drazoxolon, edifenphos, enestrobin, enoxastrobin, epoxiconazole, etaconazole, ethaboxam, ethirimol, ethoxyquin, etridiazole, famoxadone, fenamidone, fenaminstrobin, 25 fenarimol, fenbuconazole, fenfuram, fenhexamid, fenitropan, fenoxanil, fenpiclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin, ferbam, ferimzone, fluazinam, fludioxonil, flufenoxystrobin, flumorph, fluopicolide, fluopyram, fluoroimide, fluotrimazole, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fosetyl-aluminium, fuberidazole, furalaxyl, furametpyr, furconazole, 30 furmecyclox, guazatine, hexachlorobenzene, hexaconazole, hymexazol, imazalil, imibenconazole, iminoctadine-albesilate, iminoctadine-triacetate, ipconazole, iprobenfos, iprodione, iprovalicarb, isofetamid, isoprothiolane, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, laminarin, mancopper, mancozeb, mandestrobin, mandipropamid, maneb, mepanipyrim, mepronil, metalaxyl, metalaxyl-M, metam, metconazole, 35 methfuroxam, metiram, metominostrobin, metrafenone, metsulfovax, milneb, myclobutanil, nabam, natamycin, nickel bis(dimethyldithiocarbamate), nitrothal-isopropy, nuarimol, ofurace, orysastrobin, oxadixyl, oxathiapiprolin, oxine copper, oxpoconazole fumarate, oxycarboxin, pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol (PCP), penthiopyrad, 2-phenylphenol, phthalide, picoxystrobin, 40 piperalin, polycarbamate, polyoxins, polyoxorim, potassium azide, potassium hydrogen carbonate, probenazole, prochloraz, procymidone, propamocarb hydrochloride, propiconazole, propineb, proquinazid, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb-methyl, pyrifenox, pyrimethanil, pyriminostrobin, pyriofenone, pyrisoxazole, pyroquilon, quinacetol-sulfate, quinoxyfen, 45 quintozene, sedaxane, silthiofam, simeconazole, sodium hydrogen carbonate, sodium hypochlorite, spiroxamine, sulfur, tebuconazole, tebufloquin, tecoram, tetraconazole, thiabendazole, thifluzamide, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolprocarb, tolylfluanid, triadimefon, triadimenol, triazoxide, tributyltin oxide, triclopyricab, 168 tricyclazole, tridemorph, trifloxystrobin, triflumizole, triforine, triticonazole, validamycin, valifenalate, vinclozolin, zinc naphthenate, zinc sulfate, ziram, zoxamide, shiitake mushroom mycelium extracts, shiitake mushroom fruiting body extracts, BCF-082 (experimental name), NNF-0721 (experimental name) and ZF-9646 (experimental 5 name). Insecticides: such as abamectin, acephate, acetamiprid, afidopyropen, afoxolaner, alanycarb, aldicarb, allethrin, azamethiphos, azinphos-ethyl, azinphos-methyl, bacillus thuringiensis, bendiocarb, benfluthrin, benfuracarb, bensultap, bifenthrin, bioallethrin, bioresmethrin, bistrifluron, buprofezin, butocarboxim, carbaryl, carbofuran, carbosulfan, 10 cartap, chlorantraniliprole, chlorethoxyfos, chlorfenapyr, chlorfenvinphos, chlorfluazuron, chlormephos, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyanophos, cyantraniliprole, cyclaniliprole, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, betacypermethrin, zeta-cypermethrin, cyphenothrin, cyromazine, deltamethrin, diafenthiuron, 15 diazinon, dichlorvos, diflubenzuron, dimethoate, dimethylvinphos, dinotefuran, diofenolan, disulfoton, emamectin-benzoate, empenthrin, endosulfan, alpha-endosulfan, EPN, esfenvalerate, ethiofencarb, ethiprole, etofenprox, etrimfos, fenitrothion, fenobucarb, fenoxycarb, fenthion, fenvalerate, fipronil, flometoquin, flonicamid, fluazuron, flubendiamide, flucycloxuron, flucythrinate, flufenerim, flufenoxuron, flufiprole, 20 flumethrin, flupyradifurone, fluralaner, fluvalinate, tau-fluvalinate, fonofos, furathiocarb, halofenozide, heptafluthrin, hexaflumuron, hydramethylnon, imidacloprid, imiprothrin, indoxacarb, indoxacarb-MP, isoprocarb, isoxathion, lepimectin, lufenuron, malathion, meperfluthrin, metaflumizone, metaldehyde, methacrifos, methamidophos, methidathion, methomyl, methoprene, methoxychlor, methoxyfenozide, metofluthrin, muscalure, 25 nitenpyram, novaluron, noviflumuron, omethoate, oxydemeton-methyl, parathion-methyl, permethrin, phenothrin, phenthoate, phorate, phosalone, phosmet, phoxim, pirimicarb, pirimiphos-methyl, profenofos, prothiofos, pymetrozine, pyraclofos, pyrethrins, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, resmethrin, rotenone, silafluofen, spinetoram, spinosad, spirotetramat, sulfotep, sulfoxaflor, tebufenozide, teflubenzuron, tefluthrin, 30 terbufos, tetrachlorvinphos, tetramethrin, d-T-80-phthalthrin (d-tetramethrin), tetramethylfluthrin, thiacloprid, thiamethoxam, thiocyclam, thiodicarb, thiofanox, thiometon, tolfenpyrad, tralomethrin, transfluthrin, triazamate, trichlorfon, triflumuron, ME5382 (experimental name), NC-515 (experimental name) and ZDI2501 (experimental name). 35 Miticides: such as acequinocyl, acrinathrin, amidoflumet, amitraz, azocyclotin, benzoximate, bifenazate, bromopropylate, clofentezine, cyenopyrafen, cyflumetofen, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fenothiocarb, fenpropathrin, fenpyroximate, fluacrypyrim, formetanate, halfenprox, hexythiazox, milbemectin, propargite, pyflubumide, pyridaben, pyrimidifen, spirodiclofen, spiromesifen, 40 tebufenpyrad and NA-89 (experimental name). Nematicides: such as cadusafos, dichlofenthion, ethoprophos, fenamiphos, fluensulfone, fosthiazate, fosthietan, imicyafos, isamidofos, isazofos, methyl bromide, methyl isothiocyanate, oxamyl, sodium azide, BYI-1921 (experimental name) and MAI- 08015 (experimental name). 45 Vermicides: such as acriflavine, albendazole, atovaguone, azithromycin, bithionol, bromofenofos, cambendazole, carnidazole, chloroquine, clazuril, clindamycin hydrochloride, clorsulon, closantel, coumaphos, cymiazol, dichlorophen, diethylcarbamazine, diminazene, disophenol, dithiazanine iodide, doxycycline 169 hydrochloride, doramectin, emodepside, eprinomectin, febantel, fenbendazole, flubendazole, furazolidone, glycalpyramide, imidocarb, ivermectin, levamisole, mebendazole, mefloquine, melarsamine hydrochloride, metronidazole, metyridine, milbemycin oxime, monepantel, morantel tartrate, moxidectin, nicarbazin, niclosamide, 5 nitroscanate, nitroxynil, omphalotin, oxantel pamoate, oxantel tartrate, oxfendazolee, oxibendazole, oxyclozanide, pamaquine, phenothiazine, piperazine adipate, piperazine citrate, piperazine phosphate, PNU-97333 (paraherquamide A), PNU-141962 (2- deoxyparaherquamide), praziquantel, primaquine, propetamphos, propoxur, pyrantel pamoate, pyrimethamine, santonin, selamectin, sulfadimethoxine, sulfadoxine, 10 sulfamerazine, sulfamonomethoxine, sulfamoildapsone, thiabendazole, tinidazole, toltrazuril, tribromsalan and triclabendazole. Antifungal agents: such as ketoconazole and miconazole nitrate. Antibiotics: such as amoxicillin, ampicillin, bethoxazin, bithionol, bronopol, cefapirin, cefazolin, cefquinome, ceftiofur, chlortetracycline, clavulanic acid, 15 danofloxacin, difloxacin, dinitolmide, enrofloxacin, florfenicol, lincomycin, lomefloxacin, marbofloxacin, miloxacin, mirosamycin, nitrapyrin, norfloxacin, octhilinone, ofloxacin, orbifloxacin, oxolinic acid, oxytetracycline, penicillin, streptomycin, thiamphenicol, tiamulin fumarate, tilmicosin phosphate, acetylisovaleryltylosin, tylosin phosphate, tulathromycin, valnemulin, calcinated shell calcium (calcium oxide), Talaromvces, 20 Trichoderma and Coniothvrium. EXAMPLES The present invention will be described in further detail by referring to the following specific Examples of synthesis of and tests on the compounds of the present invention. 25 However, the present invention is by no means restricted thereto. [Synthetic Examples] SYNTHETIC EXAMPLE 1 (Z)-N-[2-(2,4-dichlorophenyl)-2-(methoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 1-004 of the present invention) 30 Step 1: Preparation of 2-bromo-1 -(2,4-dichlorophenyl)ethanone-0-methyloxime To 4.00 g of 2-bromo-1-(2,4-dichlorophenyl)ethanone in 20 ml of ethanol, 1.25 g of methoxyamine hydrochloride was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was mixed with 20 ml of water and 35 extracted with ethyl acetate (20 mlx2). The resulting organic layers were combined, washed with water (20 mlxl) and then dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain 3.85 g of the desired crude product as a pale yellow oil. The oil was used in the next step without further purification. 40 1 H NMR (CDCb, Me4 Si, 300MHz) 57.2-7.55 (m, 3H), 4.56 and 4.35 (s, 2H), 4.06 and 4.04 (s, 3H). Step 2: Preparation of N-[2-(2,4-dichlorophenyl)-2-(methoxyimino)ethyl]phthalimide To 2.17 g of 2-bromo-1-(2,4-dichlorophenyl)ethanone-0-methyloxime in 20 ml of N,N-dimethylformamide, 3.03 g of potassium phthalimide and 1.61 g of potassium 45 carbonate were added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 40 ml of water and extracted with ethyl acetate (50 mlxl), the resulting organic layer was washed with water (20 mlxl) and then dried over saturated aqueous sodium chloride and then 170 anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 2.10 g of the desired product as pale yellow crystals. 5 m.p.: 82.0-85.0°C 1H NMR (CDCb, Me4Si, 300MHz) 57.65-7.8 (m, 4H), 7.15-7.35 (m, 3H), 4.92 (s, 2H), 4.01 (s, 3H). Step 3: Preparation of 2-amino-1-(2,4-dichlorophenyl)ethanone-0-methyloxime To 316 mg of N-[2-(2,4-dichlorophenyl)-2-(methoxyimino)ethyl]phthalimide in 10 ml 10 of ethanol, 108 mg of hydrazine monohydrate was added, and the mixture was stirred at 60°C for 2 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 30 ml of water and extracted with ethyl acetate (40 mlxl). The resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under 15 reduced pressure to obtain 170 mg of the desired crude product as a colorless oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 57.25-7.45 (m, 3H), 3.99 (s, 3H), 3.82 (s, 2H). Step 4: Preparation of (Z)-N-[2-(2,4-dichlorophenyl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide 20 To a solution of 170 mg of 2-amino-1 -(2,4-dichlorophenyl)ethanone-0- methyloxime and 74 mg of triethylamine in 5 ml of dichloromethane, 122 mg of 2- (trifluoromethyl)benzoyl chloride was added dropwise, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was mixed with 10 ml of water and extracted with chloroform (20 mlxl), the resulting organic 25 layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was mixed with 3 ml of diisopropyl ether and crystallized to obtain 110 mg of the desired product as white crystals. m.p.: 146.0-148.0°C 30 1H NMR (CDCb, Me4Si, 300MHz) 57.25-7.7 (m, 6H), 7.05-7.15 (m, 1H), 6.31 (bs, 1H), 4.62 (d, J=6.3Hz, 2H), 4.02 (s, 3H). SYNTHETIC EXAMPLE 2 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-120 of the present invention) 35 Step 1: Preparation of 1 -(3,5-dichloropyridin-2-yl)ethanone To 20 g of 3,5-dichloropyridine-2-carbonitrile in 150 ml of tetrahydrofuran, 139 ml of a 1M tetrahydrofuran solution of methylmagnesium bromide was added dropwise with stirring under cooling with ice, and the mixture was stirred at the same temperature for 1 hour. After completion of the reaction, the reaction mixture was mixed with 15 ml of 40 concentrated hydrochloric acid and 100 ml of water and extracted with ethyl acetate (100 mlx2), the resulting organic layers were combined, washed with water (100 mlxl) and dried over saturated aqueous solution chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was dissolved in 40 ml of ethyl acetate and 10 ml of hexane, 20 g of silica gel was added, 45 the mixture was stirred at room temperature for 1 hour and then subjected to filtration, and the solvent was evaporated under reduced pressure. The precipitated solid was washed with 50 ml of hexane to obtain 17.16 g of the desired product as pale yellow crystals. 171 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.1Hz, 1H), 7.82 (d, J=2.1Hz, 1H), 2.68 (s, 3H). Step 2: Preparation of 2-bromo-1 -(3,5-dichloropyridin-2-yl)ethanone To 5.00 g of 1-(3,5-dichloropyridin-2-yl)ethanone in 75 ml of tetrahydrofuran, 9.94 5 g of trimethylphenylammonium tribromide was added, and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, the precipitated solid was filtered off through celite, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 15:85) as the eluent to obtain 6.64 g of 10 the desired product as a brown oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.51 (d, J=1.9Hz, 1H), 7.88 (d, J=1.9Hz, 1H), 4.67 (s, 2H). Step 3: Preparation of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone-0-ethyloxime To 3.00 g of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone in 25 ml of ethanol, 1.09 15 g of ethoxyamine hydrochloride was added, and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 50 ml of water and extracted with ethyl acetate (50 mlx2), the resulting organic layers were combined, washed with water (50 mlxl) and dried over saturated aqueous sodium chloride and 20 then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatograph using ethyl acetate-hexane (with a gradient of from 5:95 to 15:85) as the eluent to obtain 3.03 g of the desired product as a colorless oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.1Hz, 1H), 7.81 (d, J=2.1Hz, 1H), 4.67 25 and 4.52 (s, 2H), 4.35 and 4.32 (q, J=7.2Hz, 2H), 1.37 and 1.36 (t, J=7.2Hz, 3H). Step 4: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]phthalimide To 3.00 g of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone-0-ethyloxime in 20 ml of N,N-dimethylformamide, 2.32 g of potassium phthalimide was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the 30 reaction mixture was mixed with 50 ml of water and extracted with ethyl acetate (100 mlxl), the resulting organic layer was washed with water (50 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was washed with 10 ml of diisopropyl ether to obtain 3.08 g of the desired product as white crystals. 35 m.p.: 99.0 to 101.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.29 (d, J=2.1Hz, 1H), 7.65-7.85 (m, 5H), 4.99 (s, 2H), 4.27 (q, J=7.2Hz, 2H), 1.29 (t, J=7.2Hz, 3H). Step 5: Preparation of 2-amino-1-(3,5-dichloropyridin-2-yl)ethanone-0-ethyloxime To 3.00 g of N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]phthalimide in 30 40 ml of ethanol, 793 mg of hydrazine monohydrate was added, and the mixture was stirred at 70°C for 3 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 100 ml of water and extracted with ethyl acetate (100 mlx2). The resulting organic layers were combined, washed with water (100 mlxl) and dried over saturated aqueous sodium chloride and then 45 anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain 1.62 g of the desired crude product as a brown oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.51 and 8.48 (d, J=2.0Hz, 1H), 7.79 and 7.77 (d, 172 J=2.0Hz, 1H), 4.27 and 4.13 (q, J=6.9Hz, 2H), 3.90 and 3.74 (s, 2H), 1.34 and 1.21 (t, J=6.9Hz, 3H). Step 6: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-003 of the present invention) 5 To a solution of 200 mg of 2-amino-1-(3,5-dichloropyridin-2-yl)ethanone-0- ethyloxime and 90 mg of triethylamine in 3 ml of dichloromethane, 169 mg of 2- (trifluoromethyl)benzoyl chloride was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 30 minutes. After completion of the reaction, the reaction mixture was mixed with 10 ml of 10 water and extracted with ethyl acetate (15 mlxl), the resulting organic layer was washed with water (10 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 15 190 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.45 and 8.29 (d, J=2.1Hz, 1H), 7.80 and 7.78 (d, J=2.1Hz, 1H), 7.35-7.75 (m, 4H), 6.52 (bs, 1H), 4.75 and 4.52 (d, J=6.0Hz, 2H), 4.30 and 4.13 (q, J=7.2Hz, 2H), 1.35 and 1.21 (t, J=7.2Hz, 3H). Step 7: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]-2- 20 (trifluoromethyl)benzamide 190 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide was dissolved in 4 ml of acetonitrile, and the solution was irradiated with light for 2.5 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO 25 INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 41.3 mg of the desired product as white crystals. m.p.:84.0to86.0°C 30 1H NMR (CDCb, Me4Si, 300MHz) 58.51 (d, J=2.1 Hz, 1H), 7.79 (d, J=2.1 Hz, 1H), 7.5- 7.75 (m, 4H), 6.50 (bs, 1H), 4.53 (d, J=4.8Hz, 2H), 4.13 (q, J=7.2Hz, 2H), 1.21 (t, J=7.2Hz, 3H). SYNTHETIC EXAMPLE 3 N-[2-(3,5-dichloropyridin-2-yl)-2-(ethoxyimino)ethyl]-3-difluoromethyl-1-methyl-1H- 35 pyrazole-4-carboxamide (Compound No. 17-004 of the present invention) To 176 mg of 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid in 1 ml of dichloromethane, 10 mg of N,N-dimethylformamide and 381 mg of oxalyl chloride were added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting 40 residue was dissolved in 2 ml of dichloromethane, and to the solution, 190 mg of the 2- amino-1-(3,5-dichloropyridin-2-yl)ethanone-0-ethyloxime prepared in Step 5 in Synthetic Example 2 in 2 ml of dichloromethane and then 91 mg of pyridine were added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 2 hours. After completion of the reaction, the 45 reaction mixture was mixed with 10 ml of water and extracted with chloroform (20 mlxl), the resulting organic layer was washed with water (10 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel 173 column chromatography using ethyl acetate-hexane (with a gradient of from 1:4 to 1:1) as the eluent to obtain 165.3 mg of a pale yellow resinous substance. The resinous substance was dissolved in 5 ml of acetic acid and stirred at 70°C for 2 hours, the solvent was evaporated under reduced pressure, and the resulting residue was purified 5 by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:4 to 1:1) as the eluent to obtain 130.6 mg of the desired product as a colorless resinous substance (E/Z=1/1). 1H NMR (CDCb, Me4Si, 300MHz) 58.50 and 8.47 (d, J=2.1Hz, 1H), 7.90 and 7.86 (s, 1H), 7.76 and 7.75 (d, J=2.1 Hz, 1H), 6.9-7.1 (m, 1H), 6.84 and 6.73 (t, J=54.3Hz, 1H), 10 4.71 and 4.49 (d, J=6.0Hz, 2H), 4.31 and 4.14 (q, J=7.2Hz, 2H), 3.92 and 3.89 (s, 3H), 1.36 and 1.23 (t,J=7.2Hz,3H). SYNTHETIC EXAMPLE 4 N-[2-(3,5-dichloropyridin-2-yl)-2-(tert-butoxyimino)ethyl]-3-(trifluoromethyl)pyrazine-2- carboxamide (Compounds Nos. 9-005 and 9-006 of the present invention) 15 Step 1: Preparation of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanoneoxime To 2.00 g of the 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone prepared in Step 2 in Synthetic Example 2 in 15 ml of ethanol, 517 mg of hydroxylamine hydrochloride was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was mixed with 100 ml of water and extracted with 20 ethyl acetate (50 mlx2), the resulting organic layers were combined, washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 1.31 g of the desired 25 product as a pale orange oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.53 and 8.50 (d, J=2.1Hz, 1H), 7.82 and 7.81 (d, J=2.1 Hz, 1H), 4.75 and 4.58 (s, 2H). Step 2: Preparation of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone-0-(tert-butyl)oxime To a solution of 1.31 g of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanoneoxime and 30 1.71 g of tert-butanol in 20 ml of dichloromethane, 3.27 g of boron trifluoride diethyl ether complex was added, and the mixture was stirred at room temperature for 48 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 0:100 to 15:85) as the eluent to obtain 140 mg 35 of the desired product as a colorless oil. 1H NMR (CDCb, Me4Si, 300MHz) 68.50 and 8.48 (d, J=2.1Hz, 1H), 7.81 and 7.77 (d, J=2.1 Hz, 1H), 4.70 and 4.53 (s, 2H), 1.39 and 1.38 (s, 9H). Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(tertbutoxyimino) ethyl]phthalimide 40 To 140 mg of 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone-0-(tert-butyl)oxime in 2 ml of N,N-dimethylformamide, 91 mg of potassium phthalimide was added, and the mixture was stirred at room temperature for 5 hours. After completion of the reaction, the reaction mixture was mixed with 10 ml of water and extracted with ethyl acetate (15 mlxl), the resulting organic layer was washed with water (10 mlxl) and dried over 45 saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 2:8 to 4:6) as the eluent to obtain 162 mg of the desired product as a colorless resinous 174 substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.30 (d, J=2.1Hz, 1H), 7.7-7.85 (m, 2H), 7.74 (d, J=2.1Hz, 1H), 7.6-7.7 (m, 2H), 4.97 (s, 2H), 1.27 (s, 9H). Step 4: Preparation of 2-amino-1-(3,5-dichloropyridin-2-yl)ethanone-0-(tert-butyl)oxime 5 To 162 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(tert-butoxyimino)ethyl]phthalimide in 10 ml of ethanol, 40 mg of hydrazine monohydrate was added, and the mixture was stirred at 80°C for 1 hour. After completion of the reaction, the solvent was evaporated under reduced pressure, and the reaction mixture was mixed with 30 ml of water and extracted with ethyl acetate (25 mlx2). The resulting organic layers were combined, 10 washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain 89 mg of the desired crude product as a colorless oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.47 (d, J=2.4Hz, 1H), 7.79 (d, J=2.4Hz, 1H), 3.88 15 (bs, 2H), 1.36 (s, 9H). Step 5: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(tert-butoxyimino)ethyl]-3- (trifluoromethyl)pyrazine-2-carboxamide To 74 mg of 3-(trifluoromethyl)pyrazine-2-carboxylic acid in 3 ml of dichloromethane, 10 mg of N,N-dimethylformamide and 57 mg of oxalyl chloride were 20 added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was dissolved in 10 ml of dichloromethane. To the solution, 89 mg of 2-amino- 1-(3,5-dichloropyridin-2-yl)ethanone-0-(tert-butyl)oxime and 39 mg of triethylamine were added with stirring under cooling with ice, and the mixture was stirred at room 25 temperature for another 1 hour. After completion of the reaction, the reaction mixture was mixed with 10 ml of water and extracted with chloroform (10 mlxl), the resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate- 30 hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 22 mg of geometrical isomer A and 111 mg of geometrical isomer B of the desired product as colorless resinous substances. Isomer A: 1H NMR (CDCb, Me4Si, 300MHz) 58.77 (d, J=2.4Hz, 1H), 8.69 (d, J=2.4Hz, 1H), 8.46 (d, 35 J=2.1 Hz, 1H), 8.14 (bs, 1H), 7.78 (d, J=2.1 Hz, 1H), 4.77 (d, J=6.0Hz, 2H), 1.42 (s, 9H). Isomer B: 1H NMR (CDCb, Me4Si, 300MHz) 58.77 (d, J=2.4Hz, 1H), 8.70 (d, J=2.4Hz, 1H), 8.46 (d, J=2.1Hz, 1H), 8.17 (bs, 1H), 7.78 (d, J=2.1Hz, 1H), 4.79 (d, J=6.0Hz, 2H), 1.39 (s, 9H). SYNTHETIC EXAMPLE 5 40 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(propoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-126 of the present invention) Step 1: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]phthalimide To 3.00 g of the 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone prepared in Step 2 in Synthetic Example 2 in 30 ml of N,N-dimethylformamide, 4.13 g of potassium 45 phthalimide was added, and the mixture was stirred at 80°C for 3 hours and then at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 150 ml of water and extracted with ethyl acetate (50 mlx2), the resulting organic layers were combined, washed with water (50 mlxl) and dried over saturated 175 aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was mixed with 40 ml of a mixture of diisopropyl ether and hexane (1:1), the insolubles were filtered off, and the solvent was evaporated under reduced pressure. The resulting residue was purified by 5 silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 15:85 to 25:75) as the eluent to obtain 0.32 g of the desired product as a dark brown resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.58 (d, J=2.0Hz, 1H), 7.65-7.8 (m, 5H), 5.30 (s, 2H). Step 2: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(hydroxyimino)ethyl]phthalimide 10 To 0.32 g of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]phthalimide in 15 ml of ethanol, 0.66 g of hydroxylamine hydrochloride was added and refluxed with heating for 4 hours with stirring. After completion of the reaction, the solvent was evaporated under reduced pressure, and the reaction mixture was mixed with 30 ml of water and 50 ml of ethyl acetate, and the resulting organic layer was collected. The organic layer 15 was washed with water (30 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the resulting residue was washed with 10 ml of hexane to obtain 265 mg of the desired product as yellow crystals. m.p.: 138.0 to 141.0 °C 20 1H NMR (CDCb, Me4Si, 300MHz) 58.47 and 8.30 (d, J=2.0Hz, 1H), 8.13 and 7.52 (s, 1H), 7.65-7.9 (m, 5H), 5.05 and 4.78 (s, 2H). Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(propoxyimino)ethyl]phthalimide To 265 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(hydroxyimino)ethyl]phthalimide in 2 ml of N,N-dimethylformamide, 310 mg of potassium carbonate and 387 mg of 1- 25 iodopropane were added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 30 ml of water and extracted with ethyl acetate (50 mlxl), the resulting organic layer was washed with water (50 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The 30 resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 15:85 to 25:75) as the eluent to obtain 235 mg of the desired product as a yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.42 and 8.29 (d, J=2.0Hz, 1H), 7.65-7.9 (m, 5H), 4.99 and 4.76 (s, 2H), 4.18 and 4.00 (t, J=6.7Hz, 2H), 1.5-1.75 (m, 2H), 0.93 and 0.81 (t, 35 J=7.5Hz, 3H). Step 4: Preparation of 2-amino-1 -(3,5-dichloropyridin-2-yl)ethanone-0-propyloxime To 235 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(propoxyimino)ethyl]phthalimide in 5 ml of ethanol, 90 mg of hydrazine monohydrate was added and refluxed with heating for 3 hours with stirring. After completion of the reaction, the reaction mixture was allowed 40 to cool to room temperature, mixed with 20 ml of water and extracted with ethyl acetate (35 mlx2). The resulting organic layers were combined, washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain 151 mg of the desired crude product as a brown oil. The oil was used in the next step without further 45 purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.49 and 8.48 (d, J=2.0Hz, 1H), 7.78 and 7.76 (d, J=2.0Hz, 1H), 4.17 and 4.01 (t, J=6.6Hz, 2H), 3.89 and 3.73 (s, 2H), 1.5-1.85 (m, 2H), 0.98 and 0.86 (t, J=7.4Hz, 3H). 176 Step 5: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(propoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-004 of the present invention) In a solution of 151 mg of 2-amino-1-(3,5-dichloropyridin-2-yl)ethanone-0- propyloxime and 86 mg of triethylamine in 4 ml of dichloromethane, 154 mg of 2- 5 (trifluoromethyl)benzoyl chloride was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 2 hours. After completion of the reaction, the reaction mixture was mixed with 10 ml of water and extracted with chloroform (30 mlxl), the resulting organic layer was washed with water (10 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous 10 sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 2:8 to 3:7) as the eluent to obtain 218 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCIa, Me4Si, 300MHz) 58.49 and 8.44 (d, J=2.1Hz, 1H), 7.80 and 7.78 (d, 15 J=2.1 Hz, 1H), 7.35-7.7 (m, 4H), 6.53 and 6.49 (bs, 1H), 4.75 and 4.52 (d, J=6.3Hz, 2H), 4.21 and 4.03 (t, J=6.9Hz, 2H), 1.7-1.8 and 1.55-4.65 (m, 2H), 0.96 and 0.86 (t, J=7.5Hz, 3H). Step 6: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(propoxyimino)ethyl]-2- (trifluoromethyl)benzamide 20 To 218 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(propoxyimino)ethyl]-2- (trifluoromethyl)benzamide in 3 ml of acetonitrile, 5 mg of benzophenone was added, and the mixture was irradiated with light for 48 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply UM-103B-B). After 25 completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 25:75 to 35:65) as the eluent to obtain 83 mg of the desired product as white crystals. m.p.:80.0to83.0°C 30 1H NMR (CDCIa, Me4Si, 300MHz) 58.51 (d, J=1.9Hz, 1H), 7.79 (d, J=1.9Hz, 1H), 7.5- 7.75 (m, 4H), 6.50 (bs, 1H), 4.53 (d, J=5.2Hz, 2H), 4.04 (t, J=6.6Hz, 2H), 1.5-1.7 (m, 2H), 0.86 (t, J=7.4Hz, 3H) SYNTHETIC EXAMPLE 6 (Z)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-(cyclopropylmethoxyimino)ethyl]-2- 35 (trifluoromethyl)benzamide (Compound No. 2-024 of the present invention) Step 1: Preparation of 2-bromo-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanone To 0.82 g of 1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanone in 10 ml of tetrahydrofuran, 1.38 g of trimethylphenylammonium tribromide was added, and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, 40 the precipitated solid was filtered off through celite, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using diethyl ether as the eluent to obtain 1.43 g of the desired product as a brown oil. The oil was used in the next step without further purification. Step 2: Preparation of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- 45 oxoethyl]phthalimide To 1.43 g of 2-bromo-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanone in 10 ml of N.N-dimethylformamide, 0.68 g of potassium phthalimide and 0.01 g of potassium iodide were added, and the mixture was stirred at 85°C for 1 hour. After completion of 177 the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 10 ml of water and extracted with ethyl acetate (10 mlx3), the resulting organic layers were combined, washed with water and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced 5 pressure. The resulting residue was purified by preparative medium pressure liquid chromatography (preparative medium pressure chromatograph: YFLC-Wprep manufactured by Yamazen Science, Inc.) using ethyl acetate-hexane (with a gradient of from 5:95 to 46:60) as the eluent to obtain 0.47 g of the desired product as a pale yellow resinous substance. 10 1H NMR (CDCIs, Me4Si, 300MHz) 58.87 (d, J=1.8Hz, 1H), 8.10 (d, J=1.8Hz, 1H), 7.85- 7.95 (m, 2H), 7.7-7.8 (m, 2H), 5.32 (s, 2H). Step 3: Preparation of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (hydroxyimino)ethyl]phthalimide To a solution of 0.47 g of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- 15 oxoethyl]phthalimide and 0.54 g of hydroxylamine hydrochloride in 5 ml of ethanol, 0.94 g of pyridine was added, and the mixture was stirred at room temperature for 24 hours. After completion of the reaction, the reaction mixture was mixed with 5 ml of water and extracted with ethyl acetate (5 mlx3), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the 20 solvent was distilled off under reduced pressure. The resulting residue was purified by preparative medium pressure liquid chromatography (preparative medium pressure chromatograph: YFLC-Wprep manufactured by Yamazen Science, Inc.) using ethyl acetate-hexane (with a gradient of from 1:3 to 2:2) as the eluent to obtain 325 mg of the desired product as white crystals. 25 1H NMR (CDCIs, Me4Si, 300MHz) 610.57 and 9.75 (s, 1H), 8.7-8.8 (m, 1H), 7.9-7.95 (m, 1H), 7.6-7.85 (m, 4H), 5.07 and 4.80 (s, 2H) Step 4: Preparation of (E)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (cyclopropylmethoxyimino)ethyl]phthalimide To 300 mg of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- 30 (hydroxyimino)ethyl]phthalimide in 5 ml of N,N-dimethylformamide, 324 mg of potassium carbonate and 158 mg of cyclopropylmethyl bromide were added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 5 ml of water and extracted with ethyl acetate (5 mlx3), the resulting organic layers were combined, washed with water and dried over 35 saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative medium pressure liquid chromatography (preparative medium pressure chromatograph: YFLC-Wprep manufactured by Yamazen Science, Inc.) using ethyl acetate-hexane (with a gradient of from 1:19 to 4:16) as the eluent to obtain 98 mg of 40 the desired product as a pale yellow resinous substance. 1H NMR (CDCIs, Me4Si, 300MHz) 68.61 (d, J=1.5Hz, 1H), 7.97 (d, J=1.5Hz, 1H), 7.75- 7.85 (m, 2H), 7.65-7.75 (m, 2H), 5.03 (s, 2H), 4.03 (d, J=7.5Hz, 2H), 1.05-1.25 (m, 1H), 0.4-0.5 (m, 2H), 0.15-0.25 (m, 2H). Step 5: Preparation of (E)-2-amino-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanone- 45 0-(cyclopropylmethyl)oxime To 98 mg of (E)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (cyclopropylmethoxyimino)ethyl]phthalimide in 3 ml of ethanol, 76 mg of hydrazine monohydrate was added, and the mixture was stirred at 80°C for 1 hour. After 178 completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 5 ml of water and extracted with ethyl acetate (5 mlx3). The resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced 5 pressure. The resulting residue was purified by silica gel column chromatography using methanol-chloroform (1:10) as the eluent to obtain 65 mg of the desired product as a pale yellow oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 68.78 (d, J=1.5Hz, 1H), 8.00 (d, J=1.5Hz, 1H), 4.05 (d, J=7.2Hz, 2H), 3.96 (s, 2H), 1.66 (bs, 2H), 1.15-1.35 (m, 1H), 0.55-0.65 (m, 2H), 0.3-0.4 10 (m,2H). Step 6: Preparation of (E)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (cyclopropylmethoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-023 of the present invention) In a solution of 65 mg of (E)-2-amino-1-[3-chloro-5-(trifluoromethyl)pyridin-2- 15 yl]ethanone-0-(cyclopropylmethyl)oxime and 32 mg of triethylarnine in 2 ml of dichloromethane, 39 mg of 2-(trifluoromethyl)benzoyl chloride was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 1 hour. After completion of the reaction, the reaction mixture was mixed with 2 ml of water and extracted with dichloromethane (2 mlxl), the resulting 20 organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative medium pressure liquid chromatography (preparative medium pressure chromatograph: YFLC-Wprep manufactured by Yamazen Science, Inc.) using ethyl acetate-hexane (with a gradient of from 2:18 to 5:15) as the 25 eluent to obtain 85 mg of the desired product as white crystals. m.p.:98.0to 101.0°C 1H NMR (CDCb, Me4Si, 300MHz) 68.75 (d, J=1.5Hz, 1H), 8.02 (d, J=1.5Hz, 1H), 7.6-7.7 (m, 1H), 7.45-7.6 (m, 2H), 7.35-7.45 (m, 1H), 6.55 (bs, 1H), 4.81 (d, J=6.0Hz, 2H), 4.19 (d, J=7.2Hz, 2H), 1.15-1.3 (m, 1H), 0.3-0.4 (m, 2H), 0.5-0.6 (m, 2H). 30 Step 7: Preparation of (Z)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (cyclopropylmethoxyimino)ethyl]-2-(trifluoromethyl)benzamide To 85 mg of (E)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (cyclopropylmethoxyimino)ethyl]-2-(trifluoromethyl)benzamide in 3 ml of acetonitrile, 1 mg of benzophenone was added, and the mixture was irradiated with light for 5 hours in 35 a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 5:5) as the 40 eluent to obtain 47 mg of the desired product as white crystals. m.p.: 73.0 to 74.0°C 1H NMR (CDCb, Me4Si, 300MHz) 68.80 (d, J=1.5Hz, 1H), 8.01 (d, J=1.5Hz, 1H), 7.65- 7.75 (m, 1H), 7.5-7.65 (m, 3H), 6.52 (bs, 1H), 4.58 (d, J=6.0Hz, 2H), 3.91 (d, J=7.2Hz, 2H), 1.0-1.15 (m, 1H), 0.45-0.55 (m, 2H), 0.2-0.3 (m, 2H). 45 SYNTHETIC EXAMPLE 7 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-methoxyimino-1-methylethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-117 of the present invention) Step 1: Preparation of 1-(3,5-dichloropyridin-2-yl)-1-propanone 179 To 5.0 g of 3,5-dichloropyridin-2-carbonitrile in 50 ml of tetrahydrofuran, 38 ml of 13% ethylmagnesium bromide in tetrahydrofuran was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was 5 added dropwise to 55 ml of 1N aqueous hydrochloric acid with stirring under cooling with ice, and extracted with ethyl acetate (50 mlx2). The resulting organic layers were combined, washed with water (50 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column 10 chromatography using ethyl acetate-hexane (with a gradient of 5:95 to 15:85) as the eluent to obtain 4.4 g of the desired product as pale yellow crystals. 1H NMR (CDCIs, Me4Si, 300MHz) 58.48 (d, J=2.1Hz, 1H), 7.81 (d, J=2.1Hz, 1H), 3.10 (q, J=7.2Hz, 2H), 1.20 (t, J=7.2Hz, 3H). Step 2: Preparation of 2-bromo-1-(3,5-dichloropyridin-2-yl)-1-propanone 15 To 4.40 g of 1 -(3,5-dichloropyridin-2-yl)-1 -propanone in 20 ml of ethyl acetatechloroform (1:1), 10.12 g of copper(l) bromide was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was mixed with 30 ml of saturated aqueous sodium hydrogencarbonate, and the precipitated solid was filtered off through celite and washed with 20 ml of ethyl 20 acetate. The filtrate was mixed with 100 ml of ethyl acetate, the resulting organic layer was collected, washed with water (30 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 15:85) as 25 the eluent to obtain 5.00 g of the desired product as a pale orange oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.49 (d, J=2.1Hz, 1H), 7.86 (d, J=2.1Hz, 1H), 5.76 (q, J=6.9Hz, 1H), 1.89 (d, J=6.9Hz, 3H). Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-1-methyl-2-oxoethyl)phthalimide To 5.00 g of 2-bromo-1-(3,5-dichloropyridin-2-yl)-1 -propanone in 20 ml of N,N- 30 dimethylformamide, 3.27 g of potassium phthalimide was added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the reaction mixture was mixed with 50 ml of water and extracted with ethyl acetate (50 mlx2), and the resulting organic layers were combined, washed with water (30 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the 35 solvent was evaporated under reduced pressure to obtain 2.02 g of the desired crude product as brown crystals. The crystals were used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.34 (d, J=2.1Hz, 1H), 7.65-7.9 (m, 5H), 5.57 (q, J=6.9Hz, 1H), 1.68 (d, J=6.9Hz, 3H). 40 Step 4: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-methoxyimino-1- methylethyljphthalimide To 1.00 g of N-[2-(3,5-dichloropyridin-2-yl)-1-methyl-2-oxoethyl]phthalimide in 10 ml of ethanol, 2.39 g of methoxyamine hydrochloride and 3.40 g of pyridine were added and refluxed with heating for 18 hours with stirring. After completion of the reaction, 45 the reaction mixture was allowed to cool to room temperature, mixed with 30 ml of 1N aqueous hydrochloric acid and extracted with ethyl acetate (40 mlx2). The resulting organic layers were combined, washed with 30 ml of 1N aqueous hydrochloric acid and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and 180 the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 0.81 g of the desired product as a colorless resinous substance. 5 1H NMR (CDCb, Me4Si, 300MHz) 58.34 and 8.20 (bs, 1H), 7.65-7.85 (m, 5H), 5.95-6.05 and 5.3-5.65 (m, 1H), 4.01 and 3.86 (bs, 3H), 1.75-1.85 (m, 3H). Step 5: Preparation of 2-amino-1-(3,5-dichloropyridin-2-yl)-1-propanone-0-methyloxime To 810 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-methoxyimino-1- methylethyl]phthalimide in 30 ml of ethanol, 161 mg of hydrazine monohydrate was 10 added and refluxed with heating for 1 hour with stirring. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was mixed with 20 ml of water and extracted with ethyl acetate (30 mlxl). The resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was 15 evaporated under reduced pressure to obtain 430 mg of the desired crude product as a pale yellow oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.51 and 8.48 (d, J=2.1Hz, 1H), 7.79 and 7.77 (d, J=2.1Hz, 1H), 4.4-4.5 and 3.9-3.05 (m, 1H), 3.99 and 3.84 (s, 3H), 1.32 and 1.27 (d, J=6.9Hz, 3H). 20 Step 6: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-methoxyimino-1-methylethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-115 of the present invention) To a solution of 430 mg of 2-amino-1-(3,5-dichloropyridin-2-yl)-1-propanone-0- methyloxime and 210 mg of triethylamine in 20 ml of dichloromethane, 361 mg of 2- (trifluoromethyl)benzoyl chloride was added dropwise with stirring under cooling with ice, 25 and after the addition, the mixture was stirred at room temperature for another 1 hour. After completion of the reaction, the reaction mixture was mixed with 30 ml of water and extracted with chloroform (20 mlxl), the resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The 30 resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 296 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.50 and 8.41 (d, J=1.8Hz, 1H), 7.82 and 7.79 (d, J=1.8Hz, 1H), 7.4-7.75 (m, 4H), 6.65-7.0 (m, 1H), 5.7-5.85 and 5.2-5.3 (m, 1H), 4.05 35 and 3.87 (s, 3H), 1.56 and 1.45 (d, J=6.6Hz, 3H). Step 7: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-methoxyimino-1-methylethyl]- 2-(trifluoromethyl)benzamide 160 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-methoxyimino-1-methylethyl]-2- (trifluoromethyl)benzamide in 4 ml of acetonitrile was irradiated with light for 12 hours in 40 a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the precipitated solid was washed with 5 ml of diisopropyl ether to obtain 33 mg of the desired product as white crystals. 45 m.p.: 104.0 to 105.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.1Hz, 1H), 7.80 (d, J=2.1Hz, 1H), 7.5- 7.75 (m, 4H), 6.78 (bs, 1H), 5.2-5.35 (m, 1H), 3.87 (s, 3H), 1.45 (d, J=6.6Hz, 3H). SYNTHETIC EXAMPLE 8 181 (Z)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-185 of the present invention) Step 1: Preparation of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (ethoxyimino)ethyl]phthalimide 5 To 214 mg of the N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- oxoethyl]phthalimide prepared in Step 2 in Synthetic Example 6 in 3 ml of ethanol, 84 mg of ethoxyamine hydrochloride was added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 5 ml of water and extracted with ethyl acetate (5 mlx3), and the resulting 10 organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative medium pressure liquid chromatography (preparative medium pressure chromatograph: YFLC-Wprep manufactured by Yamazen Science, Inc.) using ethyl acetate-hexane (with a gradient of 15 from 2:18 to 5:15) as the eluent to obtain 111 mg of the desired product as a brown resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.60 (d, J=1.5Hz, 1H), 7.97 (d, J=1.5Hz, 1H), 7.8-7.9 (m, 2H), 7.65-7.75 (m, 2H), 5.02 and 4.80 (s, 2H), 4.29 and 4.11 (q, J=7.2Hz, 2H), 1.30 and 1.17 (t,J=7.2Hz,3H). 20 Step 2: Preparation of 2-amino-1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanone-0- ethyloxime To 111 mg of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (ethoxyimino)ethyl]phthalimide in 3 ml of ethanol, 86 mg of hydrazine monohydrate was added, and the mixture was stirred at 80°C for 1 hour. After completion of the reaction, 25 the reaction mixture was allowed to cool to room temperature, mixed with 5 ml of water and extracted with ethyl acetate (5 mlx3). The resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using methanol-chloroform (1:10) as the eluent to 30 obtain 47 mg of the desired product as a yellow oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.80 and 8.77 (d, J=1.5Hz, 1H), 8.00 and 7.97 (d, J=1.5Hz, 1H), 4.29 and 4.13 (q, J=7.2Hz, 2H), 3.93 and 3.77 (s, 2H), 1.70 (bs, 2H), 1.35 and 1.22 (t, J=7.2z, 3H). 35 Step 3: Preparation of N:[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (ethoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-016 of the present invention) To a solution of 47 mg of 2-amino-1-[3-chloro-5-(trifluoromethyl)pyridin-2- yl]ethanone-0-ethyloxime and 25 mg of triethylamine in 2 ml of dichlorornethane, 31 mg 40 of 2-(trif luoromethyl)benzoyl chloride was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 1 hour. After completion of the reaction, the reaction mixture was mixed with 2 ml of water and extracted with dichlorornethane (2 mlxl), the resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and 45 the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative medium pressure liquid chromatography (preparative medium pressure chromatograph: YFLC-Wprep manufactured by Yamazen Science, Inc.) using ethyl acetate-hexane (with a gradient of from 2:18 to 5:15) as the eluent to obtain 48 mg 182 of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.81 and 8.75 (d, J=1.5Hz, 1H), 8.03 and 8.00 (d, J=1.5Hz, 1H), 7.35-7.55 (m, 4H), 6.51 (bs, 1H), 4.79 and 4.58 (d, J=5.4Hz, 2H), 4.34 and 4.16 (q, J=7.2Hz, 2H), 1.38 and 1.24 (t, J=7.2Hz, 3H). 5 Step 4: Preparation of (Z)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (ethoxyimino)ethyl]-2-(trifluoromethyl)benzamide To 48 mg of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide in 3 ml of acetonitrile, 1 mg of benzophenone was added, and the mixture was irradiated with light for 4 hours in a quartz cell (manufactured by 10 Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 1:9 to 5:5) as the eluent to obtain 42 mg of the desired 15 product as white crystals. m.p.:60.0to62.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.81 (d, J=1.5Hz, 1H), 8.00 (d, J=1.5Hz, 1H), 7.5- 7.55 (m, 4H), 6.51 (bs, 1H), 4.79 (d, J=5.4Hz, 2H), 4.16 (q, J=7.2Hz, 2H), 1.24 (t, J=7.2Hz, 3H). 20 SYNTHETIC EXAMPLE 9 N-[2-(3-chloro-5-methoxypyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide (compound No. 2-083 of the present invention) Step 1: Preparation of 2-bromo-1-(3-chloro-5-methoxypyridin-2-yl)ethanone To 0.90 g of 1-(3-chloro-5-methoxypyridin-2-yl)ethanone in 10 ml of 25 tetrahydrofuran, 1.82 g of trimethylphenylammonium tribromide was added, and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, the precipitated solid was filtered off, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 30 0.57 g of the desired product as pale yellow crystals. 1H NMR (CDCb, Me4Si, 300MHz) 58.23 (d, J=2.4Hz, 1H), 7.28 (d, J=2.4Hz, 1H), 4.74 (s, 2H), 3.95 (s, 3H). Step 2: Preparation of N-[2-(3-chloro-5-methoxypyridin-2-yl)-2-oxoethyl]phthalimide To 570 mg of 2-bromo-1-(3-chloro-5-methoxypyridin-2-yl)ethanone in 10 ml of 35 N,N-dimethylformamide, 800 mg of potassium phthalimide and 36 mg of potassium iodide were added, and the mixture was stirred at 80°C for 5 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 20 ml of water and extracted with ethyl acetate (40 mlxl), the resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium 40 sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 0.12 g of the desired product as white crystals. 1H NMR (CDCb, Me4Si, 300MHz) 58.30 (d, J=2.4Hz, 1H), 7.85-7.95 (m, 2H), 7.7-7.8 45 (m, 2H), 7.27 (d, J=2.4Hz, 2H), 5.31 (s, 2H), 3.96 (s, 3H). Step 3: Preparation of N-[2-(3-chloro-5-methoxypyridin-2-yl)-2- (methoxyimino)ethyl]phthalimide To a solution of 120 mg of N-[2-(3-chloro-5-methoxypyridin-2-yl)-2- 183 oxoethyl]phthalimide and 60 mg of methoxyamine hydrochloride in 5 ml of ethanol, 85 mg of pyridine was added, and the mixture was stirred at 80°C for 6 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate- 5 hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 101 mg of the desired product as a pale yellow oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.17 and 8.01 (d, J=2.7Hz, 1H), 7.65-7.9 (m, 4H), 7.20 and 7.19 (d, J=2.7Hz, 1H), 4.99 and 4.77 (s, 2H), 4.04 and 3.84 (s, 3H), 3.84 and 3.78 (s, 3H). 10 Step 4: Preparation of N-[2-(3-chloro-5-methoxypyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide To 101 mg of N-[2-(3-chloro-5-methoxypyridin-2-yl)-2- (methoxyimino)ethyl]phthalimide in 5 ml of ethanol, 42 mg of hydrazine monohydrate was added, and the mixture was stirred at room temperature for 12 hours. After 15 completion of the reaction, the reaction mixture was mixed with 15 ml of water and extracted with ethyl acetate (30 mlxl), the resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was dissolved in 5 ml of dichloromethane, and to the solution, 46 mg 20 of 2-(trifluoromethyl)benzoyl chloride and then 33 mg of triethylamine were added, and the mixture was stirred at room temperature for one hour. After completion of the reaction, the reaction mixture was mixed with 5 ml of water and extracted with ethyl acetate (15 mlxl), the resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and 25 the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 87 mg of a pale yellow resinous substance. The resinous substance was dissolved in 5 ml of ethanol, and 0.5 ml of a 1,4-dioxane solution (4 mol/L) of hydrogen chloride, and the mixture was stirred at 70°C 30 for 2 hours. The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 80 mg of the desired product as a colorless resinous substance (E/Z=55/45). 1H NMR (CDCb, Me4Si, 300MHz) 58.23 and 8.19 (d, J=2.7Hz, 1H), 7.35-7.75 (m, 4H), 35 7.28 and 7.27 (d, J=2.7Hz, 1H), 6.57 and 6.50 (bs, 1H), 4.74 and 4.52 (d, J=6.0Hz, 2H), 4.05 and 3.87 (s, 3H), 3.84 (bs, 3H). SYNTHETIC EXAMPLE 10 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-128 of the present invention) 40 Step 1: Preparation of 1 -[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-1,3,5,7- tetraazatricyclo[3,3,1,13'7]decan-1 -ium bromide 5.00 g of the 2-bromo-1-(3,5-dichloropyridin-2-yl)ethanone prepared in Step 2 in Synthetic Example 2 in 30 ml of chloroform was added dropwise to 2.61 g of 1,3,5,7- tetraazatricyclo[3,3,1,13'7]decane in 50 ml of chloroform with stirring at room 45 temperature, and the mixture was stirred at the same temperature for 2 hours. After completion of the reaction, the precipitated crystals were collected by filtration and washed with 30 ml of chloroform to obtain 7.40 g of the desired product as white crystals. 184 m.p.>177.0°C (decomposition) Step 2: Preparation of 2-amino-1-(3,5-dichloropyridin-2-yl)ethanone hydrochloride To a suspension of 7.0 g of 1-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-1,3,5,7- tetraazatricyclo[3,3,1,13'7]decan-1-ium bromide in 70 ml of ethanol, 7 ml of concentrated 5 hydrochloric acid was added, and the mixture was stirred at room temperature for 14 hours. After completion of the reaction, the solid was collected by filtration and washed with 15 ml of ethanol to obtain 3.7 g of the desired product as white crystals. m.p.>207.0°C (decomposition) 1H NMR (CDCb, Me4Si-DMSO-d6, 300MHz) 58.83 (bs, 1H), 8.51 (bs, 1H), 4.54 (bs, 10 2H). Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2- (trifluoromethyl)benzamide To a suspension of 3.7 g of 2-amino-1-(3,5-dichloropyridin-2-yl)ethanone hydrochloride in 50 ml of ethyl acetate, 30 ml of water and 3.5 g of 2- 15 (trifluoromethyl)benzoyl chloride were added, and 6.1 g of potassium carbonate in 30 ml of water was added dropwise with stirring under cooling with ice, and the mixture was stirred at the same temperature for 30 minutes. After completion of the reaction, the reaction mixture was mixed with 20 ml of ethyl acetate, the resulting organic layer was collected, washed with water (20 mlxl) and dried over saturated aqueous sodium 20 chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 2:8 to 6:4) as the eluent to obtain 3.8 g of the desired product as pale yellow crystals. m.p.: 123.0 to 125.0°C 25 1H NMR (CDCb, Me4Si, 300MHz) 58.55 (d, J=2.1 Hz, 1H), 7.88 (d, J=2.1 Hz, 1H), 7.5- 7.75 (m, 4H), 6.69 (bs, 1H), 5.10 (d, J=4.8Hz, 2H). Step 4: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(hydroxyimino)ethyl]-2- (trifluoromethyl)benzamide To a solution of 3.38 g of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2- 30 (trifluoromethyl)benzamide and 0.934 g of hydroxylamine hydrochloride in 20 ml of ethanol, 1.10 g of sodium acetate was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 40 ml of water and extracted with ethyl acetate (20 mlx2), the resulting organic layers were combined, 35 washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 2:8 to 4:6) as the eluent to obtain 1.90 g of the desired product as white crystals. 40 m.p.: 134.0 to 136.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.52 and 8.45 (d, J=2.4Hz, 1H), 7.81 and 7.80 (d, J=2.4Hz, 1H), 7.35-7.75 (m, 4H), 6.53 (bs, 1H), 4.80 and 4.55 (d, J=6.3Hz, 2H). Step 5: Preparation of (E)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-239 of the present invention) 45 To a suspension of 300 mg of N-[2-(3,5-dichloropyridin-2-yl)-2- (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide and 315 mg of potassium carbonate in 3 ml of N,N-dimethylformamide, 195 mg of 2-iodopropane was added, and the mixture was stirred at room temperature for 6 hours. After completion of the reaction, 185 the reaction mixture was mixed with 20 ml of water and extracted with ethyl acetate (10 mlx2), the resulting organic layers were combined, washed with water (10 mlx2), the resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. 5 The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 258 mg of the desired product as white crystals. m.p.: 54.0 to 57.0°C 1H NMR (CDCIs, Me4Si, 300MHz) 58.45 (d, J=2.1Hz, 1H), 7.81 (d, J=2.1Hz, 1H), 7.35- 10 7.7 (m, 4H), 6.49 (bs, 1H), 4.76 (d, J=6.3Hz, 2H), 4.45-4.6 (m, 1H), 1.33 (d, J=6.0Hz, 6H). Step 6: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide To 258 mg of (E)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2- 15 (trifluoromethyl)benzamide in 4 ml of acetonitrile, 2 mg of benzophenone was added, and the mixture was irradiated with light for 12 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the 20 resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 231 mg of the desired product as white crystals. m.p.: 107.0 to 108.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.1Hz, 1H), 7.78 (d, J=2.1Hz, 1H), 7.5-7.8 25 (m, 4H), 6.54 (bs, 1H), 4.53 (d, J=5.1Hz, 2H), 4.3-4.45 (m, 1H), 1.18 (d, J=6.3Hz, 6H). SYNTHETIC EXAMPLE 11 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(tert-butoxyimino)ethyl]-2- (trifluoromethyl)benzamide (compound No. 2-140 of the present invention) Step 1: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(tert- butoxyimino)ethyl]-2- 30 (trifluoromethyl)benzamide (compound No. 2-139 of the present invention) To a solution of 200 mg of the N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2- (trifluoromethyl)benzamide prepared in Step 3 in Synthetic Example 10 and 199 mg of 0-(tert-butyl)hydroxylamine hydrochloride in 2.6 ml of ethanol, 167 mg of pyridine was added, and the mixture was stirred at 70°C for 18 hours. After completion of the 35 reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 2 ml of water and extracted with ethyl acetate (2 mlx2), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl 40 acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 207 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.50 and 8.44 (d, J=2.4Hz, 1H), 7.25-7.85 (m, 5H), 6.54 (bs, 1H), 4.77 and 4.54 (d, J=5.7Hz, 2H), 1.37 and 1.24 (s, 9H). Step 2: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(tert-butoxyimino)ethyl]-2- 45 (trifluoromethyl)benzamide 207 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(tert-butoxyimino)ethyl]-2- (trifluoromethyl)benzamide in 4 ml of acetonitrile was irradiated with light for 8 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W 186 high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 5:5) to obtain 5 190 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.0Hz, 1H), 7.77 (d, J=2.0Hz, 1H), 7.5- 7.75 (m, 4H), 6.56 (bs, 1H), 4.53 (d, J=5.1Hz, 2H), 1.24 (s, 9H). SYNTHETIC EXAMPLE 12 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(2,2,2-trifluoroethoxyimino)ethyl]-2- 10 (trifluoromethyl)benzamide (compound No. 2-212 of the present invention) Step 1: Preparation of tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]carbamate To 35.1 g of 2-bromo-3,5-dichloropyridine in 10 ml of tetrahydrofuran, 116.3 ml of a 1.3 M tetrahydrofuran solution of isopropylmagnesium chloride-lithium chloride complex was added dropwise with stirring at -20°C, and after the addition, the mixture 15 was stirred at the same temperature for 15 minutes. Then, to the reaction mixture, 15.0 g of N-methoxy-N-methyl-2-(tert-butoxycarbonylamino)acetamide in 114 ml of tetrahydrofuran was added dropwise, and after the addition, the mixture was stirred at the same temperature for another 2 hours. After completion of the reaction, the reaction mixture was mixed with 100 ml of saturated aqueous ammonium chloride and 20 100 ml of water and extracted with ethyl acetate (200 mlx2), the resulting organic layers were combined, washed with water (100 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 0:10 to 3:7) as the 25 eluent to obtain 12.5 g of the desired product as pale yellow crystals. m.p.: 82.0 to 84.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.51 (d, J=2.1Hz, 1H), 7.85 (d, J=2.1Hz, 1H), 5.31 (bs, 1H), 4.76 (bs, 2H), 1.47 (s, 9H). Step 2: Preparation of tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2- 30 (hydroxyimino)ethyl]carbamate To a solution of 10.6 g of tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2- oxoethyl]carbamate and 4.8 g of hydroxylamine hydrochloride in 87 ml of ethanol, 6.1 g of pyridine was added, and the mixture was stirred at room temperature for 24 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, 35 the resulting residue was mixed with 50 ml of water and extracted with ethyl acetate (100 mlx2), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 40:60) as 40 the eluent to obtain 10.1 g of the desired product as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.52 and 8.47 (d, J=2.4Hz, 1H), 7.82 and 7.79 (d, J=2.4Hz, 1H), 5.65 and 5.16 (bs, 1H), 4.46 and 4.24 (d, J=5.4Hz, 2H), 1.39 and 1.34 (s, 9H). Step 3: Preparation of tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2-(2,2,2- 45 trifluoroethoxyimino)ethyl]carbamate To 5.0 g of tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2- (hydroxyimino)ethyl]carbamate in 16.0 ml of N,N-dimethylformamide, 4.3 g of potassium carbonate and 5.4 g of 2,2,2-trifluoroethyl trifluoromethanesulfonate were added, and 187 the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 100 ml of water and extracted with ethyl acetate (100 mlx2), the resulting organic layers were combined, washed with water (50 mlx2) and dried over saturated aqueous sodium chloride and then anhydrous sodium 5 sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 0:10 to 3:7) as the eluent to obtain 4.8 g of the desired product as a pale yellow oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.51 and 8.49 (d, J=1.8Hz, 1H), 7.80 and 7.78 (d, 10 J=1.8Hz, 1H), 4.94 (bs, 1H), 4.0-4.65 (m, 4H), 1.39 and 1.34 (s, 9H). Step 4: Preparation of 2-amino1 -(3,5-dichloropyridin-2-yl)ethanone-0-(2,2,2- trifluoroethyl)oxime hydrochloride To 4.9 g of tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2-(2,2,2- trif luoroethoxyimino)ethyl]carbamate in 5 ml of 1,4-dioxane, 25 ml of a 1,4-dioxane 15 solution (4 mol/L) of hydrogen chloride was added, and the mixture was stirred at room temperature for 3 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was washed with 20 ml of hexane to obtain 3.1 g of the desired product as pale brown crystals. m.p.: 141.0 to 143.0°C 20 1H NMR (CDCb, Me4Si, 300MHz) 58.98 (bs, 3H), 8.56 and 8.52 (d, J=2.1 Hz, 1H), 7.83 and 7.80 (d, J=2.1Hz, 1H), 4.72 and 4.54 (q, J=8.7Hz, 2H), 4.28 and 4.10 (bs, 2H). Step 5: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(2,2,2-trifluoroethoxyimino)ethyl]- 2-(trifluoromethyl)benzamide (compound No. 2-011 of the present invention) To 2.0 g of 2-amino1-(3,5-dichloropyridin-2-yl)ethanone-0-(2,2,2- 25 trifluoroethyl)oxime hydrochloride in 12.0 ml of water, 1.4 g of 2-(trifluoromethyl)benzoyl chloride in 12.0 ml of dichloromethane and 2.4 g of potassium carbonate were added at room temperature with stirring, and the mixture was stirred at the same temperature for 2 hours. After completion of the reaction, the resulting organic layer was collected and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced 30 pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 2.6 g of the desired product as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.51 and 8.46 (d, J=2.1Hz, 1H), 7.82 and 7.81 (d, J=2.1Hz, 1H), 7.35-7.75 (m, 4H), 6.39 (bs, 1H), 4.80 and 4.57 (d, J=6.0Hz, 2H), 4.61 35 and 4.42 (q, J=8.4Hz, 2H). Step 6: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(2,2,2- trifluoroethoxyimino)ethyl]-2-(trifluoromethyl)benzamide 2.6 g of N-[2-(3,5-dichloropyridin-2-yl)-2-(2,2,2-trifluoroethoxyimino)ethyl]-2- (trifluoromethyl)benzamide was dissolved in 12.0 ml of acetonitrile, and the solution was 40 irradiated with light for 48 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was washed with 20 ml of hexane to obtain 2.1 g of the desired product as white crystals. 45 m.p.: 100.0 to 102.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.52 (d, J=2.1Hz, 1H), 7.45-7.85 (m, 5H), 6.39 (bs, 1H), 4.57 (d, J=5.4Hz, 2H), 4.42 (q, J=8.7Hz, 2H). SYNTHETIC EXAMPLE 13 188 (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-(Z)-(isopropoxyimino)-1-methylethyl]-2- (trifluoromethyl)benzamide (compound No. 2-132 of the present invention) Step 1: Preparation of (S)-N-methoxy-N-methyl-2-(tertbutoxycarbonylamino) propionamide 5 To 20.0 g of N-(tert-butoxycarbonyl)-L-alanine in 352 ml of dichloromethane, 12.4 g of N,0-dimethylhydroxylamine hydrochloride, 15.7 g of 1-hydroxybenzotriazole monohydrate, 24.3 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 42.7 g of triethylamine were added, and the mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the reaction mixture was 10 washed with 500 ml of saturated aqueous sodium hydrogen carbonate, 500 ml of 1N aqueous hydrochloric acid and 500 ml of water in this order, the resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was washed with 200 ml of hexane to obtain 13.1 g of the desired product as white crystals. 15 m.p.: 144.0 to 145.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 55.22 (bs, 1H), 4.68 (bs, 1H), 3.77 (s, 3H), 3.21 (s, 3H), 1.44 (s, 9H), 1.31 (d, J=6.9Hz, 3H). Step 2: Preparation of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-1-methyl-2- oxoethyl]carbamate 20 To 11.0 g of 2-bromo-3,5-dichloropyridine in 5 ml of tetrahydrofuran, 36.4 ml of a 1.3 M tetrahydrofuran solution of isopropylmagnesium chloride-lithium chloride complex was added dropwise with stirring at -20°C, and after the addition, the mixture was stirred at the same temperature for 15 minutes. Then, to the reaction mixture, 5.0 g of (S)-Nmethoxy- N-methyl-2-(tert-butoxycarbonylamino)propionamide in 36 ml of 25 tetrahydrofuran was added dropwise, and after the addition, the mixture was stirred at the same temperature for another 2 hours. After completion of the reaction, the reaction mixture was mixed with 30 ml of saturated aqueous ammonium chloride and 10 ml of water and extracted with ethyl acetate (40 mlx2), the resulting organic layers were combined, washed with water (40 mlxl) and dried over saturated aqueous sodium 30 chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 10:0 to 3:7) to obtain 4.5 g of the desired product as a pale yellow oil. 1H NMR (CDCIa, Me4Si, 300MHz) 58.51 (d, J=2.1Hz, 1H), 7.84 (d, J=2.1Hz, 1H), 5.50 35 (bs, 1H), 5.32 (bs, 1H), 1.46 (s, 9H), 1.36 (d, J=7.2Hz, 3H). Optical purity: 95% e.e. Optical rotation: [a]D17-5-20.20°(CHCI3, c=0.10) Step 3: Preparation of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-hydroxyimino-1- methylethyl]carbamate 40 To a solution of 1.0 g of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-1-methyl-2- oxoethyl]carbamate and 239 mg of hydroxylamine hydrochloride in 5 ml of ethanol, 272 mg of pyridine was added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 10 ml of water and extracted with ethyl 45 acetate (10 mlx2), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 189 40:60) as the eluent to obtain 740 mg of the desired product as pale yellow crystals. m.p.:51.0to53.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.53 (d, J=2.1Hz, 1H), 7.78 (d, J=2.1Hz, 1H), 5.15 (bs, 1H), 4.81 (bs, 1H), 1.3-1.65 (m, 12H). 5 Optical purity: 95% e.e. Optical rotation: [a]D 17-8-27.40o(CHCb, c=0.10) Step 4: Preparation of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)- 1 -methylethyl]carbamate To 655 mg of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-hydroxyimino-1- 10 methylethyl]carbamate in 1.6 ml of N,N-dimethylformamide, 445 mg of potassium carbonate and 789 mg of 2-iodopropane were added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 5 ml of water and extracted with ethyl acetate (10 mlx2), the resulting organic layers were combined, washed with water (10 mlx2) and dried over saturated 15 aqueous sodium chloride and then aqueous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 0:10 to 3:7) as the eluent to obtain 411 mg of the desired product as a colorless oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.49 and 8.44 (d, J=2.1Hz, 1H), 7.77 and 7.73 (d, 20 J=2.1 Hz, 1H), 5.20 (bs, 1H), 4.74 (bs, 1H), 4.25-4.5 (m, 1H), 1.1 -1.6 (m, 18H). Optical purity: 95% e.e. Optical rotation: [a]D 180-29.90o(CHCb, c=0.14) Step 5: Preparation of (S)-2-amino-1-(3,5-dichloropyridin-2-yl)propanone-0- isopropyloxime hydrochloride 25 To 350 mg of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)-1- methylethyl]carbamate in 3 ml of 1,4-dioxane, 5 ml of a 1,4-dioxane solution (4 mol/L) of hydrogen chloride was added, and the mixture was stirred at room temperature for 6 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was washed with 20 ml of hexane to obtain 253 mg 30 of the desired product as white crystals. m.p.: 215.0 to 216.0°C 1H NMR (CDCb, Me4Si, 300MHz) 59.00 (bs, 3H), 8.51 (d, J=2.1Hz, 1H), 7.76 (d, J=2.1Hz, 1H), 4.35-4.6 (m, 2H), 1.73 and 1.57 (d, J=6.9Hz, 3H), 1.15-1.4 (m, 6H). Optical purity: 95% e.e. 35 Optical rotation: [a]D18-6-15.50°(CHCb, c=0.10) Step 6: Preparation of (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)-1 - methylethyl]-2-(trifluoromethyl)benzamide (compound No. 2-130 of the present invention) To 210 mg of (S)-2-amino-1-(3,5-dichloropyridin-2-yl)propanone-0-isopropyloxime 40 hydrochloride in 1.3 ml of water, 151 mg of 2-(trifluoromethyl)benzoyl chloride in 1.3 ml of dichloromethane and 278 mg of potassium carbonate were added with stirring at room temperature, and the mixture was stirred at the same temperature for 2 hours. After completion of the reaction, the resulting organic layer was collected and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. 45 The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 221 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.48 and 8.40 (d, J=1.8Hz, 1H), 7.4-7.85 (m, 5H), 190 7.00 and 6.85 (bs, 1H), 5.7-5.85 and 5.15-5.3 (m, 1H), 4.25-4.55 (m, 1H), 1.15-1.6 (m, 9H). Optical purity: 95% e.e. Optical rotation: [a]D 190-13.20°(EtOH, c=0.10) 5 Step 7: Preparation of (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-[(Z)-isopropoxyimino]-1- methylethyl]-2-(trifluoromethyl)benzamide 240 mg of (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)-1-methylethyl]-2- (trifluoromethyl)benzamide was dissolved in 4 ml of acetonitrile, and the solution was irradiated with light for 8 hours in a quartz cell (manufactured by Fine, 4 clear windows 10 for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 5:5) as the eluent to obtain 153 mg of the desired product as a colorless resinous 15 substance. 1H NMR (CDCI3, Me4Si, 300MHz) 58.48 (d, J=2.1Hz, 1H), 7.78 (d, J=2.1Hz, 1H), 7.45- 7.75 (m, 4H), 6.84 (bs, 1H), 5.15-5.3 (m, 1H), 4.25-4.45 (m, 1H), 1.44 (d, J=6.6Hz, 3H), 1.18 (d, J=6.0Hz, 6H). Optical purity: 95% e.e. 20 Optical rotation: [a]D 21-8 -8.60°(EtOH, c=0.10) SYNTHETIC EXAMPLE 14 (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-[(Z)-ethoxyimino]-1-methylethyl]-2- (trifluoromethyl)benzamide (compound No. 2-124 of the present invention) Step 1: Preparation of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-ethoxyimino-1- 25 methylethyl]carbamate To a solution of 1.0 g of the tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-1-methyl- 2-oxoethyl]carbamate prepared in Step 2 in Synthetic Example 13 and 336 mg of ethoxyamine hydrochloride in 6.3 ml of ethanol, 272 mg of pyridine was added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, 30 the solvent was distilled off under reduced pressure, the resulting residue was mixed with 10 ml of water and extracted with ethyl acetate (10 mlx2), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl 35 acetate-hexane (with a gradient of from 5:95 to 40:60) as the eluent to obtain 824 mg of the desired produced as a pale yellow oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.1Hz, 1H), 7.74 (d, J=2.1Hz, 1H), 5.19 (bs, 1H),4.75(bs, 1H), 4.26 and 4.11 (q, J=7.2Hz, 2H), 1.1-1.55 (m, 15H). Optical purity: 95% e.e. 40 Optical rotation: [a]D 17-9-30.00°(CHCI3, c=0.10) Step 2: Preparation of (S)-2-amino-1-(3,5-dichloropyridin-2-yl)propanone-0-ethyloxime hydrochloride To 780 mg of tert-butyl (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-ethoxyimino-1- methylethyl]carbamate in 3 ml of 1,4-dioxane, 5 ml of a 1,4-dioxane solution (4 mol/L) of 45 hydrogen chloride was added, and the mixture was stirred at room temperature for 6 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was washed with 20 ml of hexane to obtain 643 mg of the desired product as beige crystals. 191 m.p.:209.0to210.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.98 (bs, 3H), 8.52 (d, J=2.1Hz, 1H), 7.77 (d, J=2.1Hz, 1H), 4.51 (bs, 1H), 4.35 and 4.20 (q, J=7.2Hz, 2H), 1.73 and 1.59 (d, J=7.2Hz, 3H), 1.38 and 1.25 (t, J=7.2Hz, 3H). 5 Optical purity: 95% e.e. Optical rotation: [a]D18-5-10.90o(CHCb, c=0.10) Step 3: Preparation of (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-ethoxyimino-1-methylethyl]- 2-(trifluoromethyl)benzamide (compound No. 2-122 of the present invention) To 550 mg of (S)-2-amino-1-(3,5-dichloropyridin-2-yl)propanone-0-ethyloxime 10 hydrochloride in 3.7 ml of water, 423 mg of 2-(trifluoromethyl)benzoyl chloride in 3.7 ml of dichloromethane and 763 mg of potassium carbonate were added with stirring at room temperature, and the mixture was stirred at the same temperature for 2 hours. After completion of the reaction, the organic layer was collected and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. 15 The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 800 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.49 (d, J=2.1Hz, 1H), 7.4-7.85 (m, 5H), 6.98 and 6.81 (bs, 1H), 5.75-5.85 and 5.15-5.35 (m, 1H), 4.29 and 4.12 (q, J=7.2Hz, 2H), 1.15- 20 1.65 (m,6H). Optical purity: 95% e.e. Optical rotation: [a]D 190-13.10°(EtOH, c=0.10) Step 4: Preparation of (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-[(Z)-ethoxyimino]-1- methylethyl]-2-(trifluoromethyl)benzamide 25 580 mg of (S)-N-[2-(3,5-dichloropyridin-2-yl)-2-ethoxyimino-1 -methylethyl]-2- (trifluoromethyl)benzamide was dissolved in 3 ml of acetonitrile, and the solution was irradiated with light for 8 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply. UM-103B-B). After completion of the reaction, the 30 solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 5:5) as the eluent to obtain 557 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.49 (d, J=2.1Hz, 1H), 7.4-7.85 (m, 5H), 6.81 (bs, 35 1H), 5.15-5.35 (m, 1H), 4.12 (q, J=7.2Hz, 2H), 1.45 (d, J=6.9Hz, 3H), 1.20 (t, J=7.2Hz, 3H). Optical purity: 95% e.e. Optical rotation: [a]D 217-11.40°(EtOH, c=0.10) SYNTHETIC EXAMPLE 15 40 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(sec-butoxyimino)ethyl]-2- (trifluoromethyl)benzamide (compound No. 2-136 of the present invention) Step 1: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2- (trifluoromethyl)benzamide To 5.0 g of the tert-butyl N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]carbamate 45 prepared in Step 1 in Synthetic Example 12 in 2 ml of 1,4-dioxane, 25 ml of a 1,4- dioxane solution (4 mol/L) of hydrogen chloride was added, and the mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was dissolved in 33 ml of 192 water and 33 ml of dichloromethane, and to the resulting solution, 4.5 g of potassium carbonate was added and further, 3.8 g of 2-(trifluoromethyl)benzoyl chloride was added with stirring under cooling with ice, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the resulting organic layer 5 was collected and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 2.8 g of the desired product as pale yellow crystals. m.p.: 123.0to125.0°C 10 1H NMR (CDCIa, Me4Si, 300MHz) 58.56 (d, J=2.1Hz, 1H), 7.88 (d, J=2.1Hz, 1H), 7.5-7.8 (m, 4H), 6.69 (bs, 1H), 5.10 (d, J=5.1Hz, 2H). Step 2: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(hydroxyimino)ethyl]-2- (trifluoromethyl)benzamide To 2.8 g of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2-(trifluoromethyl)benzamide 15 in 19 ml of ethanol, 1.0 g of hydroxylamine hydrochloride was added, and the mixture was stirred at room temperature for 96 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 50 ml of water and extracted with ethyl acetate (50 mlx2), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous 20 sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 2.8 g of the desired product as pale yellow crystals. m.p.: 134.0 to 136.0°C 25 1H NMR (CDCI3, Me4Si, 300MHz) 58.52 and 8.45 (d, J=2.4Hz, 1H), 7.81 and 7.80 (d, J=2.4Hz, 1H), 7.35-7.75 (m, 4H), 6.53 (bs, 1H), 4.80 and 4.55 (d, J=6.3Hz, 2H). Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(sec-butoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-009 of the present invention) To a suspension of 500 mg of N-[2-(3,5-dichloropyridin-2-yl)-2- 30 (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide and 352 mg of potassium carbonate in 1.3 ml of N,N-dimethylformamide, 704 mg of 2-iodobutane was added, and the mixture was stirred at room temperature for 12 hours. After completion the reaction, the reaction mixture was mixed with 3 ml of water and extracted with ethyl acetate (3 mlx2), the resulting organic layers were combined, washed with water (3 mlxl) and 35 dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 522 mg of the desired product as a pale yellow resinous substance. 40 1H NMR (CDCI3, Me4Si, 300MHz) 58.50 and 8.44 (d, J=2.1 Hz, 1H), 7.81 and 7.78 (d, J=2.1Hz, 1H), 7.35-7.75 (m, 4H), 6.53 (bs, 1H), 4.76 and 4.52 (d, J=5.7Hz, 2H), 4.25- 4.35 and 4.1-4.2 (m, 1H), 1.35-1.85 (m, 2H), 1.30 and 1.17 (d, J=6.3Hz, 3H), 0.94 and 0.83 (t, J=7.2Hz, 3H). Step 4: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(sec-butoxyimino)ethyl]-2- 45 (trifluoromethyl)benzamide To 522 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(sec-butoxyimino)ethyl]-2- (trifluoromethyl)benzamide in 3 ml of acetonitrile, 1 mg of benzophenone was added, and the mixture was irradiated with light for 12 hours in a quartz cell (manufactured by 193 Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate- 5 hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 416 mg of the desired product as white crystals. m.p.:68.0to70.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.1Hz, 1H), 7.45-7.8 (m, 5H), 6.53 (bs, 1H), 4.53 (d, J=4.8Hz, 2H), 4.05-4.2 (m, 1H), 1.35-1.7 (m, 2H), 1.18 (d, J=6.3Hz, 3H), 10 0.84 (t, J=7.5Hz, 3H). SYNTHETIC EXAMPLE 16 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-114 of the present invention) Step 1: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- 15 (trifluoromethyl)benzamide (Compound No. 2-002 of the present invention) To a solution of 200 mg of the N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2- (trifluoromethyl)benzamide prepared in Step 1 in Synthetic Example 15 and 133 mg of methoxyamine hydrochloride in 2.7 ml of ethanol, 168 mg of pyridine was added, and the mixture was stirred at 80°C for 6 hours. After completion of the reaction, the 20 reaction mixture was mixed with 10 ml of water and extracted with ethyl acetate (10 mlxl), the resulting organic layer was washed with water (10 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 25 3:7) as the eluent to obtain 191 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.50 and 8.45 (d, J=2.1Hz, 1H), 7.80 and 7.78 (d, J=2.1Hz, 1H), 7.35-7.75 (m, 4H), 6.48 and 6.43 (bs, 1H), 4.73 and 4.53 (d, J=6.3Hz, 2H), 4.06 and 4.02 (s, 3H). 30 Step 2: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide 191 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide in 4 ml of acetonitrile was irradiated with light for 11 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W 35 high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 149 mg of the desired product as white crystals. 40 m.p.:88.0to89.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.50 (d, J=2.0Hz, 1H), 7.78 (d, J=2.0Hz, 1H), 7.35- 7.75 (m, 4H), 6.45 (bs, 1H), 4.53 (d, J=4.8Hz, 2H), 4.02 (s, 3H). SYNTHETIC EXAMPLE 17 (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-[1-(4-fluorophenyl)ethoxyimino]ethyl]-2- 45 (trifluoromethyl)benzamide (Compound No. 2-174 of the present invention) Step 1: Preparation of N-[2-methoxy(methyl)amino-2-oxoethyl]-2- (trifluoromethyl)benzamide To 45.2 g of 2-[2-(trifluoromethyl)benzoylamino]acetic acid in 609 ml of 194 dichloromethane, 21.4 g of N,0-dimethylhydroxylamine hydrochloride, 42.0 g of 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 73.8 g of triethylamine and 2.2 g of 4-(dimethylamino)pyridine were added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was 5 washed with 500 ml of saturated anhydrous sodium hydrogen carbonate, 500 ml of 1N aqueous hydrochloric acid twice and 500 ml of water in this order, the resulting organic layer was dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was washed with 200 ml of hexane to obtain 31.4 g of the desired product as 10 white crystals. m.p.: 106.0to107.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 57.5-7.75 (m, 4H), 6.70 (bs, 1H), 4.40 (d, J=3.9Hz, 2H), 3.77 (s, 3H), 3.25 (s, 3H). Step 2: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2- 15 (trifluoromethyl)benzamide To 17.6 g of 2-bromo-3,5-dichloropyridin in 5 ml of tetrahydrofuran, 58.3 ml of a 1,3M tetrahydrofuran solution of isopropylmagnesium chloride-lithium chloride complex was added dropwise with stirring at -20°C, and after the addition, the mixture was stirred at the same temperature for 30 minutes. Then, to the reaction mixture, 10.0 g of N-[2- 20 methoxy(methyl)amino-2-oxoethyl]-2-(trifluoromethyl)benzamide in 57.4 ml of tetrahydrofuran was added dropwise, and after the addition, the mixture was stirred at room temperature for another 3 hours. After completion of the reaction, the reaction mixture was mixed with 100 ml of saturated aqueous ammonium chloride and 100 ml of water and extracted with ethyl acetate (150 mlx2), the resulting organic layers were 25 combined, washed with water (100 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 3.0 g of the desired product as pale yellow crystals. 30 m.p.: 123.0 to 125.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 58.56 (d, J=2.1Hz, 1H), 7.88 (d, J=2.1Hz, 1H), 7.5-7.8 (m, 4H), 6.69 (bs, 1H), 5.10 (d, J=5.1Hz, 2H). Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(hydroxyimino)ethyl]-2- (trifluoromethyl)benzamide 35 To 2.8 g of N-[2-(3,5-dichloropyridin-2-yl)-2-oxoethyl]-2-(trifluoromethyl)benzamide in 19 ml of ethanol, 1.0 g of hydroxylamine hydrochloride was added, and the mixture was stirred at room temperature for 96 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 50 ml of water and extracted with ethyl acetate (50 mlx2), the resulting organic layers 40 were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetatehexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 2.8 g of the desired product as white crystals. 45 m.p.: 134.0 to 136.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 68.52 and 8.45 (d, J=2.4Hz, 1H), 7.81 and 7.80 (d, J=2.4Hz, 1H), 7.35-7.75 (m, 4H), 6.53 (bs, 1H), 4.80 and 4.55 (d, J=6.3Hz, 2H). Step. 4: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-[1-(4- 195 fluorophenyl)ethoxyimino]ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-173 of the present invention) To a suspension of 200 mg of N-[2-(3,5-dichloropyridin-2-yl)-2- (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide and 211 mg of potassium carbonate 5 in 2 ml of N,N-dimethylformamide, 155 mg of 1 -(1 -bromoethyl)-4-fluorobenzene was added, and the mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 3 ml of water and extracted with ethyl acetate (3 mlx2), the resulting organic layers were combined, washed with water (3 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium 10 sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 171 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCIa, Me4Si, 300MHz) 58.52 and 8.42 (d, J=2.1 Hz, 1H), 7.80 and 7.77 (d, 15 J=2.1 Hz, 1H), 6.0-7.75 (m, 8H), 6.40 (bs, 1H), 5.38 and 5.21 (q, J=6.9Hz, 1H), 4.81 and 4.49 (d, J=5.7Hz, 2H), 1.64 and 1.45 (d, J=6.9Hz, 3H). Step 5: Preparation of (Z)-N-[2-(3,5-dichloropyridin-2-yl)-2-[1-(4- fluorophenyl)ethoxyimino]ethyl]-2-(trifluoromethyl)benzamide To 171 mg of N-[2-(3,5-dichloropyridin-2-yl)-2-[1-(4- 20 fluorophenyl)ethoxyimino]ethyl]-2-(trifluoromethyl)benzamide in 3 ml of acetonitrile, 1 mg of benzophenone was added, and the mixture was irradiated with light for 12 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated 25 under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 98 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCI3, Me4Si, 300MHz) 58.52 (d, J=2.0Hz, 1H), 7.80 (d, J=2.0Hz, 1H), 6.85- 7.75 (m, 8H), 6.38 (bs, 1H), 5.22 (q, J=6.6Hz, 1H), 4.50 (d, J=5.5Hz, 2H), 1.45 (d, 30 J=6.6Hz, 3H). SYNTHETIC EXAMPLE 18 (Z)-N-[2-(3,5-dibromopyridin-2-yl)-2-(ethoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-236 of the present invention) Step 1: Preparation of N-[2-(3,5-dibromopyridin-2-yl)-2-oxoethyl]-2- 35 (trifluoromethyl)benzamide To 5.5 g of 3,5-dibromopyridine in 1 ml of tetrahydrofuran, 22.7 ml of a 1.0M tetrahydrofuran-toluene solution of 2,2,6,6-tetramethylpiperidinylmagnesium chloridelithium chloride complex was added dropwise with stirring at -20°C, and after the addition, the mixture was stirred at the same temperature for 30 minutes. Then, to the 40 reaction mixture, 3.0 g of the N-[2-methoxy(methyl)amino-2-oxoethyl]-2- (trifluoromethyl)benzamide prepared in Step 1 in Synthetic Example 17 in 17 ml of tetrahydrofuran was added dropwise, and after the addition, the mixture was stirred at the same temperature for another 1 hour. After completion of the reaction, the reaction mixture was mixed with 30 ml of saturated aqueous ammonium chloride and 20 ml of 45 water and extracted with ethyl acetate (50 mlx2), the resulting organic layers were combined, washed with water (50 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column 196 chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 659 mg of the desired product as a pale yellow oil. 1H NMR (CDCIs, Me4Si, 300MHz) 58.69 (d, J=2.1Hz, 1H), 8.25 (d, J=2.1Hz, 1H), 7.1-7.8 (m, 4H), 6.68 (bs, 1H), 5.10 (d, J=4.8Hz, 2H). 5 Step 2: Preparation of N-[2-(3,5-dibromopyridin-2-yl)-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-235 of the present invention) To 200 mg of N-[2-(3,5-dibromopyridin-2-yl)-2-oxoethyl]-2- (trifluoromethyl)benzamide in 1.4 ml of ethanol, 63 mg of ethoxyamine hydrochloride was added, and the mixture was stirred at room temperature for 18 hours. After 10 completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was mixed with 4 ml of water and extracted with ethyl acetate (4 mlx2), the resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography 15 using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 195 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.63 and 8.58 (d, J=2.1Hz, 1H), 8.14 and 8.10 (d, J=2.1Hz, 1H), 7.1-7.75 (m, 4H), 6.43 (bs, 1H), 4.75 and 4.53 (d, J=5.7Hz, 2H), 4.30 and 4.13 (q, J=7.2Hz, 2H), 1.36 and 1.22 (t, J=7.2Hz, 3H). 20 Step 3: Preparation of (Z)-N-[2-(3,5-dibromopyridin-2-yl)-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide 195 mg of N-[2-(3,5-dibromopyridin-2-yl)-2-(ethoxyimino)ethyl]-2- (trifluoromethyl)benzamide was dissolved in 3 ml of acetonitrile, and the solution was irradiated with light for 12 hours in a quartz cell (manufactured by Fine, 4 clear windows 25 for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 5:5) as the eluent to obtain 125 mg of the desired product as a pale yellow 30 resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.63 (d, J=2.1Hz, 1H), 8.10 (d, J=2.1Hz, 1H), 7.1- 7.75 (m, 4H), 6.52 (bs, 1H), 4.53 (d, J=5.7Hz, 2H), 4.13 (q, J=7.2Hz, 2H), 1.22 (t, J=7.2Hz, 3H). SYNTHETIC EXAMPLE 19 35 N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-005 of the present invention) Step 1: Preparation of 3,5-dichloro-2-(nitromethyl)pyridine To 30.74 g of potassium tert-butoxide in 100 ml of dimethylsulfoxide, 16.72 g of nitromethane was added dropwise with stirring under cooling with ice, and after the 40 addition, the mixture was stirred at room temperature for another 1 hour. Then, the reaction mixture was cooled with ice again, and to the reaction mixture, 25.00 g of 2,3,5- trichloropyridine in 100 ml of dimethylsulfoxide was added dropwise with stirring, and after the addition, the mixture was stirred at 70°C for another 6 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, poured 45 into 200 ml of 10% aqueous hydrochloric acid with stirring under cooling with ice and extracted with ethyl acetate (200 mlxl). The resulting organic layer was washed with water (100 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. 197 The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 10:90) as the eluent to obtain 10.10 g of the desired product as a pale yellow oil. 1H NMR (CDCb, Me4Si, 300MHz) 58.53 (d, J=2.4Hz, 1H), 7.84 (d, J=2.4Hz, 1H), 5.76 (s, 5 2H). Step 2: Preparation of N-chloromethyl-2-(trifluoromethyl)benzamide To 15.50 g of N-hydroxymethyl-2-(trifluoromethyl)benzamide in 200 ml of dichloromethane, 16.83 g of thionyl chloride was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for 10 another 3 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the precipitated solid was washed with 50 ml of hexane to obtain 16.90 g of the desired product as white crystals. 1H NMR (CDCb, Me4Si, 300MHz) 57.5-7.75 (m, 4H), 6.40 (bs, 1H), 5.32 (d, J=7.5Hz, 2H). 15 Step 3: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-nitroethyl]-2- (trifluoromethyl)benzamide To 6.57 g of potassium tert-butoxide in 100 ml of N,N-dimethylformamide, 10.10 g of 3,5-dichloro-2-(nitromethyl)pyridine was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at the same temperature for 20 another 30 minutes. Then, to the reaction mixture, 11.59 g of N-chloromethyl-2- (trifluoromethyl)benzamide in 50 ml of N,N-dimethylformamide was added dropwise with stirring under cooing with ice, and after the addition, the mixture was stirred at room temperature for another 2 hours. After completion of the reaction, the reaction mixture was carefully poured into 100 ml of ice-water, acidified with 10% aqueous hydrochloric 25 acid and extracted with ethyl acetate (100 mlx2). The resulting organic layers were combined, washed with water (100 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the 30 eluent to obtain 14.00 g of the desired product as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.48 (d, J=2.1Hz, 1H), 7.87 (d, J=2.1Hz, 1H), 7.45- 7.75 (m, 4H), 6.49 (bs, 1H), 6.35 (dd, J=7.2, 4.5Hz, 1H), 4.3-4.5 (m, 2H). Step 4: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(hydroxyimino)ethyl]-2- (trifluoromethyl)benzamide 35 To 14.00 g of N-[2-(3,5-dichloropyridin-2-yl)-2-nitroethyl]-2- (trifluoromethyl)benzamide in 70 ml of a mixture of N,N-dimethylformamide-water (7:1), 16.62 g of sodium nitrite was added, and the mixture was stirred at 60°C for 18 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, poured into 100 ml of water and extracted with ethyl acetate (100 mlx2). 40 The resulting organic layers were combined, washed with water (50 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 3:7 to 1:1) as the eluent to obtain 5.90 g of the desired product as pale yellow crystals. 45 1H NMR (CDCb, Me4Si, 300MHz) 58.52 and 8.45 (d, J=2.4Hz, 1H), 7.81 and 7.80 (d, J=2.4Hz, 1H), 7.35-7.75 (m, 4H), 6.53 (bs, 1H), 4.80 and 4.55 (d, J=6.3Hz, 2H). Step 5: Preparation of N-[2-(3,5-dichloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide 198 To a suspension of 450 mg of N-[2-(3,5-dichloropyridin-2-yl)-2- (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide and 476 mg of potassium carbonate in 5 ml of N,N-dimethylformamide, 313 mg of 2-iodopropane was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, 5 the reaction mixture was mixed with 20 ml of water and extracted with ethyl acetate (25 mlx2), the resulting organic layers were combined, washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a 10 gradient of from 1:9 to 3:7) as the eluent to obtain 121 mg of a colorless resinous substance. The resinous substance was dissolved in 10 ml of ethanol, the solution was mixed with 1 ml of a 1,4-dioxane solution (4 mol/L) of hydrogen chloride and stirred at 70°C for 5 hours, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate- 15 hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 99 mg of the desired product as a colorless resinous substance (E/Z=50/50). 1H NMR (CDCIa, Me4Si, 300MHz) 58.50 and 8.45 (d, J=2.1Hz, 1H), 7.81 and 7.78 (d, J=2.1Hz, 1H), 7.35-7.75 (m, 4H), 6.53 and 6.49 (bs, 1H), 4.76 and 4.53 (d, J=6.0Hz, 2H), 4.45-4.55 and 4.3-4.45 (m, 1H), 1.33 and 1.18 (d, J=6.3Hz, 6H). 20 SYNTHETIC EXAMPLE 20 (Z)-N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-216 of the present invention) Step 1: Preparation of 5-bromo-3-chloro-2-(nitromethyl)pyridine To 12.4 g of potassium tert-butoxide in 79 ml of dimethylsulfoxide, 6.7 g of 25 nitromethane was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 1 hour. Then, the reaction mixture was added dropwise to 25.0 g of 5-bromo-2,3-dichloropyridine in 20 ml of dimethylsulfoxide with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for 23 hours and at 50°C for 6 hours. After 30 completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 100 ml of water and 100 ml of saturated aqueous ammonium chloride and extracted with ethyl acetate (200 mlx2). The resulting organic layers were combined, washed with water (100 mlx3) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under 35 reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 30:70) as the eluent to obtain 7.8 g of the desired product as a pale yellow oil. 1H NMR (CDCI3, Me4Si, 300MHz) 58.62 (d, J=2.1Hz, 1H), 7.98 (d, J=2.1Hz, 1H), 5.74 (s, 2H). 40 Step 2: Preparation of N-[2-(5-bromo-3-chloropyridin-2-yl)-2-nitroethyl]-2- (trifluoromethyl)benzamide To 4.2 g of potassium tert-butoxide in 72 ml of N,N-dimethylformamide, 7.8 g of 5- bromo-3-chloro-2-(nitromethyl)pyridine was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at the same temperature for 45 another 1 hour. Then, to the reaction mixture, 4.7 g of the N-chloromethyl-2- (trifluoromethyl)benzamide prepared in Step 2 in Synthetic Example 19 in 30 ml of N,Ndimethylformamide was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 2 hours. After 199 completion of the reaction, the reaction mixture was carefully poured into 100 ml of icewater, acidified with 10% aqueous hydrochloric acid and extracted with ethyl acetate (100 mlx2). The resulting organic layers were combined, washed with water (100 mlx2) and dried over saturated aqueous sodium chloride and then anhydrous sodium 5 sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 6.0 g of the desired product as a pale yellow oil. 1H NMR (CDCIa, Me4Si, 300MHz) 58.57 (d, J=1.8Hz, 1H), 8.01 (d, J=1.8Hz, 1H), 7.4- 10 7.75 (m, 4H), 6.48 (bs, 1H), 6.25-6.4 (m, 1H), 4.25-4.5 (m, 2H). Step 3: Preparation of N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(hydroxyimino)ethyl]-2- (trifluoromethyl)benzamide To 6.0 g of N-[2-(5-bromo-3-chloropyridin-2-yl)-2-nitroethyl]-2- (trifluoromethyl)benzamide in 65 ml of a mixture of N,N-dimethylformamide-water (7:1), 15 6.4 g of sodium nitrite was added, and the mixture was stirred at 60°C for 18 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, poured into 100 ml of water, mixed with 20 ml of saturated aqueous ammonium chloride and extracted with ethyl acetate (100 mlx2). The resulting organic layers were combined, washed with water (50 mlxl) and dried over saturated aqueous 20 sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 2:8 to 6:4) as the eluent to obtain 3.1 g of the desired product as a pale yellow resinous substance. 1H NMR (CDCI3, Me4Si, 300MHz) 58.6-8.65 and 8.5-8.6 (m, 1H), 7.9-8.0 (m, 1H), 7.35- 25 7.75 (m, 4H), 6.51 (bs, 1H), 4.75-4.85 and 4.5-4.6 (m, 2H). Step 4: Preparation of N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide To a suspension of 200 mg of N-[2-(5-bromo-3-chloropyridin-2-yl)-2- (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide and 189 mg of potassium carbonate 30 in 1 ml of N.N-dimethylformamide, 97 mg of iodomethane was added, and the mixture was stirred at room temperature for 23 hours. After completion of the reaction, the reaction mixture was mixed with 10 ml of water and extracted with ethyl acetate (20 mlx2), the resulting organic layers were combined, washed with water (10 mlx2) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and 35 the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 5:95 to 50:50) as the eluent to obtain 143 mg of the desired product as a pale yellow resinous substance. 1H NMR (CDCI3, Me4Si, 300MHz) 58.61 and 8.56 (d, J=1.8Hz, 1H), 7.96 and 7.94 (d, 40 J=1.8Hz, 1H), 7.35-7.75 (m, 4H), 6.48 (bs, 1H), 4.74 and 4.54 (d, J=5.4Hz, 2H), 4.07 and 3.88 (s, 3H). Step 5: Preparation of (Z)-N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide 143 mg of N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- 45 (trifluoromethyl)benzamide was dissolved in 3 ml of acetonitrile, and the solution was irradiated with light for 12 hours in a quartz cell (manufactured by Fine, 4 clear windows for spectroscopy) using a 100 W high-pressure mercury lamp (manufactured by USHIO INC., lamp: UM-102, power supply: UM-103B-B). After completion of the reaction, the 200 solvent was evaporated under reduced pressure, and the resulting residue was washed with 10 ml of hexane to obtain 63 mg of the desired product as pale yellow crystals. m.p.:85.0to86.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.61 (d, J=1.8Hz, 1H), 7.94 (d, J=1.8Hz, 1H), 7.5- 5 7.75 (m, 4H), 6.48 (bs, 1H), 4.54 (d, J=5.4Hz, 2H), 3.88 (s, 3H). SYNTHETIC EXAMPLE 21 (Z)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-020 of the present invention) Step 1: Preparation of N-[2-[3-chloro-5-(trifluoromethyl)pyhdin-2-yl]-2-nitroethyl]-2- 10 (trifluoromethyl)benzamide To 10.26 g of potassium tert-butoxide in 80 ml of N,N-dimethylformamide, 20.00 g of 3-chloro-2-nitromethyl-5-(trifluoromethyl)pyridine was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at the same temperature for another 30 minutes. Then, to the reaction mixture, 18.77 g of the N- 15 chloromethyl-2-(trifluoromethyl)benzamide prepared in Step 2 in Synthetic Example 19 in 20 ml of N,N-dimethylformamide was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 3 hours. After completion of the reaction, the reaction mixture was carefully poured into 150 ml of 5% aqueous hydrochloric acid under cooling with ice and extracted with ethyl 20 acetate (100 mlx2). The resulting organic layers were combined, washed with water (100 mlx2) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The precipitated solid was purified with 30 ml of diisopropyl ether to obtain 19.80 g of the desired product as white crystals. 25 m.p.: 100.0 to 102.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 58.78 (s, 1H), 8.09 (s, 1H), 7.45-7.75 (m, 4H), 6.50 (bs, 1H), 6.4-6.5 (m, 1H), 4.35-4.5 (m, 2H). Step 2: Preparation of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide 30 To 19.80 g of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-nitroethyl]-2- (trifluoromethyl)benzamide in 100 ml of a mixture of N,N-dimethylformamide-water (7:1), 21.65 g of sodium nitrite was added, and the mixture was stirred at from 45 to 50°C for 12 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, poured into 150 ml of water and extracted with ethyl acetate (100 35 mlx2). The resulting organic layers were combined, washed with water (100 mlx1) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 3:7 to 1:1) as the eluent to obtain 11.10 g of the desired product as 40 white crystals. m.p.: 110.0to113.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.82 and 8.75 (s, 1H), 8.04 (s, 1H), 7.35-7.7 (m, 4H), 6.52 (bs, 1H), 4.83 and 4.59 (d, J=6.3Hz, 2H). Step 3: Preparation of (E)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- 45 (isopropoxyimino)ethyl]-2-(trifluoromethyl)benzamide (Compound No. 2-019 of the present invention) To a suspension of 20.00 g of N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide and 19.48 g of potassium carbonate 201 in 105 ml of N,N-dimethylformamide, 10.38 g of 2-iodopropane was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was mixed with 200 ml of water and extracted with ethyl acetate (100 mlx3), the resulting organic layers were combined, washed with water (100 mlxl) 5 and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 11.00 g of the desired product as white crystals. 10 m.p.: 81.0to83.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 68.73 (s, 1H), 8.01 (s, 1H), 7.35-7.75 (m, 4H), 6.48 (bs, 1H), 4.78 (d, J=5.1Hz, 2H), 4.45-4.6 (m, 1H), 1.34 (d, J=6.0Hz, 6H). Step 4: Preparation of (Z)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (isopropoxyimino)ethyl]-2-(trifluoromethyl)benzamide 15 11.00 g of (E)-N-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2- (isopropoxyimino)ethyl]-2-(trifluoromethyl)benzamide was dissolved in 30 ml of acetic acid and stirred at 70°C for 1 hour. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-chloroform (with a gradient of from 0:100 to 20 5:95) as the eluent to obtain 5.63 g of the desired product as white crystals. m.p.:97.0to98.0°C 1H NMR (CDCIa, Me4Si, 300MHz) 58.79 (s, 1H), 7.99 (s, 1H), 7.5-7.75 (m, 4H), 6.49 (bs, 1H), 4.56 (d, J=5.1Hz, 2H), 4.3-4.45 (m, 1H), 1.19 (d, J=6.0Hz, 6H). SYNTHETIC EXAMPLE 22 25 N-[2-[3-chloro-5-(3,3-dimethyl-1-butynyl)pyridin-2-yl]-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-248 of the present invention) Step 1: Preparation of N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(isopropoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-181 of the present invention) To a suspension of 1.80 g of the N-[2-(5-bromo-3-chloropyridin-2-yl)-2- 30 (hydroxyimino)ethyl]-2-(trifluoromethyl)benzamide prepared in Step 3 in Synthetic Example 20 and 0.86 g of potassium carbonate in 10 ml of N,N-dimethylformamide, 1.30 g of 2-iodopropane was added, and the mixture was stirred at room temperature for 13 hours. After completion of the reaction, the reaction mixture was mixed with 100 ml of water and extracted with ethyl acetate (50 mlx2), the resulting organic layers were 35 combined, washed with water (100 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:4 to 2:2) as the eluent to obtain 1.26 g of the desired product as a pale yellow resinous substance. 40 1H NMR (CDCIa, Me4Si, 300MHz) 58.60 and 8.54 (d, J=1.9Hz, 1H), 7.96 and 7.93 (d, J=1.9Hz, 1H), 7.35-7.75 (m, 4H), 6.53 and 6.49 (bs, 1H), 4.75 and 4.53 (d, J=6.1 and 5.0Hz, 2H), 4.51 and 4.37 (sep, J=6.3Hz, 1H), 1.33 and 1.19 (d, J=6.3Hz, 6H). Step 2: Preparation of N-[2-[3-chloro-5-(3,3-dimethyl-1-butynyl)pyridin-2-yl]-2- (isopropoxyimino)ethyl]-2-(trifluoromethyl)benzamide 45 To a solution of 0.15 g of N-[2-(5-bromo-3-chloropyridin-2-yl)-2- (isopropoxyimino)ethyl]-2-(trifluoromethyl)benzamide and 0.05 g of 3,3-dimethyl-1- butyne in 3 ml of triethylamine, 0.04 g of copper(l) iodide and 0.02 g of dichlorobistriphenylphosphine palladium(ll) were added, and the mixture was stirred at 202 80°C for 3 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 10 ml of water and extracted with ethyl acetate (20 mlxl). The resulting organic layer was washed with water (10 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the 5 solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:5 to 2:4) as the eluent to obtain 0.15 g of the desired product as a yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.49 and 8.43 (d, J=1.7Hz, 1H), 7.76 and 7.73 (d, J=1.7Hz, 1H), 7.45-7.8 (m, 4H), 6.60 (bs, 1H), 4.77 and 4.52 (d, J=5.8 and 4.8Hz, 2H), 10 4.50 and 4.35 (sep, J=6.3Hz, 1H), 1.32 (s, 9H), 1.31 and 1.17 (d, J=6.3Hz, 6H). SYNTHETIC EXAMPLE 23 N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzthioamide (Compound No. 5-001 of the present invention) To 222 mg of the N-[2-(5-bromo-3-chloropyridin-2-yl)-2-(methoxyimino)ethyl]-2- 15 (trifluoromethyl)benzamide prepared in Step 4 in Synthetic Example 20 in 5 ml of 1,4- dioxane, 200 mg of Lawesson's Reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4- diphosphetane-2,4-disulfide) was added, and the mixture was stirred at 80°C for 3 hours and then at room temperature for 12 hours. After completion of the reaction, the reaction mixture was mixed with 40 ml of 0.05M aqueous sodium hydroxide and 20 extracted with a mixture of ethyl acetate-diethyl ether (2:1) (30 mlxl), the resulting organic layer was washed with 40 ml of 0.2M aqueous sodium hydroxide and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 25 2:8) as the eluent to obtain 133 mg of the desired product as a brown resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.61 and 8.53 (d, J=2.0Hz, 1H), 8.33 and 8.08 (bs, 1H), 7.98 and 7.96 (d, J=2.0Hz, 1H), 7.35-7.7 (m, 4H), 5.10 and 4.80 (d, J=5.1 and 4.4Hz, 2H), 4.09 and 3.89 (s, 3H). 30 SYNTHETIC EXAMPLE 24 N-[2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-N-methyl-2- (trifluoromethyl)benzamide (Compound No. 4-005 of the present invention) To 33 mg of 60% sodium hydride in oil in 5 ml of tetrahydrofuran, 300 mg of the N- [2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-2-(trifluoromethyl)benzamide 35 prepared in Step 1 in Synthetic Example 16 in 3 ml of tetrahydrofuran was added dropwise with stirring and cooling with ice, and the mixture was stirred at the same temperature for 30 minutes. Then, the reaction mixture was mixed with 157 mg of methyl iodide, warmed to room temperature and stirred for another 1 hour. After completion of the reaction, the reaction mixture was poured into 20 ml of ice-water and 40 extracted with ethyl acetate (50 mlxl), the organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 2:8) as the eluent to obtain 203 mg of the desired product 45 as a pale yellow resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.51 and 8.40 (d, J=2.0Hz, 1H), 7.81 and 7.80 (d, J=2.0Hz, 1H), 7.4-7.75 (m, 3H), 6.9-7.15 (m, 1H), 5.00 and 4.53 (d, J=15.0Hz, 1H), 4.75 and 4.34 (d, J=15.0Hz, 1H), 4.06 and 3.96 (s, 3H), 3.02 and 2.82 (s, 3H). 203 SYNTHETIC EXAMPLE 25 N-cyclopropyl-N-[2-(3,5-dichloropyridin-2-yl)-2-(methoxyimino)ethyl]-5-fluoro-1-methyl-3- trifluoromethyl-1H-pyrazole-4-carboxamide (Compound No. 17-009 of the present invention) 5 Step 1: Preparation of 2-cyclopropylamino-1-(3,5-dichloropyridin-2-yl)ethanone-0- methyloxime To 700 mg of 2-bromo-1 -(3,5-dichloropyridin-2-yl)ethanone-0-methyloxime prepared in the same manner as in Steps 1 to 3 in Synthetic Example 2 in 10 ml of acetonitrile, 402 mg of cyclopropylamine in 5 ml of acetonitrile was added, and the 10 mixture was stirred at room temperature for 18 hours. After completion of the reaction, the reaction mixture was mixed with 30 ml of water and extracted with ethyl acetate (40 mlx2, the resulting organic layers were combined, washed with water (30 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was 15 purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 3:7 to 5:5) as the eluent to obtain 450 mg of the desired product as a colorless resinous substance. 1H NMR (CDCIs, Me4Si, 300MHz) 58.48 (bs, 1H), 7.78 (bs, 1H), 3.8-4.05 (m, 5H), 1.95- 2.1 (m, 1H), 0.15-0.4 (m,4H). 20 Step 2: Preparation of N-cyclopropyl-N-[2-(3,5-dichloropyridin-2-yl)-2- (methoxyimino)ethyl]-5-fluoro-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide To 204 mg of 5-fluoro-1-methyl-3-trifluoromethyl-1 H-pyrazole-4-carboxylic acid in 3 ml of dichloromethane, 16 mg of N,N-dimethylformamide and 161 mg of oxalyl chloride were added, and the mixture was stirred at room temperature for 1 hour. After 25 completion of the reaction, the solvent was evaporated under reduced pressure, the resulting residue was dissolved in 5 ml of dichloromethane, and added dropwise to a solution of 220 mg of 2-cyclopropylamino-1-(3,5-dichloropyridin-2-yl)ethanone-0- methyloxime and 162 mg of triethylamine in 10 ml of dichloromethane with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for 30 another 1 hour. After completion of the reaction, the reaction mixture was mixed with 20 ml of water and extracted with chloroform (20 mlxl), the resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography 35 using ethyl acetate-hexane (with a gradient of from 1:4 to 2:3) as the eluent to obtain 252 mg of the desired product as white crystals. m.p.:95.0to97.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.43 (d, J=2.1Hz, 1H), 7.77 (d, J=2.1Hz, 1H), 4.81 (bs, 2H), 4.04 (s, 3H), 3.78 (s, 3H), 2.7-2.8 (m, 1H), 0.55-0.7 (m, 4H). 40 SYNTHETIC EXAMPLE 26 N-[2-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]-2-(methoxyimino)ethyl]-2- (trifluoromethyl)benzamide (Compound No. 2-223 of the present invention) Step 1: Preparation of 1-(3-chloro-5-hydroxypyridin-2-yl)ethanone To a solution of 3.8 g of the 1-(3,5-dichloropyridin-2-yl)ethanone prepared in Step 45 1 in Synthetic Example 2 and 13.8 g of potassium carbonate in 20 ml of dimethylsulfoxide, 5.9 g of acetaldoxime was added, and the mixture was stirred at 80°C for 4 hours. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 50 ml of water and washed with diethyl ether (30 204 mlxl), the resulting aqueous layer was acidified with 6N aqueous hydrochloric acid and extracted with ethyl acetate (25 mlx2). The resulting organic layers were combined, dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain 1.0 g of desired crude 5 product as brown crystals. The crystals were used in the next step without further purification. m.p.: 143.0to145.0°C 1H NMR (CDCb, Me4Si, 300MHz) 68.20 (d, J=2.4Hz, 1H), 7.30 (d, J=2.4Hz, 1H), 2.68 (s, 3H). 10 Step 2: Preparation of 1-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethanone To 1.0 g of 1-(3-chloro-5-hydroxypyridin-2-yl)ethanone in 15 ml of N,Ndimethylformamide, 1.2 g of potassium carbonate and 1.6 g of 2,2,2-trifluoroethyl trifluoromethanesulfonate were added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was mixed with 40 15 ml of water and extracted with ethyl acetate (50 mlxl), the resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 1.2 g of the 20 desired product as white crystals. m.p.:52.0to55.0°C 1H NMR (CDCb, Me4Si, 300MHz) 58.30 (d, J=2.7Hz, 1H), 7.33 (d, J=2.7Hz, 1H), 4.47 (q, J=7.8Hz, 2H), 2.68 (s, 3H). Step 3: Preparation of 2-bromo-1-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethanone 25 To 1.1 g of 1-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethanone in 20 ml of tetrahydrofuran, 1.6 g of trimethylphenylammonium tribromide was added, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the precipitated solid was filtered off through celite, and the solvent was evaporated under reduced pressure to obtain 1.3 g of the desired crude product as a pale yellow oil. 30 The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 68.32 (d, J=2.7Hz, 1H), 7.37 (d, J=2.7Hz, 1H), 4.72 (s, 2H), 4.50 (q, J=7.8Hz, 2H). Step 4: Preparation of 2-bromo-1-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2- yl]ethanone-0-methyloxime 35 To 1.3 g of 2-bromo-1 -[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethanone in 10 ml of ethanol, 362 mg of methoxyamine hydrochloride was added, and the mixture was stirred at room temperature for 13 hours. After completion of the reaction, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 0:100 to 40 5:95) to obtain 1.2 g of the desired product as a colorless oil. 1H NMR (CDCb, Me4Si, 300MHz) 68.30 (d, J=2.4Hz, 1H), 7.37 (d, J=2.4Hz, 1H), 4.51 (s, 2H), 4.44 (q, J=7.5Hz, 2H), 4.10 (s, 3H). Step 5: Preparation of N-[2-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]-2- (methoxyimino)ethyl]phthalimide 45 To 1.0 g of 2-bromo-1 -[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethanone-0- methyloxime in 10 ml of N,N-dimethylformamide, 615 mg of potassium phthalimide was added, and the mixture was stirred at room temperature for 13 hours. After completion of the reaction, the reaction mixture was mixed with 30 ml of water and extracted with 205 ethyl acetate (20 mlxl), the resulting organic layer was washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was washed with 10 ml of diisopropyl ether to obtain 790 mg of the desired product as pale 5 orange crystals. 1H NMR (CDCIs, Me4Si, 300MHz) 58.08 (d, J=2.4Hz, 1H), 7.55-7.9 (m, 4H), 7.28 (d, J=2.4Hz, 1H), 4.98 (s, 2H), 4.33 (q, J=7.8Hz, 2H), 4.04 (s, 3H). Step 6: Preparation of 2-amino-1 -[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2- yl]ethanone-0-methyloxime 10 To 790 mg of N-[2-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]-2- (methoxyimino)ethyl]phthalimide in 10 ml of ethanol, 187 mg of hydrazine monohydrate was added and refluxed with heating for 1 hour with stirring. After completion of the reaction, the reaction mixture was allowed to cool to room temperature, mixed with 30 ml of water and extracted with ethyl acetate (25 mlx2). The resulting organic layers 15 were combined, washed with water (20 mlxl) and dried over saturated aqueous sodium chloride and then anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain 446 mg of the desired crude product as a brown oil. The oil was used in the next step without further purification. 1H NMR (CDCb, Me4Si, 300MHz) 58.32 and 8.31 (d, J=2.4Hz, 1H), 7.38 and 7.37 (d, 20 J=2.4Hz, 1H), 4.4-4.5 (m, 2H), 4.03 and 3.91 (s, 2H), 3.88 and 3.75 (s, 3H). Step 7: Preparation of N-[2-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2-yl]-2- (methoxyimino)ethyl]-2-(trifluoromethyl)benzamide To a solution of 227 mg of 2-amino-1-[3-chloro-5-(2,2,2-trifluoroethoxy)pyridin-2- yl]ethanone-0-methyloxime and 92 mg of triethylarnine in 5 ml of dichlorornethane, 175 25 mg of 2-(trifluoromethyl)benzoyl chloride was added dropwise with stirring under cooling with ice, and after the addition, the mixture was stirred at room temperature for another 1 hour. After completion of the reaction, the reaction mixture was mixed with 10 ml of water and extracted with chloroform (10 mlxl), the resulting organic layer was washed with water (10 mlxl) and dried over saturated aqueous sodium chloride and then 30 anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography using ethyl acetate-hexane (with a gradient of from 1:9 to 3:7) as the eluent to obtain 249 mg of the desired product as a colorless resinous substance. 1H NMR (CDCb, Me4Si, 300MHz) 58.31 and 8.27 (d, J=3.0Hz, 1H), 7.35-7.75 (m, 5H), 35 6.52 and 6.45 (bs, 1H), 4.75 and 4.53 (d, J=6.0Hz, 2H), 4.43 (q, J=7.8Hz, 2H), 4.06 and 3.88 (s, 3H). The compounds of the present invention can be produced in accordance with the processes and Examples previously described. Examples of the oxime-substituted amide compounds of the present invention produced in the same manners as in 40 Synthetic Examples 1 to 26 are shown in Tables 4 to 32, and examples of their intermediates are shown in Tables 33 to 45. However, the oxime-substituted amide compounds of the present invention and their intermediates are by no means restricted thereto. In the Tables, Et denotes ethyl group, n-Pr denotes normal propyl group, i-Pr and 45 Pr-i denote isopropyl group, c-Pr and Pr-c denote cyclopropyl group, n-Bu denotes normal butyl group, i-Bu denotes isobutyl group, s-Bu denotes sec-butyl group, c-Bu and Bu-c denote cyclobutyl group, t-Bu and Bu-t denote tert-butyl group, Pen denotes pentyl group, c-Pen and Pen-c denote cyclopentyl group, Hex denotes hexyl group, c206 Hex and Hex-c denote cyclohexyl group, Ph denotes phenyl group, and Naph denotes naphthyl group. In the Tables, aromatic heterocyclic rings represented by D-1-1b to D-32-3b have the following structures, respectively. (Z)„ „-,-lb : JP*f* D-3-a:^Q D-5-3b : V Ti o' N D-7-a : ^ ) > N 5 4 D-7-b : N » In the Tables, T-3 to T-6 have the following structures, respectively. T-3 : T-4 T-5 OH OH ^ T-6 Further, in the Tables, the expression (R) or (S) in the column substituent R2 means that the proportion of the R-isomer or the S-isomer is at least 90% in a mixture ratio of optical isomers due to the carbon atom attached to R2, and the expression (E) or (Z) in the column substituent R1 means that the proportion of the E-isomer or the Zisomer is at least 90% in a mixture ratio of oxime geometrical isomers attached to the substituent R1. In the column m.p., " * 1 " means that the compound was oily or resinous. TABLE 4 10 In the Tables, the expression "(HCI)" in the column substituent R1 means the compound being a hydrochloride. 5 [Table 40] 241 Among the compounds shown in Tables 4 to 45, 1H NMR data of compounds of which melting points are not disclosed in the Tables are shown in Table 46. [Table 46-1] 5 Table 46 No. XH NMR (CDC13, Me4Si, 300MHz) 1-002 5 7.05-7.75 (a, 13H), 5. 45-5, 55 and 5, 1-5. 2 (m, IH), 5.13 and 5.02 (s, 2H), 1.53 and 1.36 (d, J=7.2Hz, 3H)„ 1-003 8 7. 05-7. 75 (a, 7H), 6. 48 and 6. 34 (bs, IH), 4.61 and 4.43 (d, J=6.3Hz, 2H), 4.02 and 3.85 (s, 3H)„ 1-005 8 7.1-7.9 (a, 7H), 6.72 and 6.64 (d, J=6.9Hz, IH), 5.31 and 5.05 (dq, J=6. 9 and 6.6Hz, IH), 3.96 and 3.83 (s, 3H), 1.59 and 1.45 (d, J=6. 6Hz, 3H)„ 1-006 8 7.1-7.75 (a, 7H), 6.84 and 6.69 (d, J=7. 2Hz, IH), 5.2-5.35 and 4.95-5.1 (a, IH), 4.35-4.5 and 4.25-4.35 (a, IH), 1.58 and 1.43 (d, J=6. 9Hz, 3H), 1.1-1.5 (a, 6H), 1-007 8 7.15-7.75 (a, 7H), 6.48 and 6.45 (bs, IH), 5.3-5.45 and 5.0-5.25 (a, IH), 4.54 and 4.38 (q, J=8.4Hz, 2H), 1.63 and 1.46 (d, J=6.9Hz, 3H)„ 1-008 §7.1-7.75 (a, 11H), 6. 60 and 6.50 (d, J=7.5Hz, IH), 5. 25-5. 4 and 4. 95-5. 1 (m, IH), 5. 16 and 5. 01 (s, 2H), 1.56 and 1.42 (d, J=6.9Hz, 3H). 1-009 §7.45-7.75 (a, 4H), 7.7-7.1 (m, IH), 6.96 (bs, IH), 6.7-6.8 (a, 2H), 5. 25-5, 4 and 4. 85-5. 0 (ffi, IH), 4.45-4.65 (a, IH), 4.35-4.45 and 4.2-4. 35 (a, IH), 2.36 and 2.19 (s, 3H), 1. 1-1.4 (a, 15H). 1-010 §6.6-7.75 (DI, 12H), 5. 3-5, 4 and 4. 9-5. 05 (m, IH), 5. 12 and 4.99 (s, 2H), 4.5-4.65 (a, IH), 2.25 and 2. 15 (s, 3H), 1.25-1.55 (a, 9H)„ 1-013 §6.8-7.75 (a, 9H), 5.5-5.65 and 5. 15-5.25 (a, IH), 4.0-4.25 (a, 2H), 1.58 and 1.39 (d, J=7.2Hz, 3H), 1.34 and 1.33 (s, 9H), 1.1-1.3 (a, 3H) 1-020 §6.8-7.75 (m, 14H), 5. 45-5. 6 and 5. 1-5. 25 (a, IH), 4.15-4.25 and 4. 05-4. 16 (a, 2H), 1.58 and 1.40 (d, J=7. 2Hz, 3H), 1.28 and 1.23 (t, J=7.2Hz, 3H)„ 1-022 §8.36 and 8.30 (d, J=2. 1Hz, IH), 6.5-7.75 (a, 16H), 5.0-5.6 (a, 3H), 1.54 and 1.38 (d, J=7.2Hz, 3H)S 1-023 §6.8-7.8 (a, 14H), 5.55-5.7 and 5. 15-5. 3 (a, IH), 4.2-4.3 and 4.05-4.2 (a, 2H), 1.61 and 1.43 (d, J=7.2Hz, 3H), 1.30 and 1.25 (t, J=7.2Hz, 3H)„ 1-024 § 6. 85-7. 85 (a, 14H), 5. 55-5. 7 and 5. 2-5. 35 (a, IH), 4. 4-4. 5 and 4. 25-4. 4 (m, IH), 1.15-1.65 (a, 9H)C 1-025 8 3.6-7.85 (a, 14H), 5.55-5.7 and 5.2-5.3 (a, IH), 3.8-4.05 (a, 2H), 1.63 and 1.43 (d, J=6.9Hz, 3H), 1.0-1.25 (a, IH), 0.4-0.55 (a, 2H), 0. 15-0.3 (m, 2H). 1-027 8 8.38 and 8.32 (d, J=2. 1Hz, IH), 7.2-7.8 (a, 15H), 6.58 and 6. 19 (bs, IH), 5.05-5.7 (a, 3H), 1.57 and 1.40 (d, J=6.9Hz, 3H). 1-034 §6.4-7.8 (a, 13H), 4.85-5.55 (a, 2H), 1.2-1.7 (a, 6H). 242 [Table 46-2] Table 46 (continued) No. *H NMR (CDC13, Me4Si, 300MHs) 1-035 6 7.45-8.1 (m, 7H), 6.70 and 6.64 (bs, IH), 5.35-5.55 and 5. 1-5. 25 (m, IH), 4.2-4.3 and 4.05-4,2 (m, 2H), 1.59 and 1.41 (d, J=6.9Hz, 3H), 1.30 and 1.22 (t, J=7.2Hz, 3H)C 1-036 6 6.8-7.75 (m, 9H), 5.45-5.6 and 5. 1-5.2 On, IH), 4,5-4.7 (m, IH), 4.0-4.3 (n, 2H), 1.1-1.6 On, 12H)„ 1-037 6 6.85-8.25 (a, 12H), 4.8-5.65 (m, IH), 3.95-4.35 On, 2H), 1. 1-1.65 (m, 6H)„ 1-038 6 6.4-8.25 (m, 12H), 4.85-5.85 On, IH), 4.3-4.65 On, 2H), 1, 15-1.7 (n, 3H)0 1-039 6 6.6-8.45 0B, 15H), 4.8-5.8 (m, 3H), 1.5-1.65 (m, 3H)„ 1-041 6 6.6-7.75 (a, 8H), 5. 35-5. 5 and 5. 0-5. 15 On, IH), 3.95-4,05 and 3.8-3.9 On, 2H), 1.6-1.65 and 1.4-1.45 On, 3H), 0.95-1.3 (m, IH), 0.45-0.55 (m, 2H), 0.15-0.3 On, 2H). 1-042 6 6.4-7.75 (m, 7H), 5.3-5.45 and 5. 0-5. 15 On, IH), 4.00 and 3.87 (d, J=6. 9Hz, 2H), 1.75 and 1.43 (d, J=6. 9Hz, 3H), 1.0-1.3 (m, IH), 0.45-0.6 (a, 2H), 0.15-0.3 (in, 2H)„ 1-043 6 7.1-7.75 (a, 7H), 6.66 and 6.55 (bs, IH), 5. 35-5, 5 and 5. 0-5. 15 Oft IH), 4. 25 and 4, 10 (q, J=7.2Hz, 2H), 1.60 and 1.21 (d, J=6.6Hz, 3H), 1.32 and 1.19 (t, J=7.2Hz, 3H)„ 1-044 6 7.1-7.75 (m, 7H), 6.69 and 6.61 (bs, IH), 5. 35-5.5 and 5.0-5. 15 On, IH), 4.25-4.5 (rn, IH), 1.1-1.65 (tn, 9H)„ 1-045 6 7.1-7.75 (m, 7H), 6.64 and 6.53 (bs, IH), 5. 35-5. 5 and 5. 0-5. 15 On, IH), 4. 25 and 4. 10 (q, J=7.2Hz, 2H), 1.55-1.65 and 1.35-1.45 On, 3H), 1.31 and 1.19 (t, J=7.2Hz, 3H). 1-046 6 7.1-7.75 (m, 7H), 6. 67 and 6, 59 (bs, IH), 5. 3-5. 5 and 5. 0-5. 15 On, IH), 4.25-4.5 (m, IH), 1.1-1.65 (no, 9H)0 1-047 6 7.15-7.75 On, 7H), 6.71 and 6.64 (bs, IH), 5. 35-5. 5 and 5. 0-5. 15 On, IH), 3. 95-4. 05 and 3. 8-3. 9 On, 2H), 1.6-1.65 and 1.4-1.45 On, 3H), 0.95-1.3 (m, IH), 0.4-0.55 On, 2H), 0. 15-0.3 (n, 2H)0 1-048 6 7.05-7.75 (u, 7H), 6.42 and 6.28 (bs, IH), 5, 35-5. 5 and 5. 05-5. 2 On, IH), 4. 5-4, 65 and 4. 3-4. 45 On, 2H), 1.6-1.65 and 1.4-1.45 On, 3H)0 1-049 6 6.95-7.75 (m, 6H), 6.55 (bs, IH), 5.3-5,45 and 5.0-5.1 On, IH), 4. 2-4. 3 and 4. 05-4. 2 On, 2H), 1.15-1.65 (no, 6H)Q 1-050 6 7.0-7.75 (a, 7H), 6.47 and 6.59 (bs, IH), 5. 35-5. 5 and 5. 05-5. 15 (ra, IH), 4.05-4.35 On, 2H), 1.6-1.65 and 1.4-1.45 On, 3H), 1.33 and 1.19 (t, J=7.2Hz, 3H)„ 1-051 6 6.95-7.75 (m, 6H), 6.56 and 6.47 (bs, IH), 5.3-5.45 and 5.0-5.15 On, IH), 4.01 and 3.85 (s, 3H), 1.55-1.65 and 1.4-1.45 (m, 3H)„ 1-052 6 6.95-7.75 (m, 6H), 6.5-6,7 On, IH), 5.3-5.45 and 5.0-5. 15 On, IH), 4.2-4,35 and 4.05-4.2 On, 2H), 1.6-1.65 and 1.4-1.5 (a, 3H), 1.33 and 1.21 (t, J=7.2Hz, 3H)„ 243 [Table 46-3] Table 46 (continued) No. XH NMR (CDC13, Me4Si, 300MHz) 1-053 6 6.6-7.75 (m, 8H), 5.25-5. 4 and 5.0-5. 15 (ra, IH), 4.05-4.3 (m, 2H), 1.6L and 1.46 (d, J=6.9Hz, 3H), 1.31 and 1.19 (t, J=7.2Hz, 3H), 1-054 6 7.2-7.75 (m, 7H), 6. 77 and 6. 64 (bs, IH), 5. 25-5. 4 and 5. 0-5. 1 (n, IH), 4.24 and 4.09 (q, J=7. 2Hz, 2H), 1.59 and 1.46 (d, J=6. 9Hz, 3H), 1.31 and 1.19 (t, J=7.2Hz, 3H)0 1-055 67.1-7.75 (m, 12H), 6.49 (bs, IH), 4.85-5.45 (m, 2H), 1.35-1.7 (m, 6H)„ 1-057 6 6.95-7.75 (m, 7H), 6.80 and 6.69 (bs, IH), 5. 25-5. 4 and 4. 95-5. 1 (m, IH), 4.0-4.3 (m, 2H), 1.60 and 1.45 (d, J=7.2Hz, 3H), 1.15-1.35 (m, 3H)0 1-058 6 7.15-7.75 (ra, 7H), 6.78 and 6.66 (bs, IH), 5. 25-5. 35 and 4. 95-5. 1 (m, IH), 4. 0-4. 3 (ra, 2H), 1.55-1.65 and 1.4-1.5 (m, 3H), 1.15-1.35 (tn, 3H)„ 1-060 6 7.15-7.8 (m, 7H), 6.62 (bs, IH), 5. 15-5. 3 and 4.95-5. 15 (m, IH), 4.05-4.35 (m, 2H), 3.45-3.65 (m, 2H), 3.28 and 2.96 (s, 3H), 1.61 and 1.45 (d, J=6.9Hz, 3H). 1-061 67.15-7.75 (ra, 11H), 6.41 (bs, IH), 5.0-5.5 (m, 3H), 1.60 and 1.43 (d, J=6.9Hz, 3H)0 1-062 6 7.1-7.75 (o, 7H), 6.3-6.75 (m, 3H), 4.95-5.35 (ra, 3H), 1.56 and 1.43 (d, J=6.9Hz, 3H)Q 1-063 6 8.38 and 8.28 (d, J=2. 1Hz, IH), 7.15-7.75 On, 9H), 6.41 (bs, IH), 5.0-5.45 (ra, 3H), 1.57 and 1.42 (d, J-7.2Hz, 3H). 1-064 6 8.25-8.45 (ra, IH), 7.05-7.75 (m, 9H), 6.3-6.45 (tn, IH), 5.0-5.55 (m, 3H), 1.64 and 1.44 (d., J=6. 9Hz, 3H)„ 1-065 6 7.05-7.75 (m, 7H), 6.78 and 6.66 (bs, IH), 5.2-5.45 and 4.95-5. 1 (m, IH), 4.0-4.3 (tn, 2H), 1.4-1.65 (ra, 3H), 1. 15-1.35 (ra, 3H)„ 1-066 6 7.05-7.75 (ra, 7H), 6.82 and 6.68 (bs, IH), 5.2-5.45 and 4. 95-5. 1 (m, IH), 4.2-4.5 (m, IH), 1.1-1.65 (m, 9H). 1-067 6 7.05-7.8 (m, 7H), 6.68 and 6.67 (bs, IH), 4.95-5.45 (a, IH), 3.98 and 3.85 (d, J=7.2Hz, 2H), 1.61 and 1.45 (d, J=7.2Hz, 3H), 0.95-1,2 (m, IH), 0.4-0.55 (m, 2H), 0.15-0.25 (m, 2H)„ 1-068 6 7.1-7.8 (ra, 7H), 6.46 (bs, IH), 5.3-5.45 and 5.0-5.2 (tn, IH), 4.45-4.6 and 4.3-4.45 (m., 2H), 1.63 and 1.46 (d, J=6..9Hz, 3H), 1-069 6 8.25-8.4 (m, IH), 6.4-7.75 (m, 10H), 5.0-5.45 (ra, 3H), 1.56 and 1.42 (d, J=6.9Hz, 3H), 1-070 6 7.05-7.75 (ra, 7H), 6.72 (bs, IH), 5,3-5.45 and 4.95-5. 1 (m, IH), 3.97 and 3.83 (s, 3H), 2,36 and 2.35 (s, 3H), 1.4-1.6 (m, 3H). 1-071 6 7.05-7.75 (m, 7H), 6.7-6.85 (m, IH), 5.3-5.45 and 4.95-5.1 (tn, IH), 4.0-4.3 (ra, 2H), 2.36 and 2.35 (s, 3H), 1.58 and 1.44 (d, J=6.9Hz, 3H), 1. 15-1.35 (ra, 3H), 1-072 6 6.5-8.0 (ra, 8H), 5. 25-5. 4 and 5. 0-5. 15 (m, IH), 4.2-4.3 and 4.0-4.2 (ra, 2H), 1.63 and 1.47 (d, J=6.9Hz, 3H), 1. 15-1.35 (ra, 3H)„ 244 [Table 46-4] Table 46 (continued) No. *H NMR (CDC13, Me4Si, 300MHz) 1-073 §6.65-7.75 (o, 8H), 5. 25-5.4 and 5. 0-5. 1 (a, IH), 3.75-4.0 (m, 6H), 1.57 and 1.43 (d, J=6.9Hz, 3H). 1-074 6 6.7-7.75 (a, 8H), 5.25-5.4 and 4.95-5. 1 (a, IH), 4.0-4.3 (a, 2H), 3.82 and 3.81 (s, 3H), 1.58 and 1.43 (d, J=6.9Hz, 3H), 1. 15-1.35 (a, 3H)„ 1-075 6 7. 0-7. 75 (a, 7H), 6. 6-6. 9 (a, IH), 5. 25-5. 4 and 4. 95-5. 1 (a, IH), 4.15-4.3 and 4.0-4.15 (m, 2H), 2.50 and 2.48 (Sj 3H), 1.4-1.65 (m, 3H), 1.15-1,35 (a, 3H)a 1-076 6 7.3-7.8 (a, 7H), 6.59 (bs, IH), 5. 2-5. 4 and 5. 0-5. 2 (a, IH), 4.05-4.3 (a, 2H), 2.7-2.8 (a, 3H), 1.45-1.7 (a, 3H), 1.15-1.35 (a, 3H) o 1-077 6 7.3-8.05 (a, 7H), 6.72 and 6.55 (bs, IH), 5.25-5, 35 and 5. 0-5. 15 (a, IH), 4. 26 and 4. 10 (q, J=7. 2Hz, 2H), 3.11 and 3.06 (s, 3H), 1.65 and 1.48 (d, J=6. 9Hz, 3H), 1.32 and 1.19 (t, J=7.2Hz, 3H), 1-078 6 7.3-8.05 (a, 7H), 6.65 (bs, IH), 5.25-5. 4 and 5. 0-5. 2 (a, IH), 4.25 and 4.09 (q, J=7.2Hz, 2H), 2.62 and 2.61 (s, 3H), 1.63 and 1.47 (d, J=6.9Hz, 3H), 1.32 and 1.18 (t, J=7.2Hz, 3H). 1-079 6 7.2-7.8 (a, 7H), 6.65-6.85 (a, IH), 5, 3-5.45 and 5.0-5. 15 (a, IH), 3.95-4.3 (a, 5H), 2.15-2.25 (n, 3H), 1.60 and 1.45 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)0 1-080 6 7.2-7.75 (a, 7H), 6.45-6.75 (a, IH), 5.2-5.35 and 5. 0-5. 15 (a, IH), 4.01 and 3.84 (s, 3H), 1.63 and 1.47 (d, J=6.9Hz, 3H)Q 1-081 6 7.2-7.75 (a, 7H), 6.75 and 6.55 (bs, IH), 5. 2-5. 35 and 5. 0-5. 15 (a, IH), 4. 05-4. 3 (a, 2H), 1.63 and 1.47 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)„ 1-083 6 7.15-7.75 (a, 7H), 6.6-6.8 (a, 2H), 5.7-5.85 (a, IH), 5.0-5.4 (a, 2H), 3.99 and 3.84 (s, 3H), 1.59 and 1.45 (d, J=7.2Hz, 3H)a 1-084 6 7.15-7.75 (a, 7H), 6.55-6.85 (a, 2H), 5.7-5.85 (a, IH), 5.0-5.4 (a, 2H), 4.15-4.3 and 4.0-4.15 (a, 2H), 1.60 and 1.45 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)„ 1-085 6 7.25-7.75 (a, 12H), 6.72 (bs, IH), 5.35-5.45 and 5.05-5.2 (a, IH), 4.00 and 3.87 (s, 3H), 1.63 and 1.49 (d, J=6.9Hz, 3H)„ 1-086 6 7.25-7.75 (a, 12H), 6.7-6.85 (m, IH), 5.35-5.5 and 5.05~5.2 (a, IH), 4.0-4.3 (a, 2H), 1.64 and 1,49 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)Q 1-087 67.25-7.75 (m, 11H), 6.65-6.8 (a, IH), 5.35-5.45 and 5.05-5.2 (a, IH), 4.01 and 3.87 (s, 3H), 1.63 and 1.49 (d, J=6.9Hz, 3H)„ 1-088 67.25-7.75 (a, 11H), 6.73 (bs, IH), 5.3-5.45 and 5.05-5.2 (a, IH), 4.0-4.3 (a, 2H), 1.64 and 1.49 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)„ 1-089 67.2-7.75 (a, 7H), 7.1-7.65 (a, 2H), 6.6-6.9 (m, IH), 6.3-6.4 (a, 2H), 5.3-5.45 and 5. 0-5. 15 (a, IH), 4.0-4.3 (a, 2H), 1.62 and 1.48 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)C 1-090 6 7.25-7.95 (a, 10H), 6.4-6.8 (a, IH), 5.25-5.45 and 5.0-5.2 On, IH), 4.05-4.3 (a, 2H), 1.62 and 1.47 (d, J=6.9Hz, 3H), 1.15-1.35 (a, 3H)„ 245 [Table 46-5] Table 46 (continued) No. lH NMR (CDC13J Me4Si, 300MHz) 1-091 6 7.2-8.0 (m, 8H), 6.6-6.85 (a, 2H), 5.25-5.4 and 5.0-5.2 (m, IH), 4.05-4.3 (m, 2H), 1.63 and 1,48 (d, J=6.9Hs, 3H), 1.15-1.35 (m, 3H). 1-092 6 7.0-7.75 (m, 7H), 6.70 (bs, IH), 5.25-5.4 and 5.0-5. 15 (m, IH), 4.05-4.3 On, 2H), 1.61 and 1.45 (d, J=6.9Hz, 3H), 1.15-1.35 On, 3H)a 1-093 6 6.6-7.75 (m, 8H), 5.25-5.4 and 5.0-5. 15 (m, IH), 4.05-4.3 (m, 2H), 1.15-1.65 (m, 6H)„ 1-094 6 6.9-7.75 (m, 7H), 6.61 (bs, IH), 5.0-5.3 (m, IH), 4.15-4.35 OB, 2H), 3.5-3.6 (ta, 2D, 3.29 and 2.96 (s, 3H), 1.4-1.85 (m, 3H)„ 1-095 6 6.4-7.75 (m, 7H), 5. 3-5.5 and 5.0-5. 1 (m, IH), 4.2-4.35 and 4.05-4.2 (m, 2H), 1.4-1.65 (o, 3H), 1.15-1.4 (m, 3H), 1-096 6 7.15-7.8 (m, 7H), 7. 10 and 6.81 (bs, IH), 5. 2-5.4 and 4.9-5.05 (m, IH), 4.20 and 4.07 (q, J=6.9Hz, 2H), 3.38 and 2.23 (s, 3H), 1.35-1.6 (m, 3H), 1.29 and 1.18 (t, J=6.9Hz, 3H). 1-097 6 7.0-8.05 (m, 7H), 6.91 (bs, IH), 5.2-5.4 and 4.85-5. 05 (m, IH), 4.19 and 4.06 (q, J=7. 0Hz, 2H), 2.35 and 2.34 (s, 3H), 2.32 and 2.21 (s, 3H), 1.52 and 1.38 (d, J=7.2Hz, 3H), 1.28 and 1. 18 (t, J=7. 0Hz, 3H)„ 1-098 6 7.4-7.8 (m, 7H), 6.54 (bs, IH), 5.0-5.2 (to, IH), 4.0-4.3 (en, 2H), 1.1-1.65 (m, 6H)„ 1-099 6 6.7-7.8 (n, 8H), 5.35-5.5 and 5.0-5. 15 (m, IH), 4.0-4.25 (m, 2H), 3.75-3.85 (m, 3H), 1.15-1.6 (m, 6H). 1-100 6 6.7-8.25 (m, 9H), 4.95-5.4 (m, IH), 4.0-4.3 (m, 4H), 1.0-1.6 (a, 9H)C 1-101 6 6.7-8.0 (o, 8H), 5.0-5.85 (m, 2H), 3.45-4.35 (o, 6H), 1.15-1.7 (a, 6H) 1-102 6 6.65-8.35 (n>, 11H), 5.5-5.65 and 5.05-5.2 (m, IH), 4.0-4.35 (m, 2H), 1.05-1.65 (ID, 6H)„ 2-006 6 8.49 and 8.44 (d, J=2. 1Hz, IH), 7.80 and 7.78 (d, J=2. 1Hz, IH), 7.35-7.75 On, 4H), 6.48 (bs, IH), 4.75 and 4.52 (d, J=6. 0Hz, 2H), 4.26 and 4.07 (t, J=6.9Hz, 2H), 1.65-1.8 and 1.5-1.65 (m, 2H), 1.35-1.5 and 1.2-1.35 (m, 2H), 0.93 and 0.89 (t, J=7.2Hz, 3H)„ 2-007 6 8. 50 and 8.45 (d, J=2. 1Hz, IH), 7. 80 and 7. 78 (d, J=2. 1Hz, IH), 7.35-7.75 (m, 4H), 6.48 (bs, IH), 4.77 and 4.53 (d, J=5.7Hz, 2H), 4.02 and 3.85 (d, J=6.9Hz, 2H), 1.85-2.15 (m, IH), 0.96 and 0.83 (d, J=6.9Hz, 6H)B 2-008 6 8.50 and 8.45 (bs, IH), 7.75-7.85 (m, IH), 7.35-7.7 (to, 4H), 6.59 (bs, IH), 4. 78 and 4. 53 (d, J=6. 0Hz, 2H), 4.07 and 3.89 (d, J=7.2Hz, 2H), 1,0-1.25 (o, IH), 0.4-0.6 (m, 2H), 0. 15-0.35 On, 2H)„ 2-010 6 8.51 and 8.44 (d, J-2. 1Hz, IH), 7. 80 and 7. 79 (d, J=2. 1Hz, IH), 7.35-7.75 (m, 4H), 6.49 (bs, IH), 4.75-4.9 and 4.6-4.75 (m, IH), 4.77 and 4.53 (d, J=6.0Hz, 2H), 1.95-2.4 (m, 4H), 1.5-1.85 (m, 2H)„ 2-012 68.49 and 8.44 (d, J=2. 1Hz, IH), 7. 80 and 7.79 (d, J=2. 1Hz, IH), 7.3-7.75 (m, 4H), 6,45-6.6 (m, IH), 5.8-6.1 (m, IH), 5.1-5.4 (m, 2H), 4.7-4.8 (m, 2H), 4.5-4.6 (m, 2H)a 246 [Table 46-6] Table 46 (continued) No. XH NMR (CDC13, Me4Si, 300MHz) 2-013 6 8.50 and 8.43 (d, J=2. 1Hz, IH), 7.79 and 7.77 (d, J=2. 1Hz, IH), 7.15-7.75 (m, 8H), 6.39 (bs, IH), 5.24 and 5.06 (s, 2H), 4.77 and 4. 52 (d, J=6. 3Hz, 2H)„ 2-014 § 8.80 and 8.75 (s, IH), 8.03 and 8.01 (Sj IH), 7.35-7.75 (m, 4H), 6.44 (bs, IH), 4.77 and 4.57 (d, J=5. 1Hz, 2H), 4.09 and 3.89 (s, 3H)a 2-015 6 8.79 and 8.70 (s, IH), 8.02 and 8.00 (s, IH), 7.35-7.75 (m, 4H), 6.85 and 6.70 (bs, IH), 5.78 and 5.29 (n, IH), 4.07 and 3.88 (s, 3H), 1.59 and 1.48 (d, J=6.9Hz, 3H)„ 2-017 §8.80 and 8.75 (s, IH), 8.03 and 8.00 (s, IH), 7.3-7.75 (m, 4H), 6. 46 (bs, IH), 4. 79 and 4. 57 (d, J=6. 0Hz, 2H), 4.24 and 4.05 (t, J=6.9Hz, 2H), 1.7-1.85 and 1.55-1.7 , 4H)0 2-029 6 8.79 and 8.74 (s, IH), 8.03 and 7.99 (s, IH), 7.3-7.7 On, 4H), 6. 4-6. 55 (m, IH), 4. 85-4. 9 and 4. 7-4. 75 (m, IH), 4. 77 and 4.56 (d, J=6. 3Hz, 2H), 1.5-1,95 (a, 8H)0 2-030 §8.80 and 8.76 (s, IH), 8.40 and 8.02 (s, IH), 7.3-7.75 (m, 4H), 6.39 (bs, IH), 6. 06 and 5, 95 (tt, J=55. 8 and 4. 2Hz, IH), 4.81 and 4.60 (d, J=5.7Hz, 2H), 4. 44 and 4.25 (td, J=13. 5, 4.2Hz, 2H)0 2-031 §8.76 (s, IH), 8.05 (s, IH), 7.35-7.7 (n, 4H), 6.39 (bs, IH), 6.77 (tt, J=55.2 and 4.2Hz, IH), 4.81 (d, J=6.3Hz, 2H), 4.44 (td, J=13.2, 4.2Hz, 2H)„ 247 [Table 46-7] Table 46 (continued) No. XH NMR (CDC13J Me4Si, 300MHz) 2-032 §8.81 and 8,76 (s, IH), 8.04 and 8,03 (s, IH), 7.3-7.75 (a, 4H), 6.34 (bs, IH), 4. 82 and 4.61 (d, J=6. 3Hz, 2H), 4.63 and 4.43 (q, J=8.7Hz, 2H). 2-033 6 8.82 and 8.73 (s, IH), S. 06 and 8.03 (s, IH), 7.25-7.75 (a, 4H), 6.62 (bs, IH), 5.82 and 5.36 (m, IH), 4,62 and 4.43 (q, J=8.7Hz, 2H), 1.65 and 1.49 (d, J=6.9Hz, 3H)„ 2-034 6 8.80 and 8.77 (s, IH), 8.03 and 8.01 (s, IH), 7.35-7.75 (m, 4H), 6.44 and 6.80 (bs, IH), 4.78 and 4. 58 (d, J=6. 0Hz, 2H), 4.42 and 4.24 (t, J=6.6Hz, 2H), 2.85 and 2.72 (t, J=6.6Hs, 2H), 2.06 and 2.05 (s, 3H)a 2-035 6 8.80 and 8.75 (s, IH), 8.03 and 8.00 (s, IH), 7.3-7.75 (a, 4H), 6.44 and 6.54 (bs, IH), 4.05-5.0 (a, 5H), 2.7-3.15 (a, 2H), 1.99 and 1.90 (s, 3H)„ 2-036 6 8.82 and 8.76 (s, IH), 8.07 and 8.03 (s, IH), 7.3-7.75 (a, 4H), 6.39 (bs, IH), 4.93 and 4.72 (s, 2H), 4.81 and 4.64 (d, J=6.0Hz, 2H)„ 2-037 68.83 and 8.75 (s, IH), 8.07 and 8.03 (s, IH), 7.35-7.75 (a, 4H), 6.41 (bs, IH), 5. 10 and 4.94 (q, J=6.9Hz, IH), 4.78 and 4.63 (d, J=6.0Hz, 2H), 1.77 and 1.58 (d, J=6.9Hz, 3H)„ 2-038 68.81 and 8.77 (s, IH), 8.05 and 8.03 (s, IH), 7.35-7.75 (a, 4H), 6.44 (bs, IH), 4.81 and 4.60 (d, J=6. 0Hz, 2H), 4.48 and 4.30 (t, J=6.3Hz, 2H), 2.84 and 2. 71 (t, J=6.3Hz, 2H)„ 2-039 6 8.83 and 8.72 (s, IH), 8. 10 and 8.06 (s, IH), 7.35-7.75 (a, 5H), 6.44 and 6.32 (bs, IH), 4.91 and 4.89 (bs, 2H), 4.66 and 4.64 (bs, 2H), 3.9-4.05 (m, 2H)„ 2-040 6 8.79 and 8.73 (s, IH), 8.01 and 7.99 (s, IH), 7.3-7.7 (a, 4H), 6.45-6,55 (a, IH), 5.8-6.2 (a, IH), 5.15-5.4 (a, 2H), 4. 80 and 4. 57 (d, J=6. 3Hz, 2H), 4. 75-4. 8 and 4. 55-4. 6 (a, 2H)„ 2-041 6 8.80 and 8,74 (s, IH), S. 01 (bs, IH), 7.3-7.75 (a, 4H), 6.43 (bs, IH), 4.85-5.05 (a, 2H), 4.82 and 4.57 (d, J=6.0Hz, 2H), 4.70 and 4.50 (s, 2H), 1.80 and 1.69 (s, 3H)a 2-042 6 8.81 and 8.74 (s, IH), 8.02 and 8.00 (s, IH), 7.35-7.75 (a, 4H), 6.45 (bs, IH), 5.75-6.05 (a, IH), 5.05-5.35 (a, 2H), 4. 8-4. 9 and 4. 65-4. 75 (a, IH), 4.81 and 4. 57 (d, J=6. 3Hz, 2H), 1.44 and 1.27 (d, J=6.6Hz, 3H)„ 2-044 6 8.81 and 8.75 (s, IH), 8.04 and 8.02 (s, IH), 7.35-7.75 (m, 4H), 6.41 (bs, IH), 4.87 and 4,68 (d, J=2.7Hz, 2H), 4.81 and 4.61 (d, J=6.0Hz, 2H), 2,51 and 2.46 (t, J=2.7Hz, IH), 2-046 6 8. 77 and 8. 72 (s, IH), 7. 99 and 7. 97 (s, IH), 7. 2-7. 7 (a, 6H), 6.85-7.15 On, 2H), 6.48 (bs, IH), 5.37 and 5. 18 (s, 2H), 4.78 and 4.55 (d, J=6.0Hz, 2H)„ 2-048 8 8.77 and 8.71 (s, IH), 8.00 and 7.97 (s, IH), 7.2-7.7 (a, 6H), 6. 95-7. 1 (a, 2H), 6. 45 (bs, IH), 5. 26 and 5. 06 (s, 2H), 4.78 and 4.55 (d, J=6.0Hz, 2H)„ 248 [Table 46-8] Table 46 (continued) No. XH NMR (CDC13, Me4Si, 300MHz) 2-050 68.80 and 8.72 (s, IH), 8.00 (bs, IH), 7.1-7.7 (m, 8H), 6.41 (bs, IH), 5.26 and 5.07 (s, 2H), 4.80 and 4.56 (d, J=6. OHz, 2H). 2-051 6 8.79 and 8.73 (s, IH), 8.01 and 7.99 (s, IH), 7.2-7.7 (m, 8H), 6.41 (bs, IH), 5.26 and 5.07 (s, 2H)., 4.80 and 4.56 (d, J=6. OHz, 2H)„ 2-053 6 8.77 and 8.72 (s, IH), 8.00 and 7.97 (s, IH), 7.05-7.7 (o, 8H), 6.4-6.5 (ID, IH), 5.26 and 5.08 (s, 2H), 4.78 and 4.55 (d, J=6.3Hi, 2H), 2,33 and 2.31 (s, 3H)„ 2-054 6 8.76 and 8.71 (s, IH), 7.99 and 7.96 (s, IH), 7.05-7.7 (is, 8H), 6.4-6.5 (ffl, IH), 5.25 and 5.07 (s, 2H), 4.77 and 4.54 (d, J=6. 3Hz, 2H), 2. 34 and 2. 32 (s, 3H) e 2-055 68.78 and 8.73 (s, IH), 8.00 and 7.98 (s, IH), 7.15-7.75 (a, 8H), 6.4-6.5 {m, IH), 5.27 and 5.10 (s, 2H), 4.79 and 4.57 (d, J=6.OHz, 2H), 1.32 and 1.30 (s, 9H)0 2-056 68.81 and 8.73 (s, IH), 8.00 (bs, IH), 7.25-7.7 (n, 8H), 6.45 (bs, IH), 5.51 and 5.33 (s, 2H), 4.83 and 4.57 (d, J=6.0Hz, 2H)C 2-057 6 8.79 and 8.72 (s, IH), 8.00 and 7.99 (s, IH), 7.25-7.7 (m, 8H), 6.43 (bs, IH), 5.34 and 5.15 (s, 2H), 4.81 and 4.55 (d, J=6. OHz, 2H)„ 2-058 6 8.80 and 8.72 (s, IH), 8,00 (bs, IH), 7.25-7.7 (n, 8H), 6.40 (bs, IH), 5.35 and 5.16 (s, 2H), 4.83 and 4.56 (d, J=6.0Hz, 2H)0 2-059 6 8.78 and 8.72 (s, IH), 8.00 and 7.98 (s, IH), 7.2-7.7 (m, 5H), 6.75-7.0 (m, 3H), 6.44 (bs, IH), 5.28 and 5.09 (s, 2H), 4.80 and 4.56 (d, J =6.OHz, 2H), 3.79 and 3. 76 (s, 3H)a 2-060 6 8.78 and 8.74 (s, IH), 8.01 and 7.97 (s, IH), 7.2-7.75 (m, 6H), 6.8-6.95 (a, 2H), 6.4-6.5 (m, IH), 5.24 and 5.05 (s, 2H), 4.77 and 4.56 (d, J=6. OHz, 2H), 3.81 and 3.79 (s, 3H)«, 2-061 6 8.79 and 8.73 (s, IH), 7.99 (bs, IH), 7.15-7.7 (m, 8H), 6.45 (bs, IH), 5.39 and 5.21 (s, 2H), 4.80 and 4.56 (d, J=6.3Hz, 2H)„ 2-062 68.81 and 8.73 (s, IH), 8.00 (bs, IH), 7.1-7.7 (m, 8H), 6.39 (bs, IH), 5.30 and 5.11 (s, 2H), 4.82 and 4.57 (d, J=6. 3Hz, 2H). 2-063 6 8.79 and 8.72 (s, IH), 8.01 and 7.99 (s, IH), 7.1-7.7 (m, 8H), 6.40 (bs, IH), 5.29 and 5.10 (s, 2H), 4.81 and 4.56 (d, J=6. OHz, 2H)„ 2-064 6 8.82 and 8.72 (s, IH), 7.25-8.25 (m, 9H), 6.3-6.5 (m, IH), 5.40 and 5.20 (s, 2H), 4,86 and 4.57 (d, J=6.3Hz, 2H)„ 2-065 6 8.79 and 8.72 (s, IH), 8.00 and 7.97 (s, IH), 7.3-7.7 (m, 8H), 6.63 and 6,56 (bs, IH), 5.47 and 5.29 (s, 2H), 4.84 and 4.55 (d, J=5.7Hz, 2H). 2-066 6 8.81 and 8.72 (s, IH), 8.01 (bs, IH), 7.25-7.75 (m, 8H), 6.39 (bs, IH), 5.31 and 5.12 (s, 2H), 4.82 and 4.56 (d, J=6. 3Hz, 2H)a 2-067 6 8.81 and 8.72 (s, IH), 8.00 (bs, IH), 7.25-7.7 (m, 8H), 6.43 (bs, IH), 5.36 and 5.15 (s, 2H), 4.84 and 4.56 (d, J=6. OHz, 2H)„ 2-068 6 8.80 and 8.74 (s, IH), 8.01 and 7.99 (s, IH), 7.25-7.7 (tu, 13H), 6.41 (bs, IH), 5.35 and 5.16 (s, 2H), 4.82 and 4.58 (d, J=6.3Hz, 2H)„ 249 [Table 46-9] Table 46 (continued) No. *H NMR (CDC1S, Me4Si, 300MHz) 2-069 6 8.78 and 8.72 (s, IH), 8.00 and 7.98 (s, IH), 7.25-7.75 (m, 5H), 6.6-6.9 (a, 2H), 6.43 (bs, IH), 5.31 and 5. 12 (s, 2H), 4.78 and 4.55 (d, J=6. 3Hz, 2H). 2-071 §8.80 and 8.73 (s, IH), 8.01 and 8.00 (s, IH), 6.95-7.75 (ro, 7H), 6.38 (bs, IH), 5.23 and 5.04 (s, 2H), 4.80 and 4.56 (d, J=6.0Hz, 2H), 2-072 6 8.82 and 8.73 (s, IH), 8.02 (bs, IH), 7.3-7,7 (to, 4H), 6.65-7.0 (m, 3H), 6.3-6.45 (a, IH), 5.26 and 5.06 (s, 2H), 4.83 and 4.57 (d, J=6.0Hz, 2H). 2-073 6 8.80 and 8.72 (s, IH), 8.00 (bs, IH), 7.05-7.7 (a, 7H), 6.3-6.5 (a, IH), 5.23 and 5.04 (s, 2H), 4.80 and 4.56 (d, J=6.3Hz, 2H) c 2-074 6 8.80 and 8,72 (s, IH), 8.01 (bs, IH), 7.25-7.7 (a, 4H), 6.85-7.1 (a, 2H), 6.35-6.5 (a, IH), 5.20 and 5.00 (s, 2H), 4.81 and 4.56 (d: J=6.0Hz, 2H)„ 2-075 6 8.79 and 8.73 (s, IH), 7.98 (bs, IH), 7.35-7.9 (a, 11H), 6.40 (bs, IH), 5.46 and 5.27 (s, 2H), 4.81 and 4.56 (d, J=6.0Hz, 2H)„ 2-077 6 8.83 and 8.76 (s, IH), 8.52 and 8.01 (d, J=4.5Hz, IH), 8.00 and 7,99 (s, IH), 7.05-7.7 (a, 7H), 6.45 (bs, IH), 5.44 and 5.25 (s, 2H), 4.85 and 4.59 (d( J=5.4Hz, 2H)„ 2-078 6 8.81 and 8.74 (s, IH), 8.5-8.7 (m, 2H), 8.02 and 8.00 (s, IH), 7.80 and 7.78 (t, J=2. 1Hz, IH), 7.25-7.75 (a, 5H), 6.40 (bs, IH), 5.32 and 5.13 (s, 2H), 4.81 and 4.57 (d, J=6. 3Hz, 2H)0 2-079 68.80 and 8.72 (s, IH), 8.41 and 8.31 (s, IH), 8.01 and 7.99 (s, IH), 7.77 and 7.75 (d, J=2.4Hz, IH), 7.25-7.7 (a, 5H), 6.39 (bs, IH), 5.28 and 5.09 (s, 2H), 4.80 and 4.55 (d, J=6. 3Hz, 2H)„ 2-080 68.84 and 8.74 (s, IH), 8.5-8.6 (a, 2H), 8.03 and 8.01 (s, IH), 7.15-7.7 (a, 6H), 6.47 (bs, IH), 5.33 and 5. 12 (s, 2H), 4.88 and 4.58 (d, J=6.0Hz, 2H). 2-081 6 8.81 and 8.70 (s, IH), 8.00 and 7,97 (s, IH), 7.0-7.7 (a, 9H), 6.42 and 6.36 (bs, IH), 5.41 and 5. 25 (q, J=6. 9Hz, IH), 4,8-4.9 (a, IH), 4,5-4.55 (o, IH), 1.67 and 1.47 (d, J=6.9Hz, 3H)„ 2-084 6 8.21 and 8.19 (d, J=2. 1Hz, IH), 7.35-7.75 (a, 4H), 7.28 and 7.27 (d, J=2. 1Hz, IH), 6. 54 and 6. 47 (bs, IH), 4.71 and 4,51 (d, J=6. 0Hz, 2H), 4, 06 and 3.89 (s, 3H), 3.88 and 3.85 (s, 3H)a 2-085 6 8.44 and 8.39 (d, J=2. 1Hz, IH), 7.4-7.8 (ro, 5H), 6.63 and 6.58 (bs, IH), 4.83 and 4.60 (d, J=5. 7Hz, 2H), 4.45-4.65 and 4. 35-4. 55 (a, IH), 1.33 and 1.20 (d, J=6. 3Hz, 6H)„ 2-086 6 8. 48 and 8.43 (d, J=2. 1Hz, IH), 7. 80 and 7. 77 (d, J=2. 1Hz, IH), 7.35-7.75 (a, 4H), 6.53 and 6.46 (bs, IH), 4.5-4.9 (a, 3H), 1.4-2.0 (a, 8H)„ 2-087 6 8.45-8.55 (a, IH), 7.75-7.85 (m, IH), 7,35-7.75 (a, 4H), 6.59 and 6.46 (bs, IH), 4.78 and 4.55 (d, J=5. 7Hz, 2H), 4.47 and 4.29 (t, J=6.0Hz, 2H), 3.79 and 3.67 (t, J=6,0Hz, 2H)„ 250 [Table 46-10] Table 46 (continued) No. *H NMR (CDC13, Me4Si, 300MHz) 2-088 5 8.50 and 8.45 (d, J=2. 1Hz, IH), 7.81 and 7.79 (d, J=2. lHa, IH), 7.35-7.75 On, 4H), 6.52 (bs, IH)., 5.41 and 5.24 (q, J=5. 1Hz, IH), 4.5-4.9 , 2H), 1.33 and 1.20 (d, J=6.9Hz, 3H)0 252 [Table 46-12] Table 46 (continued) No. *H NMR (CDC13, Me4Si, 300MHz) 2-118 68.49 (d, J=2. 1Hz, IH), 7.4-7.85 (m, 5H), 6.78 (bs, IH), 5.2-5.3 (in, IH), 3.86 (s, 3H), 1.45 (d., J=6.6Hz, 3H) „ 2-119 68.49 and 8.40 (d, J=1.8Hz, IH), 7.82 and 7.78 (d, J=1.8Hz, IH), 7.5-7.7 (n, 4H), 5.15-5.25 (m, IH), 4.05 and 3.88 (s, 3H), 1.85-2.05 (XD, IH), 1.6-1.75 (m, IH), 1.04 (t, J=7. 5Hz, 3H). 2-121 68,50 and 8,41 (d, J=1.8Hz, IH), 7.82 and 7.79 (d, J=1.8Hz, IH), 7.4-7,75 (m, 4H), 6.65-7.05 (m, IH), 5.75-5.85 and 5.2-5.35 (m, IH), 4.29 and 4.12 (q, .1=6.9Hz, 2H), 1.56 and 1.44 (d, J=6,9Hz, 3H), 1.26 and 1.21 (t, J=6.9Hz, 3H)„ 2-123 6 8.50 (d, J=2.0Hz, IH), 7.79 (d, J=2.0Hz, IH), 7.4-7.75 (m, 4H), 6.80 (bs, IH), 5.25 (dq, J=7.4, 6.8Hz, IH), 4.12 (q, J=7.0Hz, 2H), 1.45 (d, J=6.8Hz, 3H), 1.20 (t, J=7. 0Hz, 3H), 2-125 67.25-8,7 (a, 6H), 5.0-6.8 (m, IH), 4.1-4.35 (m, 2H), 1.15-1.35 (a, 3H), 1.00 and 0.94 (s, 9H)„ 2-127 6 8.50 (d, J=1.9Hz, IH)., 7.79 (d, J=l. 9Hz, IH), 7.45-7.75 (m, 4H), 6.81 (bs, IH), 5.15-5.35 (a, IH), 4.02 (t, J=6.7Hz, 2H), 1.5-1.7 (a, 2H), 1.45 (d, J=6.9Hz, 3H), 0.85 (t, J=7.4Hz, 3H). 2-129 6 8.49 and 8.40 (d, J=1.8Hz, IH), 7.81 and 7.78 (d, J=l. 8Hz, IH), 7.4-7.75 (a, 4H), 6.7-7.05 (m, IH), 5,7-5.85 and 5.15-5.3 (a, IH), 4.4-4.55 and 4.4.3-4.4 On, IH), 1.56 and 1.43 (d, J=6.6Hz, 3H), 1.05-1.35 On, 6H)o 2-131 6 8.49 (d, J=2.0Hz, IH), 7.78 (d, J=2.0Hz, IH), 7.45-7.75 (a, 4H), 6.84 (bs, IH), 5.24 (dq, J=7.8, 6, 8Hz, IH), 4.35 (sep, J=6. 3Hz, IH), 1.44 (d, J=6.8Hz, 3H), 1.18 (d, J=6.3Hz, 6H)„ 2-137 6 8.49 (d, J=2.0Hz, IH), 7.78 (d, J=2.0Hz, IH), 7.45-7.75 On, 4H), 6.83 (bs, IH), 5.15-5.3 (a, IH), 4.05-4,2 (n, IH), 1.35-1,7 (a, 2H), 1.44 (d, J=€.8Hz, 3H), 1.16 (d, J=6. 5Hz, 3H), 0.82 (t, J=7. 4Hz, 3H)„ 2-141 6 8. 50 and 8.45 (d, J=2. 1Hz, IH), 7. 80 and 7. 78 (d, J=2. 1Hz, IH), 7.35-7.75 On, 4H), 6.49 (bs, IH), 4.75 and 4.53 (d, J=5. 4Hz, 2H), 4.24 and 4.06 (t, J=6.6Hz, 2H), 1.15-1.8 (a, 6H), 0.8-0.95 (a, 3H). 2-144 6 8.50 and 8,45 (d, J=2, 1Hz, IH), 7.75-7.85 (a, IH), 7.35-7,75 (a, 4H), 6.54 (bs, IH), 4.78 and 4,52 (d, J=5. 7Hz, 2H), 4.0-4.2 and 3.9-4.0 (a, IH), 1.4-1.8 On, 4H), 0.94 and 0.83 (t, J-7.5Hz, 6H)„ 2-146 6 8. 50 and 8.45 (d, J=2. 1Hz, IH), 7. 80 and 7. 78 (d, J=2. 1Hz, IH), 7.35-7.75 On, 4H), 6.49 (bs, IH), 4.75 and 4.53 (d, J=5.7Hz, 2H), 4.24 and 4.06 (t, .1=6.9Hz, 2H), 1.15-1.8 (n, 8H), 0.8-0.95 (a, 3H). 2-149 6 8. 50 and 8.45 (d, J=2. 1Hz, IH), 7. 80 and 7. 78 (d, J=2. 1Hz, IH), 7.35-7.75 On, 4H), 6.47 (bs, IH), 4. 75 and 4.52 (d, J=5.7Hz, 2H), 4.06 and 3.88 (d, J=6.6Hz, 2H), 0.75-1.85 (a, UH). 2-150 6 8.51 and 8.46 (d, J=2. 1Hz, IH), 7. 82 and 7.80 (d, J=2. 1Hz, IH), 7.35-7,75 On, 4H), 6.39 (bs, IH), 6.06 and 5,95 (tt, J=55.5 and 4. 5Hz, IH), 4.78 and 4.56 (d, J=5.7Hz, 2H), 4.41 and 4.24 (td, J=13. 2, 4. 5Hz, 2H)0 253 [Table 46-13] Table 46 (continued) No. *H NMR (CDC13J Me4Si, 300MHz) 2-151 a 8.52 (d, J=2,0Hz, IH), 7.82 (d, J=2.0Hz, IH), 7.45-7.8 (a, 4H), 6.60 (bs, IH), 5.32 (dq, J=7.8, 6. 8Hz, IH).. 4.41 (q, J=8.5Hz, 2H), 1.47 (d, J=6.8Ha, 3H), 2-152 8 8. 50 and 8.48 (d, J=2. 1Hz, IH), 7.81 and 7.79 (d, J=2. 1Hz, IH), 7.4-7.75 (m, 4H), 6.90 and 6. 52 (bs, 1H)„ 4.75 and 4,54 (d, J=5.7Hz, 2H), 4.38 and 4.23 (t, J=5. 1Hz, 2H), 3.64 and 3.58 (t, J=5. 1Hz, 2H), 3.30 and 3.13 (s, 3H)„ 2-153 58.50 and 8.43 (d, J=2. 1Hz, IH), 7.75-7.85 {m, IH), 7.3-7.75 , 8H), 6.57 and 6.51 (bs, IH), 5.47 and 5.29 (s, 2H), 4.83 and 4.54 (d, J=5.7Hz, 2H). 2-164 6 8. 52 and 8.47 (d, J=2. 1Hz, IH), 7. 80 and 7. 73 (d, J=2. 1Hz, IH), 7.3-7.75 (m, 6H), 6.91 and 6.49 (bs, IH), 5.57 and 4.39 (s, 2H), 4.82 and 4.58 (d, J=5.7Hz, 2H). 2-165 6 8.45-8.8 (m, 2H), 7.79 (t, J=2. 1Hz, IH), 7.2-7.75 (m, 5H), 6.98 and 6.48 (bs, IH), 5,46 and 5.31 (bs, 2H), 4. 79 and 4. 56 (d, J=6. 0Hz, 2H). 254 [Table 46-14] Table 46 (continued) No. JH NMR (CDC13, Me4Si, 300MHz) 2-166 6 8. 51 and 8.45 (d, J=2. 1Hz, IH), 7. 80 and 7.79 (d, J=2. 1Hz, IH), 7.35-7.75 On, 4H), 7.30 and 7.08 (s, IH), 6.57 and 6.42 (bs, IH), 5.32 and 5.16 (bs, 2H), 4.80 and 4.55 (d, J=5. 7Hz, 2H)„ 2-167 6 8.51 and 8.46 (d, J=2.4Hz, IH), 7.83 and 7.79 (d, J=2.4Hz, IH), 7.3-7.75 (m, 5H), 6.40 (bs, IH), 5.34 and 5. 16 (bs, 2H), 4.76 and 4.57 (d, J=6.0Hz, 2H)„ 2-168 6 8. 51 and 8,44 (d, J=2. 1Hz, IH), 8. 42 and 8.31 (d, J=2. 1Hz, IH), 7.25-7.85 (ro, 7H), 6.37 (bs, IH), 5.27 and 5.09 (s, 2H), 4.78 and 4.53 (d, J=5. 7Hz, 2H). 2-169 6 8. 54 and 8.43 (d, J=2. 1Hz, IH), 8.25-8.4 (m, IH), 7.83 and 7.80 (d, J=2. 1Hz, IH), 7.05-7.75 On, 6H), 6.51 (bs, IH), 5.28 and 5.08 (s, 2H), 4.84 and 4.54 (d, J=5. 7Hz, 2H). 2-171 68.52 and 8.42 (d, J=2. 1Hz, IH), 7.81 and 7.77 (d, J=2. 1Hz, IH), 7.2-7.7 (a, 9H), 6.45 and 6.40 (bs, IH), 5.41 and 5.25 (q, J=6.6Hz, IH), 4.75-7.85 and 4.45-4.55 (m, 2H), 1.66 and 1.47 (d, J=6.6Hz, 3H)» 2-172 6 8.52 (d, J=2.0Hz, IH), 7.80 (d, J=2. 0Hz, IH), 7.15-7.75 (m, 9H), 6.40 (bs, IH), 5.25 (q, J=6.6Hz, IH), 4.50 (dd, J=5. 1, 1.7Hz, 2H), 1.47 (d, J=6.6Hz, 3H)„ 2-175 6 8.54 and 8.39 (d, J=2. 1Hz, IH), 7.82 and 7.74 (d, J=2. 1Hz, IH), 7.2-7.7 (to, 9H), 6. 55 and 6.35 (bs, IH), 4.87 and 4.49 (d, J=6. 3Hz, 2H), 1.74 and 1.62 (s, 6H)„ 2-176 6 8. 50 and 8.47 (d, J=2. 1Hz, IH), 7.82 and 7.76 (d, J=2. 1Hz, IH), 7.0-7.75 (m, 9H), 6.44 and 6.27 (bs, IH), 4.69 and 4.54 (d, J=5.7Hz, 2H), 4.47 and 4.28 (t, J=7. 2Hz, 2H), 3.06 and 2.92 (t, J=7.2Hz, 2H). 2-177 6 8.54 and 8.48 (dd, J=2. 1, 0.9Hz, IH), 7.0-7.9 (m, 10H), 6.61 (bs, IH), 4.99 and 4.70 (d, J=5.7Hz, 2H)„ 2-178 6 7.92 and 7.90 (d, J=7.7Hz, IH), 7.4-7.75 (to, 4H), 6.39 (bs, IH), 4.70 and 4.51 (d, J=6. 3 and 5.2Hz, 2H), 4.32 and 4.14 (q, J=7.0Hz, 2H), 1.35 and 1.22 (t, J=7.0Hz, 3H)„ 2-179 6 7.92 and 8.89 (d, J=8.3Hz, IH), 7.4-7.75 (m, 4H), 6.39 (bs, IH), 4.70 and 4.51 (d, J=6. 3 and 5.6Hz, 2H), 4.52 and 4.38 (sep, J=6.3Hz, IH), 1.33 and 1.19 (d, J=6. 3Hz, 6H)„ 2-180 6 7.4-7.75 (m, 5H), 6.53 and 6.43 (s, IH), 4.75-4.8 and 4.5-4.6 (m, 2H), 4.3-4.4 and 3.6-3.7 (m, IH), 4.00 and 3.99 (bs, 3H), 1.33 and 1.21 (d, J=6.3Hz, 6H)„ 2-184 6 8.79 (bs, IH), 8.00 (bs, IH), 7.5-7.7 (m, 4H), 6.72 (bs, IH), 5.25-5.35 (m, IH), 3.88 (s, 3H), 1.47 (d, J=6.9Hz, 3H)0 2-186 6 8.79 (bs, IH), 7.99 (bs, IH), 7.5-7.7 (m, 4H), 6.74 (bs, IH), 5.2-5.35 (m, IH), 4.12 (q, J=7.2Hz, 2H), 1.47 (d, J=6.9Hz, 3H), 1.21 (t, J=7.2Hz,, 3H)a 255 [Table 46-15] Table 46 (continued) No. JH NMR (CDC13J Me4Si, 300MHz) 2-188 6 8.78 (bs, IH), 7.98 (bs, IH), 7.5-7.7 (m, 4H), 6.78 (bs, IH), 5.2-5.35 (m, IH), 4.3-4.45 (m, IH)., 1.46 (d, J=6.9Hz, 3H), 1. 18 (d, J=6.3Hz, 6H)0 2-195 68.82 (d, J=1.9Hz, IH), 8.02 (d, J=l. 9Hz, IH), 7.15-7.8 (a, 9H), 6.37 (bs, IH), 5.26 (q, J=6.4Hz, IH), 4.54 (dd, J=5. 5, 1.8Hz, 2H), 1.48 (d, J=6.4Hz, 3H)„ 2-196 6 8.82 (d, J=2.0Hz, IH), 8.02 (d, J=2. OHz, IH), 6.85-7.75 (m, 8H), 6.35 (bs, IH), 5.24 (q, J=6.5Hz, IH), 4.53 (d, J=5.5Hz, 2H), 1.46 (d, J=6.5Hz, 3H). 2-197 6 8.23 and 8.20 (d, J=2. 8Hz, IH), 7.35-7.75 (a, 4H), 7. 29 and 7. 27 (d, J=2. 8Hz, IH), 6. 64 and 6. 59 (bs, IH), 4.76 and 4,52 (d, J=5. 8 and 5.0Hz, 2H), 4. 50 and 4. 36 (sep, J=6.2Hz, IH), 3. 89 and 3. 88 (s, 3H), 1.33 and 1.19 (d, J=6.2Hz, 6H), 2-198 6 8. 75 and 8.72 (d, J=l. 8Hz, IH), 8. 06 and 8. 04 (d, J=l. 8Hz, IH), 7.35-7.75 (m, 4H), 6.62 (bs, IH), 4. 79 and 4. 54 (d, J=6. 0 and 4. 9Hz, 2H), 4.55 and 4.37 (sep, J=6. 3Hz, IH), 4. 04 and 4. 03 (s, 3H), 2.24 and 2.21 (s, 3H), 1.34 and 1.18 (d, J=6.3Hz, 6H)„ 2-199 68.80 and 8.74 (d, J=1.7Hz, IH), 8. 05 and 8. 03 (d, J=l. 7Hz, IH), 7.35-7.75 (a, 4H), 6.42 (bs, IH), 4.77 and 4.56 (d, J=6. 1 and 5.1Hz, 2H), 4.34 and 4.15 (q, J=7. OHz, 2H), 1.37 and 1.22 (t, J=7. OHz, 3H)„ 2-200 6 8.80 and 8.74 (d, J=2. 1Hz, IH), 8. 05 and 8.02 (d, J=2. 1Hz, IH), 7.35-7.8 (a, 4H), 6.44 (bs, IH), 4.77 and 4.56 (d, J=6.0Hz, 2H), 4.54 and 4,39 (sep, J=6.3Hz, IH), 1.35 and 1.19 (d, J=6. 3Hz, 6H) „ 2-201 6 8.80 and 8.75 (d, J=2. 0 and 1. 7Hz, IH), 8.05 and 8.04 (d, J=2.0 and 1.7Hz, IH), 7.4-7.75 (m, 4H), 6.49 and 6.42 (bs, IH), 4.79 and 4.57 (d, J=6. 1 and 5. 5Hz, 2H), 4.34 and 4.15 (d, J=7.2Hz, 2H), 1.0-1.3 (m, IH), 0.45-0.65 (pa, 2H), 0. 15-0. 35 On, 2H) „ 2-202 6 8.81 and 8.70 (d, J=2. OHz, IH), 8.04 and 8.00 (d, J=2. OHz, IH), 7.15-7.55 (n, 9H), 6.40 and 6.32 (bs, IH), 5.43 and 5.26 (q, J=6.6Hz, IH), 4.5-4.85 (n, 2H), 1.68 and 1,47 (d, J=6.6Hz, 3H). 2-204 6 8.44 and 8.39 (d, J=2.4Hz, IH), 7.45-7.75 (DI, 5H), 6.52 (bs, IH), 4.77 and 4.53 (d, J=6. 1 and 5.1Hz, 2H), 4.21 and 4.03 (t, J=6.8Hz, 2H), 1.7-1.85 and 1.55-1.7 (m, 2H), 0.97 and 0. 86 (t, J=7.3Hz, 3H)„ 2-206 6 7.2-8.5 (m, 12H), 6.28 (d, J=7.2Hz, IH), 3.92 (s, 3H). 2-207 6 8.49 (d, J=2.1Hz, IH), 7.45-7.8 fcn, 5H), 6.78 (bs, IH), 5.15-5.3 (m, IH), 4.06 (t, J=6.9Hz, 2H), 1.5-1.65 (ro, 2H), 1.44 (d, J=6.9Hz, 3H), 1.2-1.4 (m, 2H), 0.87 (t, J=6.9Hz, 3H), 256 [Table 46-16] Table 46 (continued) No. XH NMR (CDC13, Me4Si, 300MHz) 2-208 6 8.49 (d, J=2. 1Hz, IH), 7,45-7.8 (m, 5H), 6.75 (bs, IH), 5.15-5.3 (m, IH), 3.84 (d, J=6.6Hz, 2H), 1.8-2.0 (m, IH), 1.45 (d, J=6.6Hz, 3H), 0.83 (d, J=6.6Hz, 6H)„ 2-209 6 8.50 (d, J=2. 1Hz, IH), 7.45-7.85 (m, 5H), 6.81 (bs, IH), 5.15-5.35 On, IH), 3.88 (d, J=7.2Hz, 2H), 1.44 (d, J =6.9Hz, 3H), 1.0-1.15 (m, IH), 0.45-0.55 (m, 2H), 0.15-0.25 (in, 2H)0 2-210 6 8.49 (d, J=2. 1Hz, IH), 7.78 (d, J=2, 1Hz, IH), 7.5-7.65 On, 4H), 6.87 (bs, IH), 5.2-5.3 On, IH), 1.44 (d, J=6.6Hz, 3H), 1.23 (s, 9H)„ 2-211 6 8.49 (d, J=2. 1Hz, IH), 7.45-7.8 (in, 5H), 6.52 (bs, IH), 4.51 (d, J=5. 1Hz, 2H), 3.85-4.0 (m, IH), 1.4-1.65 (m, 4H), 0.83 (t, J=7.5Hz, 6H)„ 2-213 6 8.49 (d, J=2. 1Hz, IH), 7.45-7.8 On, 5H), 6.49 (bs, IH), 5.75-5.9 (DI, IH), 5.05-5.2 (m, 2H), 4.6-4.75 (in, IH), 4.53 (d, J=5.1Hz, 2H), 1.26 (d, J=6. 6Hz, 3H)„ 2-214 6 7.90 (d, J=7.8Hz, IH), 7.45-7.75 (m, 4H), 6.3-6.45 (m, IH), 4.52 (d, J=4.9Hz, 2H), 4.14 (q, J=7. 1Hz, 2H), 1.22 (t, J=7. 1Hz, 3H)„ 2-219 6 8.80 (d, J=2.0Hz, IH), 8.00 (d, J=2. 0Hz, IH), 7.45-7.75 (m, 4H), 6.49 (bs, IH), 4.56 (d, .1=5.5Hz, 2H), 3.97 (qui, J=6. 1Hz, IH), 1.45-1,65 On, 4H), 0.83 (t, J=7.3Hz, 6H)„ 2-220 6 8.80 (d, J=2.0Hz, IH), 8.00 (d, J=2.0Hz, IH), 7.45-7.75 On, 4H), 6.47 (bs, IH), 5.85 (ddd, J=17.3, 10.7, 6. 2Hz, IH), 5.05-5.2 On, 2H), 4.71 (qd, J=6.8, 6.2Hz, IH), 4.58 (d, J=5. 1Hz, 2H), 1.27 (d, J=6.8Hz, 3H)„ 2-222 6 8.43 and 8.39 (d, J=2.4Hz, IH), 7.3-7.75 (a, 5H), 6.59 and 6.57 (t, J=72. OHz, IH), 6.49 and 6. 42 (bs, IH), 4.75 and 4,54 (d, J=6.3Hz, 2H), 4.07 and 3.89 (s, 3H). 2-224 6 8.51 and 8,40 (d, J-2. 1Hz, IH), 7.35-7.85 (m, 5H), 6.55-6.75 On, 2H), 5.75-5.95 (in, IH), 5.35-5,55 (m, IH), 4.3-4.8 (m, 3H), 1.33 and 1.19 (d, J=6. OHz, 6H)„ 2-226 6 8.56 (d, J=1.7Hz, IH), 7.80 (d, J=l. 7Hz, IH), 7.5-7.75 (m, 4H), 6.57 (bs, IH), 4,53 (d, J=5. 1Hz, 2H), 4.36 (sep, J=6.3Hz, IH), 1.17 (d, J=6.3Hz, 6H), 0.27 (s, 9H)0 2-227 6 8.45-8.65 On, IH), 6.35-7.8 (m, 10H), 4.3-4.85 (a, 3H), 1. 15-1.4 (m, 6H)„ 2-228 6 8.85-8.95 On, IH), 6.35-8.2 (m, 9H), 4.3-4.85 (m, 3H), 1, 15-1.4 (a, 6H)„ 2-229 6 8.91 (d, J=2.1Hz, IH), 8.65 (bs, IH), 8.15-8.2 (m, 2H), 7.5-7.75 (m, 4H), 6.55 (bs, IH), 4.58 (d, J=6.6Hz, 2H), 4.3-4.45 (m, IH), 1.20 (d, J=6. 6Hz, 6H)„ 2-232 6 8,70 and 8.64 (s, IH), 7.4-7.8 (m, 4H), 6.40 (bs, IH), 4.3-4.75 (in, 3H), 1.33 and 1.20 (d, J=6.6Hz, 6H)„ 2-234 6 8.63 (d, J=2. 1Hz, IH), 8.11 (d, J=2. 1Hz, IH), 7.5-7.75 (in, 4H), 6,5-7.0 (m, IH), 5.15-5.35 (m, IH), 3.87 (s, 3H), 1.47 (d, J=6.6Hz, 3H)0 257 [Table 46-17] Table 46 (continued) No. XH NMR (CDC13J Me4Si, 300MHz) 2-237 3 8.63 (bs, IH), 8.1-8.15 (m, IH), 7.5-7.75 (m, 4H), 6.5-7.0 (m, IH), 5.15-5.35 (m, IH)., 4.13 (q, J=7.2Hz, 2H), 1.46 (d, J=6.9Hz, 3H), 1.21 (t, J=7.2Hz, 3H)„ 2-238 6 8. 63 and 8.58 (d, J=2. 1Hz, IH), 8. 14 and 8. 10 (d, J=2. 1Hz, IH), 7.1-7.75 (m, 4H), 6.43 (bs, IH), 4.75 and 4.52 (d, J=5.7Hz, 2H), 4.21 and 4.03 (t, J=6.9Hz, 2H), 1.3-1.85 (a, 2H), 0.97 and 0.86 (t, J=7.5Hz, 3H)„ 2-242 3 8.51 (d, J=2. 1Hz, IH), 7.15-7.8 {a, 9H), 6,41 (bs, IH), 5.06 (s, 2H), 4.53 (d, J=5.1Hz, 2H). 2-243 6 8.51 (d, J =2. 1Hz, IH), 6.9-7.85 (m, 8H), 6.39 (bs, IH), 5.03 (s, 2H), 4.54 (d, J=5.4Hz, 2H)„ 2-244 6 8.59 (d, J=2.0Hz, IH), 7.94 (d, J=2.0Hz, IH), 7.15-7.7 (a, 9H), 6.41 (bs, IH), 5.24 (q, J=6.5Hz, IH), 4,99 (dd, J=5. 1, 1.7Hz, 2H), 1.47 (d, J=6.5Hz, 3H), 2-247 5 8.31 and 8.27 (d, J=2.7Hz, IH), 7,25-7.75 (a, 7H), 6.95-7.1 (a, 2H), 6.52 (bs, IH), 4.76 and 4.54 (d, J=5.8 and 5.1Hz, 2H), 4.06 and 3.89 (s, 3H)„ 2-249 6 8.65 and 8.59 (d, J=1.7Hz, IH), 7.91 and 7.87 (d, J=1.7Hz, IH), 7.35-7.75 (a, 9H), 6.59 (bs, IH), 4.80 and 4.56 (d, J=5. 8 and 5. 1Hz, 2H), 4. 54 and 4. 38 (sep, J=6.3Hz, IH), 1. 34 and 1.19 (d, J=6. 3Hz, 6H) „ 2-251 68.63 and 8.58 (d, J=1.5Hz, IH), 8. 15 and 8. 12 (d, J=1.5Hz, IH), 7. 45-7. 9 (a, 4H), 6, 48 (bs, IH), 4. 78 and 4. 55 (d, J=5. 4Hz, 2H), 4.61 and 4.41 (q, J=8.4Hz, 2H). 2-254 6 8.50 (d, J=2. 1Hz, IH), 7.79 (d, J=2. 1Hz, IH), 7.5-7.75 (a,, 4H), 6.80 (bs, IH), 5.15-5.35 (a, IH), 4.02 (t, J=6.9Hz, 2H), 1.5-1.7 (a, 2H), 1.45 (d, J=6. 9Hz, 3H), 0.86 (t, J=7.5Hz, 3H)„ 2-255 6 8.30 and 8.26 (d, J=2.4Hz, IH), 7.3-7,75 (a, 6H), 7.33 and 7.30 (d, J=2.4Hz, IH), 6.95-7.1 (a, 2H), 6.58 (bs, IH), 4. 77 and 4. 53 (d, J=5. 8 and 4. 8Hz, 2H), 4.51 and 4.37 (sep, J=6.3Hz, IH), 1.33 and 1.20 (d, J=6.3Hz, 6H)„ 2-256 68.50 and 8.44 (d, J=1.7Hz, IH), 7.75 and 7.72 (d, J=1.7Hz, 1.H), 7.35-7.75 On, 4H), 6.55 (bs, IH), 4.77 and 4.52 (d, J=6. 1 and 5. 1Hz, 2H), 4.51 and 4.36 (sep, J=6.5Hz, IH), 2.09 and 2.08 (s, 3H), 1.33 and 1.18 (d, J=6.5Hz, 6H)„ 2-257 6 8.43 (d, J=l,7Hz, IH), 7.35-7.75 (m, 4H), 7.74 (d, J=1.7Hz, IH), 6,59 (bs, IH), 4.77 (d, J=5. 1Hz, 2H), 4.36 (sep, J=4.4Hz, IH), 1.45-1.55 (a, IH), 1.20 (d, J=4.4Hz, 6H), 0.85-0.95 (m, 4H)„ 2-258 6 8.49 and 8.44 (d, J=1.7Hz, IH), 7. 76 and 7.73 (d, J=1.7Hz, IH), 7.3-7.7 (a, 4H), 6.62 (bs, IH), 4.78 and 4.53 (d, J=5.8 and 4. SHs, 2H), 4.52 and 4.36 (sep, J=6.5Hz, IH), 2.75-2.95 (a, IH), 1.9-2.15 (m, 2H), 1.5-1.9 (a, 6H), 1.34 and 1.18 (d, J=6.5Hz, 6H). 258 [Table 46-18] Table 46 (continued) No. *H NMR (CDC13J Me4Si, 300MHz;) 2-259 6 8.57 and 8.51 (d, J=1.7Hz, IH), 7.82 and 7.79 (d, J=l. 7Hz, IH), 7.3-7.75 (a, 4H), 6.52 (bs, IH), 4.77 and 4.53 (d, J=5. 8 and 5.1Hz, 2H), 4.52 and 4.38 (sep, J=6. 5Hz, IH), 1.33 and 1.18 (d, J=6. 5Hz, 6H)„ 2-260 6 8. 57 and 8.52 (d, J=2.0Hz, IH), 7. 83 and 7.79 (d, J=2. 0Hz, IH), 7.25-7.75 (a, 4H), 6.52 (bs, IH), 4. 77 and 4. 53 (d, J=5. 8 and 4. 8Hz, 2H),, 4.50 and 4.36 (sep, J=6. 1Hz, IH), 1.33 and 1.18 (d, J=6. 1Hz, 6H)„ 2-261 68.56 and 8.50 (d, J=1.7Hz, IH), 7.81 and 7.77 (d, J=1.7Hz, IH), 7.3-7.75 (a, 4H), 6.52 (bs, IH), 4.77 and 4.53 (d, J=6. 1 and 5.1Hz, 2H), 4.52 and 4.36 (sep, J=6.3Hz, IH), 1.33 and 1.18 (d, J=6. 3Hs, 6H)„ 2-262 6 8.54 and 8.48 (d, J=1.7Hz, IH), 7.80 and 7.77 (d, J=1.7Hz, IH), 7.35-7.75 (a, 4H), 6.55 (bs, IH), 4.78 and 4.54 (d, J=5. 1Hz, 2H), 4.53 and 4.36 (sep, J=6.5Hz, IH), 2.07 (bs, IH), 1.64 and 1.57 (s, 6H), 1.34 and 1.19 (d, J=6.5Hz, 6H). 2-263 6 8.53 and 8.47 (d, J=1.7Hz, IH), 7,79 and 7.76 (d, J=1.7Hz, IH), 7.3-7.75 (a, 4H), 6.54 (bs, IH), 4.77 and 4.53 (d, J=6. 1 and 4. 8Hz, 2H), 4.51 and 4.36 (sep, J=6.3Hz, IH), 1.7-2.15 (a, BE), 1.33 and 1.18 (d, J=6.3Hz, 6H). 2-264 6 8,55 and 8.49 (d, J=1.7Hz, IH), 7.81 and 7.78 (d, J=l. 7Hz, IH), 7.45-7.75 (a, 4H), 6.57 (bs, IH), 4.77 and 4.53 (d, J=6. 1 and 5.1Hz, 2H), 4.50 and 4.36 (sep, J=6.3Hz, IH), 1.55-2.05 On, 10H), 1.33 and 1.18 (d, J=6.3Hz, 6H)„ 2-265 6 8.54 and 8.49 (d, J=1.7Hz, IH), 7.81 and 7.77 (d, J=l. 7Hz, IH), 7.35-7.75 (a, 4H), 6.59 (bs, IH), 6.24 (bs, IH), 4.78 and 4.53 (d, J=6. 1 and 4. 8Hz, 2H), 4.52 and 4.36 (sep, J=6.1Hz, IH), 2.45-2.65 (a, 4H), 1.9-2.05 (a, 2H), 1.33 and 1.18 (d, J=6. 1Hz, 6H)„ 2-266 6 8.52 and 8,46 (d, J=1.7Hz, IH), 7,78 and 7.75 (d, J=1.7Hz, IH), 7.3-7.75 (a, 4H), 6.56 (bs, IH), 6.30 (bs, IH), 4.78 and 4.53 (d, J=5.8 and 4, 8Hz, 2H), 4.52 and 4.36 (sep, J=6.5Hz, IH), 2.1-2.3 (a, 4H), 1.55-1.75 (a, 4H), 1.33 and 1.18 (d, J=6.5Hz, 6H). 2-267 6 8.63 and 8.58 (d, J=1.7Hz, IH), 7.90 and 7.86 (d, J=1.7Hz, IH), 7.35-7.75 (a, 8H), 6.63 (bs, IH), 4.80 and 4.56 (d, J=5. 8 and 5.1Hz, 2H), 4.55 and 4.38 (sep, J=6.5Hz, IH), 1.35 and 1.20 (d, J=6.5Hz, 6H), 1.34 (s, 9H). 259 [Table 46-19] Table 46 (continued) No. XH NMR (CDC13J Me4Si, 300MHz) 2-268 6 8.72 and 8.66 (d, J=1.7Hz, IH), 8.6-8.65 (a, IH), 7.98 and 7.94 (d, J=l. 7Hz, IH), 7.3-7.75 On, 7H), 6.59 (bs, IH), 4.81 and 4. 57 (d, J=5. 1Hz, 2H), 4. 54 and 4.38 (sep, J=6. 1Hz, IH), 1.36 and 1.21 (d, J=6. 1Hz, 6H), 2-269 6 8.78 and 8.77 (d, J=1.0Hz, IH), 8.67 and 8.62 (d, J=l. 7Hz, IH), 8.55-8.6 (m, IH), 7.93 and 7.90 (d, J=l. 7Hz, IH), 7.85 and 7.82 (t, J=2. OHz, IH), 7.3-7.8 (m, 5H), 6.70 (bs, IH), 4.81 and 4.57 (d, J=5. 1Hz, 2H), 4.53 and 4.35 (sep, J=6. 5Hz, IH), 1.36 and 1.21 (d, J=6.5Hz, 6H). 2-270 5 8.55-8.7 (m, 3H), 7.94 and 7.91 (d, J=2. OHz, IH), 7.45-7.75 OB, 4H), 7.40 (d, J=6.3Hz, 2H), 6.72 (bs, IH), 4.81 and 4.57 (d, J=5. SHz, 2H), 4.52 and 4.39 (sep, J=6. 1Hz, IH), 1.36 and 1.21 (d, J=6. 1Hz, 6H)„ 2-271 5 8.72 and 8.71 (d, J=2. OHz, IH), 7.89 and 7.83 (d, J=2. OHz, IH), 7.05-7.75 (m, 8H), 6.81 and 6.64 (bs, IH), 4.75 and 4.58 (d, J=6. 1 and 5.1Hz, 2H), 4.39 and 4.06 (sep, J=6.3Hz, IH), 1.21 and 0.98 (d, J=6. 3Hz, 6H)„ 3-002 6 6.75-7.75 On, 12H), 5. 45-5. 6 and 5. 1-5. 2 (n, IH), 5.17 and 5.04 (ds, 2H), 1.54 and 1.37 (d, J=7.2Hz, 3H). 3-003 5 7.1-7.5 (m, 7H), 6.51 (bs, IH), 5.25-5.4 and 5.0-5. 15 (m, IH), 4.00 and 3.85 (s, 3H), 2.44 and 2.35 (s, 3H), 1.60 and 1.45 (d, J=6.9Hz, 3H)0 3-004 6 8.51 and 8.49 (d, J=2. OHz, IH), 7.95-8.15 (m, IH), 7.78 and 7.77 (d, J=2. OHz, IH), 7.0-7.65 (m, 3H), 7.53 (bs, IH), 4.79 and 4.57 (dd, J=6. 1, 1.5Hz and 4.8, 1.5Hz, 2H), 4. 34 and 4. 17 (q, J=7. OHz, 2H), 1. 38 and 1.25 (t, J=7. OHz, 3H)„ 3-005 6 8.51 and 8.47 (d, J=2. OHz, IH), 7.80 and 7.78 (d, J=2. OHz, IH), 7.25-7.45 On, IH), 6.85-7.0 (to, 2H), 6.66 and 6.61 (bs, IH), 4.76 and 4.56 (d, J=6. 1 and 5.1Hz, 2H), 4.32 and 4.15 (q, J=7.2Hz, 2H), 1.36 and 1.22 (t, J=7.2Hz, 3H)„ 3-006 5 8.51 and 8.47 (d, J=2. OHz, IH), 7.79 and 7.78 (d, J=2. OHz, IH), 7. 25-7. 7 (m, 4H), 6. 97 and 6. 89 (bs, IH), 4.77 and 4.56 (d, J=6. 1 and 5.1Hz, 2H), 4.32 and 4.15 (q, J=7. OHz, 2H), 1.37 and 1.23 (t, J=7. OHz, 3H). 3-007 6 8.50 (d, J=2. 1Hz, IH), 7.77 (d, J=2. 1Hz, IH), 7.6-7.7 (m, IH), 7.25-7.45 On, 3H), 6.96 (bs, IH), 4.55 (d, J=5. 1Hz, 2H), 4.05 (t, J=6.9Hz, 2H), 1.55-1.7 (m, 2H), 0.87 (t, J=7.5Hz, 3H)a 3-008 6 8.51 and 8.46 (d, J=2. OHz, IH), 7.80 and 7. 78 (d, J=2, OHz, IH), 7.1-7.35 (m, 2H), 6.9-7.1 (n, IH), 6.48 and 6.40 (bs, IH), 4.79 and 4.58 (d, J=6. 1 and 5.1Hz, 2H), 4.31 and 4.14 (q, J=7.0Hz, 2H), 1.36 and 1.22 (t, J=7. OHz, 3H)0 260 [Table 46-20] Table 46 (continued) No. *H NMR (CDC13, lfe4Si, 300MHz) 3-009 6 8.51 and 8.46 (d, J=2. OHz, IH), 7,80 and 7.78 (d, J=2. OHz, IH), 7.15-7.35 On, 3H), 6. 40 and 6.34 (bs, IH), 4.81 and 4.60 (d, J=6. 1 and 5.1Hz, 2H), 4,31 and 4.14 (q, J=7. OHz, 2H), 1.36 and 1.22 (t, J=6. 3Hz, 3H). 3-010 6 8.51 and 8.47 (d, J=2. OHz, IH), 7.80 and 7.78 (d, J=2. OHz, IH), 7.2-7.65 (m, 4H), 6.71 and 6.66 (bs, IH), 4.77 and 4.55 (d, J=6. 1 and 5.1Hz, 2H), 4.32 and 4.15 (q, J=7. OHz, 2H), 1.37 and 1.23 (t, J=7.0Hz, 3H)» 3-011 6 8.51 (d, J=2. 1Hz, IH), 7.78 (d, J=2. 1Hz, IH), 7.2-7.65 (a, 4H), 6.71 (bs, IH), 4.55 (d, J=5. 1Hz, 2H), 4.04 (t, J=6.9Hz, 2H), 1.55-1.7 (a, 2H), 0.86 (t, J=7.5Hz, 3H)„ 3-013 5 7.8-7.9 (a, IH), 7.05-7.5 (a, 6H), 6.59 (bs, IH), 5. 25-5, 4 and 5. 0-5. 1 On, IH), 4.26 and 4.11 (q, J=7. 2Hz, 2H), 1.45-1.65 (m, 3H), 1.34 and 1.20 (t, J=7.2Hz, 3H). 3-014 6 8.52 and 8.47 (d, JN2.0Hz, IH), 7.8-7.9 On, IH), 7.80 and 7.78 (d, J=2. OHz, IH), 7.2-7.45 (m, 2H), 7.0-7.15 On, IH), 6.48 (bs, IH), 4.77 and 4.54 (d, J=6. 1 and 5.1Hz, 2H), 4.32 and 4.15 (q, J=7. OHz, 2H), 1.37 and 1.22 (t, J=7. OHz, 3H)„ 3-015 6 8.51 (d, J=2. 1Hz, IH), 7.87 (d, J=7. SHz, IH), 7.78 (d, J=2. 1Hz, IH), 7.05-7.45 On, 3H), 6.47 (bs, IH), 4.54 (d, J=5.4Hz, 2H), 4.04 (t, J=6.6Hz, 2H), 1.5-1.7 On, 2H), 0.86 (t, J=7.5Hz, 3H)„ 3-016 6 8.51 and 8.47 (d, J=2. OHz, IH), 7.7-8.1 (m, IH), 7.80 and 7.78 (d, J=2. OHz, IH), 7.05-7.45 (n, 3H), 6.52 and 6.48 (bs, IH), 4.77 and 4.54 (d, J=6. 1 and 5.1Hz, 2H), 4.53 and 4.48 (sep, J=6.3Hz, IH), 1.34 and 1.19 (d, J=6.3Hz, 6H)0 3-017 68.52 and 8.48 (d, J=2. OHz, IH), 7.8-7.9 On, IH), 7.80 and 7.79 (d, J=2. OHz, IH), 7.2-7.45 (m, 2H), 7.0-7.15 (in, IH), 6.48 (bs, IH), 4.79 and 4.55 (d, J=6. 1 and 5.1Hz, 2H), 4.08 and 3.91 (d, J=7.2Hz, 2H), 1.0-1.3 (m, IH), 0.4-0.65 (m, 2H), 0. 15-0.35 On, 2H)0 3-018 6 8.52 and 8.43 (d, J=2. OHz, IH), 7.7-7.9 On, IH), 7.80 and 7.75 (d, J=2. OHz, IH), 7.0-7.45 On, 8H), 6.45 (bs, IH), 5.42 and 5.27 (q, J=6.6Hz, IH), 4.45-4.85 On, 2H), 1.68 and 1,47 (d, J=6.6Hz, 3H). 3-019 6 8.50 (d, J =2. 1Hz, IH), 7,78 (d, J=2. 1Hz, IH), 7.15-7.45 On, 4H), 6.41 (bs, IH), 4.52 (d, J=5.4Hz, 2H), 4.03 (t, J=6.9Hz, 2H), 2.41 (s, 3H), 1.55-1.7 On, 2H), 0.86 (t, J=7. 8Hz, 3H)Q 3-020 6 8.51 and 8.47 (d, J=2. OHz, IH), 7,81 and 7.77 (d, J=2. OHz, IH), 7.1-7.5 (a, 4H), 6.52 (bs, IH), 4.73 and 4.53 (d, J=6. 0 and 5.5Hz, 2H), 4.52 and 4.38 (sep, J=6.3Hz, IH), 2.41 and 2.32 (s, 3H), 1.34 and 1.19 (d, J=6.3Hz, 6H)„ 261 [Table 46-21] Table 46 (continued) No. XH NMR (CDC13J Me4Si, 300MHz) 3-021 5 8.51 and 8.48 (d, J=2. OHz, IH), 7.81 and 7.79 (d, J=2. 0Hz, IH), 6.95-7.3 (a, 3H), 6.42 (bs, IH), 4.72 and 4.52 (d, J=6. 1 and 5.1Hz, 2H), 4.31 and 4.14 (q, J=7.0Hz, 2H), 2.30 and 2.21 (d, J=2.4Hz, 3H), 1.36 and 1.22 (t, J=7.OHz, 3H)„ 3-023 8 8.50 and 8.47 (d, J=2. OHz, IH), 7.81 and 7.79 (d, J=2.0Hz, 1H), 7.3-8.1 (a, 4H), 7.23 and 7.12 (t, J=55. 6Hz, IH), 6.64 (bs, IH), 4.74 and 4.52 (d, J=6.2 and 4.8Hz, 2H), 4.3-4.65 (a, IH), 1.34 and 1.20 (d, J=6.3Hz, 6H). 3-024 5 8.50 and 8.45 (d, J=2.OHz, IH), 7.81 and 7.78 (d, J=2. OHz, IH), 7.25-7.65 On, 3H), 6.53 (bs, IH), 4.74 and 4.51 (d, J=6. 1 and 4. 9Hz, 2H), 4.51 and 4.37 (sep, J=6. 1Hz, 1H),1.33 and 1.19 (d, J=6. 1Hz, 6H). 3-025 5 8.50 and 8.45 (d, J=2.OHz, IH), 7.81 and 7.79 (d, J=2.0Hz, IH), 7.4-7.6 (m, 2H)., 7.25-7.4 (a, IH), 6.52 and 6.45 (bs, IH), 4.79 and 4.57 (d, J=6. 1 and 5.1Hz, 2H), 4.31 and 4.14 (q, J=7.0Hz, 2H), 1.35 and 1.21 (t, J=7. OHz, 3H)„ 3-026 8 8.60 and 8.31 (bs, IH), 8.50 and 8.48 (d, J=2. OHz, IH), 8.17 and 8.12 (dd, J=8.0, 1.8Hz, IH), 7.76 (d, J=2.0Hz, IH), 7.35-7.5 (a, IH), 6.85-7.1 (a, 2H), 4.79 and 4.57 (d, J=5.8 and 4.8Hz, 2H), 4.33 and 4.18 (q, J=7.OHz, 2H), 3.99 and 3.89 (s, 3H), 1.38 and 1.26 (t, J=7. OHz, 3H)C 3-027 5 8.51 and 8.48 (d, J=2. OHz, IH), 8.09 and 8.02 (dd, J-7.8, 1.9Hz, IH), 7.78 and 7.77 (d, J=2. OHz, IH), 7.62 (bs., IH), 7.05-7.7 (a, 3H), 6.63 and 6.53 (d, J=73. 1Hz, IH), 4.77 and 4.55 (d, J=6. 1 and 4.8Hz, 2H), 4.33 and 4.17 (q, J=7.0Hz, 2H), 1.37 and 1.24 (t, J=7. OHz, 3H), 3-028 5 8.51 and 8.47 (d, J=2. 0 and 2. 4Hz, IH), 8.02 and 7.94 (dd, J=7.9, 2.1Hz, IH), 7.79 and 7.78 (d, J=2.0 and 2.4Hz, IH), 7.2-7.6 (a, 3H), 7.44 (bs, IH), 4.77 and 4.54 (d, J=6. 1 and 4. 8Hz, 2H), 4.33 and 4.16 (q, J=7. OHz, 2H), 1.37 and 1.22 (t, J=7. OHz, 3H)0 3-029 5 8. 50 and 8.47 (d, J=2. OHz, IH), 7. 79 and 7.77 (d, J=2. OHz, IH), 7.1-7.6 (a, 4H), 7.01 (bs, IH), 4.77 and 4.56 (d, J=6. 1 and 5.1Hz, 2H), 4.32 and 4.15 (q, J=7. OHz, 2H), 2.44 and 2.39 (s, 3H), 1.37 and 1.23 (t, J=7. OHz, 3H)„ 3-030 5 8.51 and 8,45 (d, J=2. OHz, IH), 8.05 and 8.00 (dd, J=7.8, 1.2Hz, IH), 7.83 and 7.80 (d, J=2. OHz, IH), 7.35-7.75 (a, 3H), 6.50 (bs, IH), 4. 78 and 4. 56 (d, J=5. 8 and 5. 5Hz, 2H), 4. 32 and 4.15 (q, J=7. OHz, 2H), 1.36 and 1.22 (t, J=7. OHz, 3H). 3-031 8 8.51 and 8.48 (d, J=2. OHz, IH), 7.81 and 7. 79 (d, J=2. OHz, IH), 7.35-7.85 (a, 4H), 7.07 and 6.99 (bs, IH), 4.80 and 4.57 (d, J=5.8 and 5.1Hz, 2H), 4.34 and 4.17 (q, J=7. OHz, 2H), 1.37 and 1.23 (t, J=7. OHz, 3H), 262 [Table 46-22] Table 46 (continued) No. XH NMR (CDC13, Me4Si, 300MHz) 3-032 6 8.42 and 8.31 (d, J=2. 0Hz, IH), 7.72 and 7.71 (d, J=2. 0Hz, IH), 7.25-7.7 (m, 9H), 6.05 and 6.03 (bs, IH), 4.50 and 4.25 (d, J=6. 1 and 5.1Hz, 2H), 4.18 and 4.01 (q, J=7.0Hz, 2H), 1.27 and 1.14 (t, J=7. 0Hz, 3H). 3-033 6 8.45-8.55 (a, IH), 7.2-7.8 (ro, 5H), 6.95 (bs, IH), 4.75 and 4.55 (d, J=5.7Hz, 2H), 4.07 and 3.89 (s, 3H)0 3-035 6 8.50 (d, J=2. 1Hz, IH), 7.7-7.8 (m, 2H), 7.3-7.45 (m, 3H), 7.17 (bs, IH), 4.56 (d, J=4.8Hz, 2H), 1.26 (s, 9H)„ 3-037 6 8.45-8.55 (m, IH), 7.2-7.85 (n, 5H), 6.73 (bs, IH), 4.5-4.6 (a, 2H), 3.88 (s, 3H)0 3-038 6 8.51 (d, 5=2. 1Hz, IH), 7.77 (d, J=2. 1Hz, IH), 7.5-7.65 (m, 2H), 7.2-7.4 (m, 2H), 6.75 (bs, IH), 4.55 (d, J=5. 1Hz, 2H), 4.05-4.25 (a, IH), 1.15-1.7 (n, 5H), 0.84 (t, J=7. 8Hz, 3H). 3-039 6 8.50 (d, J=2. 1Hz, IH), 7.77 (d, J=2. 1Hz, IH), 7.55-7.65 (m, 2H), 7.2-7.4 (is, 2H), 6.83 (bs, IH), 4.55 (d, J=5.4Hz, 2H), 1.26 (s, 9H)„ 3-040 5 8.52 (d, J=2. 1Hz, IH), 7.81 (d, J=2. 1Hz, IH), 7.25-7.7 (m, 4H), 6.68 (bs, IH), 4.58 (d, J=5.4Hz, 2H), 4,44 (q, J=8. 4Hz, 2H), 3-042 6 8.4-8.55 (m, IH), 7.0-7.9 (m, 5H), 6.54 (bs, IH), 4. 7-4. 8 and 4. 5-4. 6 (m, 2H), 3. 85-4. 1 (m, 3H) a 3-043 6 8.51 (d, J=2. 1Hz, IH), 7,87 (d, J=8. 1Hz, IH), 7.77 (d, J=2. 1Hz, IH), 7.3-7.45 (m, 2H), 7.05-7.15 {m, IH), 6.49 (bs, IH), 4.54 (d, J=5.1Hz, 2H), 4.05-4.25 (m, IH), 1.15-1.7 (m, 5H), 0.84 (t, J-7.5Hz, 3H)„ 3-044 6 8.51 and 8.46 (d, J=2. 1Hz, IH), 7.75-7.9 (n, 2H), 7.0-7.45 (m, 3H), 6.52 (bs, IH), 4.78 and 4.54 (d, J=5.4Hz, 2H), 1.39 and 1.26 (s, 9H)„ 3-045 6 8.53 and 8.49 (d, J=2. 1Hz, IH), 7.8-7.95 (m, 2H), 7.0-7.45 (m, 3H), 6.37 (bs, IH), 4.35-4.85 (m, 4H)„ 3-046 6 8.50 and 8,47 (d, J=2. 1Hz, IH), 7. 79 and 7.78 (d, J=2. 1Hz, IH), 7.1-7.5 (m, 4H), 6.48 and 6.40 (bs, IH), 4.71 and 4.53 (d, J=6,0Hz, 2H), 4. 06 and 3.88 (s, 3H), 2.40 and 2.30 (s, 3H)„ 3-048 6 8.50 (d, J=2. 1Hz, IH), 7.77 (d, J=2. 1Hz, IH), 7.15-7.45 On, 4H), 6.45 (bs, IH), 4.53 (d, J=5. 1Hz, 2H), 2.43 (s, 3H), 1.26 (s, 9H)„ 3-051 68.64 and 8.60 (d, J=1.5Hz, IH), 8, 14 and 8. 11 (d, J=1.5Hz, IH), 7.1-7.4 (ID, 4H), 6.35 and 6.27 (bs, IH), 4.76 and 4.56 (d, J=5.4Hz, 2H), 4.61 and 4.41 (q, J-8.4Hz, 2H), 2.40 (s, 3H)„ 4-001 6 8.43 and 8.36 (d, J=2. 1Hz, IH), 7.82 (d, J=2. 1Hz, IH), 7.75 (d, J=7.8Hz, IH), 7.2-7.35 (m, IH), 6.95-7.1 (m, IH), 6.59 (d, J=7.8Hz, IH), 5.83 and 4. 14 (s, IH), 3.79 and 3.62 (s, 3H), 1.84 and 1.55 (s, 6H)C 263 [Table 46-23] Table 46 (continued) No. *H NMR (CDC13J Me4Si, 300MHz) 4-002 6 8.47 (d, J=2.4Hz, IH), 7.79 (d, J=2.4Hz, IH), 7.45-7.75 (m, 4H), 7.21 (bs, IH), 4.0-4.2 (m, 2H), 1.82 (s, 3H)., 1.75 (s, 3H), 1. 17 (t, J=7.2Hz, 3H)0 4-004 6 8.45-8.55 (a, IH), 7.35-7.75 (a, 5H), 6.59 and 6.43 (bs, IH), 4.05-4.3 (a, 2H), 2.5-3.0 Cm, 4H), 1.75-2.15 (a, 2H), 1.2-1.35 (m, 3H) 4-006 6 8.50 and 8.40 (d, J=2. 0Hz, IH), 7.80 (d, J=2. 0Hz, IH), 7.35-7.7 (a, 3H), 6.9-7.15 (a, IH), 4.88 and 4.62, 4,25 (d, J=3. 1, 15.3, 15.3Hs, 2H), 4.07 and 3.96 (s, 3H), 2.95-3.30 (a, 2H), 1.22 and 1.09 (t, J=7. 2Hz, 3HL 4-008 6 8.47 and 8.38 (d, J=2.4 and 2.0Hz, IH), 7.80 and 7.78 (d, J=2.4 and 2. GHz, IH), 7.4-7.75 (a, 3H), 7.15-7.25 On, IH), 4.25-5.3 (a, 4H), 4.08 and 3.91 (s, 3H), 3.38 and 3.15 (s, 3H)a 4-009 6 8.50 and 8.40 (d, J=2.4Hz, IH), 7.80 (d, J=2.4Hz, IH), 7.35-7.7 (a, 3H), 6.95-7.2 (a, IH), 5.5-6.0 (a, IH), 5.0-5.35 (m, 2H), 4.89 and 4.57 (d, J=15. 0Hz, IH), 4.76 and 4. 28 (d, J=15. 0Hz, 1H), 4.06 and 3.93 (s, 3H), 3.4-3.9 (a, 2H)„ 4-010 6 8. 47 and 8. 38 (d, J=2. 4Hz, IH), 7.81 and 7. 79 (d, J=2. 4Hz, IH), 7.4-7.75 (a, 3H), 7.1-7.25 (m, IH), 5.09 and 4.73 (d, J=9.6Hz, IH), 4.80 and 4.42 (d, J=9.6Hz, IH), 3.7-4.3 (a, 2H), 4.08 and 3.95 (s, 3H), 2.28 and 2.22 (t, J=2.6Hz, IH). 4-011 68.81 and 8.79 (s, IH), 8.00 and 7.98 (s, IH), 7.35-7.7 (a, 4H), 4.6-5.4 (n, 2H), 4.09 and 3.92 (s, 3H), 2.75-2.85 and 2.6-2.7 (m, IH), 0.35-0.9 (a, 4H). 4-012 6 8.52 and 8.40 (d, J=2. 0Hz, IH), 7.3-7.86 On, 4H), 7.09 and 7.02 (d, J=6.8Hz, IH), 3.95-5.1 On, 4H), 4.27 and 3.94 (s, 3H)Q 4-013 6 8.47 and 8.44 (d, J=2.0Hz, IH), 7.81 and 7. 75 (d, J=2. 0Hz, IH), 7.45-7.75 (m, 4H), 4.82 and 4.73 (s, 2H), 3.94 and 3.87 (s, 3H), 2.42 and 2.28 (s, 3H)Q 4-014 6 8. 53 and 8.44 (d, J=2. 0Hz, IH), 7. 82 and 7. 79 (d, J=2. 0Hz, IH), 7.35-7.75 0», 4H), 4.98 (bs, 2H), 4.06 and 3.90 (s, 3H), 3.63 and 3.59 (s, 3H). 4-015 6 8.52 (bs, IH), 7.4-7.9 On, 5H), 5,67 (bs, IH), 4.82 (bs, IH), 3.94 (s, 3H)Q 6-001 6 8.25-8.5 (a, 3H), 7.7-7.85 (m, 2H), 7.3-7.4 (a, IH), 4. 76 and 4.54 (d, J=6. 0Hz, 2H), 4. 34 and 4. 16 (q, J=7. 2Hz, 2H), 1.38 and 1.23 (t, J=7.2Hz, 3H)5 6-003 6 8.25-8.55 (a, 3H), 7.7-7.85 (a, 2H), 7.2-7.3 (a, IH), 4. 76 and 4.54 (d, J=5. 7Hz, 2H), 4. 33 and 4. 16 (q, J=7. 2Hz, 2H), 1.38 and 1.23 (t, J=7.2Hz, 3H), 264 [Table 46-24] Table 46 (continued) No. XH NMR (CDC13, Me4Si, 300MHz) 6-004 §8.3-8.7 (m, 3H), 7.7-7.8 (m, IH), 7.5-7.6 (m, IH), 7.2-7.35 (m, IH), 4. 74 and 4. 52 (d, J=5. 7Hz, 2H), 4. 33 and 4, 16 (q, J=7. 2Hz, 2H), 2.67 and 2.66 (s, 3H), 1.38 and 1.23 (t, J=7.2Hz, 3H)„ 6-005 §8,75 (dd, J=4.8, 1.0Hz, IH), 8.49 (d, J=2, 0Hz, IH), 8.23 (bs, IH), 8.15 (dd, J=8.2, 1.0Hz, IH), 7.75 (d, J=2.0Hz, IH), 7.56 (dd, J=8.2, 4.8Hz,, IH), 4.55 (d, J=5. 5Hz, 2H), 4.16 (q, J=7.0Hz, 2H), 1.23 (t, J=7. 0Hz, 3H)„ 6-006 6 8.45-8.5 (o, 2H), 8.32 (bs, IH), 7.79 (dd, J=8. 1, 1.5Hz, IH), 7.73 (d, J=1.8Hz, IH), 7.35 (dd, J=8. 1, 4. 5Hz, IH), 4.52 (d, J=5.7Hz, 2H), 4.35-4.45 (to, IH), 1.20 (d, J =6.0Hz, 6H). 6-007 §8.51 (dd, J=4.5, 1. 5Hz, IH), 8.48 (d, J=2. 1Hz, IH), 8.32 (bs, IH), 8.00 (dd, J=8. 1, 1.5Hz, IH), 7.73 (d, J=2. 1Hz, IH), 7.26 (dd, J=8. 1, 4. 5Hz, IH), 4.52 (d, J=5. 7Hz, 2H), 4.35-4.45 (m, IH), 1.20 (d, J=6.0Hz, 6H)0 6-008 §8.75 (dd, J=4.8, 1.5Hz, IH), 8.48 (d, J=2. 1Hz, IH), 8.25 (bs, IH), 8,15 (d, J=7.8Hz, IH), 7.74 (d, J=2. 1Hz, IH), 7.56 (dd, J=7.8, 4. 8Hz, IH), 4.55 (d, J=5. 4Hz, 2H), 4.35-4.45 (m, IH), 1.20 (d, J=6.3Hz, 6H)„ 7-001 § 8. 4-8. 5 and 8. 3-8. 4 (m, IH), 8. 0-8. 1 and 7. 8-7. 85 (m, IH), 7.15-7.5 (K, 5H), 4.65 and 4.60 (d, J=6. 3Hz, 2H), 4. 04 and 3.87 (s, 3H)„ 7-002 §8.50 and 8.47 (d, J=2. 1Hz, IH), 8.4-8.5 (ro, IH), 8.05-8.2 (m, IH), 7.80 and 7.78 (d, J=2. 1Hz, IH), 7.25-7.4 (tn, IH), 6.44 and 6.27 (bs, IH), 4.78 and 4. 56 (d, J=6. 0Hz, 2H), 4.33 and 4.16 (q, J=7.2Hz, 2H), 1.38 and 1.24 (t, J=7.2Hz, 3H)„ 7-003 §8. 51 and 8.48 (d, J=2. 1Hz, IH), 8. 08 and 8.00 (d, J=7. 8Hz, IH), 7.81 and 7.79 (d, J=2. 1Hz, IH), 7.72 and 7.69 (d, J=7.8Hz, IH), 7.07 and 7.01 (bs, IH), 4,78 and 4.56 (d, J=6. 3Hz, 2H), 4.34 and 4.16 (q, J=7.2Hz, 2H), 1.38 and 1.23 (t, J=7.2Hs, 3H)„ 7-004 §8.7-8.8 (m, IH), 7.89 and 7,73 (d, J=7.8Hz, IH), 7.1-7.6 (m, 4H), 6. 95 and 6.81 (bs, IH), 5. 2-5. 35 and 4. 95-5. 1 (m, IH), 4.36 and 4.09 (q, J=7.2Hz, 2H), 1.60 and 1.45 (d, J=7.2Hz, 3H), 1.31 and 1.18 (t, J=7.2Hz, 3H)„ 7-006 §8.4-8.55 (n, 2H), 8.05-8.15 (a, IH), 7.78 (d, J=1.8Hz, IH), 7,25-7.4 (m, 2H), 4.55 (d, J=5. 1Hz, 2H), 3.89 (s, 3H). 7-007 §8.51 (d, J=2. 1Hz, IH), 8.45-8.5 (m, IH), 8.1-8.2 (m, IH), 7.78 (d, J=2.1Hz, IH), 7.3-7.4 (m, 2H), 4.56 (d, J=4.8Hz, 2H), 4.06 (t, J=6.9Hz, 2H), 1.55-1.75 (m, 2H), 0.87 (t, J=7.5Hz, 3H)Q 7-008 §8.4-8.55 (m, 2H), 8.15-8.25 {a, IH), 7.78 (d, J=2.4Hz, IH), 7.58 (bs, IH), 7.3-7.4 (m, IH), 4.56 (d, J=4.8Hz, 2H), 1.27 (s, 9H)a 7-009 §8.5-8.55 (tn, IH), 8.45-8.5 (m, IH), 8.05-8.15 (m, IH), 7.8-7.85 (m, IH), 7.25-7.4 (in, 2H), 4.60 (d, J=5.4Hz, 2H), 4.45 (q, J=8.7Hz, 2H), 265 [Table 46-25] Table 46 (continued) No. :H NMR (CDC13, Me4Si, 300MHz) 8-001 6 8.98 (s, IH), 8.89 (d, J=4. 8Hz, IH), 8.51 (d, J=2.0Hz, IH), 7.80 (d, J=2.0Hz, IH), 7.48 (d, J=4.8Hz, IH), 6.62 (bs., IH), 4.53 (d, J=5. 1Hz, 2H), 4.14 (q, J=7. 0Hz, 2H), 1.22 (t, J=7.0Hz, 3H)a 9-001 6 8.81 (d, J=2. 1Hz, IH), 8.76 (d, J=2. 1Hz, IH), 8.48 (d, J=2. 1Hz, IH), 8.03 (bs, IH), 7.77 (d, J=2. 1Hz, IH), 4.56 (d, J=5.8Hz, 2H), 3.90 (s, 3HL 9-002 6 8.81 (d, J=2.4Hz, IH), 8.77 (d, J=2. 4Hz, IH), 8.10 (bs, IH), 7.44 (d, J=2. 1Hz, IH), 7.30 (dd, J=8. 1, 2.1Hz, IH), 7.16 (d, J=8.1Hz, IH), 5.0-5.15 (a, IH), 4.12 (q, J=7.2Hz, 2H), 1.48 (d, J=6.9Hz, 3H), 1.21 (t, J=7.2Hz, 3H)a 9-004 6 8.82 and 8.79 (d, J=2.4Hz, IH), 8. 77 and 8.71 (d, J=2. 4Hz, IH), 8.50 and 8.48 (d, J=2.0Hz, IH), 8.08 (bs, IH), 7.78 and 7.77 (d, J=2.0Hz, IH), 4.82 and 4,57 (d, J=6. 1 and 5.5Hz, 2H), 4.01 and 3.92 (d, J=7.0Hz, 2H), 1.0-1.2 (m, IH), 0.45-0.65 (m, 2H), 0. 15-0.4 (m, 2H)0 9-007 6 8.82 (d, J=2.7Hz, IH), 8.76 (d, J=2. 7Hz, IH), 8.49 (d, J=1.8Hz, IH), 8.05 (bs, IH), 7.76 (d, J=l, 8Hz, IH), 4.56 (d, J=5.1Hz, 2H), 4.35-4.45 On, IH), 1.20 (d, J=6.3Hz, 6H)„ 10-001 6 8. 50 and 8.48 (d, J=2. 1Hz, IH), 7. 78 and 7. 76 (d, J=2. 1Hz, IH), 7.44 and 7.40 (d, J=2. 1Hz, IH), 7.16 (bs, IH), 6.57 and 6.54 (d, J=2. 1Hz, IH), 4.74 and 4,51 (d, J=5.4Hz, 2H), 4. 25-4. 4 and 4. 05-4. 25 Co, 2H), 1.38 and 1.24 (t, J=7. 2Hz, 3H). 10-002 6 8.50 (d, J=2.0Hz, IH), 7.76 (d, J=2.0Hz, IH), 7.31 (d, J=1.4Hz, IH), 6.91 (s, IH), 6.32 (d, J=1.4Hz, IH), 4.48 (d, J=5. 1Hz, 2H), 4.16 (q, J=7.0Hz, 2H), 2.36 (s, 3H), 1.23 (t, J=7.0Hz, 3H)a 11-001 6 8.49 and 8.46 (d, J=2.0Hz, IH), 7.77 and 7.75 (d, J=2.0Hz, IH), 6.33 (bs, IH), 6. 00 and 5.86 (s, IH), 4.66 and 4.44 (d, J=6. 1 and 5.1Hz, 2H), 4.31 and 4.14 (q, J=7.0Hz, 2H), 2.50 and 2.45 (s, 3H), 2.24 and 2.22 (s, 3H), 1.36 and 1.23 (t, J=7.0Hz, 3H)C 11-002 6 8.50 and 8.46 (d, J=2.0Hz, IH), 7.79 and 7.77 (d, J=2.0Hz, IH), 6.69 (bs, IH), 6. 34 and 6.27 (s, IH), 4.69 and 4.47 (d, J=5.5 and 4.8Hz, 2H), 4.31 and 4.15 (q, J=7.0Hz, 2H), 2.36 and 2.33 (s, 3H), 1.36 and 1.23 (t, J=7.0Hz, 3H)C 11-003 6 8.51 and 8.48 (d, J=2.4 and 2.0Hz, IH), 7.81 and 7.79 (d, J=2.4 and 2.0Hz, IH), 7.65-7.75 (m, 2H), 7.3-7.5 (m, 3H), 6.95 and 6.88 (s, IH), 6.82 and 6.80 (bs, IH), 4.74 and 4.51 (d, J=5.8 and 4.8Hz, 2H), 4,33 and 4.16 (q, J=7.0Hz, 2H), 1.37 and 1.24 (t, J=7.0Hz, 3H). 12-001 6 6.85-7.8 (m, 7H), 5. 4-5.55 and 5. 05-5. 15 (a, IH), 4.03 and 3.88 (s, 3H), 2.55 and 2.51 (s, 3H), 1.54 and 1.35 (d, J=6.9Hz, 3H). 266 [Table 46-26] Table 46 (continued) No. lH NMR (CDC13, Me4Si, 300MHz) 12-002 6 6.85-7.75 On, 1 IH), 5. 4-5. 55 and 5. 05-5. 15 (m, IH), 5.20 and 5.07 (s, 2H), 2.47 and 2.37 (s, 3H), 1.54 and 1.34 (d, J=6.9Hz, 3H), 12-003 8 7.1-7.45 (ni, 4H), 6.88 and 6.82 , 6H), 5.2-5.45 and 5.0-5. 15 (m, IH), 4.05-4.35 (m, 2H), 1.2-1.65 (m, 6H)6 27-001 6 7.45-7.7 (m, 5H), 5.95-6.1 (m, IH), 4.8-4.9 (a, IH), 4.02 (s, 3H), 3.60 (s, 3H), 1.51 (d, J=6.9Hz, 3H), 1.35 (d, J=6.0Hz, 6H). 27-002 6 7.5-7.75 («, 4H), 6.97 (d, J=7.8Hz, IH), 5.15-5.25 (m, IH), 4.75-4.9 (E, IH), 3.90 (s, 3H), 3.64 (s, 3H), 1.40 (d, J=7.2Hz, 3H), 1.37 (d, J=6.6Hz, 6H)0 29-001 6 7.4-7.85 (a, 4H), 6.58 and 6.41 (bs, IH), 4.85 and 4.73 (d, J=5.7Hz, 2H), 4.05 and 4.03 (s, 3H)0 29-002 6 7.4-7.8 (n, 4H), 6.61 and 6.42 (bs, IH), 4.87 and 4.74 (d, J=5.4Hz, 2H), 4.2-4.4 (ro, 2H), 1.25-1.4 (m, 3H)„ 30-007 6 6.5-8.65 (m, 13H), 4.85-5.85 (m, IH), 1.4-1.7 (m, 3H)„ 30-009 6 6.95-7.75 (a, 6H), 6.3-6.7 (m, IH), 5.0-5.3 , 2H), 0.85-1.5 (n, 21H)„ 41-009 8 8. 50 and 8.47 (d, J=2. 1Hz, IH), 7. 78 and 7. 75 (d, J=2. 1Hz, IH), 5.02 (bs, IH), 3.95-4.45 (m, 4H), 1,4-1,85 (n, 2H), 1.39 and 1.35 (s, 9H), 0,98 and 0.86 (t, J-7.5Hz, 3H)0 41-010 8 8.49 and 8.46 (d, J=2.4Hz, IH), 7.77 and 7.74 (d, J=2.4Hz, IH), 5.01 (bs, IH), 4.1-4.55 (B, 3H)f 1.39 and 1.35 (s, 9H), 1.31 and 1.17 (d, J=6.3Hz, 6H)„ 41-011 88.45-8.6 (m, IH), 7.7-7.8 (m, IH), 4.25-5.3 (m, 3H), 1.1-1.6 (n, 18H), 41-013 8 8.49 and 8.46 (d, J=2. 1Hz, IH), 7.77 and 7.75 (d, J=2, 1Hz, IH), 5.05 (bs, IH), 4. 42 and 4, 19 (d, J=6. 3Hz, 2H), 4.03 and 3.88 (d, J=7.2Hz, 2H), L 39 and 1.35 (s, 9H), 1.1-1.3 (m, IH), 0. 55-0. 65 and 0. 45-0. 55 (m, 2H), 0. 3-0. 35 and 0, 2-0. 25 (m, 2H)„ 41-014 8 8. 48 and 8.46 (d, J=2. 1Hz, IH), 7. 77 and 7. 73 (d, J=2. 1Hz, IH), 5.03 (bs, IH), 4.05-4.45 (to, 3H), 0,8-1.85 (a, 17H)C 41-015 8 8.4-8.5 (m, IH), 7.7-7.8 (m, IH), 5,05 (bs, IH), 4.35-4.45 (m, 2H), 1.3-1.4 (m, 18H). 41-017 8 8. 50 and 8.43 (d, J=2. 1Hz, IH), 7. 76 and 7. 72 (d, J=2. 1Hz, IH), 7. 2-7. 4 (n, 5H), 5. 36 and 5. 24 (q, J=6. 6Hz, IH), 4.8-5. 05 (m, IH), 4.45 and 4.15 (d, J=5.4Hz, 2H), 1.63 and 1.45 (d, J=6.6Hz, 3H), 1.36 and 1.35 (s, 9H)0 41-018 8 8. 50 and 8.44 (d, J=2. 1Hz, IH), 7. 76 and 7.73 (d, J=2. 1Hz, IH), 6.9-7.4 (a, 4H), 5.34 and 5.22 (q, J=6.9Hz, IH), 4.97 (bs, IH), 4.4-4.5 and 4. 1-4.2 (m, 2H), 1.3-1.65 (m, 12H). 41-019 8 8.50 (d, J=2.1Hz, IH), 7.75 (d, J=2. 1Hz, IH), 5.21 (bs, IH), 4.75 (bs, IH), 4.02 (t, J=6.9Hz, 2H), 1.6-1.7 (in, 2H), 1.41 (s, 9H), 1.36 (d, J=6.9Hz, 3H), 0.86 (t, J=7.5Hz, 3H)0 42-001 8 7.54 (d, J=7.5Hz, IH), 7.45-7.5 (m, IH), 7.3-7.4 (n, IH), 5.30 (bs, IH), 4.95-5.1 (o, IH), 1.43 (s, 9H), 1.33 (d, J=7.2Hz, 3H). 42-005 8 8.55 (d, J=1.8Hz, IH), 7.83 (d, J=1.8Hz, IH), 5.65 (bs, IH), 5.37 (bs, IH), 1.44 (s, 9H), 0.91 (s, 9H)<, 42-006 8 8.64 (d, J=2.1Hz, IH), 8,21 (d, J=2. 1Hz, IH), 5.31 (bs, IH), 4.75 (d, J=4.5Hz, 2H), 1.47 (s, 9H)Q 275 [Test Example] Now, usefulness of the compounds of the present invention as pesticides will be described in detail by referring to the following Test Examples, but the present invention is by no restricted thereto. 5 Preparation of test solutions A: Compounds of the present invention were dissolved in a solvent for emulsion (a mixture of Sorpol (registered trademark) 3005XL (manufactured by Toho Chemical Industry Co., Ltd.): N-methylpyrrolidone:Solvesso (registered trademark) 200 (manufactured by ExxonMobil Chemical) in a ratio of 1:5:2) to prepare 20% emulsifiable 10 concentrates. Then, distilled water was added to dilute the emulsifiable concentrates to the predetermined concentration (500 ppm), and the obtained solutions were used in the following Test Examples 1 to 7. Preparation of test solutions B: Compounds of the present invention were dissolved in dimethylsulfoxide to 15 prepare 1% solutions. Then, distilled water was added to dilute the solutions to the predetermined concentration (100 ppm), and the obtained solutions were used in the following Test Examples 8 to 12. TEST EXAMPLE 1: Test on the preventive effect against cucumber powdery mildew Cucumber (cultivar: Sagami Hanjiro) was planted in 90 cm3 plastic pots, and in the 20 seed leaf stage, 5 ml per pot of test solutions A of the compounds of the present invention were spray-inoculated. After drying in air, the pots were placed in an airconditioned greenhouse (20°C), and a suspension of conidium of Erysiphe polygoni (synonym: Erysiphe betae) was sprayed. After the pots were placed at the same temperature for 9 days, the proportion of the formed lesion in the inoculated leaves was 25 measured to calculate the control value in accordance with the following formula. Here, the test was carried out in duplicate. Control value = [1-(lesion area ratio in treated plot/lesion area ratio in non-treated plot)] x 100 As a result, among the compounds tested, the following compounds showed a 30 control value of at least 70%. Compounds Nos. 1-001 to 1-015, 1-018 to 1-021, 1-023 to 1-025, 1-028 to 1-030,1-032 to 1-034, 1-036 to 1-038, 1-040 to 1-076, 1-078 to 1-102, 2-002 to 2-019, 2-020*, 2-021 to 2-081, 2-083 to 2-089, 2-090*, 2-091, 2-092, 2-093*, 2-095 to 2-111,2-113, 2-115, 2- 117 to 2-121, 2-123, 2-124, 2-126, 2-127, 2-128, 2-129, 2-131 to 2-139, 2-141 to 2-205, 35 2-207 to 2-214, 2-215*, 2-216 to 2-228, 2-230, 2-231, 2-233 to 2-235, 2-237, 2-238, 2- 240 to 2-251, 3-001, 3-003, 3-004, 3-006, 3-007, 3-010 to 3-030, 3-033 to 3-051, 4-002 to 4-006, 4-008 to 4-011, 5-001, 6-001 to 6-005, 7-001 to 7-009, 9-001 to 9-006, 10-001, 11-001, 11-002, 12-001, 12-003 to 12-017, 13-001, 13-002, 15-001, 17-001, 17-002*, 17-003 to 17-006, 17-007*, 17-008 to 17-010, 19-001, 20-001 to 20-003, 20-004*, 20- 40 005 to 20-007, 21 -001, 22-001 to 22-003, 23-001, 23-002, 23-004, 25-001 to 25-004, 26-001 to 26-003, 27-002, 28-001, 30-017, 31-007, 32-026, 32-028 and 32-032 of the present invention. The symbol * means that the test was carried out using a 100 ppm solution. TEST EXAMPLE 2: Test on the preventive effect against cucumber gray mold (spore 45 inoculation) Cucumber (cultivar: Sagami Hanjiro) was planted in 90 cm3 plastic pots, and in the seed leaf stage, 5 ml per pot of test solutions A of the compounds of the present invention were applied. After drying in air, the treated leaves were cut and put in 276 plastic containers. 30 ul of a mixture of a suspension of conidium of Botrytis cinerea and a dissolved PDA medium in a ratio of 1:1 was dropped on each treated leaf and inoculated. After the inoculation, the plastic containers were placed at 20°C in humid conditions for 3 days, and the proportion of the formed lesion in the inoculated leaves 5 was measured to calculate the control value in accordance with the same formula as in Test Example 1. Here, the test was carried out in duplicate. As a result, among the compounds tested, the following compounds showed a control value of at least 70%. Compounds Nos. 1-001, 1-005 to 1-007, 1-009, 1-024, 1-040 to 1-044, 1-046, 1-049 to 10 1-054, 1-057 to 1-060, 1-063, 1-065 to 1-067, 1-070 to 1-075, 1-079, 1-082, 1-083, 1- 085, 1-090, 1-092, 1-093, 1-096, 1-097, 1-099, 1-100, 1-102, 2-002 to 2-019, 2-020*, 2- 021 to 2-030, 2-032 to 2-034, 2-040 to 2-051, 2-053 to 2-069, 2-071 to 2-086, 2-088, 2- 089, 2-091, 2-092, 2-096 to 2-101, 2-104, 2-105, 2-107, 2-111, 2-114*, 2-115, 2-117, 2- 118, 2-120, 2-121, 2-123, 2-124, 2-126 to 2-129, 2-131 to 2-144, 2-146 to 2-150, 2-152 15 to 2-162, 2-164 to 2-166, 2-169, 2-171 to 2-175, 2-177 to 2-179, 2-181 to 2-202, 2-204, 2-205, 2-207 to 2-214, 2-215*, 2-216 to 2-228, 2-230 to 2-235, 2-237, 2-238, 2-240 to 2- 251, 3-003 to 3-007, 3-010 to 3-020, 3-022 to 3-024, 3-026, 3-027, 3-029, 3-030, 3-033 to 3-051, 4-013, 4-015, 5-001, 6-001, 6-003 to 6-005, 7-001, 7-002, 7-004 to 7-009, 9- 001 to 9-006, 10-001, 10-002, 11-001, 11-002, 12-001, 12-003 to 12-006, 12-008 to 12- 20 013, 12-015 to 12-017, 13-001, 13-002, 15-001, 17-001 to 17-007, 17-009, 17-010, 18- 001, 19-001, 20-001 to 20-003, 20-005, 20-006, 21-001, 22-001 to 22-003, 23-001 to 23-004, 24-001, 25-001, 25-002, 26-001, 26-003, 27-002 and 32-028 of the present invention. The symbol * means that the test was carried out using a 100 ppm solution. 25 TEST EXAMPLE 3: Test on the preventive effect against cucumber gray mold (mycelium inoculation) Cucumber (cultivar: Sagami Hanjiro) was planted in 90 cm3 plastic pots, and in the seed leaf stage, 5 ml per pot of test solutions A of the compounds of the present invention were applied. On the next day, the pots were put in a plastic container, and 30 agar blocks (diameter: 5 mm) containing Botrytis cinerea preliminarily cultivated in a PDA medium were inoculated to the seed leaves of the cucumber treated with the solutions. After the inoculation, the plastic container was covered with a plastic sheet and humidified, and placed at 20°C for 2 days, whereupon the proportion of the formed lesion in the inoculated leaves was measured to calculate the control value in 35 accordance with the same formula as in Test Example 1. Here, the test was carried out in duplicate. As a result, among the compounds tested, the following compounds showed a control value of at least 70%. Compounds Nos. 1-005, 1-040, 1-041, 1-043, 1-050 to 1-052, 1-057, 1-058, 1-065, 1- 40 070, 1 -072 to 1 -075, 1 -080, 1 -083, 1 -090, 1 -093, 1 -094, 1 -099, 1 -100, 2-002 to 2-018, 2-020*, 2-021, 2-022, 2-024 to 2-027, 2-029, 2-032, 2-040, 2-042, 2-044, 2-045, 2-047, 2-048, 2-051 to 2-054, 2-060, 2-065, 2-069, 2-071, 2-074, 2-075, 2-081, 2-083, 2-085, 2-092, 2-096, 2-098, 2-113, 2-114*, 2-115, 2-117, 2-118, 2-120, 2-121, 2-123, 2-124, 2- 126 to 2-129, 2-131 to 2-143, 2-146, 2-149, 2-152, 2-154, 2-156 to 2-158, 2-160 to 2- 45 162, 2-166 to 2-169, 2-171 to 2-174, 2-176, 2-178, 2-179, 2-181 to 2-196, 2-200 to 2- 202, 2-204, 2-205, 2-207 to 2-214, 2-215*, 2-216 to 2-220, 2-222, 2-223, 2-225 to 2-228, 2-230 to 2-235, 2-237, 2-238, 2-244 to 2-251, 3-004, 3-006, 3-007, 3-010, 3-011, 3-014, 3-015, 3-018 to 3-020, 3-022, 3-023, 3-026, 3-027, 3-029, 3-033 to 3-048, 3-051, 4-013, 277 4-015, 5-001, 6-001, 6-003, 6-005, 7-002, 7-004 to 7-009, 9-001 to 9-004, 9-006, 10- 001, 11-001, 11-002, 12-004, 12-008 to 12-013, 12-015 to 12-017, 13-001, 13-002, 15- 001, 17-002 to 17-004, 17-006, 17-007, 17-010, 19-001, 20-001, 20-003, 20-005, 20- 006, 21-001, 22-001 to 22-003, 23-001, 24-001 and 32-028 of the present invention. 5 The symbol * means that the test was carried out using a 100 ppm solution. TEST EXAMPLE 4: Test on the preventive effect against cucumber stem rot Cucumber (cultivar: Sagami Hanjiro) was planted in 90 cm3 plastic pots, and in the seed leaf stage, 5 ml per pot of test solutions A of the compounds of the present invention were applied. After drying in air, the pots were put in a plastic container, and 10 agar blocks (diameter: 5 mm) containing Sclerotinia sclerotiorum preliminarily cultivated in a PDA medium were inoculated to the seed leaves of the cucumber treated with the solutions. After the inoculation, the plastic container was covered with a plastic sheet and humidified, and placed at 20°C for 2 days, whereupon the proportion of the formed lesion in the inoculated leaves was measured to calculate the control value in 15 accordance with the same formula as in Test Example 1. Here, the test was carried out in duplicate. As a result, among the compounds tested, the following compounds showed a control value of at least 70%. Compounds Nos. 1-001, 1-003, 1-005, 1-006, 1-036 to 1-038, 1-040, 1-041, 1-043 to 1- 20 045, 1 -051, 1 -053, 1 -054, 1 -057, 1 -058, 1 -060, 1 -065, 1 -070, 1 -071, 1 -073 to 1 -075, 1 - 079, 1-080, 1-092, 1-093, 1-096, 1-099, 2-002 to 2-019, 2-020*, 2-021, 2-022, 2-024 to 2-030, 2-032 to 2-034, 2-040 to 2-048, 2-050, 2-051, 2-053, 2-054, 2-056, 2-059, 2-060, 2-064 to 2-067, 2-069, 2-071, 2-072, 2-076, 2-079, 2-081, 2-083 to 2-089, 2-091, 2-092, 2-093*, 2-096 to 2-102, 2-104 to 2-111, 2-113, 2-114*, 2-115, 2-117 to 2-121, 2-123, 2- 25 124, 2-126 to 2-129, 2-131 to 2-144, 2-146 to 2-169, 2-171 to 2-174, 2-176 to 2-179, 2- 181 to 2-205, 2-207 to 2-214, 2-215*, 2-216 to 2-228, 2-230 to 2-235, 2-237, 2-238, 2- 240 to 2-251, 3-003, 3-005 to 3-007, 3-010, 3-011, 3-014 to 3-020, 3-022 to 3-024, 3- 026, 3-027, 3-029, 3-030, 3-033 to 3-049, 3-051, 4-002 to 4-004, 4-013, 4-015, 5-001, 6-001, 6-003 to 6-005, 7-002, 7-004 to 7-009, 9-001 to 9-004, 9-006, 10-001, 10-002, 30 11-001, 11-002, 12-001, 12-004, 12-005, 12-009 to 12-013, 12-015 to 12-017, 13-001, 13-002, 15-001, 17-002 to 17-004, 17-006, 17-007, 17-009, 17-010, 19-001, 20-001 to 20-003, 20-005 to 20-007, 21-001, 22-001 to 22-003, 24-001, 25-001, 26-001, 27-002 and 32-028 of the present invention. The symbol * means that the test was carried out using a 100 ppm solution. 35 TEST EXAMPLE 5: Test on the preventive effect against wheat powdery mildew To wheat (cultivar: Norin-61-go) in 1.3-leaf stage planted in 90 cm3 plastic pots, 5 ml per pot of test solutions A of the compounds of the present invention were applied. On the next day, the pots were placed in an air-conditioned greenhouse (20°C), and conidium of Blumeria qraminis f. sp. tritici was inoculated to the wheat. 7 Days after, 40 the proportion of the formed lesion in the inoculated leaves was measured to calculate the control value in accordance with the same formula as in Test Example 1. Here, the test was carried out in duplicate. As a result, among the compounds tested, the following compounds showed a control value of at least 70%. 45 Compounds Nos. 1 -001, 1 -003, 1 -005 to 1 -011, 1 -014, 1 -040 to 1 -046, 1 -048 to 1 -060, 1-062, 1-063, 1-065 to 1-068, 1-070 to 1-075, 1-078 to 1-088, 1-090 to 1-093, 1-095 to 1-102, 2-002 to 2-019, 2-020*, 2-021 to 2-034, 2-036 to 2-038, 2-040 to 2-051, 2-053 to 2-075, 2-077, 2-079, 2-081, 2-083 to 2-089, 2-090*, 2-091, 2-092, 2-095 to 2-111, 2-113, 278 2-115, 2-117 to 2-121, 2-123, 2-124, 2-126 to 2-129, 2-131 to 2-134, 2-136 to 2-139, 2- 141 to 2-155, 2-157 to 2-192, 2-194 to 2-205, 2-207 to 2-214, 2-215*, 2-216 to 2-223, 2- 225 to 2-228, 2-230 to 2-235, 2-237, 2-238, 2-240 to 2-251, 3-001, 3-003, 3-006, 3-007, 3-010 to 3-020, 3-022 to 3-025, 3-027, 3-028, 3-030, 3-033 to 3-051, 4-002 to 4-006, 4- 5 008 to 4-011, 5-001, 6-001, 6-003, 6-005, 7-001, 7-002, 7-004 to 7-009, 9-001 to 9-006, 11-002, 12-001, 12-003 to 12-006, 12-008 to 12-013, 12-015 to 12-017, 13-001, 13-002, 15-001, 17-002 to 17-010, 18-001, 19-001, 20-001 to 20-003, 20-005 to 20-007, 21-001, 22-001 to 22-003, 23-001, 23-002, 23-004, 24-001, 25-001 to 25-004, 26-001, 26-003 and 31-007 of the present invention. 10 The symbol * means that the test was carried out using a 100 ppm solution. TEST EXAMPLE 6: Test on the preventive effective against wheat glume blotch To wheat (cultivar: Haruyutaka) in 1.3-leaf stage planted in 90 cm3 plastic pots, 5 ml per pot of test solutions A of the compounds of the present invention were applied. On the next day, a suspension of conidium of Phaeosphaeria nodorum synonym: 15 Septoria nodorum) was spray-inoculated to the wheat, and the pots were placed in an inoculation chamber at 20°C under a humidity of 100% for 2 days. Then, the pots were placed in an air-conditioned greenhouse (20°C) for 6 days. The proportion of the formed lesion in the inoculated leaves was measured to calculate the control value in accordance with the same formula as in Test Example 1. Here, the test was carried 20 out in duplicate. As a result, among the compounds tested, the following compounds showed a control value of at least 70%. Compounds Nos. 1-041, 1-044, 1-045, 1-058, 1-067, 1-075, 1-079, 1-082 to 1-084, 1- 101,1-102, 2-002 to 2-006, 2-008 to 2-010, 2-012 to 2-018, 2-020*, 2-021, 2-022, 2-024 25 to 2-029, 2-037, 2-040 to 2-042, 2-044, 2-047, 2-048, 2-063, 2-064, 2-066, 2-067, 2-071, 2-072, 2-074, 2-081, 2-086, 2-087, 2-092, 2-096 to 2-099, 2-101, 2-102, 2-105, 2-012 to 2-018, 2-115, 2-118, 2-120, 2-121, 2-123, 2-124, 2-127 to 2-129, 2-131, 2-132, 2-134 to 2-136, 2-139, 2-141 to 2-146, 2-148, 2-158, 2-159, 2-162, 2-167, 2-168, 2-171 to 2-179, 2-181, 2-183 to 2-187, 2-190 to 2-196, 2-198, 2-202, 2-204, 2-205, 2-207 to 2-211, 2- 30 214, 2-215*, 2-216, 2-217, 2-219, 2-220, 2-225 to 2-227, 2-231 to 2-235, 2-237, 2-238, 2-244 to 2-251, 3-007, 3-015, 3-016, 3-018, 3-020, 3-023, 3-034, 3-035, 3-038 to 3-041, 3-043, 3-047, 3-050, 4-003, 5-001, 6-003, 6-005, 7-007 to 7-009, 9-002, 9-003, 10-001, 12-008, 12-009, 12-011, 12-013, 12-015, 13-001, 15-001, 17-004, 17-009, 20-001 to 20- 003, 20-006, 22-001, 22-003 and 25-001 to 25-004 of the present invention. 35 The symbol * means that the test was carried out using a 100 ppm solution. TEST EXAMPLE 7: Test on the preventive effect against wheat brown leaf rust To wheat (cultivar: Norin-61 -go) in 1.3-leaf stage planted in 90 cm3 plastic pots, 5 ml per pot of test solutions A of the compounds of the present invention were applied. On the next day, a suspension of spore of Puccinia recondita was spray-inoculated to 40 the wheat, and the pots were placed in an inoculation chamber at 20°C under a humidity of 100% for 1 day. Then, the pots were placed in an air-conditioned greenhouse (20°C) for 8 days. The proportion of the formed lesion in the inoculated leaves was measured to calculate the control value in accordance with the same formula as in Test Example 1. Here, the test was carried out in duplicate. 45 As a result, among the compounds tested, the following compounds showed a control value of at least 70%. Compounds Nos. 1-013, 1-046, 1-049, 1-053, 1-054, 1-057, 1-065 to 1-068, 1-071, 1- 075, 1-079, 1-084 to 1-086, 1-090 to 1-092, 1-095, 2-005, 2-033, 2-075, 2-102, 2-106 to 279 2-110, 2-115, 2-117, 2-118, 2-120, 2-121, 2-123, 2-124, 2-126, 2-127, 2-129, 2-131 to 2- 133, 2-136, 2-137, 2-141, 2-142, 2-158, 2-172, 2-174, 2-178, 2-179, 2-184, 2-186 to 2- 188, 2-207 to 2-210, 2-214, 2-226, 2-232, 2-234, 2-237, 2-238, 2-248, 2-249, 3-016 to 3-018, 3-038, 3-039, 3-043, 3-044, 4-004, 5-001, 6-003, 7-004, 9-002, 12-009, 12-013, 5 12-016, 13-001, 17-010, 22-003, 25-001, 26-003, 30-011, 31-007 and 32-012 of the present invention. TEST EXAMPLE 8: Test on the antibacterial activity on Aspergillus niger 60 uJ of a potato dextrose 1 % agar medium was added to each well of a 96 well plate, and 30 uJ of sterilized water containing spores of Aspergillus niger (10 spores/3 10 u.l) was added to each well. Further, 10 u.l per well of test solutions B of the compounds of the present invention were added, and the plate was left at rest at 25°C under dark conditions. 2 Days after addition of the solutions, the flora area ratio (%) was determined to calculate the efficacy (%) relative to the non-treated plot in accordance with the following formula. 15 Efficacy (%) = [1-(flora area ratio in treated plot/flora area ratio in non-treated plot)] x 100 As a result, among the compounds tested, the following compounds showed an efficacy of at least 50%. Compounds Nos. 1-001, 1-003, 1-005 to 1-008, 1-020, 1-036 to 1-038, 1-040, 1-041, 1- 20 043 to 1-054, 1-056 to 1-070, 1-072 to 1-074, 1-080, 1-081, 1-083 to 1-087, 1-089, 1- 090, 1-092 to 1-094, 1-096, 1-097, 1-099 to 1-102, 2-002 to 2-005, 2-007 to 2-019, 2- 021, 2-024, 2-026 to 2-030, 2-032 to 2-034, 2-037, 2-040 to 2-042, 2-044 to 2-051, 2- 053, 2-054, 2-056 to 2-061, 2-064 to 2-076, 2-079 to 2-081, 2-084, 2-086 to 2-089, 2- 091 to 2-111, 2-114, 2-115, 2-117 to 2-124, 2-126 to 2-129, 2-132 to 2-137, 2-139 to 2- 25 152, 2-154, 2-156 to 2-164, 2-166 to 2-169, 2-171 to 2-176, 2-181 to 2-197, 2-199 to 2- 205, 2-207 to 2-212, 2-216 to 2-221, 2-223 to 2-227, 2-230 to 2-238, 2-245, 2-246, 3- 003, 3-006, 3-007, 3-010 to 3-025, 3-029, 3-030, 3-036, 3-040, 4-002, 4-003, 7-001, 7- 002, 7-004, 7-005, 7-007, 7-009, 9-001, 9-002, 9-004, 10-002, 12-001, 12-005, 12-006, 12-008, 12-010, 12-011, 13-001, 15-001, 17-001 to 17-010, 19-001, 20-001 to 20-003, 30 21-001, 22-001 to 22-003, 23-001 to 23-004, 26-001, 26-003 and 28-001 of the present invention. TEST EXAMPLE 9: Insecticidal test on Meloidogvne incognita 60 u.l of a potato dextrose 1% agar medium was added to each well of a 96 well plate, and 30 uJ of sterilized water containing eggs of Meloidogvne incognita (10 eggs/3 35 uJ) was added to each well. Further, 10 u.i per well of test solutions B of the compounds of the present invention were added, and the plate was left at rest at 25°C under dark conditions. 4 Days after addition of the solutions, unhatched eggs and inactive larvae were counted, to calculate the efficacy (%) relative to the non-treated plot in accordance with the following formula. 40 Efficacy (%) = [(number of unhatched eggs+inactive larvae in treated plot)/ number of active larvae in non-treated plot] x 100 As a result, among the compounds tested, the following compounds showed an efficacy of at least 50%. Compounds Nos. 1-001, 1-003, 1-005 to 1-007, 1-009, 1-020, 1-021, 1-023, 1-025, 1- 45 040, 1 -043, 1 -047 to 1 -053, 1 -058 to 1 -061, 1 -063 to 1 -069, 1 -072, 1 -078, 1 -081, 1 -083, 1-092 to 1-096, 1-099 to 1-102, 2-002 to 2-019, 2-022, 2-024, 2-027 to 2-030, 2-032, 2- 033, 2-036 to 2-040, 2-042, 2-044 to 2-048, 2-050, 2-051, 2-053 to 2-061, 2-064 to 2- 067, 2-069, 2-071 to 2-075, 2-079 to 2-081, 2-083 to 2-085, 2-087, 2-088, 2-091 to 2- 280 094, 2-096 to 2-111, 2-114, 2-115, 2-117 to 2-124, 2-126 to 2-133, 2-135 to 2-142, 2-146, 2-150 to 2-152, 2-157 to 2-164, 2-166 to 2-174, 2-176, 2-178, 2-180 to 2-189, 2-192, 2- 194 to 2-197, 2-199 to 2-202, 2-204, 2-205, 2-207 to 2-210, 2-212, 2-216, 2-217, 2-220, 2-221, 2-223, 2-226, 2-227, 2-230 to 2-238, 2-245, 2-246, 2-248, 2-249, 2-251, 3-001, 5 3-002, 3-004 to 3-008, 3-010, 3-011, 3-014 to 3-025, 3-029, 3-030, 3-036, 3-040, 3-045, 3-049, 3-051, 4-002, 4-003, 7-002, 7-004, 7-005, 7-007, 7-009, 9-001 to 9-004, 12-001, 12-002, 12-005, 12-008, 12-010, 12-011, 12-013, 12-017, 13-001, 17-002, 23-001, 26- 001 and 26-003 of the present invention. TEST EXAMPLE 10: Test on the preventive effect on Meloidogvne incognita 10 1 ml per seedling of test solutions B of the compounds of the present invention were treated to the bases of garden balsam seedlings (about 2 weeks after budding) planted in a cell tray of which each cell was filled with 10 g of soil. 1 Hour after the application, 1 ml per cell of water containing Meloidogvne incognita 2L larvae (100 2L larvae/1 ml) was applied to the bases. The tray was placed in a greenhouse for 3 15 weeks, and the root knot level formed on the root was determined in accordance with the following damage index and the damage degree to calculate the efficacy (%) relative to the non-treated plot in accordance with the following formula. 0: No knot observed. 20 1: Knot observed on a part of the root system. 2: Knot observed on the entire root system. 3: Large knot observed. 4: Large knot observed on the entire root system. [Damage degree]=[I(damage index x number of seedlings at each index)/ 25 (4 x number of seedlings investigated)] x 100 Efficacy (%) = [1-(damage degree in treated plot/damage degree in non-treated plot)] x 100 As a result, among the compounds tested, the following compounds showed an efficacy of at least 50%. 30 Compounds Nos. 1 -006, 1 -061, 1 -063, 1 -099, 2-002 to 2-006, 2-008, 2-009, 2-011 to 2- 013, 2-022, 2-024, 2-030, 2-032, 2-033, 2-044, 2-048, 2-051, 2-057, 2-058, 2-060, 2- 061, 2-064, 2-066, 2-067, 2-069, 2-071 to 2-074, 2-079, 2-087, 2-088, 2-097 to 2-100, 2-102 to 2-105, 2-114, 2-115, 2-117, 2-120, 2-121, 2-126, 2-128, 2-129, 2-133, 2-135, 2- 141,2-142, 2-150, 2-151, 2-160 to 2-163, 2-166 to 2-171,2-173, 2-174, 2-176, 2-178, 35 2-181,2-182, 2-196, 2-199, 2-201, 2-202, 2-205, 2-209, 2-212, 2-216, 2-217, 2-237, 3- 006, 3-010, 3-014, 3-016 to 3-018, 3-020, 3-021, 3-029, 3-030, 7-002, 7-005 and 12-010 of the present invention. TEST EXAMPLE 11: Insecticidal test on Pratvlenchus coffeae 60 U.I of a potato dextrose 1 % agar medium was added to each well of a 96 well 40 plate, and 30 uJ of sterilized water containing Pratvlenchus coffeae 2L larvae cultured in callus was added to each well. Further, 10 u.l per well of test solutions B of the compounds of the present invention were added, and the plate was left at rest at 25°C under dark conditions. 4 Days after addition of the solutions, inactive larvae were counted to calculate the efficacy (%) relative to the non-treated plot in accordance with 45 the following formula. Efficacy (%) = (number of inactive larvae in treated plot/number of active larvae in non-treated plot) x 100 As a result, among the compounds tested, the following compounds showed an 281 efficacy of at least 50%. Compounds Nos. 1-001, 1-003, 1-005 to 1-007, 1-058 to 1-061, 1-063, 1-064, 1-099, 2- 002 to 2-018, 2-022, 2-024, 2-027, 2-029, 2-030, 2-032 to 2-034, 2-036 to 2-040, 2-042, 2-044, 2-046 to 2-048, 2-050, 2-051, 2-053 to 2-058, 2-060, 2-061, 2-064 to 2-067, 2- 5 069, 2-071 to 2-075, 2-079 to 2-081, 2-083 to 2-085, 2-087, 2-088, 2-091, 2-093, 2-094, 2-096 to 2-108, 2-110,2-115, 2-117, 2-120, 2-121, 2-129, 2-139, 2-141,2-146, 2-150, 2- 159 to 2-164, 2-166 to 2-171,2-173, 2-176, 2-178, 2-181, 2-197, 2-199 to 2-202, 3-002, 3-005, 3-006, 3-008, 3-010, 3-014, 3-016 to 3-018, 3-020 to 3-023, 3-025, 3-030, 3-031, 7-002, 7-005, 12-002, 12-005, 12-008, 12-010 and 17-002 of the present invention. 10 TEST EXAMPLE 12: Insecticidal test on Haemonchus contortus 60 uJ of a potato dextrose 1 % agar medium was added to each plate of a 96 well plate, and 30 ul of sterilized water containing eggs of Haemonchus contortus (10 eggs/3 |il) was added to each well. Further, 10 uJ per well of test solutions B of the compounds of the present invention were added, and the plate was left at rest at 25°C 15 under dark conditions. 4 Days after addition of the solutions, unhatched eggs and inactive larvae were counted to calculate the efficacy (%) relative to the non-treated plot in accordance with the same formula as in Test Example 9. As a result, among the compounds tested, the following compounds showed an efficacy of at least 50%. 20 Compounds Nos. 1 -001 to 1 -013, 1 -017 to 1 -021, 1 -023, 1 -024, 1 -026, 1 -028, 1 -029, 1 - 031, 1-032, 1-034, 1-036 to 1-074, 1-080, 1-081, 1-083 to 1-094, 1-096, 1-097, 1-099 to 1-102, 2-001 to 2-019, 2-021 to 2-027, 2-029, 2-030, 2-032 to 2-051, 2-053 to 2-061, 2- 064 to 2-089, 2-091 to 2-115, 2-117 to 2-129, 2-132 to 2-137, 2-139 to 2-164, 2-166 to 2-178, 2-180 to 2-197, 2-199 to 2-212, 2-216 to 2-221, 2-223 to 2-227, 2-230 to 2-238, 25 2-245, 2-246, 3-001 to 3-008, 3-010, 3-011, 3-013 to 3-030, 3-036, 3-040, 3-049, 4-002, 4-003, 7-001, 7-002, 7-004, 7-005, 7-007, 7-009, 8-001, 9-002, 9-004, 10-002, 12-001 to 12-008, 12-010, 12-011, 13-001, 15-001, 17-001, 17-003, 17-004, 17-006, 20-002, 20-003, 22-001, 22-002, 23-001 to 23-004, 26-001 to 26-003, 29-001 and 29-002 of the present invention. 30 INDUSTRIAL APPLICABILITY The oxime-substituted amide compounds of the present invention are very useful compounds which are excellent in pesticidal activities, especially in fungicidal and nematocidal activities, and have little harmful effect on non-target organisms such as 35 mammals, fishes and useful insects. The entire disclosures of Japanese Patent Application No. 2012-156398 filed on July 12, 2012, Japanese Patent Application No. 2013-019666 filed on February 4, 2013 and Japanese Patent Application No. 2013-103989 filed on May 16, 2013 including 40 specifications, claims and summaries are incorporated herein by reference in their entireties. 282 CLAIMS 1. An oxime-substituted amide compound represented by the formula (I), or its Noxide or salt: W R2R3 V y R4 N i R1 wherein G1 is a structure represented by any one of G1-1 to G1-51: G2 is a structure represented by any one of G2-1 to G2-19: W is an oxygen atom or a sulfur atom, X1 is a halogen atom, cyano, nitro, -SFs, C1-C6 alkyl, (Ci-C6)alkyl optionally substituted with R6, C3-C8 cycloalkyi, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, -OR7, -S(0)rR7, -N(R9)R8, -C(0)NH2, - 5 C(S)NH2, tri(Ci-C6 alkyl)silyl, phenyl, phenyl substituted with (Z)m or D-3, each of X2, X3, X4 and X5 is independently a hydrogen atom, a halogen atom, cyano, nitro, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R6, C3-C8 cycloalkyi, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, -OH, -OR7, -SH, -S(0)rR7, -N(R9)R8, Ci-C6 alkylcarbonyl, Ci-C6 10 alkoxycarbonyl, -C(0)NH2, -C(S)NH2, phenyl, phenyl substituted with (Z)m, D-2 or D- 32, provided that when G1 is a structure represented by G1-27 and X1 is dihalomethyl, X2 is a hydrogen atom, each of Y1 and Y3 is independently a hydrogen atom, a halogen atom, cyano, 15 nitro, -SCN, -SF5, Ci-Cs alkyl, (Ci-C6)alkyl optionally substituted with R6, C3-C10 cycloalkyi, (C3-Cio)cycloalkyl optionally substituted with R6, E-1 to E-22, C2-C6 alkenyl, (C2-C6)alkenyl optionally substituted with R6, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C6 alkynyl, (C2-C6)alkynyl optionally substituted with R6, -OH, - 286 OR7, -OS(0)2R7, -SH, -S(0)rR7, -N(R9)R8, -N=C(R9a)R8a, -C(0)R1°, -C(R10)=NOH, - C(R10)=NOR1\ M-3, M-13, M-30, -C(0)OH, -C(0)OR1\ -C(0)SR11, -C(0)N(R13)R12, M- 7, M-17, M-23, M-26, -C(S)OR11, -C(S)SR11, -C(S)N(R13)R12, M-9, M-19, M-23, M-24, M-28, M-25, M-29, -S(0)2OR11, -S(0)2N(R13)R12, -Si(R14a)(R14b)R14, phenyl, phenyl 5 substituted with (Z)m, or D-1 to D-38, each of Y2, Y4 and Y5 is independently a hydrogen atom, a halogen atom, cyano, nitro, -SCN, -SF5, Ci-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R6, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, -OH, -OR7, -SH, -S(0)rR7, -NH2, Ci-C6 alkylamino, di(Ci-Ce alkyl)amino, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 10 haloalkynyl, Ci-Ce alkoxycarbonyl, -C(0)NH2 or -C(S)NH2, or, Y1, Y2, Y3 and Y4 represent that Y1 or Y3 and Y2, or Y3 and Y4, together form - CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2O-, -CH2CH2CH2CH2-, -CH2CH2S-, - CH2SCH2-, -SCH2S-, -CH2CH2N(R5)-, -CH2N(R5)CH2-, -CH2CH2CH2CH2-, - CH2CH2CH20-, -CH2CH2OCH2-, -CH2OCH2O-, -OCH2CH2O-, -OCH2CH2S-, - 15 SCH2CH2S-, -CH2CH=CH-, -N(R5)N=CH-, -OCH2CH=CH-, -CH=CHCH=CH-, - CH=CHCH=N-, -CH=CHN=CH-, -CH=NCH=N- or -N=CHCH=N- to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y1, Y2, Y3 and Y4, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom, cyano, nitro, C1-C4 alkyl or C1-C4 20 haloalkyl, and further, when G1 is a structure represented by G1-1, G1-9, G1-10, G1-12, G1- 13, G1-16toG1-20, G1-22 to G1-24, G1-26, G1-27, G1-30, G1-32, G1-35, G1-38, G1-40 or GM2 to G1-50, Y1 and Y2, Y2 and Y3, or Y3 and Y4, together may form -OCH=CH-, - SCH=CH-, -N(R5)CH=CH-, -OCH=N-, -SCH=N- or -N(R5)CH=N- to form a 5- 25 membered ring together with the carbon atoms attached to Y\ Y2, Y3 and Y4, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom, cyano, nitro, C1-C4 alkyl or C1-C4 haloalkyl, D-1 to D-38 are aromatic heterocyclic rings represented by the following structural formulae, respectively: E-1 to E-22 are saturated heterocyclic rings represented by the following structural formulae, respectively: Z is a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy(Ci- C4)alkyl, C1-C4 haloalkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 haloalkylthio(Ci-C4)alkyl, C1-C4 alkylsulfinyl(Ci-C4)alkyl, C1-C4 haloalkylsulfinyl(Ci- C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, C1-C4 haloalkylsulfonyl(Ci-C4)alkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, -OH, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylsulfonyloxy, C1-C4 haloalkylsulfonyloxy, C1-C4 alkylthio, C1-C4 haloalkylthio, C1-C4 alkylsulfinyl, C1-C4 haloalkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, -NH2, C1-C4 alkylamino, di(Ci-C4 alkyl)amino, C1-C4 alkoxycarbonyl, C1-C4 haloalkoxycarbonyl, -C(0)NH2, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkyl)aminocarbonyl, -C(S)NH2, -S(0)2NH2 or phenyl, when m or n is an integer of at least 2, the respective Z's may be identical with or 290 different from one another, and when there are two neighboring Z's, the two neighboring Z's may form -CH2CH2CH2-, -ChbChfcO-, -CH2OCH2-, -OCH2O-, - CH2CH2S-, -CH2SCH2-, -CH2CH2CH2CH2-, -CH2CH2CH2O-, -CH2CH2OCH2-, - CH2OCH20-, -OCH2CH2O-, -CH2CH2CH2S-, -OCH2CH2S- or -CH=CH-CH=CH- to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to the two Z's, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom, a cyano group, a nitro group, a methyl group, a trifluoromethyl group, a methoxy group or a methylthio group, R1 is Ci-Cs alkyl, (Ci-Cs)alkyl optionally substituted with R18, C3-C10 cycloalkyl, C3-C10 halocycloalkyi, E-2 to E-8, E-14 to E-18, E-21, Cs-Ce alkenyl, Ca-Ce haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, phenyl(C3-C6)alkynyl, phenyl or phenyl substituted with (Z)m, R2 is a hydrogen atom, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C4 alkoxy(Ci- C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfinyl(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, C3-C6 cycloalkyl or phenyl, or may form the after-mentioned ring together with R3, provided that when G1 is a structure represented by G1-1, X1 is a chlorine atom, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom or a chlorine atom, G2 is a structure represented by G2-1, Y3 is a chlorine atom, and Y1, Y2, Y4 and Y5 are hydrogen atoms, R2 is cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfinyl(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci- C4)alkyl, C3-C6 cycloalkyl or phenyl, R3 is a hydrogen atom or C1-C6 alkyl, or R3 may form, together with R2, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the carbon atom attached to R2 and R3, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a C1-C4 alkyl group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a C1-C4 alkylaminocarbonyl group, a C1-C4 haloalkylaminocarbonyl group, a di(Ci-C4 alkyl)aminocarbonyl group or a phenyl group, R4 is a hydrogen atom, cyano, nitro, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R19, C3-C8 cycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, -C(0)R20, - C(0)OR21, -C(0)SR21, -C(0)N(R23)R22, -C(0)C(0)OR21, -C(S)0R21, -C(S)SR21, - C(S)N(R23)R22, -OH, -OR21, -SR21, -N(R25)R24, -N=C(R25a)R24a, -S(0)2R21, - S(0)2N(R23)R22 or -SN(R27)R26, R5 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl or C2-C6 haloalkynyl, R6 is a halogen atom, cyano, nitro, C3-C8 cycloalkyl, C3-C8 halocycloalkyi, hydroxy(C3-C8)cycloalkyl, C1-C6 alkoxy(C3-C8)cycloalkyl, C3-C6 alkenyl, C3-C8 cycloalkenyl, E-1 to E-22, -OH, -OR7, -SH, -S(0)rR7, -N(R9)R8, -C(R10)=NOH, - C(R10)=NOR11, -C(0)OR11, -C(0)N(R13)R12, -Si(R14a)(R14b)R14, phenyl, phenyl substituted with (Z)m or D-1 to D-38, R7 is Ci-Ce alkyl, (Ci-Ce) alkyl optionally substituted with R28, Cs-Ce cycloalkyl, (C3-C8)cycloalkyl optionally substituted with R28, E-2 to E-8, E-14 to E-18, E-21, C2-C6 alkenyl, (C2-C6)alkenyl optionally substituted with R28, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, (C3-C6)alkynyl optionally substituted with R28, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, phenyl, phenyl substituted with (Z)m, D-1, D-2, D291 4 to D-6, D-8 to D-10, D-12 to D-19, D-21, D-23, D-25, D-27 or D-30 to D-38, R8 is a hydrogen atom, C1-C6 alkyl, (Ci-Cejalkyl optionally substituted with R28, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, Cs-Ce haloalkynyl, -C(0)R10, -C(0)C(0)R11, -C(0)OR11, -C(0)C(0)OR11, -C(0)SR11, - C(0)N(R13)R12, -C(S)OR11, -C(S)SR11, -C(S)N(R13)R12, -OH, -S(0)2R11 or- S(0)2N(R13)R12, or may form the after-mentioned ring together with R9, R9 is a hydrogen atom, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3-C8 cycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, - CHO, C1-C6 alkylcarbonyl, C1-C6 haloalkylcarbonyl or C1-C6 alkoxycarbonyl, or R9 may form, together with R8, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R8 and R9, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, an oxo group or a thioxo group, R8a is Ci-Ce alkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, C3-C6 alkenyloxy, phenoxy or phenoxy substituted with (Z)m, or may form the after-mentioned ring together with R9a, R9a is a hydrogen atom, Ci-Ce alkyl, C1-C6 haloalkyl, C3-C6 alkenyl, phenyl or phenyl substituted with (Z)m, or R9a may form, together with R8a, a C4-C6 alkylene chain to form a 5- to 7- membered ring together with the carbon atom attached to R8a and R9a, wherein the alkylene chain may contain an oxygen atom or sulfur atom, R10 is a hydrogen atom, Ci-Ce alkyl, (Ci-C6)alkyl optionally substituted with R28, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R11 is Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R28, Cs-Cs cycloalkyl, C3-C8 halocycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D-6, D-8 to D-10, D-12 to D-19, D-21, D-23, D-25, D-27 or D-30 i to D-38, R12 is a hydrogen atom, C1-C6 alkyl, (Ci-C6)alkyl optionally substituted with R28, C3-C8 cycloalkyl, C3-C8 halocycloalkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, C1-C6 alkylcarbonyl, C1-C6 haloalkylcarbonyl, phenylcarbonyl, C1-C6 alkoxycarbonyl, phenyl, phenyl substituted with (Z)m, D-1 to D-25 or D-27 to D-38, or i may form the after-mentioned ring together with R13, R13 is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, cyano(Ci-C4)alkyl, C3-C6 alkenyl or C3-C6 alkynyl, or R13 may form, together with R12, a C2-C6 alkylene chain to form a 3- to 7- ) membered ring together with the nitrogen atom attached to R12 and R13, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group or a C1-C4 alkoxycarbonyl group, R14 is C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, phenyl or phenyl substituted with 3 (Z)m, each of R14a and R14b is independently Ci-Ce alkyl, Ci-Ce haloalkyl or Ci-Ce alkoxy, R15 is a hydrogen atom, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci292 C4)alkyl, hydroxy(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 haloalkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 haloalkylthio(Ci-C4)alkyl, C1-C4 alkylamino(Ci- C4)alkyl, di(Ci-C4 alkyl)amino(Ci-C4)alkyl, cyano(Ci-C4)alkyl, C1-C4 alkoxycarbonyl(Ci- C4)alkyl, C1-C4 haloalkoxycarbonyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl substituted with (Z)m, C3-C6 cycloalkyi, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C1-C6 alkylcarbonyl, phenylcarbonyl, phenylcarbonyl substituted with (Z)m, Ci-Ce alkoxycarbonyl, Ci-Ce haloalkoxycarbonyl, di(Ci-Ce alkyl)aminocarbonyl, C1-C6 alkylsulfonyl, phenylsulfonyl, phenylsulfonyl substituted with (Z)m, di(Ci-Ce alkyl)aminosulfonyl, phenyl, phenyl substituted with (Z)m, or Ci-Ce alkoxy, and further, when R15 and Z are neighboring, the neighboring R15 and Z may form -CH2CH2CH2CH2-, -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CHN= CH- or -CH=CH-CH=N- to form a 6-membered ring together with the atoms respectively attached to R15 and Z, wherein hydrogen atoms on the respective ringconstituting carbon atoms may optionally be substituted with a halogen atom, a methyl group or a trifluoromethyl group, R16 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyi, C3-C6 halocycloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, - C(0)R1°, -C(0)C(0)R11, -C(0)OR11, -C(0)C(0)OR11, -C(0)SR11, -C(0)N(R13)R12, - C(S)OR11, -C(S)SR11, -C(S)N(R13)R12, -S(0)2R11, -S(0)2N(R13)R12, phenyl, phenyl substituted with (Z)m or D-3, R16a is a hydrogen atom, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, Ci-Ce alkylcarbonyl, Ci-Ce haloalkylcarbonyl, Ci-Ce alkoxycarbonyl, C1-C6 haloalkoxycarbonyl, C1-C6 alkylsulfonyl or Ci-Ce haloalkylsulfonyl, R17 is a halogen atom, cyano, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4) alkyl, C1-C4 alkoxycarbonyl(Ci-C4)alkyl, Ci-Ce alkoxy, Ci-Ce alkylthio, Ci-Ce alkylamino, di(Ci-Ce alkyl)amino, C1-C6 alkoxycarbonyl, phenyl or phenyl substituted with (Z)m, when p is an integer of at least 2, the respective R17's may be identical with or different from one another, and further, when two R17's are on the same carbon atom, the two R17's together may form C1-C4 alkylidene, oxo, thioxo, imino, C1-C4 alkylimino or C1-C4 alkoxyimino, R18 is a halogen atom, cyano, nitro, C3-C10 cycloalkyi, C3-C10 halocycloalkyl, E-1 to E-22, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, -OR29, -N(R30)R29, -SH, - S(0)rR31, -S(0)t(R31)=NR16a, -C(0)R32, -C(R32)=NOH, -C(R32)=NOR33, -C(0)OH, - C(0)OR33, -C(0)SR33, -C(0)N(R35)R34, -C(0)C(0)OR33, -C(S)OR33, -C(S)SR33, - C(S)N(R35)R34, -S(0)2OH, -S(0)2OR33, -S(0)2N(R35)R34, -Si(R14a)(R14b)R14, M-1 to M- 30, phenyl, phenyl substituted with (Z)m or D-1 to D-38, M-1 to M-30 are partial saturated heterocyclic rings represented by the following structural formulae, respectively: R19 is a halogen atom, cyano, nitro, C3-C8 cycloalkyi, E-5, E-6, E-14, E-15, C5-C10 cycloalkenyl, -OR36, -S(0)rR37, -C(R32)=NOH, -C(R32)=NOR33, M-3, -C(0)OR33, - C(0)SR33, -C(0)NH2, M-7, M-17, -C(0)C(0)OR33, -C(S)OR33, -C(S)SR33, -C(S)NH2, M294 9, M-19, -S(0)2N(R35)R34or-Si(R14a)(R14b)R14, R20 is a hydrogen atom, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3-C8 cycloalkyi, C3-C8 halocycloalkyi, C2-C6 alkenyl, C2-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C6 alkynyl or C2-C6 haloalkynyl, R21 is Ci-Ce alkyl, (Ci-C6)alkyl optionally substituted with R28, Ca-Cs cycloalkyi, C3-C8 halocycloalkyi, C3-C6 alkenyl, C3-C6 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C3-C6 alkynyl or C3-C6 haloalkynyl, R22 is a hydrogen atom, C1-C6 alkyl, (Ci-Ce)alkyl optionally substituted with R28, C3-C8 cycloalkyi, C3-C8 halocycloalkyi, C2-C6 alkenyl, C2-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, Ci-C6alkylcarbonyl, C1-C6 haloalkylcarbonyl, phenylcarbonyl, C1-C6 alkoxycarbonyl, phenyl, phenyl substituted with (Z)m, D-1 to D-25 or D-27 to D-38, or may form the after-mentioned ring together with R23, R23 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, C1-C4 alkylsulfonyl(Ci-C4)alkyl, cyano(Ci-C4)alkyl, C3-C6 alkenyl or C3-C6 alkynyl, or R23 may form, together with R22, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R22 and R23, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group or a C1-C4 alkoxycarbonyl group, R24 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C8 cycloalkyi, C3-C8 halocycloalkyi, C3-C8 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, - S(0)2R33 or -S(0)2N(R35)R34, or may form the after-mentioned ring together with R25, R25 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl or C3-C6 haloalkynyl, or R25 may form, together with R24, a C4-C5 alkylene chain to form a 5- to 6- membered ring together with the nitrogen atom attached to R24 and R25, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, an oxo group or a thioxo group, R24a is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C8 cycloalkyi, phenyl or phenyl substituted with (Z)m, or may form the after-mentioned ring together with R25a, R25a is a hydrogen atom, Ci-Ce alkyl, C1-C6 alkoxy, Ci-Ce alkylthio or di(Ci-Ce alkyl)amino, or R25a may form, together with R24a, a C3-C5 alkylene chain to form a 4- to 6- membered ring together with the carbon atom attached to R24a and R25a, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a -CHO group, a C1-C4 alkylcarbonyl group or a C1-C4 alkoxycarbonyl group, R26 is C1-C12 alkyl, C1-C12 haloalkyl, C1-C12 alkoxy(Ci-Ci2)alkyl, cyano(Ci- Ci2)alkyl, C1-C12 alkoxycarbonyl(Ci-Ci2)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl substituted with (Z)m, C3-C12 alkenyl, C3-C12 haloalkenyl, C3-C12 alkynyl, C3-C12 haloalkynyl, C1-C12 alkylcarbonyl, C1-C12 alkoxycarbonyl, -C(0)ON=C(CH3)SCH3, - C(0)ON=C(SCH3)C(0)N(CH3)2, phenyl or phenyl substituted with (Z)m, or may form the after-mentioned ring together with R27, R27 is C1-C12 alkyl, C1-C12 haloalkyl, C1-C12 alkoxy(Ci-Ci2 alkyl), cyano(Ci-Ci2) alkyl, C1-C12 alkoxycarbonyl(Ci-Ci2)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl 295 substituted with (Z)m, C3-C12 alkenyl, C3-C12 haloalkenyl, C3-C12 alkynyl, C3-C12 haloalkynyl, phenyl or phenyl substituted with (Z)m, or R27 may form, together with R26, a C4-C7 alkylene chain to form a 5- to 8- membered ring together with the nitrogen atom attached to R26 and R27, wherein the alkylene chain may contain an oxygen atom or sulfur atom, and may optionally be substituted with a C1-C4 alkyl group or a C1-C4 alkoxy group, R28 is a halogen atom, cyano, nitro, C3-C8 cycloalkyi, C3-C8 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, di(Ci- C6 alkyl)amino, C1-C6 alkoxycarbonyl, C1-C6 haloalkoxycarbonyl, -C(0)NH2, C1-C6 alkylaminocarbonyl, di(Ci-C6 alkyl)aminocarbonyl, -C(S)NH2, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R29 is a hydrogen atom, Ci-Cs alkyl, (Ci-Cs)alkyl optionally substituted with R38, Cs-Cs cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C3-C8 alkenyl, (C3-Cs)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-C8)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR4°, - C(0)C(0)OR4°, -C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR40, - C(S)N(R42)R41, -S(0)2R4°, -S(0)2N(R42)R41, -Si(R14a)(R14b)R14, -P(0)(OR43)2, - P(S)(OR43)2, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D-6, D-8 to D-10, D- 12 to D-19, D-21, D-23, D-25, D-27 or D-30 to D-38, or may form the after-mentioned ring together with R30, R30 is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C3-C4 cycloalkyl(Ci-C4)alkyl, C1-C4 alkoxy(Ci-C4)alkyl, C1-C4 alkylthio(Ci-C4)alkyl, cyano(Ci-C4)alkyl, C3-Ce cycloalkyi, C3-C6 alkenyl, C3-C6 alkynyl, C1-C6 haloalkylcarbonyl, C1-C6 alkoxycarbonyl, C1-C6 alkoxy, C1-C6 alkylsulfonyl, phenyl or phenyl substituted with (Z)m, or R30 may form, together with R29, a C2-C6 alkylene chain to form a 3- to 7- membered ring together with the nitrogen atom attached to R29 and R30, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a phenyl group, a phenyl group substituted with (Z)m, an oxo group or a thioxo group, R31 is Ci-C8 alkyl, (Ci-C8)alkyl optionally substituted with R38, C3-C8 cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C3-Cs alkenyl, (C3-Cs)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-Cs)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR4°, -C(0)C(0)OR40, - C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR40, -C(S)N(R42)R41, -SH, Ci- Ce alkylthio, C1-C6 haloalkylthio, phenylthio, phenylthio substituted with (Z)m, - P(0)(OR43)2, -P(S)(OR43)2, phenyl, phenyl substituted with (Z)m, D-9, D-10, D-12, D-14 to D-17, D-30 or D-32 to D-35, R32 is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyi(Ci-C4)alkyl, Ci-Ce alkoxy(Ci-C4)alkyl, Ci-Ce haloalkoxy(Ci-C4)alkyl, Ci-Ce alkylthio(Ci-C4)alkyl, Ci- Ce haloalkylthio(Ci-C4)alkyl, Ci-Ce alkylsulfonyl(Ci-C4)alkyl, Ci-Ce haloalkylsulfonyl(Ci- C4)alkyl, phenyl(Ci-C4)alkyl, phenyl(Ci-C4)alkyl substituted with (Z)m, C3-C6 cycloalkyi, phenyl or phenyl substituted with (Z)m, R33 is Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R38, Cs-Cs cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C2-C6 alkenyl, (C2-C6)alkenyl optionally substituted with R38, C3-C6 alkynyl, (C3-C6)alkynyl 296 optionally substituted with R38, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D- 6, D-8 to D-10, D-12 to D-19, D-21, D-23, D-25, D-27 or D-30 to D-38, R34 is a hydrogen atom, Ci-Ce alkyl, (Ci-C6)alkyl optionally substituted with R38, C3-Ce cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C2-C6 alkenyl, (C2-Ce)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-Ce)alkynyl optionally substituted with R38, phenyl, phenyl substituted with (Z)m, D-1 to D25 or D-27 to D-38, or may form the after-mentioned ring together with R35, R35 is a hydrogen atom, Ci-Ce alkyl, (Ci-Ce)alkyl optionally substituted with R38, C3-C6 alkenyl, C3-C6 haloalkenyl, C3-C6 alkynyl, C3-C6 haloalkynyl, phenyl or phenyl substituted with (Z)m, or R35 may form, together with R34, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the nitrogen atom attached to R34 and R35, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a phenyl group, a phenyl group substituted with (Z)m or an oxo group, R36 is a hydrogen atom, Ci-Ce alkyl, (Ci-C8)alkyl optionally substituted with R38, C3-C8 cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C3-C8 alkenyl, (C3-Ce)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-C8)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R40, -C(0)OR40, - C(0)C(0)OR40, -C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR4°, - C(S)N(R42)R41, -S(0)2R4°, -S(0)2N(R42)R41, -Si(R14a)(R14b)R14, -P(0)(OR43)2 or- P(S)(OR43)2, R37 is Ci-Ce alkyl, (Ci-C8)alkyl optionally substituted with R38, Cs-Ce cycloalkyi, (C3-C8)cycloalkyl optionally substituted with R38, E-2 to E-6, E-8, E-14 to E-21, C3-C8 alkenyl, (C3-Ce)alkenyl optionally substituted with R38, C3-C8 alkynyl, (C3-Ce)alkynyl optionally substituted with R38, -C(0)R39, -C(0)C(0)R4°, -C(0)OR40, -C(0)C(0)OR40, - C(0)SR40, -C(0)N(R42)R41, -C(S)R39, -C(S)OR40, -C(S)SR40, -C(S)N(R42)R41, -SH, Ci- Ce alkylthio, Ci-Ce haloalkylthio, phenylthio, phenylthio substituted with (Z)m, - P(0)(OR43)2 or -P(S)(OR43)2, R38 is a halogen atom, cyano, nitro, C3-C8 cycloalkyi, C3-C8 halocycloalkyl, E-5, E-6, E-9, E-10, E-12, E-14, E-15, E-18, E-19, E-21, -OH, -OR40, -OC(0)R39, - OC(0)OR40, -OC(0)N(R42)R41, -OC(S)N(R42)R41, -SH, -S(0)rR4°, -SC(0)R39, - SC(0)0R4°, -SC(0)N(R42)R41, -SC(S)N(R42)R41, -N(R42)R41, -N(R42)C(0)R39, - N(R42)C(0)OR4°, -N(R42)C(0)SR40, -N(R42)C(0)N(R42)R41, -N(R42)C(S)N(R42)R41, - N(R42)S(0)2R4°, -C(0)R39, -C(0)OH, -C(0)OR40, -C(0)SR40, -C(0)N(R42)R41, - C(0)C(0)OR40, -C(S)SR40, -C(S)N(R42)R41, -Si(R14a)(R14b)R14, -P(0)(OR43)2, - P(S)(OR43)2, -P(phenyl)2, -P(0)(phenyl)2, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R39 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, (Ci-C4)alkyl optionally substituted with R44, C3-C6 cycloalkyi, C3-Ce halocycloalkyl, E-5, E-6, E-14, E-15, C2-C8 alkenyl, C2-C8 haloalkenyl, C5-C10 cycloalkenyl, C5-C10 halocycloalkenyl, C2-C8 alkynyl, C2-C8 haloalkynyl, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R40 is Ci-Ce alkyl, Ci-Ce haloalkyl, (Ci-C4)alkyl optionally substituted with R44, C3- Ce cycloalkyi, E-5, E-6, C2-C8 alkenyl, C2-C8 haloalkenyl, C3-C8 alkynyl or phenyl, R41 is a hydrogen atom, Ci-Ce alkyl, Ci-Ce haloalkyl, (Ci-C4)alkyl optionally substituted with R44, C3-C6 cycloalkyi, E-5, E-6, E-14, C2-C8 alkenyl, C2-C8 haloalkenyl, C3-C8 alkynyl, phenyl, phenyl substituted with (Z)m, D-1 to D-25 or D-27 to D-38, or 297 may form the after-mentioned ring together with R42, R42 is a hydrogen atom, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C3-C6 alkenyl or C3-C6 alkynyl, or R42 may form, together with R41, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the nitrogen atom attached to R41 and R42, wherein the alkylene chain may contain an oxygen atom, sulfur atom or nitrogen atom, and may optionally be substituted with a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a -CHO group, a C1-C4 alkylcarbonyl group, a C1-C4 alkoxycarbonyl group, a phenyl group or a phenyl group substituted with (Z)m, R43 is Ci-Ce alkyl or Ci-Ce haloalkyl, R44 is cyano, Ca-Ce cycloalkyl, Ca-Ce halocycloalkyl, E-5, E-6, E-14, E-15, C1-C4 alkoxy, C1-C4 haloalkoxy, phenoxy, phenoxy substituted with (Z)m, C1-C4 alkylthio, C1- C4 haloalkylthio, phenylthio, phenylthio substituted with (Z)m, C1-C4 alkylsulfonyl, C1-C4 haloalkylsulfonyl, phenylsulfonyl, phenylsulfonyl substituted with (Z)m, -N(R46)R45, C1- C4 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkoxycarbonyl, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkyl)aminocarbonyl, tri(Ci-C4 alkyl)silyl, phenyl, phenyl substituted with (Z)m, or D-1 to D-38, R45 is a hydrogen atom, C1-C4 alkyl, C1-C4 alkylcarbonyl, C1-C4 haloalkylcarbonyl, C1-C4 alkoxycarbonyl, phenylcarbonyl or phenylcarbonyl substituted with (Z)m, R46 is a hydrogen atom or C1-C4 alkyl, m is an integer of 1, 2, 3, 4 or 5, n is an integer of 0, 1, 2, 3 or 4, p is an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9, r is an integer of 0, 1 or 2, and t is an integer of 0 or 1. 2. The oxime-substituted amide compound according to Claim 1, wherein G1 is a structure represented by any one of G1-1 to G1-5, G1-7 to G1-13, G1-16, G1-19, G1-20, G1-23, G1-27, G1-30 to G1-33, GM1, GM3 to GM6 and G1-49 to G1-51, G2 is a structure represented by any one of G2-1 to G2-7, G2-9 to G2-12, G2-14, G2-16andG2-17, X1 is a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 haloalkylthio, -NH2, phenyl or D- 3, X2 is a hydrogen atom or a halogen atom, provided that when G1 is a structure represented by G1-27 and X1 is dihalomethyl, X2 is a hydrogen atom, X3 is a hydrogen atom, a halogen atom, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2 or phenyl, X4 is a hydrogen atom, a halogen atom ortrifluoromethyl, X5 is a hydrogen atom or a halogen atom, Y1 is a hydrogen atom, a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxymethyl, E-9, C1-C4 alkoxy, C1-C4 haloalkoxy, phenoxy, C1-C4 alkylthio or -C(R10)=NOR11, or may form the after-mentioned ring together with Y2, Y2 is a hydrogen atom, a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, phenoxy or C1-C4 alkyothio, or may form the after-mentioned ring together with Y3, or Y2 may form, together with Y\ -OCH2O-, -CH2CH2CH2CH2-, -OCH2CH2O- or - CH=CHCH=CH- to form a 5-membered ring or a 6-membered ring together with the 298 carbon atoms attached to Y1 and Y2, wherein hydrogen atoms on the respective ringconstituting carbon atoms may optionally be substituted with a halogen atom or methyl, Y3 is a hydrogen atom, a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxymethyl, C3-C6 cycloalkyl, -OR7, -S(0)rR7, -N(R9)R8, -C(0)R10, -C(R10)=NOR11, M-3, -C(0)NH2, M-7, -C(S)NH2, -S02N(CH3)2, C2-C4 alkenyl, C2-C6 alkynyl, (C2-Ce)alkynyl substituted with R6, phenyl, phenyl substituted with (Z)m, D-3, D- 7, D-11, D-22, D-28 or D-29, or may form the after-mentioned ring together with Y4, or Y3 may form, together with Y2, -OCH2O-, -OCH2CH2O- or -CH=CHCH=CH- to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y2 and Y3, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom or methyl, Y4 is a hydrogen atom, a halogen atom, cyano, methyl, trifluoromethyl or methoxy, or Y4 may form, together with Y3, -OCH2O-, -OCH2CH2O- or -CH=CHCH=CH- to form a 5-membered ring or a 6-membered ring together with the carbon atoms attached to Y3 and Y4, wherein hydrogen atoms on the respective ring-constituting carbon atoms may optionally be substituted with a halogen atom or methyl, Y5 is a hydrogen atom, a halogen atom or methyl, Z is a halogen atom, cyano, nitro, C1-C4 alkyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, methylthio, methylsulfinyl, methylsulfonyl, trifluoromethylthio, trifluoromethylsulfinyl, trifluoromethylsulfonyl or phenyl, when m or n is an integer of at least 2, the respective Z's may be identical with or different from one another, and when there are two neighboring Z's, the two neighboring Z's may form -CH=CH-CH=CH-, to form a 6-membered ring together with the carbon atoms attached to the two Z's, R1 is C1-C6 alkyl, C1-C4 haloalkyl, (Ci-C4)alkyl optionally substituted with R18, C3- C6 cycloalkyl, Ca-Ce halocycloalkyl, E-2 to E-6, E-8, E-14, E-15, E-17, Ca-Ce alkenyl, C3-C4 haloalkenyl, C3-C6 alkynyl, C3-C4 haloalkynyl or phenyl, R2 is a hydrogen atom, C1-C4 alkyl, fluoromethyl, trifluoromethyl, methoxymethyl, methylthiomethyl, methylsulfinylmethyl, methylsulfonylmethyl, cyclopropyl, cyclobutyl or phenyl, or may form the after-mentioned ring together with R3, provided that when G1 is a structure represented by G1-1, X1 is a chlorine atom, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom or a chlorine atom, G2 is a structure represented by G2-1, Y3 is a chlorine atom, and Y1, Y2, Y4 and Y5 are hydrogen atoms, R2 is C1-C4 alkyl, fluoromethyl, trifluoromethyl, methoxymethyl, methylthiomethyl, methylsulfinylmethyl, methylsulfonylmethyl, cyclopropyl, cyclobutyl or phenyl, R3 is a hydrogen atom or C1-C4 alkyl, or R3 may form, together with R2, a C2-C5 alkylene chain to form a 3- to 6- membered ring together with the carbon atom attached to R2 and R3, wherein the alkylene chain may contain an oxygen atom or sulfur atom, R4 is a hydrogen atom, C1-C4 alkyl, (Ci-C2)alkyl substituted with R19, C3-C6 cycloalkyl, C2-C4 alkenyl, C2-C4 alkynyl, -C(0)R20, -C(0)OR2\ C1-C4 alkoxy or C1-C4 haloalkylthio, R5 is C1-C4 alkyl, C1-C4 haloalkyl or Cs-Ce cycloalkyl, R6 is a halogen atom, C3-C6 cycloalkyl, hydroxy(C3-C6)cycloalkyl, C3-C4 alkenyl, Cs-Ce cycloalkenyl, -OH, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, -Si(R14a)(R14b)R14, phenyl, phenyl substituted with (Z)m, D-1.D-2, D-4, D-12orD-32, 299 R7 is C1-C4 alkyl, C1-C4 haloalkyl, C2-C4 haloalkenyl, C3-C4 haloalkynyl, phenyl or phenyl substituted with (Z)m, R8 and R9 together form a C4-C5 alkylene chain to form a 5- to 6-membered ring together with the nitrogen atom attached to R8 and R9, and the alkylene chain may contain an oxygen atom or sulfur atom, R10 is a hydrogen atom, C1-C4 alkyl or cyclopropyl, R11 is C1-C4 alkyl or C1-C4 haloalkyl, R14 is C1-C4 alkyl or phenyl, each of R14a and R14b is independently C1-C4 alkyl, R16is-C(O)R10or-C(O)OR11, R17 is C1-C4 alkyl, and when p is 2, the respective R17's may be identical with or different from one another, R18 is a halogen atom, cyano, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, E-2 to E-6, E-8, E-9, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio, -C(R32)=NOR33, M-3, M-4, C1-C4 alkoxycarbonyl, -C(0)NH2, C1-C4 haloalkylaminocarbonyl, -C(S)NH2, trimethylsilyl, phenyl, phenyl substituted with (Z)m, D-1, D-2, D-4 to D-6, D-8 to D-10, D-12, D-14, D-15, D-17 or D-32, R19 is cyano, -OR36, -C(0)NH2 or -C(S)NH2, R20 is a hydrogen atom, C1-C4 alkyl, C1-C4 alkoxymethyl, C1-C4 alkylthiomethyl, C1-C4 alkylsulfonylmethyl, C3-C4 cycloalkyl or C2-C4 alkenyl, R21 is C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy(Ci-C2)alkyl, allyl or propargyl, R32 is a hydrogen atom, C1-C4 alkyl or C3-C6 cycloalkyl, R33 is C1-C4 alkyl or C1-C4 haloalkyl, R36 is C1-C4 alkyl, C2-C4 haloalkyl, C1-C4 alkylcarbonyl, C3-C6 cycloalkylcarbonyl or C1-C4 alkoxycarbonyl, m is an integer of 1, 2 or 3, n is an integer of 0,1 or 2, and p is an integer of 0, 1 or 2. 3. The oxime-substituted amide compound according to Claim 2, wherein G1 is a structure represented by any one of G1-1 to G1-4, G1-7to G1-9, G1-11 to G1-13, G1-16, G1-20, G1-27, G1-30, G1-32, G1-33, G1-44 and G1-50, G2 is a structure represented by any one of G2-1 to G2-3, G2-6, G2-9 to G2-12 and G2-17, X1 is a halogen atom, cyano, nitro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1- C4 haloalkoxy, C1-C4 alkylthio or phenyl, X3 is a hydrogen atom, methyl, trifluoromethyl or phenyl, Y1 is a hydrogen atom, a halogen atom, methyl, trifluoromethyl, E-9, methoxy or -C(R10)=NOR11, or may form the after-mentioned ring together with Y2, Y2 is a hydrogen atom, a halogen atom, cyano or C1-C4 alkoxy, or may form the after-mentioned ring together with Y3, or Y2 may form, together with Y1, -CH=CHCH=CH- to form a 6-membered ring together with the carbon atoms attached to Y1 and Y2, Y3 is a hydrogen atom, a halogen atom, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1- C4 alkoxymethyl, -OR7, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, - C(0)R10, -C(R10)=NOR11, M-7, C2-C4 alkenyl, C2-C6 alkynyl, (C2-C6)alkynyl substituted with R6, phenyl, phenyl substituted with (Z)m, D-3, D-7 or D-22, or Y3 may form, together with Y2, -CH=CHCH=CH- to form a 6-membered ring together with the carbon atoms attached to Y2 and Y3, 300 Y4 is a hydrogen atom, a halogen atom, trifluoromethyl or methoxy, Y5 is a hydrogen atom or a halogen atom, Z is a halogen atom, cyano, nitro, C1-C4 alkyl, trifluoromethyl, methoxy, trifluoromethoxy, trifluoromethylthio or phenyl, when m or n is an integer of at least 2, the respective Z's may be identical with or different from one another, and when there are two neighboring Z's, the two neighboring Z's may form -CH=CH-CH=CH- to form a 6-membered ring together with the carbon atoms attached to the two Z's, R1 is C1-C6 alkyl, C1-C4 haloalkyl, (Ci-C4)alkyl substituted with R18, Ca-Ce cycloalkyl, E-2, E-14, C3-C6 alkenyl, C3-C4 haloalkenyl, C3-C6 alkynyl or phenyl, R2 is a hydrogen atom, C1-C4 alkyl or phenyl, or may form the after-mentioned ring together with R3, provided that when G1 is a structure represented by G1-1, X1 is a chlorine atom, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom or a chlorine atom, G2 is a structure represented by G2-1, Y3 is a chlorine atom, and Y1, Y2, Y4 and Y5 are hydrogen atoms, R2 is C1-C4 alkyl or phenyl, R3 is a hydrogen atom or methyl, or R3 may form, together with R2, a C2-C5 alkylene chain to form a 3- to 6-membered ring together with the carbon atom attached to R2 and R3, R4 is a hydrogen atom, C1-C4 alkyl, (Ci-C2)alkyl substituted with R19, cyclopropyl, allyl, propargyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl or C1-C4 haloalkylthio, R5 is C1-C4 alkyl, R6 is a halogen atom, C3-C6 cycloalkyl, hydroxy(C3-C6)cycloalkyl, Cs-Ce cycloalkenyl, -OH, tri(Ci-C4 alkyl)silyl, phenyl, phenyl substituted with (Z)m or D-32, R7 is C1-C4 alkyl, C1-C4 haloalkyl, phenyl or phenyl substituted with (Z)m, R10 is a hydrogen atom or C1-C4 alkyl, R11 is C1-C4 alkyl, R17 is methyl, R18 is cyano, C3-C6 cycloalkyl, E-5, E-9, C1-C4 alkoxy, C1-C4 alkylthio, -C(R32)=NOR33, M-4, C1-C4 alkoxycarbonyl, C1-C4 haloalkylaminocarbonyl, trimethylsilyl, phenyl, phenyl substituted with (Z)m, D-1, D-5, D-10 or D-32, R19 is C1-C4 alkoxy, R32 is a hydrogen atom or C1-C4 alkyl, R33 is C1-C4 alkyl, and risO. 4. The oxime-substituted amide compound according to Claim 3, wherein G1 is a structure represented by any one of G1-1 to G1-3, G1-7, G1-9, G1-11, G1-12, G1-16, G1- 27, G1-32, G1-33 and G1-50, G2 is a structure represented by any one of G2-1, G2-2, G2-6, G2-9 and G2-10, W is an oxygen atom, X1 is a halogen atom, nitro, methyl, difluoromethyl or trifluoromethyl, X2 is a hydrogen atom, and when G1 is a structure represented by G1-27 and X1 is trifluoromethyl, X2 may be a halogen atom, X3 is a hydrogen atom or methyl, X4 is a hydrogen atom or a halogen atom, X5 is a hydrogen atom, Y1 is a hydrogen atom, a halogen atom, methyl, trifluoromethyl or methoxy, Y2 is a hydrogen atom, a halogen atom or cyano, or may form the after301 mentioned ring together with Y3, Y3 is a hydrogen atom, a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, -C(R10)=NOR11, C2-C4 alkenyl, C2-C6 alkynyl, (C2-Ce)alkynyl substituted with R6, phenyl, D-3 or D-7, or Y3 may form, together with Y2, -CH=CHCH=CH- to form a 6-membered ring together with the carbon atoms attached to Y2 and Y3, Y4 is a hydrogen atom or a halogen atom, R1 is Ci-Ce alkyl, C1-C4 haloalkyl, (Ci-C4)alkyl substituted with R18, Cs-Ce cycloalkyl, C3-C6 alkenyl, C3-C4 haloalkenyl, C3-C6 alkynyl or phenyl, R2 is a hydrogen atom, methyl or ethyl, or may form a cyclopropyl ring together with R3, provided that when G1 is a structure represented by G1-1, X1 is a chlorine atom, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom or a chlorine atom, G2 is a structure represented by G2-1, Y3 is a chlorine atom, and Y1, Y2, Y4 and Y5 are hydrogen atoms, R2 is methyl or ethyl, R3 is a hydrogen atom or methyl, or R3 may form a cyclopropyl ring together with R2, R4 is a hydrogen atom, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl or C1-C4 haloalkylthio, R5 is methyl, R6 is a halogen atom, C3-C6 cycloalkyl, -OH, trimethylsilyl or phenyl, R10 is methyl, R11 is methyl or ethyl, R18 is cyano, C3-C6 cycloalkyl, E-5, C1-C4 alkoxy, C1-C4 alkylthio, -C(R32)=NOR33, trimethylsilyl, phenyl, phenyl substituted with (Z)m, D-5, D-10 or D-32, R32 is methyl, R33 is methyl or ethyl, and p isO. 5. The oxime-substituted amide compound according to Claim 4, wherein G1 is a structure represented by any one of G1-1 to G1-3, G1-7, G1-11, G1-12, G1-16, G1-27 and G1-33, G2 is a structure represented by G2-1 or G2-2, X1 is a halogen atom, methyl, difluoromethyl or trifluoromethyl, X2 is a hydrogen atom, X4 is a hydrogen atom, Y1 is a halogen atom, Y2 is a hydrogen atom or a halogen atom, Y3 is a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 haloalkoxy, - C(R10)=NOR11, C2-C6 alkynyl, cyclopropylethynyl, trimethylsilylethynyl or phenylethynyl, Y5 is a hydrogen atom, R1 is Ci-Ce alkyl, C1-C4 haloalkyl, (Ci-C4)alkyl substituted with R18, Cs-Ce cycloalkyl, C3-C6 alkenyl, C3-C4 haloalkenyl or C3-C6 alkynyl, R2 is a hydrogen atom or methyl, provided that when G2 is a structure represented by G2-1, R2 is methyl, R3 is a hydrogen atom, R4 is a hydrogen atom, R18 is C3-C6 cycloalkyl, trimethylsilyl, phenyl, phenyl substituted with (Z)m or D-32, Z is a halogen atom, cyano, nitro, methyl, trifluoromethyl or trifluoromethoxy, and 302 when m is an integer of at least 2, the respective Z's may be identical with or different from one another, and n is 1. 6. The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-1, X1 is a halogen atom, methyl, difluoromethyl ortrifluoromethyl, and X2, X3, X4 and X5 are hydrogen atoms. 7 The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-2 or G1-3, X1 is a halogen atom, methyl ortrifluoromethyl, and X2, X3, X4 and X5 are hydrogen atoms. 8 The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-7, X1 is trifluoromethyl, and X3 and X4 are hydrogen atoms. 9. The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-11 or G1-12, X1 is a halogen atom, methyl or trifluoromethyl, and X2, X3 and X4 are hydrogen atoms. 10. The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-16, X1 is trifluoromethyl, X2 and X4 are hydrogen atoms, and R5 is methyl. 11. The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-27, X1 is difluoromethyl or trifluoromethyl, X2 is a hydrogen atom, and R5 is methyl. 12. The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G1 is a structure represented by G1-33, X1 is difluoromethyl ortrifluoromethyl, and X3 is methyl. 13. The oxime-substituted amide compound according to any one of Claims 1 to 5, wherein G2 is a structure represented by G2-2, Y1 is a halogen atom, Y2 is a hydrogen atom or a halogen atom, Y3 is a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 haloalkoxy, -C(R10)=NOR11, C2-C6 alkynyl, cyclopropylethynyl, trimethylsilylethynyl or phenylethynyl, Y4 is a hydrogen atom or a halogen atom, R10 is methyl, and R11 is methyl or ethyl. 14. An intermediate of the oxime-substituted amide compound as defined in any one of Claims 1 to 13, which is represented by the formula (Ma): 303 Y! R2 R3 H2N II N *N' "h. i R1 (Ha) wherein Y1 is a halogen atom, Y2 is a hydrogen atom, a halogen atom or cyano, Y3 is a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, -C(R10)=NOR11, C2-C4 alkenyl, C2-C6 alkynyl, (C2-Ce)alkynyl substituted with R6, D-3 or D-7, Y4 is a hydrogen atom or a halogen atom, R1 is Ci-Ce alkyl, C1-C4 haloalkyl, (Ci-C4)alkyl substituted with R18, Ca-Ce cycloalkyl, C3-C6 alkenyl, C3-C4 haloalkenyl, C3-C6 alkynyl or phenyl, R2 is a hydrogen atom, methyl or ethyl, R3 is a hydrogen atom or methyl, or R3 may form a cyclopropyl ring together with R2, R6 is a halogen atom, C3-C6 cycloalkyl, -OH, trimethylsilyl or phenyl, R10 is methyl, R11 is methyl or ethyl, R18 is cyano, Ca-Ce cycloalkyl, E-5, C1-C4 alkoxy, C1-C4 alkylthio, -C(R32)=NOR33, trimethylsilyl, phenyl, phenyl substituted with (Z)m, D-5, D-10 or D-32, R32 is methyl, R33 is methyl or ethyl, Z is a halogen atom, cyano, nitro, C1-C4 alkyl, trifluoromethyl, methoxy, trifluoromethoxy, trifluoromethylthio or phenyl, when m or n is an integer of at least 2, the respective Z's may be identical with or different from one another, and when there are two neighboring Z's, the two neighboring Z's may form -CH=CH-CH=CH- to form a 6-membered ring together with the carbon atoms attached to the two Z's, m is 1, 2 or 3, n is an integer of 0, 1 or 2, and p is 0. 15. An intermediate of the oxime-substituted amide compound as defined in any one of Claims 1 to 7 and 13, which is represented by the formula (IVa): Y2 /3 (IVa) wherein G1 is a structure represented by any one of G1-1, G1-2 and G1-3: 304 IS xz xA N G1-! G1-! G*-3 X1 is a halogen atom, nitro, methyl, difluoromethyl or trifluoromethyl, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom, and when G1 is G1-1, X4 may be a halogen atom, Y1 is a halogen atom, Y2 is a hydrogen atom, a halogen atom or cyano, Y3 is a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, -C(R10)=NOR11, C2-C4 alkenyl, C2-C6 alkynyl, (C2-Ce)alkynyl substituted with R6, D-3 or D-7, Y4 is a hydrogen atom or a halogen atom, R2 is a hydrogen atom or methyl, R6 is a halogen atom, C3-C6 cycloalkyl, -OH, trimethylsilyl or phenyl, R10 is methyl, R11 is methyl or ethyl, and n is 0. 16. An intermediate of the oxime-substituted amide compound as defined in any one of Claims 1 to 13, which is represented by the formula (Via) or (Villa): 1 Y1 JL Y3 (Via) wherein A is C-H or N, G1 is a structure represented by any one of G1 -1 to G1 -3, G1 -7, G1 -9, G1 -11, G1 -12, G1 -16, G1 -27, G1 -32, G1 -33 and G1 -50: N02 (Villa) X1 is a halogen atom, nitro, methyl, difluoromethyl or trifluoromethyl, X2 is a hydrogen atom, and when G1 is a structure represented by G1-27 and X1 is trifluoromethyl, X2 may be a halogen atom, X3 is a hydrogen atom or methyl, X4 is a hydrogen atom or a halogen atom, X5 is a hydrogen atom, Y1 is a halogen atom, Y2 is a hydrogen atom, a halogen atom or cyano, Y3 is a halogen atom, cyano, methyl, trifluoromethyl, C1-C4 alkoxy, C1-C4 haloalkoxy, -C(R10)=NOR11, C2-C4 alkenyl, C2-C6 alkynyl, (C2-Ce)alkynyl substituted with R6, D-3 or D-7, Y4 is a hydrogen atom or a halogen atom, R2 is a hydrogen atom, methyl or ethyl, provided that when G1 is a structure represented by G1-1, X1 is a chlorine atom, X2, X3 and X5 are hydrogen atoms, X4 is a hydrogen atom or a chlorine atom, A is C-H, Y3 is a chlorine atom, and Y1, Y2 and Y4 are hydrogen atoms, R2 is methyl or ethyl, R3 is a hydrogen atom or methyl, or R3 may form a cyclopropyl ring together with R2, R5 is methyl, R6 is a halogen atom, C3-C6 cycloalkyl, -OH, trimethylsilyl or phenyl, R10 is methyl, R11 is methyl or ethyl, n is 0, and risO. 17. A pesticidal composition containing at least one member selected from the 306 oxime-substituted amide compounds as defined in Claims 1 to 13, as active ingredient(s). 18. An agricultural fungicidal or nematocidal composition containing at least one member selected from the oxime-substituted amide compounds as defined in Claims 1 to 13, as active ingredient(s). 19. The agricultural fungicidal or nematocidal composition according to Claim 1 &, which is applied to plants by foliar treatment. 20. The agricultural fungicidal or nematocidal composition according to Claim 18, which is used to treat soil in which plants grow. 21. The agricultural fungicidal or nematocidal composition according to Claim 18, which is used to treat seeds, tuberous roots or rhizomes of plants. 22. An antifungal or parasrticidal composition for a mammal or bird, which contains at least one member selected from the oxime-substituted amide compounds as defined in Claims 1 to 13, as active ingredient(s). 23. The parasiticidal composition according to Claim 22, which is against internal parasites in a mammal or bird by oral administration. 24. The parasiticidal composition according to Claim 22, which is against internal parasites in a mammal or bird by parenteral administration. 25. The parasiticidal composition according to Claim 22, which is against internal parasites in a mammal or bird by percutaneous administration.